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Abstract 
Atrial fibrillation (AF) cardiac arrhythmia is associated with [Ca2+]i overload contributing in 
disturbed action potential prolongation, and in alteration of gap junctional connexin protein 
expression and phosphorylation status. Episodes of AF are more frequent during daytime, 
suggesting a possible involvement of circadian rhythms (and the clock genes driving it, in 
particular Bmal1) contributing to its occurrence.  Also, Bmal1 reported to directly regulate 
Ca2+ and Na+ ionic currents, as well as, Ca2+-related release channels, however, the 
relationship between AF-mediated pathways, Bmal1 clock gene expression and circadian 
rhythmicity is far from clear.  This study aimed to explore the involvement of Bmal1 in driving 
the AF occurrence via changes in Ca2+ homeostasis through sustained activation of NaP 
channels and/or alteration in connexin expression and phosphorylation status by Ca2+-
dependent protein phosphatase calcineurin (CaN).   
HL-1 clone 6 (HL1-6) cells were used as an in vitro model and synchronised with 50 % fetal 
bovine serum for the interpretation of circadian characteristics. HL1-6 cells were treated with 
anemonia sulcata toxin II (ATXII; 1 nM) in presence and/or absence of Ranolazine (10 µM), 
BAPTA-AM (5 µM) or CAIP (25 µM).  Bmal1 gene circadian rhythmicity was observed 
under control conditions (26.09±0.78 hrs). Such pattern was highly disturbed under raised 
[Ca2+]i by ATXII (17.05±1.07 hrs) and was restored in presence of Ranolazine (25.32±0.97 
hrs) and BAPTA-AM (25.91±0.54 hrs).  This suggests that Ca2+ mediated changes in the 
cellular circadian clock are an integral part of the aetiology of atrial arrhythmia’s, and that the 
NaP/raised Ca
2+ arrhythmogenic pathway directly affects Bmal1 circadian expression in atria; 
hence strengthens its association with AF occurrence.   
BMAL1 oscillatory protein expression observed under ATXII treatment was similarly 
reversed in presence of Ranolazine, proposing the involvement of Nav1.5. channel subtype 
driving such mechanisms.  BMAL1 protein expression was also affected by CAIP (in presence 
of ATXII), suggesting a possible action of CaN on Ser42 residue.  Interestingly, the pCx43-
Ser368 show a similar protein expression pattern as BMAL1, proposing an immediate 
association of circadian mechanisms driving Cx43 (but not Cx40) expression in AF 
occurrence. Finally, the phosphorylated Cx43-Ser368 protein expression levels and 
oscillatory pattern were restored in presence of CAIP, proposing CaN involvement in 
mediating the ATXII-effects under AF occurrence.  This further implies that the Ca2+/CaN 
signalling pathway is driving BMAL1 protein expression and localisation in atria. 
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1. Introduction 
Cardiovascular diseases (CVD) are one of the leading causes of mortality and morbidity in UK, 
affecting more than 1/3 of the Western world population over the age of 65 years, and has a 
huge economic burden on the National Health Services (World Health Organisation., 2015).  
Given the impact of CVDs, intensive research efforts are being made to understand their 
aetiologies.  One area of investigation that has gained momentum in recent years is the influence 
of 24-hour rhythms on healthy and adverse cardiovascular biology.     
Circadian rhythms or 24-hours, are seen in many behavioural and physiological rhythms.  
Circadian rhythms have evolved in response to daily changes in the environment, and as part 
of that all mammalian species express an intrinsic circadian clock which is there to anticipate 
these changes.  Physiologic parameters of the cardiovascular system, such as heart rate (HR), 
blood pressure (BP), QT interval (a measure of the time between the start of the Q wave and 
the end of the T wave in the heart's electrical cycle), vascular tone and atrioventricular 
conduction demonstrate significant daily rhythmic patterns, referred to as diurnal variations 
(Muller J, 1999; Dilaveris et al., 2001; Molnar et al., 1996; Cooke and Lynch., 1994).  Such 
rhythms might be driven by the external environment or the intrinsic circadian clock.  Also, it 
has been found that cardiovascular adverse effects exhibit daily rhythmic patterns, with peak 
susceptibility in the early morning hours: these cardiovascular adverse effects include 
atrioventricular arrhythmias, sudden cardiac death (SCD), stroke, thromboembolism, 
pulmonary embolism and myocardial infarction (MI) (Cohen et al., 1997; Sacco et al., 2009; 
Muller et al., 1985; Mehta et al., 2002).   
Additionally, there is strong evidence showing that disruption of these rhythms is a significant 
risk factor for many cardiovascular diseases, as it was shown to affect heart structure and 
function in both animal and human models (Durgan et al., 2010; Durgan et al., 2011; Takeda et 
al., 2011).  Therefore, the possible interaction between circadian rhythmicity of cardiac 
peripheral clock genes and cellular physiology and pathophysiology is the focus of this thesis.  
1.1. Heart structure and function  
The human heart’s main function is to receive deoxygenated blood from the whole body via 
vena cava to the lungs to become oxygenated and finally be re-distributed to the whole body 
through its four chambers namely; the left atrium (LA) and the right atrium (RA) located at the 
upper part of the heart; and the left ventricle (LV) and right ventricle (RV) located at the lower 
parts of the heart (Bootman et al., 2006; Fukuta and Little., 2008).  The blood circulates at 
physiological blood pressure to ensure good perfusion of all body organs.  The LA and L
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pump the blood trough the systemic circulation while the RA and RV pump blood across the 
pulmonary circulation through contraction and relaxation of the heart (Bootman et al., 2006).  
The contraction and relaxation of the atria and ventricles for efficient blood flow is known as 
cardiac cycle, which consists of two phases known as systolic phase and diastolic phase.  During 
the systolic phase of the cardiac cycle, the ventricles walls contracts while atrioventricular valve 
(AV) remains closed to create a greater pressure than in the pulmonary artery.  Such pressure 
will lead to the outlet valve open, allowing blood out of the ventricles, completing the systole 
phase of the cardiac cycle (Fukuta and Little., 2008). The diastole phase starts when the AV 
opens while the outlet valve closes and intraventricular chamber relaxes to allow blood fill in 
the chamber.  After the fill of blood in the ventricles, the AV closes and the systolic phase 
restarts. The ventricular contraction (systole) and relaxation (diastole) is coordinated by 
different types of cells lining the heart to allow efficient pumping action of the heart. 
The heart is lined with difference types of cells such as fibroblasts, endothelial cells that lines 
the endocardium, vascular smooth muscle cells that lines the myocardium, Purkinje fibres and 
atrial and ventricular cardiomyocytes (Pellman et al., 2016). The cardiac myocytes are known 
as the “principle building blocks” of the heart, as they account for approximately 75 % of the 
total heart volume while the atrial myocytes are important for rapid atrial contraction regulated 
by electric impulse to pump blood into the ventricle chambers (McArthur et al., 2015; Laks et 
al., 1991). The heart can provide electric impulses through a specialised conduction pathway, 
which is controlled through sinoatrial (SA) node, atrial ventricular (AV) node, bundle of His, 
the left and right bundle branches and Purkinje fibres to generate rhythmic impulses known as 
action potential (AP) and distributing them to different parts of the myocardium (Bootman et 
al., 2006). 
The action potential (AP) generated by the heart is recorded by electrocardiogram (ECG). The 
AP is initiated by the natural pacemaker, known as SA node, located below the RA epicardium 
and at the junction of the vena cava, possess intrinsic rhythm and determines the heart beat 
(Laks et al., 1991).  Impulses generated at the SA node travel throughout the RA and LA to 
stimulate atria contraction once the atria is filled.  This causes the depolarisation of the atria 
and is captured on the electrocardiogram (ECG) as the P wave (Figure 1.1.). As the AP enters 
the AV node through interatrial bundles of conduction fibres, the AV node conductions slows 
down to allow complete contraction of the atria to facilitate blood into the ventricles. Once the 
ventricles are filled receive electrical impulses from Purkinje fibres via the Bundle of His 
causing them to contract (Bootman et al., 2006) and this causes depolarisation of the ventricles 
which is captured as the QRS complex on the ECG (Figure 1.1.). The QRS waves represent the 
entire ventricular depolarisation and at the same time the atria repolarise. Once the impulses 
have passed the AV node and reaches the ventricles, the conduction velocity increases as the
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impulse is relayed towards the Bundle of His to allow the AV valve close as refill the atria and 
the ventricles repolarises causing a T wave on the ECG (Bootman et al., 2006). The cycle 
repeats itself with every heartbeat (Fukuta and Little., 2008). 
 
 
 
 
 
 
 
Figure 1.1. Electrocardiogram (ECG) of a heart in normal sinus rhythm.  P wave symbolised depolarisation 
of atria, whereas QRS and T wave indicate depolarisation and relaxation of the ventricles respectively. The QT 
interval indicates the duration of action potential (Modified from Ashley and Niebauer., 2004) 
 
1.2. Atrial action potential 
Action potential (AP) of different regions of the heart are not identical and have different 
characteristic that facilitates the cardiac excitation (Bootman et al., 2011). Cardiac AP differs 
between the cardiac muscle cell and the AV node cell types, as well as, between the ventricles 
and the atria. Atrial cardiac myocytes have a stable resting membrane potential of around -
85mV and hence requires an electrical stimulus to trigger AP generation. The changes in 
membrane voltage is caused by activation and inactivation of voltage-gated ion channels, as 
well as ion-pumps and exchangers at specific times to create an AP (Lopatin et al., 2001; Brown 
et al., 1981; Levick et al., 2010; Sakmann et al., 2000).  
Action potential in the atria has four phases as shown in Figure 1.2. During phase 0 cardiac 
membrane permeability to Na+ rapidly increases while the K+ permeability reduces leading to 
depolarisation of the membrane from ~85 mV to ~20 mV, resulting in the generation of a rapid 
AP upstroke phase due to activation of fast voltage-gated Na+ channels which favor Na+ entry 
inside the cell (INa) (Lopatin et al., 2001).  Immediately after the initial Na
+ upstroke (phase 0), 
a transient early repolarisation (phase 1) in membrane potential occurs mainly mediated by 
activation of a transient outward K+ current (ITo).   
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At such depolarising membrane potential, the plateau phase (phase 2) of the action potential is 
initiated and mediated by the activation of the long-lasting voltage-dependent inward (L-type) 
Ca2+ current which is activated at - 40 mV.   The net small Ca2+ influx during phase 2 triggers 
a larger release from intracellular Ca2+ stores; sarcoplasmic reticulum (SR), to initiate 
contraction.  Recently, it has been shown that slow activating Na+ channels, known as persistent 
or late Na+ channels (NaP) are also opened during the plateau phase, contributing to the entry 
of Ca2+ and initiation of contraction through similar mechanisms (Chadda et al., 2017; 
Antzelevitch et al., 2014; Benito et al., 2008; Hove-Madsen et al., 2004).  Ca2+ entry at this 
phase is also mediated by the activation of Na+/Ca2+ exchanger (NCX) which is partly triggered 
by the opening of the NaP channels.  NaP channels will cause influx of Na
+ ions, hence 
subsequent increase in intracellular [Na+] (via activation of NCX) which cause Ca2+ entry inside 
the cells and subsequently increase in intracellular [Ca2+].  The duration of phase 2 in atrial 
action potential is slightly shorter (250 milliseconds) than the ventricular action potential (300 
milliseconds) due to a Ca2+ influx through the Ca2+ channels, as a result of decreased K+ 
membrane permeability to create contraction as seen in ventricles.  The balance between inward 
currents and outward currents during plateau phase is extremely important as it determines the 
duration of action potential (APD; 200-300 milliseconds), which in turn modulates intracellular 
Ca2+ transient and hence contraction.  A prolonged increase in inward currents will lead to 
prolongation of APD, hence leading to the generation of arrhythmias, whereas an increase in 
outward currents abbreviates it.   
 
 
 
 
 
 
Figure 1.2. Schematic representation of atrial action potential.  Atrial action potential has 4 phases, each driven 
by activation and inactivation of voltage-gated ion channels, as well as ion-pumps and exchangers.  Depolarisation 
phase (phase 1), is facilitated by Na+ entry by voltage gated Na+ channels, plateau phase is a result of Na+ and Ca2+ 
entry via voltage gated Ca2+ channels, persistent or slow Na+ channels (NaP) and Na+/Ca2+ exchanger (NCX). 
Repolarisation phase (phase 3) is facilitated by K+ exit through voltage-gated delayed rectifier K+ channels and 
resting phase is a result of K1 entry.  Atrial action potential duration is approximately 250 milliseconds (ms) 
(Modified from Levick et al., 2010) 
250 ms 
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The repolarisation phase (phase 3) is brought on by inactivation of ICaL, INCX, INaP currents and 
activation of voltage-dependent delayed rectifier outward K+ channels, along with Na+/K+ 
pump, to fully repolarise the membrane back to its resting potential (Deal et al., 1996).  The re-
opening of IK1 channels work to repolarise the cell; hence maintains the resting membrane 
potential at -85 mV (phase 4) (Lopatin et al., 2001).  
1.3. Atrial excitation-contraction coupling - Ca2+ importance 
Ca2+ is a ubiquitous second messenger intrinsic to the dynamic regulation of a wide range of 
physiological functions inducing the process of excitation-contraction coupling (E-C coupling) 
in cardiac myocytes (Bers., 2014).  Therefore, the ability of the heart to maintain Ca2+ levels 
within a physiological range (200 nM intracellular [Ca2+] and 1.8 mM extracellular [Ca2+]) 
under resting conditions is essential to prevent deterioration to pathological conditions, such as 
seen in arrhythmias.  The cell must expand energy to maintain a low intracellular [Ca2+] to 
prevent it from rising above its physiological level and hence activate interaction between actin 
and myosin filaments to facilitate contraction (Carmeliet., 1978; Kentish., 1984; Bers., 2006; 
Bers., 2014).   
The bridge between cardiac myocyte membrane depolarisation (excitation of cells) and 
initiation of contraction is achieved by intracellular Ca2+ entry during phase 2 (plateau phase) 
of the AP and the further triggered release from intracellular Ca2+ stores (SR; sarcoplasmic 
reticulum).  Following the rapid Na+ upstroke (phase 1), L-type channels are activated allowing 
Ca2+ entry into a narrow (~10 nm) cleft formed by the sarcolemma and the SR (Ayettey et al., 
1978).  Ca2+ will bind to the SR-Ca2+-gated-Ca2+ release channels (also known as Ryanodine 
Receptors; RyRs) found in close proximity to these L-type Ca2+ channels, leading to fast efflux 
of Ca2+ from SR to the cytoplasm (Bers., 2006).  Within the SR there is a high Ca2+ 
concentration [1 mM] as compared to levels found in the cytoplasm [200 nM], and RyR 
activation causes its opening leading to a rapid release of Ca2+ from the SR, known as the 
Ca2+spark, or as Ca2+-induced Ca2+ release (CICR) process (Figure 1.3.).  This subsequent rise 
of intracellular [Ca2+] triggers the process of contraction trough binding of Ca2+ to troponin C 
(which is found within the myofibrils) and subsequent conformational change to Troponin I, 
allowing exposure of the myosin binding site. The exposure of this myosin binding site allows 
the engagement of actin filaments with myosin contractile filaments which promotes cross 
bridge formation (slide past each other) and subsequent muscle contraction (Bers., 2014).  
Interestingly, opening of NaP channels during the plateau phase was shown to similarly 
contribute to cellular Ca2+ entry and facilitation of contraction via E-C coupling (Chadda et al., 
2017).  
Following contraction, the cell must return to physiological [Ca2+] levels via the NCX action, 
which functions to interchange three Na+ ions for one Ca2+ ion through a single 
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contraction/relaxation cycle (Delbridge et al., 1996).  The Ca2+ removal from the cytoplasm 
back into the SR through a sarcoplasmic reticulum Ca2+ ATPase (SERCA) enzyme, allows 
restoration of Ca2+ levels back to normal and subsequent muscle relaxation initiation.   
 
   
 
 
 
 
 
 
Figure 1.3. Excitation-contraction (E-C) coupling schematic representation.  The cardiac excitation-
contraction (EC) coupling requires activation of L-type Ca2+ channels to cause Ca2+ influx in the sarcolemma and 
T-tubules. (Bers., 2006) 
 
Despite the variability in the ultrastructure, morphology and molecular composition of cardiac 
myocytes located within different regions of the heart, E-C coupling is involved with the 
initiation of Ca2+ signals within all electrically excitable cardiomyocytes (Bootman et al., 2006; 
Bootman et al., 2011).  Given the importance of Ca2+ signalling under physiological conditions, 
disturbance in the Ca2+ levels lead to derangements in signalling and electrochemical function 
of the heart and is associated with cardiovascular adverse such as cardiac arrhythmias (Balke 
and Shorofsky et al., 1998; Maier et al., 1998; Yeah et al., 2008).            
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1.4. Cardiac arrhythmias – Atrial fibrillation 
The SA node sends a depolarisation wave through the AV node and His-Purkinje fibres to the 
atria and depolarises the ventricles in a systemic way.  Any distances in this systemic rhythm 
leads to generation of cardiac arrhythmias; hence arrhythmias are the abnormalities in the 
normal activation of the heart (Markides., 2003). The two predominant factors contributing to 
arrhythmogenesis are abnormal action potential configuration and/or abnormal conduction of 
action potential across the heart.  Cardiac arrhythmias can be due to; 1) the failure of 
automaticity, that is failure to generate action potential such as sick sinus syndrome or 
inappropriate sinus tachycardia, 2) triggered activity which is the early afterdepolarisations 
(EADs) and delayed afterdepolarisations (DADs) causing ventricular arrhythmias or due to 3) 
re-entry occurring when the AP fails to terminate itself and reactivates a part that has recovered 
from refractoriness leading to heart diseases.  In addition, cardiac arrhythmias may be due to 
secondary heart diseases such as myocardial infarction, ischemia reperfusion injury, left 
ventricular hypertrophy and dilated cardiomyopathies (Wit and Janse, 1992; Benjamin et al., 
1998; Severs et al., 2006).  Furthermore, arrhythmias can lead to electrical and mechanical 
remodeling of the atria leading to an asymptomatic condition known as atrial fibrillation. 
Atrial fibrillation (AF) is the most common cardiac arrhythmias with substantial level of 
morbidity and mortality in the world (Benjamin et al., 1998; Spence., 2009; Apostolakis et al., 
2013).  During an episode of atrial arrhythmias, the heart rate increased significantly to almost 
> 150 beats per minute, and could also be highly irregular resulting in ineffective contraction 
of the atria (Allessie et al., 2002; Nattel, 2002).  This can lead to blood stasis and initiation of 
clot formation and thromboembolism, thus maximising the risk of stroke and myocardial 
infarction (Sun., 2001).  It has been reported that AF contributes to almost 10 % incidences of 
stroke which highlights its importance for investigation.  Epidemiological studies such as 
Framingham emphasised the strong and consistent association of AF incidences with age 
(Wang et al., 2003).  The prevalence of AF is 2.3 % of people over 40 years, 5.9 % in those 
older than 65 years and approximately 10 % in those older than 80 years (Feinberg et al., 1993).  
AF can be classified by its temporal pattern, for example patients may have a “first detected 
episode” of AF or in case of documentation of previous episodes, a “recurrent arrhythmia”.  
Episodes themselves may be “paroxysmal”, if they terminate spontaneously (within a timeline 
of 7 days), “persistent” if the arrhythmia requires drugs in order to be alleviated or “permanent” 
if the arrhythmia cannot be terminated by the use of drugs and/or has longer than 1-year duration 
(Markides et al, 2003).  In addition, the aetiology, or cause, of AF can be used as a way of 
classification for the different types of AF.  For instance, lone AF, is known as the AF that 
occurs without identifiable aetiology in patients with a perfectly normal heart structure, whereas 
valvular AF refers to patients with artificial heart valves (Markides et al., 2003).    
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1.4.1. Pro-arrhythmic mechanisms: ectopic automaticity, after-
depolarisations and re-entry 
Initiation of atrial abnormal rhythmicity which may lead to AF, is achieved through rapid focal 
ectopic activity or by re-entry (Nattel and Dobrev., 2012).  Ectopic automaticity refers to the 
generation of spontaneous depolarisation at a site in the atria separate to the SA node.  Studies 
by Haïssaguerre et al., (1998) established that ectopic foci mainly originates from the 
pulmonary veins and some localised from left atrial posterior wall.  The aetiology of focal 
ectopic activity is afterdepolarisations of membrane potentials of which two main types exist; 
delayed afterdepolarisations (DADs) and early afterdepolarisations (EADs).  Both DADs and 
EADs are dictated by ectopic activity either during or at the end of the action potential durations 
(APDs), respectively.  DADs occur after full repolarisation of AP, whereas EADs precede full 
repolarisation characteristically during the end of the phase 2 or early in phase 3 of AP.   
The key denominator of DADs generation is the transient rise of diastolic Ca2+ (SR Ca2+ leak) 
during Ca2+ overload.  This initiates an influx of Na+ through the NCX, thereby providing 
sufficient transient membrane depolarisation.  If it reaches threshold potential, then an AP will 
be prematurely generated (Nattel and Dobrev, 2012).  The propensity for DADs is enhanced by 
a reduced refractory period and thus a reduced APD.  In contrast, EADs occur because of 
abnormal APD prolongation, which in turn increases susceptibility for ectopic firing in adjacent 
myocytes due to their subsequent depolarisation.  EADs are triggered by sustained activation 
of either ICaL, INaP or reduced IK currents enhancing Ca
2+ influx mainly during phase 2 (Samie 
and Jalife., 2001; Nattel et al., 2007; Ravens and Cerbai., 2008) (Figure 1.4.).  Recent 
development of AF understanding proposed that the involvement of INaP current could be 
implicated in AF development, which also will be our main focus in this thesis (Allessie., 2002).   
 
 
 
 
 
 
Figure 1.4. Basic pro-arrhythmic mechanism underlying atrial fibrillation (AF).  Maintenance of AF can be 
achieved by focal ectopic activity cellular mechanism known as early afterdepolarisations (EADs).  Ca2+-related 
functions occur under EADs are indicated in red, whereas NaP-related functions are indicated in blue (Nattel and 
Drobrev., 2012).                    
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1.4.2. Abnormal AP propagation: Role and Origin of persistent Na+ channels 
The cardiac action potential arises from a delicate balance of depolarisation and repolarisation 
orchestrated through precisely timed opening and closing of ion channels (Moreno et al., 2012).  
Activation of Na+ channel produces an influx of Na+ ions that causes membrane depolarisation 
and subsequently membrane excitation that leads to rapid voltage dependent inactivation of Na+ 
channels and nearly complete shutdown of the current.  Fast Na+ current (INa) is observed and 
is mainly responsible for the rapid AP upstroke phase and in coupled tissue AP propagation.  
A second component of Na+ current that persists throughout the duration (phase 2) of the AP 
has also been identified, and because it occurs subsequently to the fast INa, is termed as late or 
persistent Na current (INaP).  INaP occurs throughout the low conductance phase of the AP and 
thus contributes in maintaining the morphology of AP, plateau potentials, APD in human 
ventricular myocytes and in Na+ accumulation in cardiac cells (Coraboeuf et al., 1979; Noble 
and Noble., 2006; Undrovinas and Maltsev., 2008).  Biophysically, INaP has similar properties 
to INa except that the inactivation component is missing or greatly slowed in INaP.  This implies 
that at more positive potential than resting potential, the fast INa current is inactivated but the 
INaP current is not.  In addition, INaP current deactivates very rapidly during repolarisation phase 
and has slightly different activation properties to INa at the macroscopic level (Saint et al., 1992).  
For example, in rat ventricular cells INaP is activated at about 20 mV more negative potential 
than INa.  Furthermore, INaP in cardiac cells has the same ionic selectivity as INa, and the single 
channels have the same conductance, mean open time and reversal potential as the INa channel 
(Gintant et al., 1984).  Even though INaP is small, since it is non-inactivating, the amount of 
charge and Na+ that can be carried by during AP can be the same order as that carried by the 
INa.  Therefore, its blocking will reduce the Na
+ load on the cell. 
Nearly all cardiac myocytes physiologically express INaP, however the expression is not 
uniformly distributed throughout the myocardium as differential expression was observed 
within the cardiac conduction system.  Studies of canine ventricular wall showed 47 % greater 
density of INaP in specialised epithelial cells (mid-myocardial cells; M cells) in comparison to 
endocardial and epicardial cells (Zygmunt et al., 2001; Sakmann et al., 2000). In addition, 
despite the presence of INaP exclusively in ventricular human myocytes (and absence in other 
species such as pig and rabbit), rabbit atrial cells reported similar INaP current density to 
ventricular myocytes, whereas Purkinje fibers have increased INaP current expression compared 
to ventricular cells, meaning that such current might be species-dependent (Gintant et al., 1984; 
Maltsev et al., 1998; Sakmann et al., 2000; Maltsev and Undrovinas 2006; Maltsev et al., 2007; 
Vassalle et al., 2007).  Furthermore, differences in NaP channel inactivation properties have 
been described between atrial and ventricular myocytes.  For example, a study by Burashnikov 
et al., (2011) demonstrated approximal 14-16 mV more negative half-inactivation voltage in 
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atria compare to the ventricles in canine heart.  Similar negative atrioventricular inactivation 
difference was also observed in guinea pig heart (Li et al., 2002).   
The physiological role of INaP in the heart is still unclear.  Apart from its certain contribution 
in shortening of the AP plateau phase duration in ventricular and atrial cardiomyocytes in a 
variety of mammalian species (including humans), such effect does not seem large enough to 
produce contractile changes under physiological conditions (Brette and Orchard., 2006; 
Undrovinas and Maltsev 2008).  Under pathological conditions, this sustained INaP was shown 
to promote transmural heterogeneity in conduction slowing and predisposing to 
arrhythmogenesis due to its impact on APD and repolarisation abnormalities, as well as Na+ 
and Ca2+ homeostasis (Moreno et al., 2012).  The first evidence for the potential role of INaP in 
arrhythmogenesis derived from experiments in rat ventricular myocytes, with INaP levels 
significantly increased during hypoxia.  In addition, it was suggested to give rise to EADs and 
arrhythmias during hypoxic states (Saint et al., 1992; Ju et al., 1996; Noble et al., 2006).  Later 
the importance of INaP in atrial arrhythmias was reported through experiments that acted to 
normalised the pathologic INaP levels, resulting in normalisation of repolarisation, decrease in 
variability of APD from beat-to-beat and improvement in Ca2+ handling and contractility 
(Maltsev et al., 1998; Undrovinas et al., 1999; Undrovinas et al., 2006).   
Under atrial arrhythmias related conditions (including AF), intracellular Na+ quickly rises due 
to both deranged ion homeostasis (both Na+ and Ca2+) as well as altered Na+ channel gating, 
leading to an increased INaP (Maier et al., 2009).  Sustained activation and prolonged opening 
of persistent Na+ channels during plateau phase (phase 2) of the AP, stimulates overload of 
intracellular Na+ concentration.  A direct consequence of intracellular Na+ overload is an 
increase in cytosolic Ca2+ accumulation due to reduction of the electrochemical gradient for 
Ca2+ extrusion by the NCX.  Intracellular Na+ accumulation causes the NCX to work in reverse-
mode (3 Na+ ions extruded for 1 Ca2+ influx) (Figure 1.5.).  Entry of Ca2+ ions into the myocyte 
via the NCX ultimately exceeds Ca2+ efflux and precipitates Ca2+ overload.  Deranged 
Ca2+ homeostasis (accumulation and cycling) leads to spontaneous SR Ca2+ release, a 
pathological version of the Ca2+-induced-Ca2+ release process, contributing to prolongation of 
APD, contractile dysfunction and generation of EADs; the primary mechanism of AF-triggered 
arrhythmias (Grandi et al., 2011; Grandi and Pandit., 2012; Shryock et al., 2013).   
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Figure 1.5. Schematic diagram of persistent Na+ (NaP) channels mechanism of action.  Under normal 
physiological conditions NaP channels opening during plateau phase of the atrial action potential, allowing entry 
of Na+ ions in the cell via its concentration gradient. The intracellular increase of Na+ concentration ([Na+]) due to 
NaP channel opening, is exchanged for 3 Ca2+ ions (in exchange of 1 Na+ ion) via the Na+/Ca2+ exchanger (NCX) 
into the cell.  The sustain and prolong activation of Nap channels during phase 2 results in intracellular [Na+] 
overload which in turn leads to reduction of the electrochemical gradient for Ca2+ extrusion by the NCX, causing 
overload of intracellular [Ca2+] which is considered arrhythmogenic, leading to cardiac pathologies including atrial 
fibrillation (AF).        
 
Cardiac INa flows through a channel formed by the α-subunit Nav1.5; the major Na+ channel 
subtype in the heart, encoded by the SCN5A gene (Balser et al., 1999).  Although the α-subunit 
alone accounts for major features of INa, it is part of a macromolecular complex consisting of 
auxiliary subunits and associated channel interacting proteins (Figure 1.6.).  The biophysical 
mechanisms by which α-subunit structure and interacting proteins in the complex affect INaP are 
not completely understood.  However, INaP is generally thought to be a modification of or failure 
in the inactivation process.  A structure responsible for fast inactivation of INa resides in 
isoleucine-phenylalanine-methionine motif on the DIII-DIV linker and on the bottom of the 
S4-S5 linker as a receptor (Ruan et al., 2009; Balser et al., 2001).  INaP current roles were only 
identified after “gain of function” mutations in the SCN5A gene resulted in long-QT syndrome 
type 3 (LQT3) (Wang et al., 1995; Bennett et al., 1995).  Interestingly, LQT3 patients are also 
at high risk for AF (Benito et al., 2008; Darbar et al., 2008).  Point mutations in the SCN5A 
gene may lead to life-threatening arrhythmias highlighting the importance of Nav1.5. channel 
in the heart (Zimmer and Surber., 2008).  Most of these mutations reported to disrupt the 
inactivation of NaP channel, impairing the ability of the channel to close completely and thereby 
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generating INaP current which further leads to APD prolongation and arrhythmogenesis.  Also, 
patients carrying mutations in the SCN5A gene are more prone to arrhythmias (both atrial and 
ventricular) and in extreme cases to Brugada syndrome, in which fibrillation may lead to death 
(Bennett et al., 1995; Kapplinger et al., 2010).     
Figure 1.6. Voltage gated Na+ (Nav) channel structure.  Schematic diagram of the structure and membrane 
topology of the voltage-gated sodium channel showing the main regulatory sites. Given a-subunits have four 
domains (DI–DIV) each composed of six transmembrane segments. Within the latter, segment four contains 
positively charged amino acids and this is the main voltage-sensitive region; the loop between transmembrane 
segments 5 and 6 is negatively charged and forms the pore region (Fraser et al., 2013). 
 
Although Nav1.5 underlies the majority of INa, other “non-cardiac” isoforms may make up an 
important part of cardiac INa. In particular, the nerve/brain isoforms Nav1.1, Nav1.6 and Nav1.8 
which may underlie an important part of INaP in human heart (Zicha et al., 2004; Asatryan and 
Medeiros-Domingo., 2007; Yang et al., 2012; Mishra et al., 2015).  The Nav1.1 channel subtype 
is broadly expressed in the central nervous system (CNS) but was also later identified in the 
heart, with greater expression in the ventricles than the atrial region.  Nav1.1 expression was 
observed in failing ventricular cardiomyocytes, along with Nav1.5 and Nav1.6 channel 
subtypes and found to contribute to INaP current in failing hearts (Mishra et al. 2014).  Mutation 
of the SCN1A gene (encodes the Nav1.1 channel subtype) resulted in complex changes in 
Nav1.1 channel gating, including depolarising shift in the voltage dependence of inactivation, 
accelerated recovery from inactivation and increased INaP current leading to hyperexcitability 
of the cells (Cestele et al., 2008).  In addition, despite the expression of Nav1.6 channels in a 
variety of cell types (i.e. Purkinje cells, excitatory motor neurons and glial cells) have also been 
identified in both atrial and ventricular myocytes (Caldwell et al., 2000; Kearney et al., 2002). 
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Nav1.6. channel subtype reported to generate INaP current in the heart, hence its mutation can 
similarly cause defects in NaP channel inactivation gating leading to generation of arrhythmias 
(Eijkelkamp et al., 2012).  Recently, a de novo pathogenic SCN8A gene (encoding Nav1.6. 
channel subtype) mutation demonstrated to be associated with a greatly increased INaP current 
and was shown to disrupt ventricular AP propagation and E-C coupling in mice (Veeramah et 
al., 2012; Noujaim et al., 2012).  Furthermore, although it has been established that the Nav1.8. 
channels are expressed and have a clear function in sensory neurons, recent studies have also 
shown that are expressed in cardiomyocytes where they act as NaP channels (Zimmer et al., 
2004). This implies that even the identity of the key channel subunits for INaP in cardiomyocytes 
is still unclear and under investigation.  
1.4.2.1. Persistent Na+ (NaP) channel openers and inhibitors  
Given the functional importance of NaP evident from the effects of various Na
+ channel gene 
mutations on cardiac contractile activity, specific blocking of these channels might be a useful 
way of understanding them and allow insight on the pathologies that their dysfunction harbours.  
(Lampl et al., 1998; Maltsev et al., 1998; Moreno and Clancy 2012; Yang et al., 2012; Shryick 
et al., 2013).   
In experimental settings, toxins have been extremely useful in understanding the structural and 
molecular determinants of NaP channels, through their modifying actions on the gating of the 
channels (Catterall et al., 2007).  At least six different toxin target-binding sites have been 
identified on specific regions of the Na+ channels.  Binding of the toxin to these sites will affect 
the ion conduction or gating of the channel, as well as sequence differences in the residues 
involved contributing to subtype specificity (Catterall, 2000).  Anemone toxin II (ATXII) 
belongs to the Anemonia sulcata neurotoxin family along with ATXI and ATXIII neurotoxins.  
ATXI and ATXII paralysing toxins have shown to cause cardiotoxic and neurotoxic effects, 
whereas ATXIII causes muscular contraction with subsequent paralysis.  ATXII is highly 
potent at Na+ channel subtypes, Nav1.1 and Nav1.2, as it was shown to interact with amino acid 
residues on their transmembrane loops affecting the channel’s activity in rats (Rogers et al., 
1996).  However, recent studies reported ATXII effect involvement on Nav1.5. channel gating, 
in addition to binding specificity on Nav1.6. channels (Wanke et al., 2004; Karan et al., 2017; 
Elies et al., 2014; Spencer., 2009).    
ATXII major mode of action is through delaying the inactivation of the NaP channel by slowing 
the conformational changes required its closure, this is achieved by binding of ATXII across 
the extracellular loop of the channel domains (Chapman 1979).  The function of ATXII to 
inactivate the Na+ channels, hence the ATXII-induced prolongation in APD could be linked to 
the entry of extra Na+ ions during the plateau phase of AP, via prolong opening of the NaP 
channels (Chapman 1979).  A prolonged NaP channel activity contributes to the elevation of 
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intracellular [Na+] observed during atrial arrhythmias resulting in increased [Ca2+]i overload, 
and subsequent generation of cardiac arrhythmias (Murphy et al., 1991).  Experimental findings 
demonstrated APD prolongation by ATXII treatment in cultured embryonic chicken cardiac 
muscle cells, providing further evidence of its actions on specific Na+ channels and its 
downstream function in controlling the generation of AP (Romey et al., 1980).   
However, ATXII activity can be blocked by the NaP channel inhibitor, Ranolazine.  More 
specifically, Ranolazine has been shown to reverse the sustained rise in diastolic and systolic 
Ca2+ caused by ATXII, in addition to recovery of abnormal heart rhythm observed after ATXII 
intervention (Song et al., 2004; Fraser et al., 2006).  Experiments done from canine to guinea 
pig hearts showed that Ranolazine causes a concentration, voltage, and frequency-dependent 
inhibition of INaP current in cardiac myocytes (Antzelevitch et al., 2004).  The major mechanism 
of action of Ranolazine is to inhibit INaP in the heart, thus preventing cellular Na
+ overload (by 
preventing the reverse mode of NCX), leading to a decrease in intercellular [Ca2+] and Ca2+ 
loading in SR; hence preventing abnormal heart contraction (Hayashida et al., 1994; Sossalla 
et al., 2007).  In addition, Ranolazine is reported to inhibit INaP current with greater potency 
than it inhibits other ion currents (i.e. K+) which highlights its potency as a selective NaP channel 
inhibitor (Antzelevitch et al., 2004).   
Other NaP channel blockers currently available include tetrodoxin (TTX), lidocaine, mexiletine, 
and flecainide.  TTX blocks skeletal and neuronal muscle isoforms of Na+ channels with greater 
potency than it blocks Nav1.5 channel cardiac subtype (Heinemann et al., 1992).  Nevertheless, 
TTX reported to inhibit persistent AF with greater potency than peak Na+ currents (Wu et al., 
2009).  Drugs such as lidocaine, mexiletine and flecainide are also prototypical Na+ channel 
blockers that reported to inhibit cardiac INaP , however their efficacies for blocking persistent 
versus peak Na+ currents, and specificity for binding to Na+ channels relative to other proteins 
is currently unknown (Le Grand et al., 2008).  
1.4.3. Abnormal AP conduction: role of gap junctions 
The other contributor of atrial arrhythmias is based on abnormal AP propagation due to slowed 
conduction velocity across the heart.   AP conduction velocity is a function of gap junction 
electrical conductance (Gj)
 and its decrease would slow AP conduction velocity within the 
atrium (Dhillon et al., 2013).  Gap junction conductance is a product of the number of gap 
junction channels and their open probability.  This section aims to provide a background on gap 
junctions; functional properties and its role in normal and abnormal AP propagation in 
myocardium.                  
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1.4.3.1. Structure of gap junctions 
Gap junctions are low-resistance intracellular channels which provide direct cytoplasmic 
continuity between adjacent cells, allowing transmission of ionic and electrical currents, as well 
as small metabolites from one cell to another (Herve and Dhein., 2006).  Gap junctions are 
located at the intercalated discs in the myocardium allowing rapid electrical cell-to-cell 
coupling required for successful spread of electrical activity across the heart, and the precise 
electrical conductance provided is therefore essential in regulating AP conduction velocity.  The 
half-life of gap junctions is relatively short (1-5 hours) and a consequent high turnover rate in 
comparison to most functional and structural proteins, however the precise reason regarding 
this phenomenon has not yet been fully elucidated (Segretain and Falk, 2004). 
Gap junction is composed of connexins (Cx) serine-rich transmembrane phosphoproteins.  
Connexins are most commonly referred to as an abbreviated Cx followed by their molecular 
weight in kD, for example 40 kD variant is known as Cx40.  The life-cycle of connexins 
(synthesis, trafficking, gap junction channel formation and degradation) has been widely 
studied (Segretain and Falk, 2004).  Connexins (Cxs) are synthesised at the endoplasmic 
reticulum (ER) and then translocated to Golgi apparatus in order to oligomerise into a 
hexameric Cxs (Segretain and Falk, 2004).  The Cxs via membrane vesicles are then transported 
into the plasma membrane where they form a functional channel with its neighbouring cell.  
Connexins are formed of four transmembrane α-helices and two extracellular loops (Shol, G. 
2004).  These consist of cysteine residues allowing the disulphide bond formation which is 
needed for docking at the adjacent cell and hence, hemichannel formation.  The assembly of six 
Cxs into a hexameric structure forms a connexon or a hemichannel (Segretain and Falk., 2004).  
The combination (one inserted into either membrane of each of the neighbouring myocytes) of 
two connexons create the gap junctions by producing a low resistance pathway between the two 
cells (Figure 1.7.).   
Homomeric connexons comprised of only one Cx subtype, for example a homomeric Cx40 
connexon is formed with six Cx40 subunits, on the other hand, heteromeric Cx40 connexon 
comprised at least two different Cx subtypes.  Homotypic channels are the channels where both 
connexons are identical, made up with either single Cx subtype or the same configuration of 
different Cx isoforms.  Heterotypic channels are the channels where the constituent connexons 
are not of identical connexin subtype composition (Cottrell and Burt, 2005).  The magnitude of 
possible Cx subtype configurations marks the importance of gap junction complexity.  In atria, 
the most common Cx pairing is Cx43 and Cx40, a result of their dual expression (Cottrell and 
Burt, 2001; Jabr et al., 2016). 
 
Chapter 1. Gap junctional proteins 
 
17 | P a g e  
 
 
 
 
 
 
 
 
Figure 1.7. Gap junction (GJ) channel and its components.  The connexin is the single protein unit of a GJ 
channel.  The connexon is a hexamer of connexins which docks into the plasma membrane of one cell, together 
with a connexon of an adjacent myocyte forming a functional GJ allowing passage of small metabolites and ionic 
currents (Modified from Genet et al., 2018).     
 
Twenty different connexin protein isoforms exist in the mouse species and twenty-one in human 
(Willecke et al., 2002; Sohl and Willecke, 2004).  Expression of Cx isoforms is chamber and 
tissue specific, playing a pivotal role in myocardial intercellular conductance and 
communication through gap junctions.  From the plethora of Cxs, Cx40, Cx43 and Cx45 are 
expressed in the gap junction channels of the heart, with Cx43 having the greater abundance 
and distribution across the myocardium (Marquez-Rosado et al., 2012) (Figure 1.8.).  Atrial gap 
junctions composed mainly Cx43 and Cx40 isoforms, in a relatively similar abundance, and in 
less extent Cx45 (Vozzi et al, 1999; Lin et al., 2010).  The ventricles however, express 
predominantly Cx43 as they lack Cx40.   
 
 
 
 
 
Figure 1.8. Connexin (Cx) expression localisation in the heart.  Typical human cardiac Cxs patterns of 
expression.  In both left and right atrium Cx distribution is quite similar, with Cx43 been the highest and Cx45 
been the lowest (Severs et al., 2017).       
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1.4.3.2. Altered connexin expression and distribution in cardiac pathologies  
Remodeling of gap junctions and alteration to Cxs result in conduction abnormalities and 
subsequent cardiac pathologies.  Altered connexin expression or changes to its phosphorylation 
state as a proarrhythmic substrate has been widely studied (Severs, 1994; Peters et al., 1995; 
Severs et al., 2006; van Rijen et al., 2006; Saffitz et al., 2007; Severs et al., 2008; Chaldoupi et 
al., 2009; De et al., 2011).  The contribution of Cxs to cardiac AP conduction and hence function 
have been shown using specific Cx knock-out mice models.  For example, the cardiac specific 
Cx43 null and conditional knock-out mice (Cx43 -/-) have been shown to develop lethal 
ventricular arrhythmias (Gutstein et al., 2001; Danik et al., 2004).  In neonatal Cx43 
heterozygotes (Cx43-/+), the conduction velocity was slowed only in the ventricles, where Cx43 
is the predominant isoform, but the atrial conduction velocity was similar to that of wildtype 
mice (Cx43 +/+) (Thomas et al., 1998).  
Down-regulation and abnormal cellular expression and distribution of Cx43 mediate with the 
disturbed AP in several cardiac pathologies, including AF, myocardial ischemia, ventricular 
hypertrophy and hypoxia (Dhein et al., 2011, Severs, 1994, Sepp et al., 1996, Solan et al., 2007).    
Dhein and colleagues reported increased Cx43 expression in AF patients (Dhein et al., 2008).  
Remodeling of Cx40 has also been identified in atrial events (such as AF), with enhanced Cx40 
expression observed in post-operative AF patients (Dupont et al., 2001).  Given that the 
alterations in the expression and localisation of Cx may vary within the disease progression, 
also gained great interest for investigation in this thesis (Akar et al., 2007). 
1.4.3.3. Modulation of gap junction and connexins: Role of Calcineurin 
Gap junction are modulated by several factors, in particular ions concentration, connexin 
protein phosphorylation states and gap junction blockers (Dhein, 2004; Herve and Dhein, 2006; 
Marquez-Rosado et al., 2012).  Gap junctions are modulated by concentration of intracellular 
ions, including Ca2+ and H+ under physiological and pathophysiological conditions (Dhein, 
2004; Peracchia, 2004).  A rise in intracellular [Ca2+] 320-560 nM reported to reduce the 
conductance of gap junctions in ventricular myocardium of guinea pig hearts.  Elevated 
intracellular [Na+] may also result in reduced gap junction conductance because of increased 
intracellular [Ca2+] through the (NCX) (De Mello, 1976).     
A significant mechanism of alteration to gap junction properties is through changes to their 
phosphorylation state.  Phosphorylation and/or dephosphorylation of connexin proteins, occurs 
predominantly on serine residues but also some threonine sites, through the activity of serine/ 
threonine protein kinases (PKs) such as PKA and PKC, and protein phosphatases (PPs) such as 
Calcineurin, PP1 and PP2A (Herve and Dhein., 2006).  Changes to phosphorylation state of 
connexins may lead to both physiological and pathological functions, including life-cycle 
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regulation, turnover and open probability, gap junction conductance and intercellular 
communication (Herve et al., 2004; Solan and Lampe, 2005; Herve and Dhein, 2010; Burstein 
et al., 2009).   
Cx43 has been gain great attention due to its predominance in the heart and significant role in 
facilitating intercellular communication in addition to its abundance of identified sites that may 
be phosphorylated (Cooper et al., 2000; Huang et al., 2011). Twenty-One Cx43 phosphorylation 
sites have been identified in the C-terminus of Cx43, nineteen of which were serine residues 
and two tyrosine residues, with serine 368 (Ser368) residue been the most commonly studied.  
This is due to the reported association of Ser368 with reduced AP conduction (Jabr et al., 2016).  
Ser368 and Ser365 have been identified as mutually regulated in an opposing fashion, for 
example, when Ser365 is phosphorylated Ser368 is dephosphorylated and vice versa (Jabr et 
al., 2016; Solan et al., 2007).  It has been demonstrated that Cx43 phosphorylation at Ser368 
occurs through PKC-dependent pathway (Jabr et al., 2016; Solan et al., 2003). Under 
physiological conditions, Cx43 is phosphorylated at Ser365 maintaining the function of Ser368 
by inhibiting its phosphorylation from protein kinase C (PKC) (Solan., 2009).  This will activate 
the gap junction and allows them to remain open resulting in normal electrical conductance.  
Whereas, under raised intracellular [Ca2+] pathological conditions (such as the ones observed 
in atrial arrhythmias), Cx43 is phosphorylated at Ser368 site by PKC resulting in closure of gap 
junctions, which decreases cellular communication and inhibits electrical conductance (Solan 
and Lampe., 2005).  Changes in Cx40 phosphorylation status equally leads to disruption of gap 
junctional electrical conductance.  Phosphorylation of Cx40 by cAMP-dependent pathways and 
alterations in channel properties (i.e. electrophoretic mobility) are likely to be mediated by 
PKA, but other kinases and/or phosphatases may also play key role in regulating Cx40 channel 
function in the heart (Rijen et al., 2009).   
Few studies investigated the effect of specific serine/threonine PPs on connexin 
phosphorylation (Chu et al., 2004; Jeyaraman et al., 2003; Totzeck et al., 2008).  The 
serine/threonine PPs are classed into two main groups PP1 and PP2.  PP2 is further subdivided 
into PP2A, PP2B (also known as calcineurin) and PP2C.  Calcineurin (CaN) is most commonly 
known as the Ca2+-dependent phosphatase, while PP2C is Mg2+-dependent.  Calcineurin protein 
phosphatase, is a heterodimer composed of a catalytic subunit (CnA; 60 kDa) and a smaller 
regulatory subunit (CnB; 19 kDa) (Shou et al., 2015).  The CnA subunit, further contains an N-
terminal catalytic domain, a CnB binding domain, a calmodulin (CaM) binding domain and a 
C-terminal autoinhibitory domain (AID) (Figure 1.9.).  Whereas, the CnB regulatory subunit 
contains four EF-hand Ca2+ binding sites (Shou et al., 2015).  Binding of Ca2+ to the regulatory 
sites of CaN, initiates a series of conformation changes that allow binding of Ca2+/CaM complex 
and a change in AID orientation in order to expose CaN active site, yielding to a constitutively 
active phosphatase (CnA).  
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Figure 1.9. Calcineurin structure, activation and inactivation. Calcineurin (CaN) composed of two subunits; 
CnA catalytic subunit (60 kDa) and CnB regulatory subunit (19 kDa).  The CnA subunit contains a catalytic 
domain on the N-terminal region, a CnB binding domain, a calmodulin (CaM) binding domain, and an 
autoinhibitory (AID) domain on the C-terminal region.  The CnB subunit contains four Ca2+ binding EF-motifs 
with high Ca2+ affinity.  Raised intracellular Ca2+ concentration results CaN activation, by forming a heterodimer 
with CaM (Ca2+/CaM) which leads to changes in AID orientation and subsequently exposure of CaN active site.  
Calcineurin autoinhibitory peptide (CAIP), which corresponds to the AID, binds to and completely inhibits CaN 
phosphatase activity (Modified from Shou et al., 2015).   
 
Calcineurin activation was reported as a result of elevated levels of intracellular [Ca2+] and 
calmodulin (CaM) which are associated with atrial arrhythmias in animals and with chronic AF 
in patients (Jabr et al., 2016).  Ca2+/CaM calcineurin activation was shown to cause 
dephosphorylation of Inhibitor 1 (I1) at Threonine 35 (Thr35).  This will facilitate protein 
phosphatase 1 (PP1) dissociation from I1, which under control conditions are expressed as a 
complex.  The dissociation of PP1 from I1 results in PP1 activation to induce Cx43 
dephosphorylation at Ser365 site, and further expose the Ser368 residue to PKC-induced 
phosphorylation, hence reduce gap junction conductance which is considered arrhythmogenic 
(Jabr et al., 2016).  Cx43-Ser368 phosphorylation by PKC was shown to be equally mediated 
by protein phosphatase 2A (PP2A) via initial Cx43-Ser365 dephosphorylation.  Interestingly, 
raised intracellular [Ca2+] also reported to increase Cx40 phosphorylation levels and such 
change was solely mediated by calcineurin with partial involvement of PP2A (Hatch et al., 
2015).  In addition, upon increase of the intracellular [Ca2+] through manipulation of the NCX 
using low Na+ solution, resulted in slowed conduction in a calcineurin-dependent manner (Jabr 
et al., 2016).  Jabr et al (2016), also showed increased Cx43 dephosphorylation in the left 
ventricular papillary muscle under elevated intracellular [Ca2+] and reduced conduction (Jabr 
et al., 2016).  Taken together these findings, suggest that the slowed conduction observed is a 
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result of increased intracellular [Ca2+] modulating Cx43 thereby increasing gap junction 
resistivity during cardiac events, such as AF. 
A plethora of immunosuppressant drugs are available to inhibit calcineurin activity, including 
cyclosporin A (CsA), tacrolimus (known as FK-506) and calcineurin autoinhibitory peptide 
(CAIP).  Both CsA and FK-506 require immunophilin binding proteins, such as cyclophilins 
and FKBP12 respectively, in order to form a heterodimer that can bind to the active site of 
calcineurin and inhibit its enzymatic activity (Liu et al., 1991).  On the other hand, CAIP is a 
peptide sequence corresponding to the autoinhibitory domain of calcineurin, where it binds and 
completely inhibits its phosphatase activity (Figure 1.8.) (Terada et al., 2003).  Compare to the 
native domains, binding of CAIP is not relieved upon sustained elevation of intracellular [Ca2+] 
levels, which trigger Ca2+/CaM activation (Jabr et al., 2016).  CAIP has demonstrated to exhibit 
stronger inhibitory effect on calcineurin phosphatase activity, than the rest immunosuppressant 
drugs marking it as a selective calcineurin inhibitor to use.  Considering that Cx 
phosphorylation status is modulated by various protein phosphates and kinases, understanding 
these proteins will allow further insight on the pathologies that their dysfunction harbours. 
Interestingly, AF has been shown to most likely occur at certain times of the day, namely in the 
early morning hours, whereas ventricular arrhythmias occur during the day (Viskin et al, 1999; 
Jeyaraj et al., 2012). Studies reported that atrial arrhythmias demonstrate significant daily 
rhythmic patterns, referred to as diurnal variations, thus suggests a correlation between atrial 
clock genes (driving these patterns) and the intracellular mechanisms underlying AF; irregular 
cardiac AP propagation caused by alterations in Cx expression and/or phosphorylation status, 
or ion homeostasis (Huikuri et al, 1995; Jeyaraj et al., 2012).  Recent evidence demonstrated 
that connexins, in addition to ion channels, involved in facilitation of abnormal propagation of 
AP and cardiac contraction, also exhibit time-of-day-dependent oscillations in mouse heart.  
However, less is known about their expression, as well as, involvement in diurnal occurrence 
of atrial-related pathologies that are associated with (Tong et al., 2016).   
1.5. Circadian rhythms 
Circadian (~24 hour) rhythms are endogenously generated timing systems that coordinate 
behavioural, physiological and biochemical processes within the 24-hour light/dark 
environment (Schibler., 2005).  Circadian rhythms are entrained to the external environment by 
cues termed zeitgebers (Albrecht., 2002; Kalsbeek et al., 2006; Merrow et al., 2005; Schibler., 
2005; Reyes et al., 2008).  The most common zeitgeber across species is light, with organisms 
responding and entraining to photic cues, whereas non-photic zeitgebers include food supply, 
temperature, exercise and atmospheric conditions (Merrow et al., 2005).  Circadian rhythms are 
generated by cellular molecular clocks. The mammalian circadian clocks can be divided into 
two major classes: the central and peripheral circadian clocks (Karaganis., 2011).  The central
Chapter 1. Circadian rhythms 
 
22 | P a g e  
 
circadian clock, which is also known as the “master clock”, is found within the suprachiasmatic 
nucleus (SCN) of the hypothalamus located in the brain, whereas all the other clocks (including 
in the heart) are called peripheral (to the master clock).  In humans, circadian rhythmicity 
controls sleep/wake cycles, thus time of activity and rest, and hormonal daily fluctuation. For 
example, cortisol shows increasing concentrations at the start of the wake period, acting as an 
alerting signal to begin the day (Buckley and Schatzberg., 2005). Another example is insulin 
sensitivity, which shows marked reduction at night; at a time when we would normally not be 
feeding (Morgan et al., 1998). Thus, the body is able to predict changes over the course of the 
day and alter its physiology accordingly.  
Growing evidence show that intrinsic circadian clocks are also tightly related to cardiovascular 
functions and that pathology also exhibits circadian rhythmicity.  The blood pressure and heart 
rate cardiac physiological parameters are well known to demonstrate significant daily rhythmic 
patterns; diurnal variations.  In addition, the onset of many cardiovascular events or diseases 
reported to exhibit temporal trends aswell. For instance, in humans the myocardial infraction 
(MI) incidences tend to be higher during early morning hours (06:00 - 12:00 am), just as patients 
arise from bed (Muller et al., 1985; Maemura et al., 2007). Similar early morning prevalence 
was reported from patients suffering from ventricular arrhythmias, ischemic strokes and sudden 
cardiac death (Argentino et al., 1990; Tofler et al., 1995; Kong et al., 1995; Simantirakis., 2001; 
Mahmoud et al., 2011).  The occurrence of such events during early morning hours is linked 
with the increase in blood pressure due to a circadian reduction in arterial wall dilation at similar 
time, as well as with the simultaneous increase of platelets accumulation and subsequently the 
development of thrombosis in the early morning hours (Muller et al., 1989).   
In terms of atrial arrhythmias, such as atrial fibrillation (AF), even though the circadian 
variation patterns have been less studied possibly due to their relatively benign nature, reported 
to exhibit diurnal patterning with higher frequency at 12:00 - 02:00 am, which poses an 
increased threat to individuals suffering from cardiovascular diseases (CVDs).  This high risk 
is possibly associated and/or driven by a disrupted circadian clock, hence highlighting possible 
involvement and/or contribution of core genes driving it, in particular Bmal1, to AF occurrence.  
In addition, there is a strong evidence from animal models and epidemiological studies showing 
that circadian rhythms disruption act as a significant risk factor for CVDs, and the intervention 
of such cardiac events may have a time-dependent effect (Young et al., 2016).  However, despite 
the known expression of Bmal1 in other mammalian tissues (i.e., liver, kidneys, pancreas) and 
its involvement in pathological conditions (i.e., hypertension, diabetes, obesity), little is known 
about its circadian expression in the heart and more specifically in atrial region.  Interestingly, 
circadian rhythmicity and involvement of clock genes have been proposed in atria by van der 
Veen et al., (2012), who reported Period 1 and Period 2 clock gene mRNA expression in mouse 
atrial explant culture cells, with the Period 2 exhibiting circadian expression and rhythmicity.
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This further enhance the importance for investigation of core clock genes (in particular Bmal1) 
expression and rhythmicity in the atria and its association with atrial-related pathologic events. 
1.5.1. Master & peripheral clock 
The SCN are a pair of nuclei in the hypothalamus that are located above the optic chiasm and 
house the master pacemaker.  SCN comprised of densely packed neurons and is subdivided into 
ventral and dorsomedial regions.  The ventral region, which is also known as core, receives 
direct photic input via the retinohypothalamic tract (RHT), as well as indirect photic input from 
the intergeniculate leaflet (IGL). In comparison, the vasopressin-containing neurons 
dorsomedial area does not receive substantial visual input.  Evidence have shown that the SCN 
is the central pacemaker in mammals, as not only SCN lesions result in behavioural and 
physiological rhythms loss, but cells of the SCN neurons still exhibit circadian patterns of 
electrical activity (Moore and Eichler., 1972; Stephan and Zucker., 1972; Green and Gillette., 
1982; Groos and Hendriks., 1982).  A study by Lehman et al., (1987) also reported that 
transplantation of embryonic SCN can restore the rhythmicity in rodents with SCN lesions.  
Additionally, reinstated rhythms always exhibit the donor genotype periodicity, irrespective of 
the genotype of the host, illustrating that the basic period of the endogenous circadian rhythm 
is dictated by the SCN (Ralph et al., 1990).   
SCN entrainment to the solar day requires a functional retina, and is achieved directly via the 
RHT or indirectly via the IGL (De Haro and Panda., 2006).  Day light is perceived by opsins in 
rods and cones, as well as the recently identified non-visual photopigment melanopsin located 
in the intrinsic photosensitive retinal-ganglion cells (ipRGCs) in mammals which project 
directly to the SCN (Karaganis., 2011).  All these photoreceptors aid in the reset of the central 
circadian clock located there.  The ipRGCs contain the photopigment melanopsin and their 
signals also transverses over the RHT direct pathway leading to SCN (Cassone et al., 1987).  
During the day, light depolarises the ipRGCs, activates the RHT and result in glutamate release 
from the RHT nerve terminals (Foster and Hankins., 2007).  This subsequently cause activation 
of the SCN cells via N-methyl-D-aspartate (NMDA) receptors and increases firing rate in the 
SCN ventral neurons.  Such neurons will synchronise the signals among SCN neurons and 
couple the dorsomedial and ventral regions within the SCN (Hastings et al., 2003).  Activation 
of SCN receptors also results in downstream binding of promoter elements to core clock genes 
(Aryl hydrocarbon receptor nuclear translocator-like protein 1; Arntl, also known as Bmal1, and 
circadian locomotor output cycles kaput; Clock), and subsequently to light induced clock gene 
expression (Etchegaray et al., 2002; Kuhlman and McMahon, 2006)   
The presence of a morning and evening oscillator (light/ photic input) in the SCN provides 
information to the clock regarding photoperiod (Pittendrigh and Daan., 1976; Cassone et al.,
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1987).  In addition, the SCN regulates a variety of physiological parameters by receiving neural 
and hormonal inputs, including feeding/fasting, core body temperature, sleep/wakefulness, 
plasma glucose concentrations, and hormone production (Cailotto et al., 2005; Stratmann and 
Schibler., 2006; Buhr et al., 2010).  Circadian molecular oscillators have also been found in 
many tissue types outside of the SCN, including the heart, lung, liver, kidney, adipose tissue, 
brain regions and ovaries (Shearman et al., 2000; Stratmann and Schibler., 2006; Ball., 2007; 
Buhr et al., 2010). These clocks are termed peripheral (to the master clock) and are proposed to 
regulate localised physiological processes (i.e., metabolism, blood pressure, heart rate), thereby 
enhancing the functional message of the master pacemaker in the SCN.  Peripheral clocks, 
unlike the SCN, are incapable of entraining to external light cues via the RHT due to the absence 
of visual input.  Studies have shown that peripheral clocks entrainment under normal conditions 
is achieved by humoral and neural signals release from the SCN, but also by a plethora of no-
photic signals such as food and temperature (Balsalobre et al., 2000; Balsalobre et al., 2000; 
Stratmann and Schibler., 2006; Kalsbeek et al., 2006; Buhr et al., 2010).     
Similar to Walsh et al., (1992) who demonstrated that neonatal rat SCN neurons exhibit cell 
autonomous rhythmic firing in vitro, peripheral tissue explants also retain rhythmicity in vitro; 
hence further supporting the feature of self-sustained rhythm in the absence of rhythmic input.  
With the use of a clock:luciferase fusion protein or Luciferase enzyme in mice, under the control 
of a circadian gene promoter as real-time reported of circadian characteristics, it was shown 
that SCN-lesioned animals exhibited oscillations in bioluminescence readings in heart, liver, 
lung and kidney regions and were stably maintained for 3-5 weeks (Yoo et al., 2004). 
1.5.2. Circadian clock synchronisation  
Synchronisation of cell populations offers a unique strategy to study the molecular as well as 
structural events taking place throughout the cell cycle.  It allows the exact study of individual 
cell cycle phases, the regulatory mechanisms which determine cell cycle regulation at the level 
of gene expression and protein post-translational modifications.  During the synchronisation 
process, cells are selected during different stages of the cell cycle and brought to the same phase.  
This will allow synchronisation of existing rhythms amongst adjacent cells and subsequently 
investigation of circadian changes across time.   
Circadian clocks of mammalian cell cultures can be synchronised by a plethora of experimental 
strategies. Their oscillators are sensitive to compounds activating virtually every signaling 
pathway tested to date (Balsalobre et al., 1998; Balsalobre et al., 2000; Aoi and Tsuchiya et al., 
2005).  The serum-shock technique is well-known to phase align the molecular clocks in 
individual cells and can be induced to synchronise existing rhythms amongst adjacent cells by 
provision of high serum concentrations (Balsalobre et al., 1998; Balsalobre et al., 2000; Nagoshi 
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et al., 2004).  It became one of the most popular in vitro approach methods to dissect the 
molecular mechanisms that comprise circadian rhythms.  Robust rhythms in clock gene 
expression have been demonstrated in serum-shock fibroblasts and tissue explants 
(Grundschober et al., 2001; Tamaru et al. 2003; Yoo et al., 2004; Noguchi et al., 2013).  
Balsalobre et al., (1998) used serum-shock technique to synchronise the circadian clock in 
immortalised rat fibroblasts (Rat-1), which involved a 2-hour incubation with high 
concentration horse serum followed by serum-free medium.  The Rat-1 fibroblasts were able to 
maintained in cell culture for enormous amount of time (over 25 years), and still exhibit an 
accurate circadian clock (Balsalobre et al. 1998).  Using Luciferase under the control of a 
circadian gene promoter in vitro, Balsalobre et al. (2000) also revealed that serum impulse 
causes transcription of Bmal1 gene followed by cyclic mRNA expression of other core clock 
elements (i.e., Period 1, Period 2, Cryptochrome 1, Cryptochrome 2, Rev-erbα).  Similar 
concept was also used by van der Veen et al., (2012) who reported for the first time Period 1 
and Period 2 circadian expression and rhythmicity in mouse atrial explant culture cells.  Hence, 
putting into map the investigation of further core clock genes in the heart and more specifically 
in the atria.  
Interestingly, serum pulse reported to synchronise previously oscillatory but de-synchronised 
cells across the culture.  Nagoshi et al., (2004) showed that oscillations in individual 
unsynchronised NIH-3T3 cells displayed robust but out-of phase bioluminescence recordings 
following the use of a reporter gene driven by a circadian promoter.  Following the provision 
of a serum pulse, synchronisation of intracellular rhythms across the culture was enable, even 
when the cells were out of phase (12 hours) with the new induced timing (Nagoshi et al., 2004).  
This mark serum-shock methodology a good way for understanding and examining robust and 
independent circadian rhythms of cells in culture.  Additionally, considering that the variability 
in periodicity of circadian rhythms (19.1-30.3 hours) in individual cells will lead to a gradual 
loss of rhythm synchronisation, the use of serum pulse is preferable to cell types that do not 
lack of intercellular coupling (Welsh et al., 2004).  Therefore, HL1-6 atrial myocytes cells of 
interest are in favour to such synchronisation technique due to their high gap junctional 
intracellular communication system that allows their simultaneous and spontaneous beating 
mimicking the heart function (Claycomb et al., 1998).  Thus, providing strong evidence for the 
use of serum-shock zeitgaber (external or environmental cue that entrains or synchronises) in 
this thesis.  
Although serum-shock promotes the immediate exprsion of clock genes (Bmal1, Clock, Period 
1, Period 2 etc) thereby altering their circadian expression profiles, other pharmacological 
stimuli, including the glucocorticoid receptor agonist dexamethasone and glucose have also 
been used in pulse experiments leading to similar responses (Balsalobre et al., 2000; Tsuchiya 
et al., 2003; Hirota et al., 2010).  Such stimuli reported to cause activation of intracellular 
kinases (i.e. PKA, PKC, MAPK) and subsequently activation of cAMP response element 
Chapter 1. Circadian clock synchronisation 
 
26 | P a g e  
 
binding protein (CREB) sequences localised in the promoter region of Bmal1 and Clock core 
clock genes (Hastings et al., 2003).  Moreover, the glucocorticoid receptor agonist 
dexamethasone is a very potent phase-shifting agent for tissue culture cells (Balsalobre et al., 
2000; Balsalobre et al., 2000).  Studies also shown that glucocorticoid hormones (cortisol) are 
an example for blood-borne factors with clock-resetting properties (Balsalobre et al., 2000; Le 
Minh et al., 2001; Dickmeis et al., 2007; So et al., 2008; Homma et al., 2015). The production 
of corticosterone/cortisone is under the control of the SCN and serum glucocorticoid levels 
display a robust diurnal rhythm.  In addition, the epinephrine and norepinephrine (NE) 
hormones also express clock-resetting properties (Morioka et al., 2010; O’Reilly et al., 2011; 
Li et al., 2015).  The use of NE, which is also essential for the initiation, proliferation and 
preservation of HL1-6 atrial myocytes beating in culture, described as a physiological zeitgeber 
for the circadian clock within adult rat cardiomyocytes (Claycomb et al., 1998; Durgan et al., 
2005). On the other hand, incubated adult rat cardiomyocytes with 10 µM of NE for 2 hours, 
reported to cause reactivation of the circadian clock in the cells which were also cultured in 
complete absence of serum throughout the whole experiment (Durgan et al., 2005).  However, 
considering the fact that similar synchronisation method was essential for direct comparison 
between the two investigated cell lines (HL1-6s and primary mouse embryonic fibroblasts; 
pMEFs), the use of NE (as a way of synchronisation) was not taken into consideration in order 
to avoid a possible interaction between the HL1-6 NE-cultured medium and NE-shock medium, 
as well as due to the absence of NE use in maintenance of pMEFs culture.  In addition, no 
studies are available regarding the use of NE as a way of pMEFs synchronisation, instead 
serum-shock effect is clearly stated in great success (Tamaru et al. 2003; Yoo et al., 2004).     
Furthermore, circadian rhythms can be entrained by low amplitude square wave temperature 
cycles and sustained by applying telemetrically recorded body temperature cycles to cultured 
rat fibroblasts (Hitraya et al., 1995; Brown et al., 2005; Tamaru et al., 2011; Xu et al., 2015; 
Blair et al., 2019). Interesting, the expression of Bmal1/Clock and Period2 can be induced by a 
heat shock itself, and two conserved heat shock factor 1 (HSF1) binding sites were identified 
in the Period2 promoter region allowing efficient facilitation of circadian rhythmicity (Reinke 
et al., 2008; Tamaru et al., 2011). Based on these observations, it is clear that there are several 
independent pathways that might cooperate in the synchronisation of peripheral clocks (and 
subsequently regulation of clock genes), however for the purpose of this thesis serum-shock 
method was widely used.  
1.5.3. Mammalian molecular oscillator – Role of BMAL1 
Whilst photic input to mammalian clock gene expression entrains the endogenous oscillator to 
external cues, the mechanism underlying this, is the molecular oscillator.  The molecular 
oscillator is comprised of a series of autoregulatory transcriptional/ translational feedback loops 
(TTFLs), the cycle length of approximately 24 hours.  Interestingly, similar core mechanisms 
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function in both the SCN and peripheral tissues (Yagita et al., 2001).  The core members of the 
positive feedback loop include basic helix-loop-helix (bHLH-PAS) proteins encoded by brain 
and muscle arnt-like protein 1 (Bmal1) and circadian locomotor output cycle kaput (Clock) 
(Gekakis et al., 1998).  Such proteins are transcription factors (TF) with a bHLH motif 
facilitating DNA-binding, and a PAS domain for protein heteromeric interactions (Edery., 
2000; Sehgal., 2004).  In mammals, the circadian clock mechanism is made up by at least three 
negative and a positive regulatory feedback loops that require translational, post translational 
and transcriptional events (Figure 1.10.).  BMAL1 protein plays a key role as one of the positive 
elements in the mammalian autoregulatory TFFL, which is responsible for generating 
molecular circadian rhythms.   
 
Figure 1.10. Intracellular molecular clock model. BMAL1 and CLOCK proteins heterodimerise in the nucleus 
marking the first regulatory feedback loop. The BMAL1/CLOCK complex translocate into the cytoplasm were it 
initiate the transcription of Period and Cryptochrome genes following binding to their E-box promoter region.  
The PER/CRY heterodimer, translocate back into the nucleus to repress their own transcription. BMAL1/CLOCK 
complex also binds the E-box of Rev-erbaα and Rorα genes similarly initiating their transcription. Once RORα 
protein is translated it activates BMAL1 protein expression, whereas REV-ERBα repress it (Modified from Chen 
et al., 2015). 
One of the negative regulatory feedback loops that is fully understood up to date implicates the 
period (PER) proteins encoded by three period genes (Per1, Per2, Per3), and the cryptochrome 
(CRY) proteins encoded by two cryptochrome genes (Cry1, Cry2) (King and Takahashi., 2000; 
Sun et al., 1998; Tei et al., 1997).  The BMAL1 protein encoded by the Bmal1 gene, 
heterodimerise with CLOCK protein forming a complex (CLOCK/BMAL1) in the cytoplasm 
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and then translocate into the nucleus (Gekakis et al., 1998; Edery., 1994; Ueda et al., 2005). 
Via its bHLH domain this heterodimer binds to the E-box response elements in the promoter 
regions of Per and Cry genes causing upregulation of the transcription and translation of PER 
and CRY proteins in the cytoplasm, contributing significantly to the activation of their 
expression (Muñoz and Baler., 2003).  Bmal1 mRNA expression peaks in the middle of the 
night, whereas Clock mRNA and protein is constitutively expressed throughout the circadian 
day and night.  Interestingly, Bmal1 it is a point of sensitivity within the clock gene regulatory 
network, as it is the only gene whose single knockout in a murine model that generates 
arrhythmicity at both molecular and behavioural levels in all tissues (Bunger et al., 2000; 
DeBruyne et al., 2007).  This suggests that BMAL1 is obligatory in some peripheral tissues to 
maintain rhythmicity. 
The most important regulatory mechanism of the CLOCK/BMAL1 transcription complex is the 
result of feedback inhibition from CLOCK/BMAL1 regulated output.  PER and CRY proteins 
do not possess bHLH regions to facilitate DNA binding, and thus influence CLOCK/BMAL1 
transcriptional activity without an attachment to their promoter region (Muñoz and Baler., 
2003).  Following translation in the cytoplasm, PER bind to CRY forming large multimeric 
complexes (PER/CRY) with other proteins, such as casein kinases (CKIε/δ) (Kume et al., 1999; 
Lee et al., 2001) (Figure 1.10.).  It is these multimeric complexes that are believed to be 
important in the negative loop of the clock mechanism.  Adequate production of PER/CRY 
levels drives their entry in the nucleus, where CRY interacts with CLOCK/BMAL1 inducing 
its post-translational modification and/or recruitment of co-repressors; hence blocks 
CLOCK/BMAL1 E-box-mediated gene transcription (Etchegaray et al., 2002; Kiyohara et al., 
2006; Sato et al., 2014; Bollinger and Schibler., 2014).  This results in repression of 
CLOCK/BMAL1 complex functionality and down-regulation of Per and Cry genes 
transcription, therefore their respective PER and CRY protein levels also drop shutting off their 
own transcription.  Such TTFL is modulated in the cytoplasm by phosphorylation of PER 
proteins by CKIε/δ, which signal these proteins for degradation (Buhr and Takahashi., 2013; 
Hastings et al., 2014).  Degradation of PER proteins prevent the formation of the large protein 
complex and thus prevents the inhibition of CLOCK/BMAL1 heterodimer transcriptional 
activity. The CRY protein is also signaled for degradation by FBXL3 protein, equally prevents 
the inhibition of the CLOCK/BMAL1 heterodimer and allows transcription of the Per and Cry 
genes to resume (Buhr and Takahashi., 2013).  This process occurs with a period length of 
approximately 24 hours and supports the notion that this molecular mechanism is rhythmic 
(Vanselow et al., 2006).  
In addition to the circadian regulatory TTFL described above, BMAL1 transcription is also 
regulated by competitive binding to the retinoic acid-related orphan receptor response element 
(RORE) and Dpb-binding sites within the Bmal1 promoter region (Ko and Takahashi., 2006). 
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In the nucleus, the CLOCK/BMAL1 complex binds to the E-box elements present in the 
promoter region of the genes that encode for the reverse of erythroblastic leukaemia virus α 
(Rev-erbα) and retinoid-related orphan receptor α (Rorα), causing upregulation of the 
transcription and translation of REV-ERBα and RORα proteins respectively. The REV-ERBα 
and RORα proteins regulate BMAL1 expression via a secondary feedback loop and compete to 
bind to Rev-erbaα/Rorα response elements in the Bmal1 promoter region resulting either in 
repression of BMAL1 expression by REV-ERBα or in activation of BMAL1 by RORα proteins, 
causing in that way alteration in nuclear BMAL1 protein levels (Preitner et al., 2002; Ko and 
Takahashi., 2006; Wang et al., 2003). Similarly, nuclear receptors of the same families 
including RORβ, RORγ and Rev-erbaβ have also shown to act on Bmal1 transcriptional activity 
(Liu et al., 2008; Guillaumond et al., 2005).  Bmal1 expression is inhibited until REV-ERBα 
has been degraded (Gallego and Virshup, 2007; Preitner et al., 2002; Wang et al., 2003). 
Despite the well-known targets of BMAL1 involved in driving robust circadian oscillation 
through the proposed feedback loops mentioned above, Hatanaka et al., (2010) uncovered 32 
BMAL1-binding sites on promoters, using chromatin immunoprecipitation-based systematic 
analyses and DNA microarray assay (Table 1.1.).  They revealed a significant proportion of 
BMAL1-target genes; all known as clock-controlled genes (CCGs) driven by E-boxes that 
encode central regulators of key physiological processes, however do not utilise the canonical 
CLOCK/BMAL1 core clock complex. This implies that these non-core circadian genes appear 
to be regulated by a combination of BMAL1 with other transcription factors for which many 
binding elements may exist on their promoter regions, hence utilise alternative pathways of 
regulation.  (Hatanaka et al., 2010).  
Table 1.1. Summary table of BMAL1-regulating genes 
BMAL1 target genes References 
Period 1, Period 2, 
Period 3 
Sun et al., 1997; Tei et al., 1997; King and Takahashi., 2000;  
Muñoz and Baler., 2003 
Cryptochrome 1, 
Cryptochrome 2  
Etchegaray et al., 2003; Kiyohara et al., 2006; Sato et al., 2006;  
Bollinger and Schibler., 2014 
Rev-erbα, Rev-erbβ Preitner et al., 2002; Ko., 2006; Wang et al., 2003; Gallego and Virshup,2007 
Rorα, Rorβ, Rorγ Preitner et al., 2002; Ko., 2006; Wang et al., 2003, Liu et al., 2008 
Crispld2 Hatanaka et al.,2010; Wittenbrink et al., 2018 
Nptn Hatanaka et al.,2010; Guillaumond et al., 2012 
Hlf Hatanaka et al.,2010; Yu et al., 2019 
Dbp Hatanaka et al.,2010; Dang et al., 2016 
Tef  Hatanaka et al.,2010; Yu et al., 2019 
Dec1, Dec2 Li et al., 2004; Hatanaka et al.,2010 
Rsad1 Hatanaka et al.,2010; Guillaumond et al., 2012 
Gm129 Hatanaka et al.,2010; Annayev et al., 2014 
Cops7b Hatanaka et al.,2010; Gaspar et al., 2017 
Thra Hatanaka et al.,2010 
Dlx2 Hatanaka et al.,2010 
Klf11 Hatanaka et al.,2010  
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1.5.4. Post-translational modifications (PTMs) 
Positive and negative feedback loops at the transcriptional and post-translational level influence 
the molecular core of circadian clocks function and rhythmicity, as it enables the clock to 
oscillate over 24 hours (Tamaru et al., 2003; Tomita et al., 2005; Tamaru et al., 2009).  This is 
achieved by altering cellular localisation of core oscillator components and/or by modifying 
their protein stability.  Among the different clock proteins, BMAL1 is the only one that 
undergoes an extensive repertoire of posttranslational modifications (PTMs) including 
phosphorylation, ubiquitination and acetylation (Table 1.2.).   
1.5.4.1. Phosphorylation 
Phosphorylation of BMAL1 regulates its fate, transcriptional activity and cellular localisation, 
and all is dependent on the protein kinase action; hence the targeted BMAL1 phosphorylation 
site.  Up to date, BMAL1 is subjected to multiple phosphorylation events directed by distinct 
kinases, which regulate its transcriptional activities (Eide et al., 2002; Ripperger and Schibler, 
2006; Tamaru et al., 2009; Robles et al., 2010; Tamaru et al., 2015).  For example, CKIε/δ 
reported to induce BMAL1 phosphorylation in human embryonic kidney 293 (HEK293) cells 
and mediate its transcription after nuclear entry, however the phospho-acceptor sites on 
BMAL1 have not yet been identified (Eide et al., 2002).  Additionally, CKIε/δ are essential 
PER kinases capable of phosphorylating PER proteins on multiple sites and targeting them for 
proteasomal degradation upon their high accumulation in the cytoplasm (Eide et al., 2005; 
Shirogane et al., 2005).  Lee et al., (2001) showed that PTM of PER/CRY complex enables its 
translocation to the nucleus. Phosphorylation of PER by CKIε/δ is associated with the nuclear 
localisation signal (NLS), whereas CRY is required in the complex for PER stability (Lee et 
Hbp1 Hatanaka et al.,2010 
Polr3f Hatanaka et al.,2010 
Hus1 Hatanaka et al.,2010 
Wdr36 Hatanaka et al.,2010 
Magoh Hatanaka et al.,2010 
Cdk4 Hatanaka et al.,2010 
Trub2 Hatanaka et al.,2010 
Alkbh3 Hatanaka et al.,2010 
Mrpl13, Mrpl21, Mrpl45 Hatanaka et al.,2010 
March9 Hatanaka et al.,2010 
Vps11, Vps33a Hatanaka et al.,2010 
Pex1, Pex13 Hatanaka et al.,2010 
Mtbp Hatanaka et al.,2010 
Krr1 Hatanaka et al.,2010 
Igsf8 Hatanaka et al.,2010 
Ttc35 Hatanaka et al.,2010 
Ighmbp2 Hatanaka et al.,2010 
C030048B08Rik Hatanaka et al.,2010 
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al., 2001).  Interestingly, CRY and CKIε/δ levels are constitutively higher than PER levels, 
therefore PER transcription or translation appears to be the rate limiting step in the circadian 
molecular clock cyclic process.  In contrast, CKIε/δ – mediated hyperphosphorylation above 
threshold targets the PER/CRY complex for degradation and reaches a zenith prior to 
breakdown.  Such process is negatively regulated by the Ca2+-independent protein phosphatase 
1 (PP1) – mediated dephosphorylation affecting PER circadian oscillatory expression pattern 
(Gallego et al., 2006; Vanselow et al., 2006).  Inhibition of PP1 in CKIε/δ deficient mouse 
embryonic fibroblasts, accelerated PER degradation resulting in BMAL1 overexpression, due 
to mishandling of BMAL1 acetylation and repression of the negative feedback loop (Lee et al., 
2011).  Whereas, the disruption of another Ca2+-independent protein phosphatase (PP2A), 
which is also known to induce PER dephosphorylation, had no effect on PER expression 
(Sathyanarayanan et al., 2004; Lee et al., 2011).  Additionally, a further study by Schmutz et 
al., (2011) reported a modest effect of PP1 inhibition on BMAL1 nuclear accumulation in 
mouse brain and liver, demonstrating that PP1 may induce epigenetic modifications on the 
transcriptional machinery resulting in changes of BMAL1 concentration.  Nevertheless, the 
association between Ca2+-dependent protein phosphatases and BMAL1 expression is currently 
unknown.   
Furthermore, in vivo and in vitro studies reported that CK2α rhythmically phosphorylates 
BMAL1 at Serine 90 (Ser90) residue and promotes its nuclear entry, which is essential for 
regulating the mammalian circadian clock (Tamaru et al., 2009). Interestingly, CK2α 
hyperphosphorylation of BMAL1 protein in CRY-deficient mice, propose that BMAL1 
modification contributes to CRY stability (Lee et al., 2001; Tamaru et al., 2003).  Mutation 
and/or depletion of CK2α-phosphorylation site on BMAL1 (Ser90) have an adverse effect on 
the nuclear BMAL1 circadian accumulation and result in impaired nuclear BMAL1 
accumulation and loss of circadian rhythmicity in HEK293 cells (Tamaru et al., 2009).  In 
addition, Dang et al., (2016) provide evidence that BMAL1 transcriptional activity is regulated 
by insulin, through a reduction of BMAL1 nuclear accumulation in mouse liver. The nuclear 
accumulation was altered via Akt-mediated Serine 42 (Ser42) phosphorylation in the liver; 
hence promoted BMAL1 accumulation in the cytosol and facilitation of protein synthesis.  A 
recent study by Young et al., (2017) showed that genetic disruption of the cardiomyocyte 
circadian clock resulted in subsequent changes in gene and protein expression of multiple 
insulin signalling components, leading to a chronic activation of the Akt/mTOR/S6K signalling, 
elevated BMAL1 protein synthesis in the cytosol and cardiac size, hence subsequent circadian 
disruption. 
Moreover, extensive proteomic analysis demonstrated that GSK-3β phosphorylates BMAL1 
specifically on Serine 17 (Ser17) and Threonine 21 (Thr21) residues, which phosphorylation, 
in turn, facilitates its ubiquitylation and the degradation required for the maintenance of stable 
clock oscillation (Sahar et al., 2010).  In mammals, GSK3β was also reported to cause PER2, 
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CRY2 and REV-ERBα phosphorylation, however appeared to have differential effect on the 
stability of the certain substrates.  On the other hand, similar to CLOCK protein, the CRY 
repressors stabilise BMAL1 by impairing its phosphorylation, which in turn blocks 
transactivation of the clock genes coupled with degradation of the transcription complex 
(Kondratov et al., 2006; Kwon et al., 2006; Dardente et al., 2007). Interestingly, a receptor for 
activated C kinase-1 (RACK1) was found to stimulate the phosphorylation of BMAL1 by 
protein kinase C alpha (PKCα), as this protein is recruited into the nuclear BMAL1 complex 
during the negative feedback phase of the circadian cycle (Robles et al., 2010).  On another 
note the detailed role of RCAN1 in calcineurin (CaN; Ca2+ calmodulin dependent protein 
phosphatase) signalling is a topic of ongoing debate. RCAN1 physically interacts with CaN, 
inhibiting its phosphatase activity in vitro, and blocks the activation of NFAT in cultured 
mammalian cell lines when over-expressed (Gorlach et al., 2000; Kingsbury and Cunningham., 
2000; Rothermel et al., 2001; Chan et al., 2005). Transgenic over-expression of RCAN1 in the 
heart diminished the cardiac hypertrophy triggered by expression of constitutively active CaN, 
by β-adrenergic receptor stimulation with isoproterenol, or by exercise, in each case presumably 
by depressing CaN-NFAT signaling pathway (Rothermel et al., 2001).  
Taken together all the studies mentioned above, it is far from clear that phosphorylation plays 
an important role in mediating the sub-cellular localisation and stability of BMAL1 core clock 
gene in a dimerisation-dependent manner, as well as interaction with the related kinases and 
co-regulators during the circadian and signal-regulated transcription of clock genes.  In 
addition, BMAL1 phosphorylation status is known to modulated by a plethora of protein 
kinases and phosphatases, however its association with Ca2+- dependent protein phosphatases 
and kinases in the heart remains elusive.    
1.5.4.2. Sumoylation 
CLOCK/BMAL1 nuclear accumulation is not circadian and therefore does not account for 
rhythmic gene transcription (Ripperger and Schibler, 2006). Despite the permanent attach of 
CLOCK/BMAL1 complex to E-boxes throughout the circadian cycle, BMAL1 exhibits 
circadian protein turnover (Lee et al., 2001).  Immunoprecipitation analysis has shown that 
BMAL1 is rhythmically modified by the small ubiquitin-related modifier protein (SUMO) in a 
CLOCK-dependent manner in vivo (Cardone., 2005; Stojkovic et al., 2014; Hirano et al., 2016).  
Following their binding to BMAL1 lysine residues (Lys259), found between the PAS domains 
of the CLOCK/BMAL1 heterodimer, SUMO proteins result in reduced BMAL1 stability and 
subsequent circadian degradation; hence regulation of the circadian clock.  Mutation of the 
target lysine residue (K259R) was shown to prevent sumoylation and stabilises the BMAL1 
protein, which in turn impairs the normal circadian rhythm of clock gene expression.  BMAL1 
was further shown to be mainly modified by SUMO 2/3, which is a prerequisite for its 
ubiquitination leading to proteasomal degradation during the transactivation stage (Lee et al., 
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2008; Lee et al., 2014). Given that phosphorylation also primes BMAL1 for its ubiquitin-
mediated degradation as mentioned above, the interplay between phosphorylation and 
sumoylation seems to underlie the transcription-coupled degradation of BMAL1 (Lee et al., 
2008; Sahar et al., 2010).   
1.5.4.3. Acetylation 
Circadian rhythms have also been found to be regulated by dynamic chromatin remodeling. For 
example, the rhythmic acetylation of histones H3/H4 in the chromatin region spanning the 
promoters of the clock genes (Per1, Per2 and Cry1) is coupled with their circadian transcription 
(Etchegaray et al. 2003; Naruse et al. 2004).  Histone acetylation and deacetylation modify the 
chromatin structure and thus regulate gene transcription by increasing or decreasing the DNA 
accessibility of the transcriptional apparatus (Vaissiere et al. 2008). Besides targeting histones, 
CLOCK also acetylates BMAL1 at Lys537 residue (Hirayama et al. 2007). Interestingly, the 
acetylation of BMAL1 by CLOCK promotes CRY recruitment, thereby inhibiting its 
transcriptional activity without altering its subcellular localisation, stability, phosphorylation or 
interaction with CLOCK (Hirayama et al. 2007). 
Table 1.2. Summary table of BMAL1 posttranslational modifications (PTMs) studies  
PTMs Target Target 
residue 
Target organ/ cell type References 
Phosphorylation CKIε/δ 
CK2α 
Akt 
GSK-3β 
RACK1/ 
PKCα 
PP1/ CK1ε/δ 
N/A 
Serine 90 
Serine 42 
Serine 17, 21 
Serine 133 
 
N/A 
 
Human embryonic kidney 293   
Mouse heart, cardiomyocytes 
Mouse liver, cardiomyocytes 
Human embryonic kidney 293   
Mouse embryonic fibroblasts 
 
Mouse embryonic fibroblasts 
Eide et al.,2002 
Tamaru et al.,2003 & 2009 
Dang et al.,2016; Young et al.,2017 
Sahar et al.,2010 
Robles et al.,2010 
 
Schmutz et al.,2011 
Sumoylation SUMO1 
 
SUMO2/3 
Lysine 259 
 
Lysine 259 
NIH3T3 mouse embryonic 
fibroblasts 
NIH3T3 mouse embryonic 
fibroblasts 
Bellet et al.,2010; Stojkovic et 
al.,2014;Hirano et al.,2016 
Lee et al., 2008; Lee et al., 2014 
Acetylation  Histone3/4 
 
CLOCK 
Lysine 4, 79 
 
Lysine 537 
Drosophila melanogaster Kc 
 
Mouse liver 
Etchegaray et al.2003; Naruse et 
al.2004; Vaissiere et al.2008 
Hirayama et al.2007 
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1.6. Circadian biology and Cardiovascular diseases  
There is a plethora of evidence linking the circadian clock to cardiovascular diseases (CVDs).  
Marked time-of-day-dependent oscillations in cardiovascular function are observed in 
mammals during the awake period, including increased heart rate, blood pressure and/or cardiac 
output (Richards et al., 1986; Degaute et al., 1991; Delp et al., 1991; Degaute et al., 1994).  
Adverse cardiovascular events (e.g. myocardial infarction, sudden cardiac death, arrhythmias) 
also exhibit a time-of-day-dependence in humans, with their onset being consistent during 
certain times of the day (Muller et al., 1989; Carson et al., 2000).  Disturbances in both daily 
rhythms and sleep are associated with increased risk of heart disease, adverse cardiovascular 
events and worsening outcomes.  For example, the importance of maintaining normal daily 
rhythms is highlighted by epidemiologic observations that night shift workers present with 
increased incidence of CVDs (Morgan et al., 1998; Hamma and Ilmarinen., 1999).   
Rhythmicity in cardiac processes is mediated by a complex interaction between extracardiac 
influences (e.g. behaviors and associated neural and humoral fluctuations) and intracardiac 
influences.  The oscillation of various neurohumoral factors (e.g. epinephrine, norepinephrine) 
over the course of the day may equally contribute to daily rhythms of physiological and 
pathological cardiovascular parameters, including heart rate, blood pressure and fibrinolytic 
activity (Muller et al., 1989; Scheer et al., 2010; Shea et al., 2011).  However, there is now clear 
evidence that during the day the intrinsic properties of the myocardium vary at the levels of 
gene and protein expression, metabolism, responsiveness to extracellular stimuli/stress, as well 
as ion homeostasis, all of which affect its contractility (e.g., heart rate and force generation) and 
likely contributing to the development of adverse cardiovascular events (Muller et al., 1989; 
Collins and Rodrigo., 2010; Durgan et al., 2010; Durgan and Young., 2010; Sachan et al., 2011; 
Young et al.,2014).   
The intrinsic mechanism that has emerged as a significant modulator of the responsiveness of 
cardiovascular-relevant cells in the intrinsic properties of the heart is the circadian clock 
(Young., 2009; Rudic and Fulton., 2009; Young et al., 2014; Martino and Young et al., 2015).  
In addition, the importance of this mechanism is further underscored by studies reporting that 
disruption of circadian clock through genetic manipulation (single gene knockout, double gene 
knockout and/or mutation), results in development of cardiac diseases and premature death in 
mouse model. 
1.6.1. Cardiomyocyte circadian clock 
A plethora of circadian clock components and output genes oscillate with a time-dependent 
manner in the heart (Young et al., 2001; Durgan et al., 2005).  The first ever study was 
conducted by Storch and colleagues (2002), who performed microarray analysis for the 
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comparison of liver and heart circadian transcriptome of a mouse model and reported that 
approximately 8 % of cardiac genes (462 genes) exhibited circadian oscillations (Storch et al., 
2002).  Another microarray analysis of the expression of rhythmic genes in murine atria and 
ventricles by Bray et al., (2007), demonstrated a surprising divergence in the number of CCGs 
expressed within the two tissues, with 548 genes exhibiting circadian transcriptional rhythms 
in the atria, compared to 176 genes in the ventricles.  Recently, Zhang et al., (2014) used a high 
temporal resolution of RNA-sequencing data and found that 4 and 6 % of clock protein coding 
genes showed circadian rhythms in mouse aorta and heart transcription, respectively.  
Additionally, in human hearts clock genes were reported to express in a time-dependent manner 
(Leibetseder et al., 2009).   
Consistent with the autonomous nature of the circadian clock, studies by Davidson and 
colleagues (2005), demonstrated persistent 24-hour oscillations in bioluminescence of ex vivo 
cardiac explants from transgenic rat models, in which luciferase expression was driven by Per1 
clock gene.  Interestingly, intact rat heart reported to express all known Cry and Per gene 
isoforms, with Cry2 being the predominant clock component, and Per1/2 isoforms expressed 
to a greater extent than Per3 (Kong et al., 1995).  Furthermore, Cry2 and Per1/2 clock 
components showed similar peak time of expression with similar absolute levels of expression 
relative to one another in intact rat hearts (Kong et al., 1995).  Transcript and protein levels of 
other clock components have also been reported to oscillate in in vitro cultured cell types 
present in the intact heart, following serum-shock cell synchronisation (Balsalobre et al., 1998; 
McNamara et al., 2001; Takeda et al., 2007; Durgan et al., 2005).  This includes, vascular 
smooth muscle cells, endothelial cells, fibroblasts and cardiomyocytes.  In cardiomyocytes, 
Bmal1, Per2, Rev-erbα clock genes and Dbp output genes reported to oscillate with a 
periodicity of 24 hours for approximately 3 days (Durgan et al., 2005).  Moreover, phases of 
these gene expression oscillations in vitro are identical to the ones observed in the intact heart, 
where Bmal1 clock gene oscillation is antiphase to Per2 and Dbp gene oscillations, fact also 
supported in the literature (Durgan et al., 2005; Martino et al., 2007). 
Despite the known expression of clock genes in the heart, little is known about the circadian 
expression of Bmal1 core clock gene in the cardiac compartments; atria or ventricles.  Circadian 
rhythmicity and involvement of clock genes have been proposed in atria by van der Veen et al., 
(2012), who reported Per1 and Per2 clock gene expression in mouse atrial explant culture cells, 
and the Per2 exhibiting circadian expression and rhythmicity, whereas Per3 had no response.  
This propose the importance of further investigation of clock genes (in particular Bmal1) 
expression and rhythmicity in the atria.  In addition, given that all cell types in the intact heart 
posses circadian clocks, it is possible that cardiac processes are influenced by clocks within any 
of these cell types.  
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1.6.1.1. Cardiomyocyte circadian clock: Role in Cardiovascular diseases 
Cardiovascular diseases reported to be associated with altered circadian clock gene expression 
in wildtype mice models.  Alterations in the expression of Per2 and Bmal1 circadian clocks 
have been demonstrated in hypertrophic rat models. Mohri et al., (2003) were able to show an 
association between hypertrophy and decreased amplitude of Bmal1 and Per2 circadian 
expression in the heart. Rhythmic expression of several circadian clock genes (Clock, Bmal1, 
Per1,2,3, and Cry1,2) in the heart were similarly observed in pressure overload rat models after 
constriction of ascending aorta (Young et al., 2001; Young et al., 20015). The effects of I/R 
injury on the expression of circadian clock genes in the rat hearts have also been investigated. 
Npas2, Per1,2,3, Cry1,2 and Rev-erba clock genes showed decreased peak expression, whereas 
Clock and Bmal1 exhibited a rapid and persistent peak expression in their oscillations within 
the ischemic region when compared to control (Kung et al., 2007; Dias et al., 2014). 
The contribution of the circadian clock mechanism in the plethora of clinically relevant 
cardiovascular conditions has been widely studied using transgenic, mutant, and knockout mice 
models.  For instance, mice lacking Bmal1 (Bmal1–/–) develop dilated cardiomyopathy with 
reduced cardiac contractility and disorganisation of the sarcomere; the basic contractile unit of 
the cardiac muscle, at the cellular level (Lefta et al., 2012).  In addition, simultaneous knockout 
of the Dbp clock output transcription factor contribute to the development of hypertrophic 
cardiomyopathy (Wang et al., 2010).  Deletion of Per2 clock gene in mice, attenuated cardiac 
injury following experimentally induced-MI and I/R, implicating reduced inflammation and 
preservation of mitochondrial function in cardioprotection (Virag et al., 2010; Virag et al., 
2013). In addition, studies using mutant Bmal1 mice model revealed that Bmal1 leads to 
disruption of circadian variation in blood pressure and heart rate, and to increased susceptibility 
of vascular injury (Anea et al., 2009; Curtis et al., 2007).  Specific deletion of Bmal1 in mice 
ventricular cardiomyocytes, resulted in abnormal electrocardiography with prolonged RR and 
QRS intervals, signs of arrhythmogenesis (Wang et al., 2008; Schroder et al., 2013). Also, 
deletion of Bmal1 in vascular smooth muscle cells and mice endothelial cells, abrogated blood 
pressure circadian rhythmicity accompanied with hypotension (reduced blood pressure) (Curtis 
et al., 2007; Westgate et al., 2008).  Circadian clock disruption using Bmal1–/– mice or CLOCK 
mutant mice (ClockΔ19/Δ19) is also associated with metabolic pathologies which are considered 
risk factors for heart disease, including diabetes, obesity and metabolic syndrome (Kannel and 
McGee., 1979; Eckel and Krauss., 1998; Marcheva et al., 2010; Carvas et al., 2012; Lefta et al., 
2012).   
Interestingly, both cardiomyocyte-specific CLOCK mutant (CCM) and cardiomyocyte-specific 
BMAL1 knockout (CBK) mice models are predisposed to development of cardiac hypertrophy, 
but also exhibit increased cardiac expression of remodeling-associated fetal genes (Durgan et 
al., 2011; Young et al., 2014).  CBK mice develop an age-onset dilated cardiomyopathy and 
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decreased lifespan, comparable to the phenotype observed in germline BMAL1 null mice; thus, 
highlighting the importance of BMAL1 role in cardiac form and function (Lefta et al., 2012; 
Young et al., 2014).  Durgan et al., (2010) also reported in wildtype mice that infarct size is 
dependent on the time of day at which I/R occurs, where hearts with I/R at the sleep-to-wake 
transition stage have larger infarcts and worse outcomes.  Such findings are consistent with the 
presence and importance of intrinsic clocks in the heart and emphasise that any disruption of 
their molecular clock may result to detrimental cardiac defects. Nevertheless, no studies have 
yet conducted investigating the expression and circadian rhythmicity of clock genes in atrial 
arrhythmias, which further emphasise the importance of our thesis.   
1.6.2. Onset timing of Cardiovascular diseases 
Cardiovascular diseases are the leading cause of mortality in the Western word, and recent 
evidence indicate that the occurrence of these events do not occur randomly throughout the day 
(Hunt et al., 2009; Heran et al., 2011; Heart and Stroke Foundation 2014).  In particular, 
ventricular-associated abnormalities such as, myocardial infarction (MI), stroke, angina, 
ventricular tachyarrhythmia, defibrillation, ventricular refractroriness and sudden cardiac death 
(SCD) reported to exhibit a daily pattern with the highest incidence during the early morning 
hours (06:00 - 12:00 am) (Cohen et al., 1997; Muller et al., 1985; Kong et al., 1995; Muller et 
al., 1987; Willich et al., 1989; Cannon et al., 1997; Eksik et al., 2007).  In terms of atrial 
arrhythmias, the circadian variation patterns have been less studied possibly due to their 
relatively benign nature. Atrial arrhythmias, including atrial fibrillation (AF), tachycardias and 
premature beats appear to exhibit diurnal patterning, with higher frequency during sleep time 
hours between 12:00 and 02:00 am (Argentino et al., 1990; Tofler et al., 1995; Kong et al., 
1995; Simantirakis., 2001; Mahmoud et al., 2011).  This poses additional threat to individuals 
suffering from atrial arrhythmic events hence prompt circadian investigation of the factors 
contributing to its occurrence, in particular ion homeostasis and channel dysfunction.   
1.6.3. Diurnal variation of Cardiac contractility and electrophysiological 
characteristics associated with Atrial fibrillation 
Atrial fibrillation cardiac event is caused by changes in action potential configuration through 
alteration in ion channel (NaP) activity and subsequent changes in Ca
2+ homeostasis leading to 
improper atrial contraction.  In addition, atrial arrhythmias may equally develop through 
abnormal propagation of action potential due to slowed conduction velocity, following 
structural remodelling of the connexin gap junction proteins after raised intracellular [Ca2+].  
However, less is known about the impact of the diurnal rhythms on ion channels and ion 
homeostasis. 
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Time-of-day-dependent oscillations in contractility persist when rodent hearts reach a steady 
state in the ex vivo setting, and peak during the dark phase (Young et al., 2001; Bray et al., 
2008).  Furthermore, when ex vivo perfused hearts subjected to a workload challenge (increased 
afterload plus epinephrine), exhibit greater cardiac output during the dark phase, revealing 
increased contractile reserve at such time slots.  Interestingly, increased contractility peak times, 
are in-line with AF occurrence timing, revealing a possible correlation between the two (Bray 
et al., 2008).  Mechanistically, several possibilities exist with regard to how contractility is 
intrinsically increased during the active period, including time-of-day-dependent fluctuations 
in contractile proteins, ion homeostasis and subsequent signaling (Young et al., 2015).  Time-
of-day-dependent oscillations have been reported in the rodent heart for the two major myosin 
heavy chain (MHC) contractile protein isoforms (MHCα and MHCβ) at the transcript level 
(Wang et al., 1999; Young et al., 2001).  Whereas, the fact that the half-life of MHC proteins is 
generally considered to be longer than 24 hours, makes it unlikely to oscillate over the course 
of the day. On the other hand, myosin ATPase Ca2+-sensitivity exhibits a daily variation with 
peaks during the dark phase (active period) in mouse hearts (Podobed et al., 2014).  This 
reported to be associated with the time-of-day dependent rhythms in the protein levels of 
various myofilament components (desmin, tropomyosin, troponin I and C) contributing to 
synchronous and coordinate facilitation of contraction between adherent cardiomyocytes 
(Bers., 2014; Podobed et al., 2014).  The mRNA levels of these myofilament components are 
circadian regulated and the protein levels peak around wake time (Podobed et al., 2014).  This 
is also consistent with the increased sensitivity of myosin ATPase to Ca2+ at this time, indicating 
that myofilament composition and function differ and are time-of-day dependent, suggesting 
immediate association of Ca2+ activated structural components with the occurrence of Ca2+ 
activated related cardiac events, such as AF.    
Furthermore, there are numerous findings on biological rhythms of Cx43 (major atrial gap 
junction component) in the mouse bladder urothelium driven by components of the circadian 
clock.  This suggests an indirect regulation of connexins by clock genes (Negoro et al., 2012; 
Negoro et al., 2018).  Additionally, Tong et al., (2016) investigated circadian rhythmicity of 
connexin (Cx40 and Cx43) gap junction structural proteins, in the mouse heart using 
suprachiasmatic nucleus (SCN) lesion and pharmacological ANS block mouse.  They suggested 
that the rhythmicity of Cx40 and Cx43 might be mediated by the SCN, which is the central 
biological clock in the body, due to the significant circadian variations observed in their 
expression in SCN lesion mouse. However, loss of connexin circadian rhythmicity was 
observed in the ANS mouse, suggesting that connexin gene expressions have clear circadian 
rhythm which is regulated by the central clock in the SCN and not through the activity of 
biological clock genes in peripheral clocks (i.e. heart).  The circadian variation in connexin 
rhythmicity further suggests that the electrical conductance at atrial gap junctions and thus ease 
of cardiac action potential propagation through cardiac tissue increases and decreases at 
Chapter 1. Circadian rhythms & CVDs 
 
39 | P a g e  
 
different times of the day.  This further supports the AF diurnal variations reported in the 
literature (Bollmann et al, 2000).  Furthermore, despite the absence of further studies 
established on the circadian rhythmicity of connexins in the heart, further investigation is 
required as part of this thesis.   
Alteration of connexin’s phosphorylation status is well documented to cause remodeling in 
connexin structure and function contributing to the generation of abnormal gap junction 
conduction velocity which is considered arrhythmogenic (Jabr et al., 2016). Hence investigating 
circadian oscillations of phosphoproteins or kinases involved in modulating the 
phosphorylation status of the gap junctional structural components is equally important, and 
could provide further insight on the timing that AF occurs.  Indeed, studies have shown that the 
diurnal pattern of calcineurin (Ca2+-dependent protein phosphatase) activation is compatible 
with heart health (Molkentin et al., 1998; Parra and Rothermel., 2017).  Studies by Sachan et 
al. (2011), suggest daily variation of the Ca2+- activated protein phosphatase CaN activity in the 
heart, with lowest activity at the sleep-to-wake transition phase (during the end of the animal’s 
active period), immediately precedes a time-of-day when the heart is less susceptible to 
arrhythmogenesis.  They proposed that increased β-adrenergic signaling in the heart at this time 
promotes PKA-mediated phospholamban phosphorylation and subsequently increased 
SERCA2 activity, thereby diminishing Ca2+ availability for calcineurin activation during 
excitation-contraction coupling (Sachan et al., 2011).  The susceptibility in calcineurin diurnal 
changes, appear to be mediated by changes in RCAN1 levels; a known calcineurin inhibitor 
(Rotter et al., 2018).  In addition, Dyar et al., (2015) shown that calcineurin circadian activation 
in skeletal muscle was independent of the transcriptional circadian clock mechanism and was 
driven purely by muscle innervation and contractile activity. Thus, suggesting that circadian 
activation of calcineurin is not unique to the heart.  In addition, no studies are available 
investigating the possible involvement of circadian clock genes driving calcineurin activation 
in the heart, and more specifically the atria.   
In terms of ion homeostasis various studies highlight that the electrophysiological properties of 
the heart differ markedly with respect to time of day.  For example, Collins and Rodrigo 
(2010) reported variations in Ca2+ transients depending on the time-of-day at which adult rat 
cardiomyocytes were isolated. More specifically, they reported that both diastolic and systolic 
Ca2+ levels, as well as peak Ca2+ release and relaxation of the Ca2+ transient, are elevated in 
cardiomyocytes isolated during the light phase (resting period) compare to dark phase (active 
period) (Collins and Rodrigo., 2010). However, despite the increased gene and protein 
expression of the α1D subunit of the L-type voltage-gated Ca2+ channel during the light phase, 
peak L-type Ca2+ current density was lower in cardiomyocytes at resting period (Collins and 
Rodrigo., 2010; Ko et al., 2011).  Rhythms have also been reported for K+ transients in the 
heart.  Following a screen of 14 different K+ channels in the rat heart, the protein levels of Kv1.5 
and Kv4.2 channel isoforms, peak during the dark and light periods, respectively, exhibiting 
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opposing daily rhythms (Yamashita et al., 2003). Oscillations of these channels are associated 
with predicted time-of-day-dependent differences in K+ transients (Yamashita et al., 2003). 
Recent studies by Jeyaraj et al., (2012), confirmed Kv4.2 (the α subunit of the transient outward 
K+ current) oscillations and reported similar rhythms in KChIP2 (the regulatory β subunit of 
the transient outward K+ current). Less is known with regard to daily rhythms in Na+ currents 
in the heart.  Even though various Na+ channel subunits have been measured over the course of 
the day (e.g. SCN5A gene which encodes the major Na+ channel subtype in the heart; Nav1.5.), 
the direct assessment of cardiac Na+ currents at different stages in the light/dark cycle still 
remains unclear (Schroder et al., 2013).  Also, it is important to note that the responsiveness of 
the heart to these factors exhibits a daily variation in multiple parameters including, heart rate, 
Ca2+ transients and induction of arrhythmia (Bray et al., 2008; Collins and Rodrigo et al., 2010).  
1.6.4. Involvement of clock genes in Cardiac contractility and 
electrophysiological characteristics associated with Atrial fibrillation.   
Several lines of evidence support the concept that circadian clocks affect cardiac contractile 
function over the course of the day, hence possibly contributing to the occurrence of cardiac 
events associated with contractile abnormalities (such as AF), at certain times of the day.  Light 
reported to increase heart rate in a dose-dependent manner in humans (Scheer et al., 2010).  In 
murine models, daily heart rate rhythms are abolished in rats with SCN lesions (Saleh and 
Winget., 1977).  Reduced heart rate and contractility oscillations were also reported in 
ClockΔ19/Δ19 and BMAL1 null mice, revealing a role of the peripheral circadian gene network 
in the heart (Bray et al., 2007; Curtis et al., 2007; Sei et al., 2008).  Similarly, a study by Wu et 
al., (2011) reported that PER2 mutant mice lack heart function daily variations observed in 
wildtype mice.   
Cardiomyocyte-specific CLOCK mutant (CCM) mice were used for the investigation of the 
role of cardiomyocyte circadian clock in mediating time-of-day-dependent variations in cardiac 
contractility.  CCM mice exhibit abolished time-of-day-dependent rhythms in contractile 
reserve (Bray et al., 2008).  Furthermore, unlike the wildtype hearts, cardiac myofilaments from 
CCM hearts do not exhibit a rhythm in Ca2+ sensitivity across the light/dark cycle (Podobed et 
al., 2014).  Recent studies demonstrated that a key component of the sarcomeric structure that 
underlies cardiac contraction was shown to be transcriptionally targeted by BMAL1 and 
CLOCK core circadian proteins, leading to its cardiac mRNA and protein rhythmic expression 
(Podobed et al., 2014; Candasamy et al., 2014; Linke and Hamdani., 2014).  A study by Xie et 
al., (2015) showed that selective Bmal1 deletion in vascular smooth muscle cells, not only 
abolished the diurnal variations of constriction of blood vessels (which subsequently increased 
the blood pressure), but also affected phosphorylation status of myosin filaments involved in 
the contractile machinery.  Interestingly, Boateng and Qi (2006) showed that increased 
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contractile activity with 10 μM phenylephrine, and subsequently Ca2+ levels, enhance CLOCK 
protein expression levels and nuclear translocation in cardiac myofilaments.  On another note, 
Tong et al., (2016) has found that the circadian rhythmicity of gap junctional Cx40 and Cx43 
proteins is not regulated by the biological clock gene BMAL1, as clear circadian rhythmicity 
was observed in BMAL1-ablated mouse heart.  This suggests that connexins are mediated by 
the central biological clock in the body (SCN) and not by peripheral clocks (i.e. in the heart).  
Whereas, Negoro and team (2013) reported that Rev-Erbα clock component upregulates the 
transactivation of Cx43, by forming a complex with SP1 (a transactivation factor), in the 
bladder (Negoro et al., 2013). This confirms that the involvement of clock genes in mediating 
connexin expression and circadian rhythmicity may be tissue specific.  
Evidence has also emerged in support of the concept that the cardiomyocyte circadian clock 
directly influences cardiac electrophysiology.  A study by Schroder et al., (2013) demonstrated 
loss of SCN5A gene circadian expression and Nav1.5. expression after the use of inducible 
cardiac specific deletion of Bmal1 gene (iCSΔBmal1). They also reported bradycardia and 
reduced microscopic Na+ current in isolated ventricular myocytes, suggesting a direct 
association between Bmal1 clock component and Nav1.5. NaP channel subtype (Schroder et al., 
2013). Additionally, SCN5A gene point mutations may lead to life-threatening arrhythmias 
highlighting the importance of Nav1.5. channel in the heart (Zimmer et al., 2008).  Furthermore, 
a study by Han et al., (2012) reported reduced amplitude of circadian rhythms in SCN1A gene 
(encoded the Nav1.1. channel) following Bmal1 knockout, which further strengthen the link 
between various Na+ channel subtypes and circadian expression.  Interestingly, Ca2+ and K+ 
channels reported to be differentially expressed in CCM and CBK hearts relative to wildtype 
hearts (Bray et al., 2008; Young et al., 2014).  Taken together, these studies strongly suggest 
that the cardiomyocyte circadian clock affects contractility and cardiac ion homeostasis, 
therefore highly involved in maintenance and development of cardiac abnormalities (i.e. 
arrhythmias) associated with changes in such physiological factors.  
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1.7. Summary 
Atrial fibrillation (AF) arrhythmias, reported to exhibit a daily pattern with higher frequency 
during sleep time, thus proposing the involvement of an intrinsic circadian clock mechanism, 
and subsequently the core clock genes maintaining it (in particular Bmal1), driving these events 
and therefore contributing to its occurrence (Ripamonti et al., 2017).  However, the presence of 
Bmal1 in atrial myocytes, as well as its role in atrial arrhythmias has not yet been established.  
There are various factors contributing to the generation of atrial arrhythmias and all are based 
on abnormal excitation and/or disturbed conduction of electrical activity across the heart 
(Allessie., 2002). Abnormal propagation of electrical activity is associated with enhanced 
intracellular Ca2+ load due to Nap channels sustained activation. Whereas, disturbed conduction 
of electrical activity across the heart is associated with altered gap junction electrical 
conductance (following raised intracellular [Ca2+]), hence gap junctional proteins (connexins) 
are of great interest.  The discovery of AF diurnal variations further suggests the existence of 
cardiomyocyte circadian clock in the factors contributing to its occurrence.  Indeed, studies 
support a strong link between the different Nap channel subtypes and circadian expression, 
following cardiac specific deletion of Bmal1 (iCSΔBmal1) in mouse heart (Schroder et al., 
2013).  At the same time, findings revealed that connexin circadian expression is not regulated 
by Bmal1 in mouse heart, but it is in the liver, revealing a tissue specificity of clock genes in 
mediating connexin expression (Negoro et al., 2013; Tong et al., 2016).  This further suggests 
that BMAL1 affects cardiac contractility and ion homeostasis, therefore highlights its 
involvement in maintenance and development of cardiac arrhythmias associated with changes 
in such physiological factors. The relationship between Bmal1 expression and its circadian 
oscillation in the atria, in response to the intracellular mechanisms underlying AF, is unknown. 
Several protein kinases were characterised as regulators of the circadian clock. However, the 
function of protein phosphatases, which balance phosphorylation events, in the mammalian 
clock mechanism is less well understood.  Increased levels of intracellular [Ca2+] and CaM, are 
shown to be associated with atrial arrhythmias in animals and chronic AF in patients, can induce 
calcineurin (CaN) activation.  CaN – Ca2+ dependent protein phosphatase will result in reduce 
gap junction conductance through PP1 dephosphorylation/ PKC-induced phosphorylation 
pathway which affects connexin phosphorylation status and conformational change leading to 
AF occurrence (Jabr et al., 2016).  On another note PP1 – mediated dephosphorylation reported 
to affect PER circadian oscillatory expression pattern in mouse embryonic fibroblasts (Gallego 
et al., 2006; Vanselow et al., 2006).  Schmutz et al., (2011) reported a modest effect of PP1 
inhibition on BMAL1 nuclear accumulation in mouse brain and liver, demonstrating that PP1 
may induce epigenetic modifications on the transcriptional machinery resulting in changes of 
BMAL1 concentration.  This also suggests a possible link between BMAL1 and PP1 - CaN 
activated pathway following raised intracellular [Ca2+]; factor contributes to facilitation of AF. 
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1.8. Hypothesis 
We hypothesise that Bmal1 clock gene transcription and protein expression exhibit circadian 
rhythmicity in cultured atrial HL-1 clone 6 myocytes under normal physiological conditions. 
Such rhythmicity is disrupted by ATXII-induced rise in intracellular [Ca2+] triggered by the 
activation of Ca2+-CaM dependent protein phosphatase, calcineurin as well as alteration in the 
circadian pattern of gap junction proteins expression- connexins 40 and 43. Such alterations are 
known to be arrhythmogenic and may provide novel insights on the underlying mechanisms of 
atrial arrhythmias’ (e.g., AF) diurnal variations.   
1.8.1. Aims & objectives  
• Determine Bmal1 clock gene expression pattern and circadian rhythmicity in 
synchronised HL-1 clone 6 (HL1-6) cells (in vitro model for studying atrial physiology 
and pathophysiology), under control conditions.   
• Assess changes in intracellular [Ca2+] ([Ca2+]i), as a model of atrial arrhythmias, on 
Bmal1 clock gene expression pattern and circadian rhythmicity in synchronised HL1-6 
cells.  This will be done in presence ATXII alone (to raise intracellular [Ca2+] via sustain 
opening of NaP channels), or in combination with Ranolazine (to inhibit NaP channels), 
or in combination with BAPTA-AM Ca2+ chelator.  
• Measure intracellular [Ca2+] levels circadian pattern in synchronised HL1-6 atrial 
myocytes.  This will be done under control conditions, in presence of ATXII alone, or 
in combination with Ranolazine, or in calcineurin autoinhibitory peptide (CAIP) to 
assess the effects of calcineurin. 
• Determine BMAL1 and phosphorylated BMAL1-Ser42 protein expression and 
circadian rhythmicity in synchronised HL1-6 total cell lysates.  This will be done under 
control conditions, increased [Ca2+]i by ATXII as a model of atrial arrhythmias, in 
presence of Ranolazine, as well as in presence of CAIP to report effects of calcineurin.    
• Determine Cx43, phosphorylated Cx43-Ser368 and Cx40 protein expression and 
circadian rhythmicity in synchronised HL1-6 total cell lysates, under control conditions 
as well as, increased [Ca2+]i by ATXII (as a model of atrial arrhythmias), in presence of 
Ranolazine, as well as in presence of CAIP to report effects of calcineurin.    
• Determine NaP channel subtypes (Nav1.1., Nav1.5. & Nav1.6.) protein expression and 
circadian rhythmicity in synchronised HL1-6 total cell lysates, under control conditions, 
raised [Ca2+]i by ATXII and Ranolazine. 
• Assess BMAL1 protein localisation changes in HL1-6 cells, under control conditions, 
in ATXII-induced [Ca2+]i as model of atrial arrhythmias, in combination with 
Ranolazine or CAIP (to assess effects calcineurin).
 44 | P a g e  
 
 
 
 
 
 
 
 
Chapter 2. 
Materials and Methods 
 
 
 
 
 
 
 
 
Chapter 2. HL-1 clone 6 cells 
 
45 | P a g e  
 
2.1. Origin & use of the HL-1 clone 6 cells (HL1-6s) 
HL-1 cells clone 6 were used as a model throughout this thesis for the investigation of AF-
related intracellular signalling pathways in response to circadian expression changes.  The HL-
1 cell line has been established in 1998 by Claycomb (Claycomb et al., 1998).  They are the 
best known validated atrial myocyte model for in-vitro culture studies, with a similar phenotype 
to adult cardiomyocytes.  Claycomb et al., (1998) designed the HL-1 cell line from the AT-1 
mouse atrial cardiomyocyte tumor lineage.  HL-1 cells have the ability to be passaged many 
times (up to 240 times) while maintaining their ability to contract and retain differentiated 
cardiac morphological, biochemical and electrophysiological properties (Claycomb et al., 
1998).  
HL-1 cells characteristics include an ultrastructure similar to embryonic atrial cardiac muscle 
cells. Immunohistochemical staining for the microscopic investigation of HL-1 cell 
ultrastructure morphology showed that HL-1 cells consist a highly organised sarcomeric 
structure suitable for mediating the contractile activity of primary atrial cardiomyocytes when 
cultured to confluency (Claycomb et al., 1998).  At all reported passages (10, 20, 34 and 86), 
the HL-1 cells contained cardiac-specific sarcomeric myosin and specific desmin intermediate 
filaments, similar to those observed in normal myofibril development in mitotic 
cardiomyocytes in the developing heart (Dias et al., 2014).  In addition, Claycomb showed that 
HL-1 cells have the ability of spontaneous contractions while remaining in a mitotic state.  That 
is due to HL-1 cells containing highly ordered contracting myofibrils, a characteristic also seen 
in cultured primary cardiomyocytes and in mitotically active atrial cardiomyocytes.  Also, 
during mitosis HL-1 cells remained attached to adjacent cells via cardiac specific junctions in 
the form of intercalated discs, allowing facilitation of action potential and hence generation of 
contraction along the cells providing evidence of the presence of gap junction proteins 
(connexins) in these cells (Claycomb et al., 1998).  
Reverse transcriptase polymerase chain reaction (RT-PCR) analysis confirmed similar gene 
expression pattern of contractile protein isoforms (i.e. Ca2+ - handling proteins; NCX, SERCA2, RyR2), 
atrial natriuretic factor (ANF) and gap junction proteins; in particular Cx43 (the major protein of cardiac 
myocyte gap junctions), to that of adult atrial myocytes (Claycomb et al., 1998).  At a functional 
level, electrophysiological characterisation of HL-1 cells using patch-clamp technique 
demonstrated similar action potential currents to atrial normal cardiac myocytes, including the 
presence of the outward delayed rectifier K+ currents (IKr) which is specific for cardiac cells, 
and the inward L-type Ca2+ (ICaL) and Na
+ (INa) currents required for the generation of action 
potential contraction in adult cardiomyocytes (Claycomb et al., 1998; Dias et al., 2014).  Further 
work carried out by Dias et al., (2014) reported the existence of six separate sub-clones; HL1-
1, HL1-2, HL1-3, HL1-4, HL1-5 and HL1-6.  The HL1-5 cell line was discontinued due to lack 
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of proliferation, whereas the remaining sub-clones revealed differing contractile characteristics 
from sub-clone to sub-clone, as well as varying connexin 40, 43 and 45 expression quantities 
following northern blot mRNA analysis (Dias et al., 2014).  
The HL-1 clone 6 (also denoted HL1-6) was reported as the only clone that expresses similar 
electrophysiological properties as dispersed adult primary atrial myocytes (Dias et al., 2014).  
HL1-6, the only highly contractile clone among the rest of them, express a maximal conduction 
velocity (42 mm/second) (Mureli et al., 2013).  This could be caused by cellular heterogeneity 
of Cx43, leading to increased conduction velocity propagation in cardiomyocytes isolated from 
mice (Desplantez et al., 2012).  In addition, a high Ca2+ peak current density was observed in 
HL1-6 cells leading to faster Ca2+-induced Ca2+ release (CICR), comparable to those recorded 
from cells of in-vivo atrial origin (Shih., 1994).  This rapid decay of the Ca2+ transient could be 
explained by higher amounts of Na+/Ca2+ exchanger (NCX) and sarco/endoplasmic reticulum 
Ca2+-ATPase (SERCA) transporters in HL1-6 sub-clone, involved in the removal of Ca2+ ions 
from the cytoplasm (Dias et al., 2014). Therefore, the HL1-6 sub-clone provides the most stable 
model, retaining many of the specific characteristic seen in normal atrial myocytes in-vivo.   
Additionally, the HL1-6 cell line has also been validated as a good model for the investigation 
of atrial arrhythmias-related events, such as AF, given that its occurrence is associated with 
changes in Ca2+ homeostasis (rise of intracellular [Ca2+]) due to sustain activation of NaP 
channels and alteration in connexins expression via changes on their phosphorylation status 
(Dupont et al., 2001; Dhein et al., 2011; Shryock et al., 2013). That is due to the fact that HL1 
cells clone 6 display spontaneous electrophysiological and mechanical activity, as well as 
evidence of electrical automaticity and functional cellular Ca2+ regulatory systems while 
maintaining a differentiated cardiac phenotype and display resilience to death from the Ca2+ 
paradox (Claycomb et al., 2004; Touchberry et al., 2011; Dias et al., 2014).  Also, further 
evidence regarding the already known existence of NaP channels in HL1-6 cells, and loss of 
SCN5A gene circadian expression; the major contributor of Nav1.5 channel protein expression, 
after the use of inducible cardiac specific deletion of the Bmal1 clock gene in murine ventricular 
myocytes gain our attention and further explains the rationale of the use of HL1-6 in this thesis 
(Strege et al., 2012; Schroder et al., (2013).  Furthermore, the HL1-6 cells constitute of Cx43 
and Cx40 gap junctional proteins, the main connexin subtypes exist within the atrial region of 
the heart.  Studies have proposed that reduction in Cxs distribution, abundance and therefore 
performance are associated with decreased conduction velocity which induces AF, this suggests 
a tight correlation between Cxs expression and electrical conductance hence using the 
appropriate cell lines for their investigation is a key (Jennings., 2013; Dhillon et al., 2014).  The 
HL-1 cell line has been validated as a good model for the investigation of arrhythmogenic 
mechanisms, given its intrinsic slow conduction in vitro compare to other cardiac cell lines 
(Dias et al., 2014, Touchberry, et al., 2011).  Under pathological conditions reduced Cx43 
protein expression was reported to be associated with low gap junction conductance and 
subsequent cardiac arrhythmias (Glukhov et al, 2012).  Whereas, increased Cx40 protein 
expression has shown to be associated with atrial arrhythmic events (i.e. AF) in humans, thus
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consolidating the importance of the role of connexins in the disease, as well as the use of HL-1 
cells for their investigation (Polontchouk et al, 2001). 
2.2. Origin and use of Primary Mouse Embryonic Fibroblast (pMEFs)  
Primary Mouse Embryonic Fibroblast Cells (pMEFs) were also used in this thesis and were a 
kind gift from Dr Lisiane Meira (University of Surrey, Guildford, United Kingdom).  Isolation 
of pMEFs was performed as follows:  Female C57BL/6J mice were culled by CO2 inhalation 
and death confirmed by cervical dislocation on 12.5-13.5 days of confirmed pregnancy.  Both 
uterine horns were dissected out of the pregnant mouse and placed in 30 mL of PBS.  Each 
individual mouse embryo was dissected from the uterus, followed by placenta and yolk sac 
separation, in the laminar flow hood.  Then, using a 1 mL syringe (without needle) each mouse 
embryo was homogenised onto 0.1 % Bacto-Gelatin pre-coated 60 mm dish containing 5 mL 
of complete Dulbecco’s Modified Eagle’s Medium (DMEM; D5671, Sigma-Aldrich).  The 
homogenisation was carried out by drawing embryonic tissue up and down, until the 
disaggregated tissue moved freely in and out of the syringe, followed by overnight incubation 
at 37 °C with 5 % CO2.  The following day, the medium was replaced with fresh complete 
DMEM, and cells incubated until 80 % confluence.  Once confluence was reached, DMEM was 
replaced with fresh complete DMEM medium 4 hours prior to cell passaging or freezing 
(Passage 1). 
pMEFs have become a well-used model system for the study of circadian rhythms in peripheral 
mammalian tissue, hence were use in this thesis as a comparable cell line for validating reasons 
of circadian presence, as well as due to their excellent response to serum-shock synchronisation 
method (Balsalobre et al., 1998; Balsalobre et al., 2000).  Serum-shock was shown to initiate 
rhythms of gene expression in pMEFs populations in culture, even though further studies 
demonstrate that a variety of signals can synchronise the rhythms in these cells including 
forskolin, dexamethasone (DEX) and MAP kinase cascade (Balsalobre et al., 2000; Yagita and 
Okamura., 2001; Akashi and Nishida., 2000).  Most of the genes implicated in the mammalian 
clockwork (i.e. Bmal1, Clock, Per1, Per2, Cry1, Cry2, Rev-erbα) are expressed in a similar 
fashion in fibroblasts suggesting a similar clock mechanism (Yagita et al., 2001; Dufflied et al., 
2002).  This also indicates that fibroblast cell cultures are reliable tools for determined circadian 
rhythmicity using bioluminescence technique, therefore were selected for use in this thesis.  
The concept of transient transfection of fibroblasts with a luminescence reporter was introduced 
by Ueda et al., (2002) which encouraged the possibility of using real-time bioluminescence 
recording as a monitor of circadian gene regulation as expressed by promoter activity.  
Luciferin, the reporter gene, produced a protein that illuminates the cell, so insertion of 
luciferase into the host genome near genes is relatively important for establishing the circadian
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rhythm promoted gene circadian expression and consequently expression of luciferase, 
allowing light up of the fibroblast cultures in time with the circadian clock.  Studies have shown 
that infection of mouse fibroblast tissue cultures with a virus engineered to report with a certain 
host resulted in circadian gene and protein expression of various clock genes (i.e. Bmal1, Clock, 
Per2) with an approximately circadian cycle of 24.5 hours (Schibler et al., 2002; Nagoshi et al., 
2004; Sahar et al., 2010; Hoyle et al., 2017).  Thus, suggesting that these rhythmically glowing 
cells are an excellent model system for non-invasive monitoring of circadian clocks in 
mammalian cells.  Additionally, the absence of NaP channels in pMEFs further supports the use 
of these cells in our study, considering that persistent activation of NaP channels under raised 
intracellular [Ca2+] are known to maintain atrial abnormal electrical activity during atrial 
arrhythmias, in particular AF (Strege et al., 2012).  
2.3. Culturing of HL1-6 cells and pMEFs 
All the cell culture work was conducted in a type 2 laminar flow cabinet.  All solutions added 
on the cell culture were pre-warmed in a water bath at 37 ºC, and experimental cells were 
incubated at 37 °C in a humidified atmosphere with 5 % carbon dioxide (CO2). 
2.3.1. Culture medium for HL1-6 cells 
HL1-6 atrial cells were maintained in Claycomb medium containing phenol red (51800C, 
Sigma-Aldrich, Gillangham, UK).  For the purpose of normal culturing the Claycomb medium  
was supplemented with 2 mM L-Glutamine (G7153, Sigma-Aldrich, Gillangham, UK), 0.1 mM 
norepinephrine [(±)-Arterenol] (NE; A0937, Sigma-Aldrich, Gillangham, UK), 10 % fetal 
bovine serum (FBS; TMS-016, Sigma-Aldrich, Gillangham, UK), 100 units/ mL of penicillin 
and 100 μg/ mL of streptomycin (P/S; P4333, Sigma-Aldrich, Gillangham, UK), also shown in 
Table 2.1.  The complete Claycomb medium was wrapped in aluminium foil, due to the light 
sensitive characteristics of NE and stored at 4 °C until its use.   
Table 2.1. Complete Claycomb medium supplements 
Product name Volume in 
total 100 mL 
Final 
concentration 
Supplier Product 
Ref. no. 
Claycomb medium 87 mL 87 % Sigma-Aldrich 51800C 
Fetal bovine serum (FBS) 10 mL 10 % Sigma-Aldrich TMS-016 
L-Glutamine 1 mL 2 mM Sigma-Aldrich G7153 
Norepinephrine (NE) [(±)-Arterenol] 1 mL 0.1 mM Sigma-Aldrich A0937 
L-ascorbic acid 1 mL 30 mM Sigma-Aldrich A92902 
Penicillin - Streptomycin (P/S) 1 mL 100 units / mL Sigma-Aldrich P4333 
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2.3.1.1. 0.1 mM Norepinephrine (NE) 
Ten (10) mM NE (stock) was made up in 30 mM of L-ascorbic acid (A0937, Sigma-Aldrich, 
Gillangham, UK).  L-ascorbic acid ensures NE stability by preventing its oxidation.  We 
dissolved 0.59 g of L-ascorbic acid into 100 mL of sterilised distilled water (dH2O) to make a 
30 mM and added 320 mg of NE to the L-Ascorbic to make 10 mM NE. The solution was 
filtered through a 0.2 µm Acrodisc syringe filter unit (4192, ThermoFisher Scientific, 
Loughborough, UK). The 10 mM NE stocks were stored at -20 °C until used, upon which the 
working final concentration of 0.1 mM final concentration in 500mL media. 
2.3.2. Culture medium for pMEFs  
pMEFs were used as a positive control throughout the thesis and were maintained in phenol red 
Dulbecco’s Modified Eagle’s Medium (DMEM; D5671, Sigma-Aldrich) formulated with high 
glucose [24.98 M].  The DMEM was supplemented with 2 mM of L-Glutamine (G7153; Sigma-
Aldrich, Gillangham, UK), 10 % foetal bovine serum (FBS; F0804, Sigma-Aldrich, 
Gillangham, UK), 100 units/ mL penicillin and 100 μg/ mL streptomycin (P/S; P4333, Sigma-
Aldrich, Gillangham, UK) as listed in Table 2.2.  The complete DMEM was stored at 4 °C and 
pre-heated at 37 °C in water-bath prior to its use. 
Table 2.2. Complete Dulbecco’s Modified Eagle’s Medium (DMEM) supplements 
Product name 
Volume in total 
100 mL 
Final 
concentration 
Supplier Product Ref. no. 
DMEM 87 mL 87 % Sigma-Aldrich D5671 
Foetal bovine serum (FBS) 10 mL 10 % Sigma-Aldrich F0804 
L-Glutamine 1 mL 2 mM Sigma-Aldrich G7153 
Penicillin - Streptomycin  1 mL 100 units / mL Sigma-Aldrich P4333 
 
2.3.3. Pre-coating of culture flasks and/or dishes  
Culture flasks and/or dishes were pre-coated with 0.02 % fibronectin solution (0.5 mL/ 35 mm 
dish, 1 mL/ 6-well plate, 2 mL/ 25 cm2 culture flask (T25) or 6 mL/ 75 cm2 culture flask (T75)) 
and incubated at 37 °C for 3 hours or overnight prior to each experimental day to promote cell 
attachment.  
2.3.3.1. 0.02 % fibronectin/ gelatin  
For the preparation of 0.02 % fibronectin/ gelatin solution (F1141, Sigma-Aldrich, Gillangham, 
UK), 0.1 g of Bacto-Gelatin (G9391, Sigma-Aldrich, Gillangham, UK) was added into a glass 
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bottle containing autoclaved 500 mL dH2O.  1 mL fibronectin (1 mg/ mL) was diluted in 199 
mL of 0.02 % Bacto-Gelatin stock solution, gently mixed until dissolved, and immediately 
aliquoted (5 mL) into sterile 15 mL falcon tubes and stored at - 20 °C until use. 
2.3.4. Beginning of a fresh cell culture – Thawing of HL1-6 cells and pMEFs 
HL1-6 cells (passage 2) were a gift from Dr Emmanuel Dupont (Imperial College London, 
London, United Kingdom) and the pMEFs (passage 2) were gift from Dr Lisiane Meira 
(University of Surrey, Guildford, United Kingdom).  Frozen cryovials containing the cells were 
quickly thawed for approximately 1 minute in a 37 °C water bath, and the cell suspension was 
immediately transferred into a sterile 15 mL falcon tube containing 5 mL pre-warmed complete 
Claycomb medium (HL1-6 cells) or DMEM (pMEFs), and centrifuged (accuSpin™ 400; 
ThermoFisher Scientific, Loughborough, UK) at 500 g for 5 minutes.  The cell supernatant was 
aspirated and the cell pellets were resuspended in 2 mL of complete Claycomb medium or 
DMEM, and transferred into T25 flask pre-coated with fibronectin containing 5 mL of complete 
Claycomb medium or DMEM, or into 2-3 35 mm dishes containing 1 mL of complete 
Claycomb medium or DMEM.  The flask and/ or dishes were incubated at 37 ºC with 5 % CO2 
and the following day the medium was replaced with fresh complete Claycomb medium or 
DMEM.  HL1-6 cells and pMEFs were split twice before any use in experiments, where they 
were subjected to drug treatments or transfected with Bmal1::Luciferase lentiviral (Bmal1::Luc 
LV) particles as described below. 
2.3.5 Splitting of HL1-6 cells and pMEFs 
The cells were permitted to reach 85-90% confluence, at which point each T25 flask was split 
at 1:2 ratio (1 mL of cell suspension solution per 2 mL of complete Claycomb medium or 
DMEM) resulting in four new T25 flasks (passage 3).  One of these four T25 flasks was further 
used as the “working” set of cells.  The remaining three T25 flasks were split at a ratio 1:3 (1 
mL of cell suspension per 3 mL of culture medium) into T75 flasks which once they reached 
85-90% confluence were frozen down for future use (passage 4).   
For splitting, the complete Claycomb medium or DMEM was aspirated from the remaining T25 
“working” flask and the cells were washed (6 mL/ T25 flask) twice with sterile pre-heated 
phosphate buffered saline (PBS; D8537, Sigma-Aldrich, Gillangham, UK) solution and then 
incubated (1 mL/ T25 flask) with pre-warmed 0.05 % trypsin-ethylenediaminetetraacetic acid 
(trypsin-EDTA) solution (T3924, Sigma-Aldrich, Gillangham, UK) for 5-8 minutes (HL1-6 
cells)/ 2-3 minutes (pMEFs) at 37 °C with 5 % CO2.  The flasks were gently agitated to ensure 
even coverage of the cells with trypsin-EDTA solution and then then cells observed (x40 
magnification) microscopically (EVOS®; ThermoFisher Scientific, Loughborough, UK). The 
flasks were tapped on the sides to facilitate dislodgment of the cells adhering to the bottom of 
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the flask.  Following trypsin treatment, 1 part of soybean trypsin inhibitor (T6522, Sigma-
Aldrich, Gillangham, UK) was mixed with 2 parts of Claycomb medium to stop the trypsin 
reaction. Such step was only followed for the HL1-6 cells, whereas trypsin inactivation for the 
pMEFs was achieved with a 1:4 trypsin inhibitor- DMEM medium. All cell suspension were 
centrifuged at 500 g for 5 minutes.  Meanwhile, the fibronectin solution was removed from each 
new T75 flask (3 in total) and 14 mL of complete Claycomb medium or DMEM was added and 
set aside inside the laminar flow cabinet.  The supernatants were removed by aspiration and the 
remaining cell pellets were gently resuspended in 3 mL complete Claycomb medium or 
DMEM.  1 mL of the cell suspension was transferred into each new pre-coated fibronectin T75 
flasks which were set aside earlier (15 mL total volume per T75 flask). The cells were then 
incubated at 37 °C with 5 % CO2 and were allowed to grow until 85-90 % confluent, at which 
point they were further split 1:3 into T75 flasks or frozen down (passage 3).  The complete 
Claycomb medium was changed every weekday and the cells were maintained up to Passage 5. 
For bioluminescence recordings, the HL1-6 cells and pMEFs were seeded in 35 mm dishes 
(Corning Incorportated, Corning, NY). The cell pellet was now resuspended in 2 mL complete 
Claycomb medium or DMEM, and the cell density in the medium was established by 
haemocytometer counting.  10 µL of cell suspension solution was placed on the 
haemocytometer and the viable cells were counted under the microscope using the following 
calculations:  
Total cell number = (cells per mL) x (original volume of medium/cell suspension)  
Where, 
• the number of cells per mL is equivalent to the average count of cells per square of the   
haemocytometer x the dilution factor x 104 (count 10 squares).  For example, if the average 
count per square is 40 cells x 1 (dilution factor) x 104 (count 10 squares) = 400.000 or 4.0 x 105 
cells/ mL  
• the original volume (i.e. 2 mL) of medium/ cell suspension from which the cell sample was 
removed and counted.   
Therefore, (4.0 x 105 cells/ mL) x (2 mL original volume) = 8.0 x 105 total cells 
Then the cell suspension volume that needs to be added into each 35 mm dish was calculated 
so that final concentration into each 35 mm dish was 1.0 x 107 per 1 mL (for the HL1-6 cells) 
or 1.0 x 105 per 1 mL (for the pMEFs) of medium, based on the following formula.  
 
C1 x V1 = C2 x V2 
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Where,  
• C1 is the total cell number into the current cell suspension solution (i.e. 8.0 x 105) 
• V1 is the desire volume that needs to be taken from the initial cell suspension solution 
into the 35 mm dish for the cells to meet the desired final cell concentration.   
• C2 desired final cell concentration (i.e. 1.0 x 105 or 1.0 x 107 per 1 mL of medium) 
• V2 is the final volume per 35 mm dish (3 mL) 
 
                       For example,    V1 = (1.0 x 105 cells/mL) x (3.0 mL) 
                              (8.0 x 105 cells/mL) 
The calculated cell suspension volume was added into each 35 mm dish which were then top 
up with fresh complete Claycomb medium or DMEM, up to 3 mL.  The 35 mm dishes were 
then incubated for 24 hours prior to each experimental day at 37 °C and 5 % CO2 allowing cells 
attachment to the dish surface and subsequent growth.   
2.3.6. Cryopreservation of new HL1-6 cells and pMEFs 
Following initial cell plating upon delivery, the cells were thawed and split into T75 flasks as 
described in Section 2.3.5, which was counted as passage 3.  Once HL1-6 cells or pMEFs 
reached 85-90 % confluence, they were split 1:3 into 3 new T75 flasks or 35 mm dishes (passage 
4), and once reached similar confluency (85-90 %) they were trypsinised (3 mL/ T75 flask or 
0.5 mL/ 35 mm dish) and incubated at 37 ºC for 3 minutes.  Trypsin-EDTA was replaced with 
fresh 3 mL or 0.5 mL trypsin-EDTA solution and incubated at 37 ºC for 2-3 minutes.  The cells 
were then observed microscopically (x40 magnification) to ensure cell dislodgment from the 
culture flask and 3 mL of soybean trypsin inhibitor was added to each flask to stop trypsin-
EDTA digestion (for the HL1-6 cells) or 3 mL complete DMEM (for pMEFs).  The cell 
suspension solution was transferred into 15 mL falcon tubes and the flask and/or 35 mm dishes 
were further washed with fresh complete Claycomb medium or DMEM which was also 
transferred into the 15 mL falcon tube for centrifugation at 500 g for 5 minutes.  For the HL1-
6 cells, the medium discarded and the cell pellet was gently resuspended in 1.5 mL pre-warmed 
freezing medium containing 95 % FBS and 5 % dimethyl sulfoxide (DMSO; sc358801, Santa 
Cruz Biotechnology, Texas, USA), at a concentration of 1.0 x 107 cells/mL. The pMEFs were 
resuspended in 1 mL of medium containing 90 % compete DMEM and 10 % DMSO, at a 
concentration of 1.0 x 105 cells/mL.   
The cryovials containing the HL1-6 cells or pMEFs were immediately placed in a freezing 
container (5100-0001, ThermoFisher Scientific, Loughborough, UK)  containing isopropanol
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at -80 °C for 2 hours prior to their liquid nitrogen storage, enabling that way radical cooling at 
a rate of -1 °C/ minute. 
2.4. Synchronisation of cells with serum-shocking medium 
The serum-shock technique is well-known to phase align the molecular clocks in individual 
cells and can be induced to synchronise existing rhythms amongst adjacent cells by provision 
of high serum concentrations (Balsalobre et al., 1998; Balsalobre et al., 2000; Nagoshi et al., 
2004).  The serum-shock model has become a popular in vitro approach method to dissect the 
molecular mechanisms that comprise circadian rhythms. It was shown that serum-shock can 
cause stimulation in oscillation of Bmal1, Clock, Period 1, Period 2, Cryptochrome 1, 
Cryptochrome 2 and Rev-erbα clock mRNA genes abundant in cultured fibroblasts through a 
period close to 24 hours, which sustains in culture for few circadian cycles (Balsalobre et al., 
1998; Balsalobre et al., 2000). 
Both HL1-6 atrial cells and pMEFs were seeded in 35 mm dishes, 6 well dishes or T75 flasks 
containing the appropriate volume of complete Claycomb medium (HL1-6s) or DMEM 
(pMEFs) 24 hours prior to each experimental day and incubated at 37 °C with 5 % CO2.  Once 
the cells reached 70-80 % confluency (timepoint 0 hours), they were serum-shocked 
synchronised as follows.  The complete Claycomb medium or DMEM was aspirated from the 
wells and the cells were washed twice with PBS solution in order to remove excess medium 
solution.  Following that, the cells were synchronised with serum-shocking Claycomb medium 
or DMEM containing 50 % FBS, 1 % Penicillin/ Streptomycin, 1 % L-Glutamine (and/or 0.1 
mM NE for HL1-6s cells; see section 2.3.1.1.) and incubated for 2 hours at 37 °C with 5 % CO2 
environment (timepoint 2 hours).  After 2 hours, the serum-shocking Claycomb medium or 
DMEM was exchanged for fresh complete Claycomb or DMEM until the completion of the 
experiment.  This marks the control groups used for all set of experiments described below.  
Additionally, cells were also subjected to persistent sodium (NaP) channel opener anemonia 
sulcate toxin II (ATXII, 1 nM final concentration prepared in DMSO, from 10 mM stock; 
A0981, Sigma-Aldrich, Gillingham, UK) to induce atrial arrhythmias.  
2.4.1. Collection of cells at time-intervals  
Upon serum-shock incubation time, the cells were collected at different timepoints for 36 or 48 
hours (i.e. 6-hour interval for HL1-6 atrial myocytes and 4-hour interval for pMEFs), as 
indicated in Figure 2.1.  The serum-shocking Claycomb medium or DMEM was removed, and 
cells were washed twice with PBS solution.  The cells were then detached with 2 mL of Trypsin-
EDTA solution followed by 2-8 minutes of incubation time (depending on the cell line; see 
section 2.3.5.) at 37 °C with 5 % CO2.  The cells were then washed with 2 mL of serum-free
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Claycomb medium or DMEM and centrifuged (accuSpin™ 400; ThermoFisher Scientific, 
Loughborough, UK) at 500 g for 5 minutes.  The supernatant was removed by aspiration and 
the remaining cell pellet was resuspended in 1 mL of PBS solution and then transferred into 
sterile 1.5 mL Eppendorf tubes for centrifugation at 200 g for 10 minutes.  The remaining PBS 
volume was discarded using a needle attached to a syringe without disturbing the cell pellet.  
The cell pellet was then stored at -80 °C until further processing.  This process was similarly 
followed for each timepoint collection.   
 
Figure 2.1. Schematic representation of 4 and 6-hour interval time-dependent experiment.  The HL1-6 cells 
and pMEFs were serum-shocked for 2 hours using 50 % fetal bovine serum (FBS) Claycomb medium (HL1-6s) 
or DMEM (pMEFs).  After serum-shock synchronisation the cells were collected every 4 hours (pMEFs) for 48 
hours or 6 hours (HL1-6s) for 36 hours, following similar protocol (Control).  In another experiment the HL1-6 
cells were also treated with 1 nM ATXII to induce atrial arrhythmias, prior to their collection time points.    
2.5. RNA extraction using RNeasy Mini Kit (QIAGEN) 
RNA was isolated from HL1-6 and pMEFs total cell lysates for each timepoint collected (see 
section 2.4.1.), using the RNeasy Mini Kit (74104, QIAGEN, Manchester, UK).  RNA 
extraction was performed according to manufacturer’s specification as follows.  Each cell pellet 
was lysed using 350 μL RNeasy lysis buffer (RLT; 79216, QIAGEN, Manchester, UK) 
followed by cell lysate homogenisation using a Polytron® PT 1200E hand-held homogenizer 
(VWR International Ltd, Leicestershire, UK) for 30 seconds.  The samples were then mixed 
with 350 μL of 70 % ethanol, and transferred to RNeasy spin column inserted into a collection 
tube.  The RNeasy spin column was centrifuged (accuSpin™ 400; ThermoFisher Scientific, 
Loughborough, UK) at 200 g for 15 seconds.  This allows the sample to pulled through the 
RNeasy spin column which has high RNA binding capacity (100 µg).  The remaining flow-
through was discarded from each collection tube following cell lysate centrifugation, 
minimising in that way the chances of RNA contamination.  The column-bound RNA was then 
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washed with 350 μL of RNeasy washing buffer (RW1; 1053394, QIAGEN, Manchester, UK) 
and the RNeasy spin column were further centrifuged at 200 g for 15 minutes.  The RW1 
washing buffer contains a guanidine salt and ethanol, and is used for an efficient removal of 
non-specifically bound biomolecules (i.e. proteins, fatty acids) from the RNeasy spin column, 
hence allowing RNA isolation, as RNA fragments larger than 200 bases remained bound to the 
column.  Following flow-through discard from the collection tube after centrifugation, 80 μL 
of DNase1/ RNeasy digestion (RDD) buffer solution (79254, QIAGEN, Manchester, UK) was 
directly added to the membrane of the RNeasy spin column for 10 minutes (room temperature 
incubation).  The RDD buffers allows DNA digestion on the RNeasy spin column, as well as 
ensures RNA binding to the column while DNA digestion is occurring. 
Any traces of salts on the RNeasy spin column from buffers used earlier in the protocol, were 
removed following a series of washing steps.  At first, 350 μL of RW1 buffer was added to each 
RNeasy spin column and centrifuged for 15 seconds. The remaining flow-through was 
discarded from the collection tube, and the membrane bound RNA was further washed twice 
with 500 μL RPE buffer (1018013, QIAGEN, Manchester, UK) for 15 seconds and 2 minutes 
centrifuge time, respectively.  Each RNeasy spin column was then carefully removed from the 
collection tube and transferred into a new 1.5 mL Eppendorf collection tube.  50 μL of RNase-
free water (129112, QIAGEN, Manchester, UK) was then added to the membrane of RNeasy 
spin column and centrifuged at 200 g for 1 minute.  The RNA is now in the RNase-free water 
collected into the Eppendorf tube.  The RNeasy spin column was then discarded, and the 
Eppendorf tube containing the RNA sample was transferred into PCR tube on ice and/or freeze 
at -80 °C until further processing.  The amount and purity of the RNA sample was subsequently 
quantified using a NanoDrop 8000 spectrophotometer (ThermoFisher Scientific, 
Loughborough, UK).  The amount of RNA required to be used for the synthesis of cDNA, was 
calculated based on the following formula: 
          RNA template (µL) = (1/ RNA amount) x 1000 
The RNA concentration was typically between 1000-1200 ng/ mL.  The RNA purity was also 
determined based on the absorbance of RNA at 260/280 and 260/230 nm ratios.  A ratio of 
absorbance of 1.8-2.0 at 260/280 nm wavelength was accepted as pure RNA sample.  Any ratio 
lower than 1.8, indicated the presence of contaminants that absorbed at 280 nm.  The 260/230 
nm ratio was used as a secondary measure for RNA purity, with a ratio of purity at 2.0-2.2.  
Similarly, any ratio lower than 2.0 indicated the presence of contaminants that absorbed 230 
nm.  The RNA extraction process was equally followed for all timepoint samples collected 
(Figure 2.1.).              
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2.6. cDNA synthesis from RNA template  
For the synthesis of complementary DNA (cDNA), cDNA pre-mix (24 μL) and master-mix (16 
μL) solutions were used per sample.  For the cDNA pre-mix solution preparation, a total RNA 
of 1 μg (prepared in RNase-free water) was added into 1.5 mL Eppendorf tube, in addition to 1 
μL 500 ng random oligodeoxy-ribonucleotides primers (48190-011, ThermoFisher Scientific, 
Loughborough, UK) and 2 μL 10 mM deoxynucleotide triphosphates (dNTP; AM8200, 
ThermoFisher Scientific, Loughborough, UK).  The cDNA pre-mix was incubated at 65 °C for 
5 minutes on a heat block (Grant; Grant Instruments Ltd, Cambridgeshire, UK) allowing 
denaturation of the secondary structures of RNA formed in the sample during that time, and 
then placed on ice in order to cool down. 
The master-mix (16 μL) was prepared with 2 μL Moloey Murine Leukemia virus reverse 
transcriptase enzyme (M-MLV RT; 28025013, ThermoFisher Scientific, Loughborough, UK), 
8 μL 5X First Strand Buffer ([250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 mM MgCl2]; 
01234560, ThermoFisher Scientific, Loughborough, UK), 4 μL 0.1 M dithiothreitol (DTT; 
ThermoFisher Scientific, Loughborough, UK) and 2 μL RNaseOUT™ recombinant 
ribonuclease (10777-019, ThermoFisher Scientific, Loughborough, UK).  An additional sample 
(used as negative control) was prepared and run with the rest of the samples, without the 
addition of M-MLV reverse transcriptase (maximal enzyme mix); avoiding in that way the 
catalyse of cDNA synthesis from the RNA template in the samples.  
The cDNA pre-mix (24 μL) and master-mix (16 μL) solutions were mixed followed by a 10-
minute incubation at room temperature (annealing).  This was followed by 1-hour incubation 
at 37 °C (extension) in a thermal cycler (GeneAmp® PCR System 2700; Applied Biosystems, 
UK) and a 15-minute incubation at 70 °C to stop the reaction by inactivation of reverse 
transcriptase enzyme.  The cDNA sample was stored at -80 °C until future use.  This process 
was equally followed for all timepoint samples collected (see section 2.4.1).  
2.7. Real time-quantitative polymerase chain reaction (RT-QPCR)  
mRNA expression and existence of Bmal1 clock gene circadian rhythmicity in HL1-6 atrial 
myocytes and pMEFs, was determined using real time – quantitative polymerase chain reaction 
(RT-QPCR).  Bmal1 gene was amplified by RT-QPCR, using ABsolute™ QPCR ROX mix 
(AB1139A, ThermoFisher Scientific, Loughborough, UK).  The ABsolute™ QPCR ROX mix 
is a 2x master mix that contains a Rox reference dsDNA-binding dye, GoTaq® hot start 
polymerase enzyme, magnesium chloride (MgCl2), dNTPs and a proprietary reaction buffer 
excluding the cDNA sample as well as the primers and probes of genes of interest.                  
Chapter 2. RT-QPCR 
 
57 | P a g e  
 
The reactions were run on a MicroAmp optical 96-well plate (N8010560, ThermoFisher 
Scientific, Loughborough, UK). Technical replicates (3) of each timepoint cDNA samples, 
negative control and standard curve samples were prepared and run in each 96-well plate. Each 
well contained 2.5 μL cDNA sample, negative control or standard curve sample, and 22.5 μL 
of QPCR mix.  Stock solutions of QPCR mix containing 1 μL of forward primer (per cDNA 
sample), 1 μL of reverse primer (per cDNA sample), 0.5 μL of probe (per cDNA sample), 12.5 
μL of ABsolute™ QPCR ROX mix (per cDNA sample) and 7.5 μL of RNase-free water 
(R0581; ThermoFisher Scientific, Loughborough, UK) (per cDNA sample) were prepared 
separately for the housekeeping gene (GAPDH; glyceraldehyde 3 – phosphate dehydrogenase) 
and the genes of interest (Bmal1 clock gene). The list of primers and probes used in the 
experiments is shown in Table 2.3. 
 
Table 2.3. Forward primers, reverse primers and probes onomatology and sequencing representation 
 
 
 
 
 
 
 
 
The standard curve was prepared by serial dilutions of DNA samples in RNase-free water, at 
concentration of 101 - 105 per 96-well plate.  The standard curve was equally run on each plate 
and used as a way to determine the concentration of the expressed Bmal1 gene of interest in 
each cDNA sample.  The 96-well plate was then sealed using an adhesive ABsolute™ QPCR 
seal (AB1170, ThermoFisher Scientific, Loughborough, UK) and vortexed for even mixing of 
the cDNA samples with the QPCR mix.  The 96-well plate was centrifuged at 200 g for 4 
minutes and placed into 7500 Real Time-PCR machine (Applied Biosystems, UK).  The QPCR 
reactions were carried as follows: 95 °C for cDNA denaturation (15 minutes), 60 °C for cDNA 
amplification (1 minute; this was repeated for 50 cycles) and 72 °C for cDNA dissociation (1 
minute).             
            
                  
 Gene Names Sequences (5ʹ- 3ʹ) Annealing 
Temp. (˚C) 
 Bmal1   
F.p. MBMAL1L 5́-CTCAGCTGCCTCGTTGCAA-3 ́ 67.9 
R.p. MBMAL1R 5́-TCCATAGATTTCACCCGTATTTCC-3 ́ 65.5 
Probe MBMAL1P 5́-CGCCTGCACTCGCACATGCTTC-3 ́ 76.0 
 GAPDH   
F.p. MGAPDHL 5́-CAAGGTCATCCATGACAACTTTG-3 ́ 65.3 
R.p. MGAPDHR 5́-GGGCCATCCACAGTCTTCTG-3 ́ 67.0 
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The RT-QPCR method allows quantification of the amount of BMAL1 mRNA sequence within 
each sample, by measuring the intensity of fluorescence emitted by BMAL1 probe at each 
cycle.  Relative mRNA gene expression was calculated using the standard curve method. The 
relative mRNA expression was calculated as a function of threshold cycles (CT), the number 
of cycles required for the fluorescent signal (emitted by the probe) to cross the threshold.  The 
threshold was set the same for all samples in the 96-well plate based on a value at which all 
samples are in the linear amplification phase (i.e. background signal).  The CT levels are 
inversely proportional to the amount of amplified DNA within the reaction; samples with a high 
initial expression level show an earlier rise compare to those with a low target level.  In other 
words, the higher the initial number of DNA molecules in a sample, the ealier the fluorescence 
will be emitted during RT-QPCR cycles, hence samples containing more DNA will get detected 
in earlier cycles. 
2.7.1. Data acquisition and statistical analysis  
The quantify of the real expression of targeted gene (Bmal1) in specific timepoints is relatively 
to GAPDH housekeeping gene and was calculated from the measured CT.  Bmal1 mRNA 
expression was normalised to GAPDH which was used as a control in order to provide 
standardised expression throughout the different time points.  The second normalisation was 
performed using the CT of the non-synchronised cells and presented as a fold change from 
control.  All calculations were performed with Microsoft Office Excel 2016 software.  Data are 
presented as mean of 3 technical replicates and standard error of the mean (SEM). The statistical 
analysis of data was conducted using GraphPad Prism version 7 software (La Jolla, California, 
USA).  A cosine curve was also fitted allowing period determination on the best fit of this cosine 
curve.  The period length of protein expression was defined as the distance between peaks or 
troughs over the 24-48 hours post serum-shock synchronisation.  The cosinor curve was fitted 
using Graph-Pad Prism software as follow: 
 
y = (Mesor + Amplitude*cos (((2*PI)*(X-Acrophase))/24))*exp(-X/Damping) 
Where:  
 
X = time   
Mesor = the average value around which the variable oscillates 
Amplitude = the difference between the trough and the mean value of a wave 
Acrophase = the time at which the rhythm peaks or troughs 
Damping = decrease in amplitude of the rhythm’s amplitude over time distance between two 
consecutive peaks or troughs               
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All data are presented as Mean ± SEM (Standard Error of the Mean).  Two-way ANOVA 
(analysis of variance) test was employed with the aim to test the overall divergence between 
the treated and the untreated (Control) groups and the effect of time (0-48 hours), followed by 
post hoc analysis of significant main and interaction effects using Bonferroni multiple pairwise 
comparison test.  A Student’s t test (unpaired t test) was set at 0.05; as a result, the p-values < 
0.05 were interpreted as significant. 
 
2.8. Lentivirus production & quantification 
Lentiviral (LV) particles containing a plasmid that has a Bmal1 promoter driving a luciferase 
reaction were used for the quantification of Bmal1 circadian rhythmicity using bioluminescence 
recordings.  
2.8.1. Lentivirus production using Human Embryonic Kidney 293T cells 
(HEK293T)  
The components necessary for the production of lentiviral particles are divided into packing, 
envelop and transfer plasmids.  The packing (i.e. PsPAX2) and envelope (i.e. pMD2.G) 
plasmids encode components of the viral capsid and envelope, respectively, whereas the 
transfer plasmids (i.e. pWPI) encode the viral genome.  For the production of LV particles the 
addition of 275.7 ng/ μL PsPAX2, 115 ng/ μL pMD2.G, 102.5 ng/ μL pWPI and 200.35 ng/ μL 
pABpuro-BluF Bmal1::Luciferin plasmids was required, creating a DNAmix plasmid.  The 
PsPAX2 is a packing plasmid suitable for the production of viral particles, which contains a 
robust CAG promoter for efficient expression of packing proteins.  The pMD2G is an envelope 
expressing plasmid, whereas the pWPI is a lentiviral vector plasmid that allows simultaneous 
expression of a transgene.  Green Fluorescent Protein (GFP) marker is used to track transduced 
cells.  The pABpuro-BluF act as a luciferase reporter for Bmal1 (gene of interest) promoter.  
All plasmids were kindly provided by Professor S. A. Brown (University of Zϋrich, Zurich, 
Switzerland).  
The LV particles were generated in Human Embryonic Kidney 293T (HEK293T) cells.  The 
HEK293T cells derived from the HEK293 cell line mixed with a SV40 large T antigen which 
is known to allow replication of transfected plasmids containing the SV40 origin of replication. 
This allows amplification of the transfected plasmids and temporal expression of desired gene 
products in the plasmids.  HEK293T cells were maintained in DMEM formulated with glucose 
[5.5 M] (11965092, ThermoFisher Scientific, Loughborough, UK) and supplemented with 2 
mM of L-glutamine (G7513, Sigma-Aldrich, Gillingham, UK), 100 units / mL of P/S (P4333, 
Sigma-Aldrich, Gillingham, UK), 10 % FBS (F0804, Sigma-Aldrich, Gillingham, UK) and 100 
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μg / mL non-essential amino acids (11140035, ThermoFisher Scientific, Loughborough, UK). 
The DMEM was stored at 4 °C (fridge) or pre-heated at 37 °C in water-bath prior to its use. 
2.8.2. Transfecting HEK293T cells using lentiviral particles  
The HEK293T cells were split at a ratio of 1:6 (9 T75 flasks in total; x3 for day 1 LV collection, 
x3 for day 2 LV collection, x3 for day 3 LV collection) 48 hours prior to the transfection day 
ensuring that the cells were actively dividing and were at the appropriate cell density (50-70 %) 
the day of transfection.  For the preparation of DNAmix plasmids (see section 2.8.1.), a stock 
solution containing 3892.5 µL of OptiMEM 1 reduced-serum free medium without phenol red 
colour (11058021, ThermoFisher Scientific, Loughborough, UK) and 135 μL of X-tremeGENE 
9 (06365809001, Sigma-Aldrich, Gillingham, UK) transfection reagent were prepared in a 
separate sterile 15 mL falcon tube.  The OptiMEM 1/ X-tremeGENE 9 stock solution was mixed 
together by gently flicking the bottom of the falcon tube and allowing it to set for 10 minutes 
at room temperature.  The DNAmix plasmids were then added to the OptiMEM 1/ X-
tremeGENE 9 stock solution, followed by 30 minutes incubation at room temperature.  The 
DNA/ X-tremeGENE 9 mix plasmids solution was then mixed with 90 mL of fresh complete 
DMEM, which was then used to replace the medium maintaining the HEK293T cells (10 mL/ 
T75 flask; 9 flasks in total).  The HEK293T cells were incubated with the DNA/ X-tremeGENE 
9 mix plasmid medium solution for 3 days allowing the production of lentivirus.  
2.8.3. Collection of Lentivirus  
After 24 hours of transfecting the HEK293T cells with the DNA/ X-tremeGENE 9 mix plasmid 
medium for the generation of lentivirus (LV), the LV-containing medium was transferred from 
all T75 flasks (9 in total; x3 for day 1 LV collection, x3 for day 2 LV collection and x3 for day 
3 LV collection) into separate sterile 50 mL conical centrifuge tubes (430921, Cole-Parmer, 
Cambridgeshire, UK) using a pipette, and centrifuged at 3300 g for 10 minutes.  The LV-
containing medium was aspirated, and immediately replaced with fresh complete DMEM until 
further LV collection.  
The LV-containing supernatant was filtered through 0.22 μm filter units (10268401, 
ThermoFisher Scientific, Loughborough, UK) and then centrifuged at 3000 g overnight.  The 
following day (48 hours post-transfection) the supernatant was carefully decanted off (leaving 
a cell pellet) and replaced with 50 μL (per 50 mL falcon) of serum-free DMEM.  The conical 
centrifuge tubes were covered with parafilm and incubated for 45 minutes on ice.  After the 
incubation time, the LV medium was gently mixed by pipetting several times up and down and 
aliquoted into sterile cryotubes (9 μL per cryotube) which were later stored at -80 °C until 
further processing.  This finalised the collection of day 1 lentivirus.  Such process was similarly 
followed for the collection of day 2 and day 3 lentivirus.     
Chapter 2. Lentivirus quantification  
 
61 | P a g e  
 
2.8.4. Quantification of lentivirus using QuickTiter™ LV titer kit  
Lentivirus particles were produced from HEK293T cells through transient transfection of 4 
plasmids that encodes for the components of the virion. Viral particles were harvested within 
48-72 hours post transient transfection. Viral titer was determined to ensure that there was 
controlled number of copies of the integrated viral constructs per cell before proceeding with 
transduction experiments. Quantification of LV particles was determined using the 
QuickTiterTM lentivirus titer kit (VPK-112, Cell Biolabs, San Diego, USA).  The kit does not 
involve infection of the cells; instead it specifically measures the lentiviral nucleic acid content 
of unpurified viral supernatant samples.  The LV particles were quantified against eight 
QuickTiterTM Lentivirus RNA standards from a serial dilution with concentrations of 1.5625, 
3.125, 6.25, 12.5, 25, 50, 100 and 200 μg/mL using QuickTiterTM Solutions based on the 
manufacturer’s instructions.  Then, the viral samples were thawed, and each sample volume 
was adjusted to 1 mL with PBS containing 10 mM magnesium chloride (MgCl2) and 1 mM 
calcium chloride (CaCl2).  A QuickTiter
TM Solution A; enzyme cocktail suitable for the 
digestion of non-viral nucleic acids, was added (10 μL) into each assay tube containing the viral 
samples, mixed and incubated for 30 minutes at 37 °C.  Post incubation time, 40 μL of 
QuickTiterTM LV Capture Solution containing beads that bind to the lentivirus was added into 
each assay tube followed by 10-minute incubation at room temperature on a MaxQ orbital 
shaker (ThermoFisher Scientific, Loughborough, UK).  
After spinning down the assay tubes at 2000 g for 30 seconds, the supernatant was carefully 
discarded, and the viral beads were washed with 750 μL of Tris-based QuickTiterTM Solution 
B buffer.  The assay tubes were then inverted up and down several times allowing even mixing 
of the solutions with viral beads and then centrifuged at 2000 g for 30 seconds.  The final wash 
was aspirated, and the assay tubes centrifuged again at 2000 g for 30 seconds for the removal 
of the last bit of liquid.  Then, 20 μL of QuickTiterTM Solution C was added into each assay 
tube allowing lysis of the viral particles and released of RNA.  The assay tubes were centrifuged 
at 12000 g for 30 seconds and the viral supernatant of each tube was transferred to a 96-well 
microtiter plate (ThermoFisher Scientific, Loughborough, UK) suitable for fluorometer.  The 
wells were toped up with 95 μL of CyQuant® GR Dye, which binds to the viral RNA providing 
quantification.  Similar prospect was followed for the addition of standards into the wells.   
The plate was finally measured at 480/520 nm using a fluorescence plate reader (Labsystems 
Original Multiscan RC; ThermoFisher Scientific, Loughborough, UK). Using Microsoft Office 
Excel 2016 software, the fluorescent readings of the known QuickTiterTM Lentivirus RNA 
standards were used to produce a standard curve of relative fluorescence units (RFU) vs. 
concentration from which the LV titer RNA concentration could be determined (Figure 2.2.).  
The desired coefficient of determination (R2) was always over 0.96.     
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Figure 2.2. Example of lentivirus titer standard curve.  The curve represents the amount of relative fluorescence 
unit (RFU) exist in LV RNA samples.   
 
For the determination of LV titer RNA amount the net relative fluorescence unit (RFU) was 
calculated using the following formula:  
 
Then using the standard curve, the LV titer RNA amount of each sample was determined.  
For the calculation of LV Titer amount the following formula was used:  
 
2.9. Bioluminescent analysis of Bmal1 gene circadian expression  
To assess Bmal1 clock gene circadian rhythmicity, HL1-6 atrial myocytes and pMEFs were 
transfected with Bmal1::Luc LV particles infection and subsequently serum-shocked 
synchronised allowing phase align existing rhythms amongst adjacent cells. Bmal1 
bioluminescence recordings were monitored during the experiment using a luminometer 
machine.                   
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2.9.1. Cell lines transfection with Bmal1::Luc LV particles infection 
Both HL1-6 atrial myocytes and pMEFs were transiently transfected with the luciferase based 
reporter gene containing Bmal1 promoter (Bmal1::Luc) LV particles.  The cells were initially 
seeded in 35 mm dishes (see section 2.3.5.) for LV transfection, at a density of 1.0 x 107 cells/ 
dish (HL1-6s) or 1.0 x 105 cells/ dish (pMEFs).  Once the cells reached 60-80 % confluence, 
the LV transfection procedure was carried out in category 2 laboratory under sterilised laminar 
flow hood.  At first, the medium was aspirated and the cells were washed with PBS solution.  
The PBS was then replaced with 2 mL fresh complete Claycomb medium (HL1-6s) or DMEM 
(pMEFs) supplemented with 10 mg/mL protamine sulfate (0.8 µL/ mL of medium for 8 µg/ mL 
final concentration; Sigma-Aldrich, Gillangham, UK).  Addition of protamine sulphate is 
essential as it reduces the repulsion forces between the cell and the virus, and mediates the 
binding of lentiviral particle to the cell surface resulting in a higher efficiency of transduction.  
Then, lentiviral particles of Bmal1::Luc luciferase reporter were added at least 6 x 1010 viral 
particles per 1 mL of medium for a successful transfection and the 35 mm dishes were swirled 
allowing even mixing of the lentiviral particles with the medium.  Post transfection, the cells 
were subjected for incubation at 37 °C with 5 % CO2 for 24 hours and then the medium was 
replaced with fresh complete Claycomb medium or DMEM.  On the following day, the cells 
were passaged from 35 mm dish into T25 flask containing 5 mL complete Claycomb medium 
or DMEM, at a ratio of 1:3 once they reached 85-90 % confluency.  Some T25 flasks went 
through cryopreservation procedure creating a cell bank for future experiments, whereas the 
rest of them were passaged and/or platted in 35 mm dishes for bioluminescence experiment 
testing the transfection efficiency. 
2.9.2. Bioluminescent recordings of Bmal1 gene expression  
Bmal1 clock gene expression recordings were reported using HL1-6 atrial myocytes and pMEFs 
of passage 3-4 transfected with Bmal1::Luc promoter LV particles.  A schematic representation 
of bioluminescence experimental protocol is presented in Figure 2.3.  In details, the cells were 
plated at a density of 1.0 x 107 (HL1-6s cells) or 1.0 x 105 (pMEFs) per 35 mm dish containing 
2.0 mL of complete Claycomb medium or DMEM, and incubated for 24 hours at 37 °C with 5 
% CO2.  Once the cells reached 70-80 % confluence, were synchronised by serum-shock 
allowing synchronisation and resetting of the clock genes inside the cells.  This was achieved 
by aspirating the medium from the dishes and washing of the cells twice with PBS solution.  
Following that, the cells were synchronised with 2.0 mL per 35 mm dish of serum-shocking 
Claycomb medium or DMEM (see section 2.4.) and incubated for 2 hours at 37 °C with 5 % 
CO2.  This marks the Control group used for the upcoming experiments.  At this point cells 
were also subjected to persistent sodium (NaP) channel opener anemonia sulcate toxin II 
(ATXII, 1 nM final concentration prepared in DMSO, from 10 mM stock; A0981, Sigma-
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Aldrich, Gillingham, UK) to induce atrial arrhythmias, in the presence or absence of Ranolazine 
(NaP channel blocker, 10 µM final concentration prepared in DMSO, from 50 mM stock; 
R6152, Sigma-Aldrich, Gillingham, UK), in presence of bis (2-aminophenoxy) ethane 
tetracetic acid (BAPTA) cell-permeant AM (BAPTA-AM, 5 µM final concentration prepared 
in DMSO, from 30 mM stock; A1076, Sigma-Aldrich, Gillingham, UK), or in presence of 
calcineurin autoinhibitory peptide (CAIP, 25 µM final concentration prepared in 50 mM 
aqueous solution; 207001, Calbiochem, Merck Millipore, UK) following 2-hour serum-shock 
synchronisation. 
Post serum-shock synchronisation, the cells were rinsed twice with PBS solution and then 
treated with 2.5 mL bioluminescence DMEM without phenol red (D5921, Sigma-Aldrich, 
Gillingham, UK) or Claycomb medium containing 15 % FBS, 1 % P/S, 1 % L-Glutamine 
(and/or 0.1 mM NE for HL1-6s cells; see section 2.3.1.1.) and 0.1 mM Luciferin-EF™ 
endotoxin (1 µL of 0.1 M stock solution per 1 mL of medium; E6551, Promega, Wisconsin, 
USA) under minimum light exposure. For the preparation of 0.1 M stock Luciferin-EF™ 
solution, 25 mg of Luciferin powder was dissolved with 826 µL of sterilised water.  Luciferin-
EF™ stock aliquoted were stored at -80 °C until required.  The dishes were sealed with grease 
and 40 mm diameter glass coverslips, and then transferred into LumiCycle 32-channel 
luminometer (Actimetrics, Illinois, USA) for bioluminescence monitoring and recording.  The 
temperature was kept at 37 °C throughout the experiment (4 days).  The luminometer allows up 
to 4 dishes to be counted at the same time as it is equipped with 4 photon-counting multiplier 
tubes selected for low dark counts with high sensitivity in the green portion of the spectrum.  
This implies that every 10 minutes 32 of 35 mm dishes bioluminescence could be recorded all 
at once, for 1 minute. Bmal1 bioluminescence recordings were monitored during the experiment 
using Actimetrics LumiCycle Analysis software for the determination of Bmal1 circadian 
characteristics as described below.  Any affected readings due to opening of the LumiCycle 32-
channel luminometer were discarded due to misfolded results. 
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Figure 2.3. Schematic representation of Bmal1 bioluminescence recordings experimental set-up. HL1-6 atrial 
myocytes and pMEFs were subjected to Bmal1::Luc LV particles and then subsequently synchronised with 50 % 
FBS cell culture medium for 2 hours, followed by Bmal1 bioluminescence monitoring.  Cells were further 
subjected to several drug treatments to monitor changes in Bmal1 circadian rhythmicity under various changes of 
intracellular [Ca2+].      
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2.9.3. Data acquisition and statistical analysis  
Microsoft Office Excel 2016 software was used for the analysis of trended, and subsequently 
detrended, Bmal1 bioluminescence recorded as followed.  The average bioluminescence count 
of 24 hours (12 hours before and 12 hours after each time point) was calculated (trend) based 
on that.  The data were recorded once each 10-minutes for 24 hours (1440 minutes) marking 
the total time of recorded data to 144 time points (1440/10 = 144 time points).  Therefore, the 
average recorded bioluminescence of 144 time-points before and after each time point was 
calculated as the trend.  The trend of each time point was then subtracted from the actual 
recorded data of that point resulting in the detrended data.  Following that, the detrended 
bioluminescence data were baseline subtracted (5-hour smoothing) and fitted using a cosine 
curve (Graph-Pad Prism version 7 software) for the determination of peaks and trough points.  
Cosine curve fitting data of 24 hour (estimated time for a complete cycle) prior to the different 
treatment conditions, by a least-squares procedure using the averaged smoothed Bmal1 
bioluminescence count. 
The baseline subtracted data were also analysed for circadian characteristics including period 
and amplitude using Actimetrics LumiCycle Analysis 2.50 software.  A cosine curve was also 
fitted allowing period determination on the best fit of this cosine curve (see section 2.7.1.).  The 
period length of bioluminescence is defined as the distance between peaks or troughs over the 
24-60 hours post serum-shock, whereas amplitude calculated based on the distance between the 
peaks or troughs effect and the baseline (Figure 2.4.). 
Figure 2.4. Circadian rhythm characteristics. A representative circadian rhythm is depicted in which the level 
of a particular measure (e.g. bioluminescence levels) varies across time.  The difference in the level between peak 
and trough values is the amplitude of the rhythm.  The timing of timing of a reference point in the cycle (e.g. the 
peak) relative to a fixed event (e.g. the beginning of the night phase) is the phase.  The time interval between phase 
reference pints (e.g. two peaks) is called the period. 
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The statistical analysis of period and amplitude characteristics of the bioluminescence recording 
data, was conducted using a Student’s t test (unpaired t test) on the GraphPad Prism version 7 
software.  Differences were expressed as mean of technical replicates and standard error of the 
mean (SEM).  The Student’s t test was set at 0.05; as a result, the p-values < 0.05 were 
interpreted as significant.  One-way ANOVA (analysis of variance) test was employed with the 
aim to test the overall divergence between the treated and the untreated (Control) groups.   
2.10. MTS cell viability assay 
Cell viability could be assessed by indirect or direct assays. Trypan blue dye method is an 
indirect standard method based on the concept that only non-viable cells take up the dye and 
the number of blue-dyed cells will then be counted using haemocytometer (Strober et al., 2001).  
Hence the cell viability is assessed indirectly by exclusion will only where the dye diffuses.  
This method can only be used as a screening method.  A better approach is to directly measure 
cell viability via detection of a by-product produced only by metabolically active cells.   
One of the most used methods is the MTS assay which is a colorometric method used to 
determine the number of viable and metabolically active cells (Riss et al., 2013).  This assay is 
equally use to assess cell proliferation and cytotoxicity.  The MTS assay kit contains the 
CellTiter96® Aqueous One Solution Reagent, which is made up by MTS [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner 
salt] and phenazine ethosulfate (PES; electron coupling reagent) (G3582, Promega, 
Southampton, UK).  The electron coupling reagent, PES, binds to MTS and forms a stable MTS 
tetrazolium compound, which is taken up by only viable and metabolically active cells.  The 
MTS tetrazolium compound is reduced to a coloured formazan product that is soluble in tissue 
culture medium.  Such conversion is accomplished by NADPH or NADH produced by 
dehydrogenase enzymes. The formazan product will then have diffused into the culture medium 
and quantified at 490 nm absorbance.  The quantity of formazan product as measured by 
absorbance at 490 nm, is directly proportional to the number of living cells in culture.  The 
MTS assay is indeed a high-throughput assay and has several advantages when compared to 
the MTT assay, in particular, its easy application which include one step cell treatment.  
The MTS assay was used to assess the cell viability of cultured HL1-6 cells and pMEFs after 
1, 2 and 3 days incubation duration in control complete Claycomb medium (HL1-6 cells) or 
DMEM (pMEFs), following serum-shock synchronisation, in the absence or presence of 1 nM 
ATXII alone or in combination with 10 µM ranolazine.  HL1-6 cells and pMEFs were seeded 
at 1 x 105 cells/ well in 96-well plates (and incubated for 24 hours at 37 °C with 5 % CO2).  The 
following day, and once the cells reached 70-80 % confluence, they were synchronised for 2 
hours with serum-shock Claycomb medium or DMEM (see section 2.4.). The synchronised 
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cells were washed with their respective fresh control culture medium and incubated for 1, 2 and 
3 days in control medium alone; or treated with 1 nM ATXII in the absence or presence of 10 
µM ranolazine; 10 µM Ranolazine alone; and vehicles (1 % DMSO; concentration of solvent 
used for ATXII or Ranolazine).  At day 1, 2 or 3, the CellTiter96® Aqueous One Solution 
Reagent was thawed in a water bath at 37 °C for 10 minutes and then 20 µL of 0.5 mg/mL final 
concentration were added into each well containing 100 µL of culture medium and/or treatment 
medium.  The 96-well plates were incubated for 2 hours at 37 °C with 5 % CO2 and light 
exposure was minimised by running the experiment in dim light as well as using aluminium 
foil to shield the 96 well plates.  Spectrophotometric absorbance was measured at 490 nm using 
a plate reader (Labsystems Original Multiscan RC; ThermoFisher Scientific, Loughborough, 
UK). This process was similarly followed for 3 subsequent days assessing the cytotoxic effect 
of variable treatments in cell survival during day 1, day 2 and day 3. 
2.10.1. Data acquisition and statistical analysis 
Experiments were performed in sample size of 3 technical replicates and the relative cell 
viability was expressed as a percentage (%) relative to the untreated control cells (serum-
shocked medium).  All calculations were performed with Microsoft Office Excel 2016 software 
as followed:   
𝐂𝐞𝐥𝐥 𝐯𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲 (%) =
𝐓𝐞𝐬𝐭𝐞𝐝 𝐬𝐚𝐦𝐩𝐥𝐞
𝐂𝐨𝐧𝐭𝐫𝐨𝐥 𝐬𝐚𝐦𝐩𝐥𝐞
 𝐱 𝟏𝟎𝟎 
The statistical analysis of data was conducted using GraphPad Prism version 7 software.  Two-
way ANOVA (analysis of variance) test was employed with the aim to test the overall 
divergence between the treated and the untreated (Control) cells and the effect of time (day1, 
2, 3), followed by post hoc analysis of significant main and interaction effects using Bonferroni 
multiple pairwise comparison test.  A Student’s t test (unpaired t test) was set at 0.05; as a result, 
the p-values < 0.05 were interpreted as significant.   
 
2.11. Measurement of intracellular [Ca] using the ratiometric Ca2+ 
ionophore; Fura-2 AM 
The main underlying mechanism for ATXII-mediated effects in this thesis is triggered by 
intracellular [Ca2+].  Therefore, its crucial to measure [Ca2+]i directly in order to confirm its role 
in the majority of studies carried out in this thesis. Indeed, several Ca2+ fluorophores can be 
used such as Fluo 4 (non ratiometric) and Fura 2/ Fura 8 (ratiometric) (Kaposi et al., 2007).  
Indeed, the ratiometric fluorophore has the advantage that estimated [Ca2+] is independent of
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the absolute fluorescence intensities (and hence dye concentration in the cell).  Fura-2 
acetoxymethylester (Fura-2 AM; Sigma-Aldrich, Gillingham, UK) is ratiometric Ca2+ 
fluorophore, enabling the dynamic measurement of intracellular [Ca2+].  Fura-2 AM is lipophilic 
cell permeable form. Once enters the cell it is activated by cleavage of the acetoxymethyl group 
by intracellular esterase.  The activated free form of Fura-2 is membrane impermeable and 
hence remains trapped inside the cell.  The Fura-2 loaded cells were then excited at 340 or 380 
nm. Once bound to Ca2+ ion, Fura-2 is maximally excited by a 340 nm wavelength, but in its 
unbound state is maximally excited by 380 nm, while the emission maximum remains at 510 
nm (Grynkiewicz et al. 1985).  Hence, the ratio of fluorescence emission when excited at 340 
nm or 380 nm is a function of the intracellular [Ca2+] (Figure 2.5.). 
Cultured spontaneously contracting HL1-6 cells were seeded (1.0 x 107) on 24-well clear 
fibronectin-coated plates at a confluence of 85-90 % and kept in culture for 24 hours to allow 
time for cells to adhere to the bottom of each well.  The cells were then serum-shocked for 2 
hours using 50% FBS containing Claycomb medium (see section 2.4.) to synchronise and reset 
all endogenous peripheral clock genes.  The cells were then washed twice in physiological 
HEPES buffer saline solution (20 mM HEPES, 115 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 
0.8 mM MgCl2, 13.8 mM glucose, pH 7.4), to remove excess serum-shock Claycomb medium 
from the wells.  The medium was then replaced with fresh complete Claycomb medium 
(control) in addition to ATXII (1 nM) alone or in combination with either ranolazine (10 µM) 
or calcineurin autoinhibitory peptide (CAIP; 25 µM).  
 
 
 
 
 
 
 
 
Figure 2.5. Fura-2 fluorescence emission. Fura-2 fluorescence emission as a function of excitation frequency 
measured at 510 nm in pH 7.2 buffer (reflects physiological intracellular pH), at varying free Ca2+ concentrations. 
Upon Ca2+ binding an absorption shift in the Fura-2 excitation spectrum is observed. The 340/ 380 nm excitation 
(indicated by dashed lines) varies with [Ca2+], and is at its greatest at 39.8 μM and decreases with decreasing 
concentration (Molecular probes, Invitrogen handbook). 
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At specific timepoints (2, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 hours post serum-shock 
effect), the cells were passively loaded with 10 µM cell-permeable Fura-2/AM as followed.  A 
stock solution of Fura 2-AM (F1221, ThermoFisher Scientific, Loughborough, UK), was 
initially prepared by mixing 50 µg of Fura2 with 50 µL DMSO in darkness and stored at -20 
ºC covered in foil until use.  Following that, 1 mM Fura 2-AM working solution was prepared 
by diluting 1 mM Fura 2-AM/ DMSO solution with similar HEPES buffer saline solution 
mentioned above (pH 7.4).  The culture medium and/or drug treated medium was removed, and 
0.5 mL of the Fura-2 AM working solution was added to the cells with room light turned off.  
The 24-well plate was covered with foil and cells were incubated for 30 minutes at 37 ºC with 
5 % CO2, allowing diffusion Fura-2 AM into the cells.  Wells without Fura2-AM loading were 
also run on the 24-well plate and used as a control background emission.  The Fura2-AM 
working solution was removed from the wells and replaced with HEPES buffer saline solution 
before measuring of the Ca2+ fluorescent.  The excitation spectra of 340 nm (Ca2+ complex) and 
380 nm (Ca2+ free) with fixed 510 nm emission (340/510 nm and 380/510 nm) was monitored 
and measured using a plate reader (Labsystems Original Multiscan RC; ThermoFisher 
Scientific, Loughborough, UK).  Technical replicates (3) of each timepoint samples per 
condition (control, ATXII, ATXII/Ranolazine, Ranolazine, ATXII/CAIP) were run in each 24-
well plate, in addition to 3 wells free of Fura-2 loading (containing only HEPES buffered saline 
solution) which were used as a background control.  This process was equally followed for all 
timepoints (2, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 hours post serum-shock effect). 
2.11.1. Data acquisition and statistical analysis 
The background fluorescence emission (wells free of Fura-2 loading) was subtracted from each 
fluorescence excitation spectra (340/510 nm and 380/510 nm) followed loading with Fura-2, 
for the interpretation of corrected Ca2+ fluorescent emission recording.  The average Ca2+ 
fluorescent emission per excitation spectra (340/510 nm and 380/510 nm) was calculated based 
on 3 technical replicates per timepoint.  All calculations were performed with Microsoft Office 
Excel 2016 software.  The average of 340/510 nm spectra was then divided by the average of 
380/510 nm spectra for the interpretation of Ca2+ fluorescent emission per timepoint (steps are 
also shown below). 
Step 1.  Corrected Ca2+fluorescent = (Fura − 2 loading well (380/510 nm)) −
                                                                        (Free of Fura − 2 loading well (380/510 nm))  
Step 2.  Corrected Ca2+fluorescent = (Fura − 2 loading well (340/510 nm)) −
                                                                        (Free of Fura − 2 loading well (340/510 nm))       
Step 3.  Calculation of average of 340/510 nm corrected (based on step 1)   
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Step 4.  Calculation of average 380/510 nm corrected (based on step 2) 
Step 5.  (Average of 340/510 nm corrected)/(Average of 380/510 nm corrected)  
The Ca2+ fluorescent obtained against the different timepoints using the average values for 3 
technical triplicates, was expressed as expressed as Mean ± SEM using GraphPad Prism version 
7 software.  The statistical analysis of data was also conducted using GraphPad Prism version 
7 software.  Intracellular [Ca2+] measurements are presented as Mean ± SEM.  Two-way 
ANOVA (analysis of variance) test was employed with the aim to test the overall divergence 
between the treated and the untreated (Control) groups and the effect of time (12-48 hours), 
followed by post hoc analysis of significant main and interaction effects using Bonferroni 
multiple pairwise comparison test.  A Student’s t test (unpaired t test) was set at 0.05; as a result, 
the p-values < 0.05 were interpreted as significant.  A cosine curve was also fitted allowing 
period determination on the best fit of this cosine curve, by fitting data of 24 hour (estimated 
time for a complete cycle) prior to the different treatment conditions (see section 2.7.1.).  
 
2.12. SDS-PAGE and Western Blotting 
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (SDS-PAGE) and western 
blotting were used to quantify the protein expression levels of BMAL1, gap junction connexin 
protein isoforms (Cx40 and Cx43), persistent sodium channel protein isoforms (Nav1.1, 
Nav1.5, Nav1.6). HL1-6 atrial myocytes total cell homogenate at specific timepoints (0, 2, 4, 
8, 12, 16, 20, 24, 28, 32, 36, 40, 40, 44, 48 hours) post serum-shock synchronisation under 
control conditions, in presence of ATXII [1 nM] alone or in combination with Ranolazine [10 
µM] or CAIP [25 µM].   
2.12.1. Whole cell lysis and homogenisation  
To determine the protein expression and existence of circadian rhythmicity of Bmal1 clock gene 
in HL1-6 atrial myocytes were seeded at a density of 1.0 x 107 cells in a T25 cm2 culture flask 
(39 flasks in total; 13 flasks per condition) containing 5.0 mL of complete Claycomb medium 
and incubated for 24 hours at 37 °C with 5 % CO2.  Once the cells reached 85-90 % confluence, 
the culture medium was aspirated from the flasks and cells were washed twice with PBS 
solution.  Following that, the cells were serum-shocked with serum-shocking cell culture 
Claycomb medium (see section 2.3.), for 2 hours at 37 °C with 5 % CO2 environment.  At the 
end of incubation time the cells were washed with PBS (3 mL/ T25 flask) and then replaced 
with fresh complete Claycomb medium.  This marks the Control group used for the upcoming 
experiments.  In terms of treated groups, HL1-6 cells were treated with ATXII (1 nM) to induce 
atrial arrhythmias in the presence or absence of Nap inhibitor ranolazine (10 µM) and/or CAIP 
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(25 µM).  Upon serum-shock incubation time, cell lysates were collected every 4 hours for 48 
hours as shown in Figure 2.6.     
Figure 2.6. Schematic representation of HL1-6 atrial myocytes collection time points for protein lysate 
quantification.  The HL1-6 cells were serum shocked for 2 hours using 50 % FBS culture medium and then 
collected every 4 hours for 48 hours (Control).  In another experiment the HL1-6 cells were also treated with 1 nM 
ATXII, in the presence and/or absence of 10 µM Ranolazine or 25 µM CAIP, prior to their collection time points.    
 
Each T25 flasks was initially removed from the incubator and placed on ice ensuring that the 
temperature will remain as close to 4 °C as possible, inhibiting that way any enzymatic activity 
that might cause protein degradation (proteases) or dephosphorylation of phosphatases.  The 
medium was decanted of and cells were carefully washed twice with cold PBS (3 mL/ T25 
flask). Whole-cell lysates were prepared by extraction using 200 µL/ flask of 
radioimmunoprecipitation assay (RIPA; R0278, Sigma-Aldrich, Gillingham, UK) lysis buffer 
(10 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.1% SDS; 1% Triton-X100; 1% Sodium 
deoxycholate; 1 mM NaF; 5 mM EDTA; 1 mM sodium orthovanadate)/ MS-SAFEä protease 
and phosphatase inhibitor cocktail (MSSAFE, Sigma-Aldrich, Gillingham, UK) on ice.  The 
cells were then scraped using a cell scraper and all the lysate was collected in one corner of the 
flask and transferred into labelled 1.5 mL Eppendorf tube.  Each cell lysate was then clarified 
by centrifugation at 4 °C for 15 minutes at 500 g.  The supernatant was carefully transferred 
without disturbing the cell pellet, into new labelled 1.5 mL Eppendorf tube.  Total cell lysates 
(samples) were assayed for protein quantification following procedure on section 2.12.2 and 
then stored at -20 °C until further analysis. 
2.12.2. Protein determination  
Protein concentration in each prepared total cell lysate was determined using the detergent 
compatible protein assay kit; PierceTM Bicinchoninic (BCA) (23225, ThermoFisher Scientific, 
Loughborough, UK) for colorimetric detection.  BCA assay is modified from Lowry’s method 
which is based on the principle of reduction of Cu2+ to Cu+ by proteins in the alkaline 
environment (Lowry et al., 1951).  The BCA assay primarily consist of two reactions.  Firstly, 
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a temperature-dependent reaction where the protein peptide bonds reduce copper (Cu2+) ions 
from the cupric sulfate to cuprous cation (Cu+).  Secondly, the formed Cu+ ions chelate with 
two molecules of bicinchoninic acid, forming a purple-coloured product that strongly absorbs 
light at a wavelength of 562 nm.  The intensity of the purple-colour product (BCA/ Cu+ 
complex) or reduced Cu2+ is proportional to the amount of protein present in the sample (Olson 
and Markwell, 2007). 
Protein lysates were quantified against seven bovine serum albumin (BSA) standards from a 
serial dilution with concentrations of 0.125, 0.25, 0.5, 0.75, 1, 1.5 and 2 mg/mL using 
radioimmunoprecipitation assay (RIPA) lysis buffer based on the manufacturer’s instructions 
(23225, ThermoFisher Scientific, Loughborough, UK).  Then, duplicates of samples and 
standards (10 µL each) were added into a 96-well plate.  Duplicates of blank samples were also 
used, were blank was RIPA lysis buffer only.  The solution of the PierceTM BCA kit was then 
prepared as per instructions (50 parts of reagent A and 1 part of reagent B) and added (200 µL) 
to the wells containing blank, samples and standards at a 1:1 dilution.  The plate was gently 
mixed for few seconds on a MaxQ orbital shaker (ThermoFisher Scientific, Loughborough, 
UK) and then incubated at 37 °C for 30 minutes allowing a purple colour to be developed in 
the wells.  The absorbance readings in each well was measured at 562 nm using the plate reader 
(Versa max, microplate reader, Molecular Devices, UK) in combination with the built-in 
specialist software (SoftMax Pro, V.5.4, Molecular Devices, UK).  
All absorbance readings obtained for the known BSA standards were then exported and viewed 
on Microsoft Office Excel 2016 software. A standard curve of absorbance vs. concentration 
was generated.  Only standard curves with high coefficient of determination (R2 > 0.96) was 
used to extrapolate and determine the protein concentration of cell lysate samples.  Any samples 
quantified to be too concentrated or outside the standard’s absorbance range were diluted and 
re-measured.  
2.12.3. Sample preparation and protein denaturation for electrophoresis  
In order to optimised the proteins’ size (molecular weight) separation by gel electrophoresis, 
protein samples were prepared by mixing them in a 1:5 ratio with loading buffer (EC-887, 
National Diagnostics, Nottingham, UK) containing 1.0 M Tris-HCl (pH 8.5), 8 % lithium 
dodecyl sulfate, 40 % glycerol, 2 mM EDTA, 0.5 M DTT and 0.1 % bromophenyl blue in dH2O.  
The functionally of each loading buffer constituent’s differs from one another. The lithium 
dodecyl sulfate (LDS) contained in the loading buffer will denaturate secondary and non-
disulphide-linked tertiary structures by applying a negative charge to each protein in proportion 
to its mass.  This negative charge allows separation by electrophoretic size. The glycerol will 
be increasing the density of the samples within the well of gel, so that the sample will remain 
in the bottom of the gels rather than floating out.  The ethylenediaminetetraacetic acid (EDTA; 
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metal ion chelating salt) will affect the movement of the sample by migrating it from negatively 
charged electrode to positively charged one.  In addition, the dithiothreitol (DTT) will cause 
disruption of protein disulphide bonds and the 0.1 % bromophenol blue is the tracking dye 
essential to monitor protein migration ensuring that way that polypeptides are not run off the 
gel. The samples were then heated to 95 °C for 6 minutes on a heating block (Grant; Grant 
Instruments Ltd, Cambridgeshire, UK) allowing further protein denaturation and LDS binding. 
The samples were then processed for western blotting or stored at -20 °C until needed. 
2.12.4. Gels preparation 
SDS-PAGE gels were prepared using gel stacking apparatus.  Resolving gels of 10 % bis-
acrylamide solution were prepared using 30 % Protogel (acrylamide solution; EC-890, National 
Diagnostics, Nottingham, UK), resolving buffer (0.375 M Tris-HCl, 0.1% SDS; EC-892, 
National Diagnostics, Nottingham, UK), ultrapure water, 10 % ammonium persulfate (APS; 
A3678, Sigma-Aldrich, Gillingham, UK) and 1 % tetramethylethylenediamine (TEMED; EC-
503, National Diagnostics, Nottingham, UK).  
The bis-acrylamide solution was poured into 1 mm glass plates to approximately two thirds of 
the glass plate height. The rest of the glass plate space was used for pouring the stacking gel 
once the resolving gel was set.  Directly after the resolving gel was poured, water-saturated 
butanol (B7906; Sigma-Aldrich, Gillingham, UK) was added on top of it, allowing smooth 
bubble free resolving surface to develop before polymerisation occurred. Following gel 
polymerisation, the excess butanol solution was removed using thin filter paper and the stacking 
gel (6 % bis-acrylamide) was added on top of the resolving gel. The 6 % bis-acrylamide was 
prepared using 30 % Protogel, Protogel stacking buffer (0.125 M Tris-HCl, 0.1% SDS; EC-
893, National Diagnostics, Nottingham, UK), ultrapure water, 10 % APS and 1 % TEMED.  
Following stacking gel pouring on top of the resolving gel, a 15-well plastic comb (1653366, 
Bio-rad, Watford, UK) was inserted until the stacking gel was set, allowing in that way the 
formation of the wells for loading of the different samples.  
2.12.5. SDS-PAGE, Electrophoretic Transfer and Immunoblotting  
Protein samples of 30 μg were loaded in the wells along with 5 µL pre-stained molecular weight 
(MW 10-250 kDa) protein ladder (11832124, ThermoFisher Scientific, Loughborough, UK) as 
shown in Figure 2.6.  The loaded SDS- polyacrylamide gels which were fitted into cassettes, 
were then dipped into the gel tank containing 1 L 1x Tris-Glycine SDS running buffer (EC-870, 
National Diagnostics, Nottingham, UK) and connected to a PowerPac™ basic power supply 
(6371, Bio-rad, Watford, UK).  The polyacrylamide gels run for 1.5 hours at 100 volts. 
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Figure 2.7. Sample loading order into polyacrylamide gel for western blotting experiment.  The molecular 
weight (MW) marker was always loaded in the first well, followed by loading of the different timepoint samples 
from 0-48 hours.    
 
Then polyvinylidene fluoride (PVDF) pre-cut membranes of 0.45 µm pore size (LC2002, 
ThermoFisher Scientific, Loughborough, UK) were pre-soaked in methanol for 2-3 minutes to 
enable protein binding and to activate the PVDF membrane, and then equilibrated in 1x transfer 
buffer (192 mM glycine, 25 mM Tris and 20 % methanol, pH 8-8.4) prepared in ultrapure water.  
The SDS-gels which were placed inside the cassette earlier, were removed from the gel tank 
and carefully prepared for protein transfer.  
The western blot transfer apparatus was assembled as followed (see Figure 2.8.).  The transfer 
case was rinsed with 1x transfer buffer, and a coarse sponge placed on top followed by pre-cut 
7.5 x 10 cm blotting paper (1703965, Bio-rad, Watford, UK). The PVDF membrane was then 
placed on top of the blotting paper and followed by the gel placed on top by making sure the 
orientation was as loaded (gel not flipped/ reversed).  Any air bubbles captured between the gel 
and the membrane were popped using a western blot roller (84747, ThermoFisher Scientific, 
Loughborough, UK).  The second blotting paper was then carefully placed on top of the gel, 
followed by the second sponge.  The “sandwich” created, was sealed in the cassette ensuring 
the orientation of the membrane within the transfer tank was facing the positive side and the 
gel was facing the negative side.  The cassette was then placed into a Mini Trans Blot Cell 
(1704150, Bio-rad, Watford, UK) filled with 1 L 1x transfer buffer (0.025 M Tris, 0.2 M 
Glycome, 20 % methanol) prepared in ultrapure water.  The negatively charged proteins transfer 
from the gel to the PVDF membrane at 70 volts for 2 hours or at constant voltage of 35 volts 
overnight (16 hours) at 4 °C (fridge).   
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Figure 2.8. Schematic representation of electrotransfer “sandwich”.  The above layout is the organisation of 
the different components required for a wet electrotransfer procedure.   
 
At the end of transfer, the membranes were carefully removed and washed with ultrapure water.  
Successful transfer was determined by incubating the membranes with ATX Ponceau-S (09189, 
Sigma-Aldrich, Gillingham, UK) red staining for 30 seconds allowing total protein 
visualisation.  The membranes were then rinsed with ultrapure water and blocked with 
Odyssey® blocking buffer (Tris-buffered saline (TBS); 927-50000, LI-COR Biosciences, 
Nebraska, US) for 1 hour at room temperature on a MaxQ orbital shaker, to minimise non-
specific protein binding.  The membranes were then washed three times (10 minutes each) with 
TBS containing 0.1 % Tween® 20 (TBS-T; P9416, Sigma-Aldrich, Gillingham, UK) and 
probed with primary antibodies (protein of interest & housekeeping GAPDH protein; 
Glyceraldehyde-3-phosphate dehydrogenase) diluted in Odyssey® blocking buffer and 1 % 
Bovine Serum Albumin (BSA; A2153, Sigma-Aldrich, Gillangham, UK) (see Table 2.4.). 
GAPDH is one of the most commonly used loading or normalisation controls for the 
comparisons of mRNA, gene and protein expression data and its expression is expected to be 
relatively time-invariant (Shinohara et al., 1998).  Despite the unaffected expression of GAPDH 
mRNA in 72 different pathologically normal human tissue types (Barber et al., 2005), and the 
assumption that is a reliable reference gene for quantitative expression analysis, studies in 
isolated Neurospora crassa clock controlled genes (ccg) show that is regulated on a daily basis 
(peaking around the early morning; CT 4–6 under constant conditions in the dark) by the 
circadian clock, reinforcing the unique importance of this protein expression circadian influence 
(Shinohara et al., 1998).  This means that its use as a loading control for the investigation of 
circadian changes of proteins of interest is this thesis is controversial.  However, its use in the 
experiments performed for this thesis was based on studies investigating the protein expression 
of similar proteins of interest (BMAL1 clock gene, connexins and NaP channel subtypes) across 
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an analogous time frame, where GAPDH reported stable protein expression across time 
following serum-shock synchronisation method.  For example, the studies by Akagi et al., 
(2017) and Bee et al., (2015) who reported circadian changes of BMAL1 protein expression 
and unaffected GAPDH protein expression levels across single circadian cycles, 24-48 hours 
and 12-44 hours respectively, following cell’s synchronisation.  Furthermore, the study by 
Pervolaraki et al., (2017) who investigated connexin expression in fetal hearts, and showed that 
GAPDH did not demonstrate developmental regulation despite the connexin expression 
changes observed.  As well as, the study by Tong et al., (2016) who investigated the circadian 
expression of connexins in mouse heart and all data were normalised against GAPDH and 
double plotted.  The use of GAPDH housekeeping protein for the investigation of NaP channel 
changes across time has not yet been reported, due to absence of studies available.  On the other 
hand, there are studies including the use of GAPDH for the investigation of NaP channel 
expression in cultured cells despite the time factor, where relative NaP channel protein 
expression was measured compared to that of GAPDH, which remained unaffected throughout 
the experiment (Zhao et al., 2015; Ni et al., 2019).  Most importantly, the expression of GAPDH 
throughout this thesis was monitored in each and every experiment, and marked as constant 
among the various time intervals (0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 hours) 
considering the absence of light zeitgeber and the presence of serum-shock as a model of cell’s 
synchronisation; hence marking GAPDH a “constitutive” control in this study (Balsalobre et 
al., 1998; Balsalobre et al., 2000; Nagoshi et al., 2004).  
Primary and housekeeping (GAPDH) antibodies were incubated at room temperature for 1-2 
hours or at 4 °C overnight (fridge) on a MaxQ orbital shaker.  The membranes were then washed 
with TBS-T three times (10 minutes each) and then incubated for 1 hour at room temperature 
(covered in foil) with the appropriate horseradish peroxidase (HRP) conjugated secondary 
antibodies diluted in Odyssey® blocking buffer and 1 % BSA (Table 2.5.). The probed 
membranes were then washed, and immediately scanned using ODYSSEY®CLx imager 
scanner system (LI-COR Biotechnology, Cambridge, UK) for detection of the protein bands.  
Each experiment was repeated at least three times. 
2.12.6. Data acquisition and statistical analysis  
The intensity of the protein of interest and housekeeping (GAPDH) protein bands (indication 
of protein amount expressed in the cell) was analysed using Image Studio (IS) 13.1 software.  
The molecular weight ladder was used as a marker for the identification of molecular weight of 
samples.  Each protein band intensity (phosphorylated or total form) was normalised to 
equivalent GAPDH band intensity, due to GAPDH been constitutively expressed in almost all 
tissues in high amounts, as followed: 
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𝐍𝐨𝐫𝐦𝐚𝐥𝐢𝐬𝐞𝐝 𝐩𝐫𝐨𝐭𝐞𝐢𝐧 𝐞𝐱𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 =
𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐨𝐟 𝐢𝐧𝐭𝐫𝐞𝐬𝐭 𝐛𝐚𝐧𝐝 𝐢𝐧𝐭𝐞𝐧𝐬𝐢𝐭𝐲
𝐆𝐀𝐏𝐃𝐇 𝐛𝐚𝐧𝐝 𝐢𝐧𝐭𝐞𝐧𝐬𝐢𝐭𝐲
 
The normalised phosphorylated protein form was further divided with the normalised total 
protein form and presented as a ratio.  An average of the normalised protein (total or 
phosphorylated form) expression was obtained at each time point from technical triplicates and 
expressed as Mean ± standard error of the mean (SEM) using GraphPad Prism version 7 
software.  All calculations were performed with Microsoft Office Excel 2016 software.  Data 
were analysed using two-way ANOVA (analysis of variance) to test the overall divergence 
between the treated and the untreated (Control) groups and the effect of time (12-48 hours), 
followed by post-hoc analysis of significant main and interaction effects using Bonferroni 
multiple pairwise comparison test.   
A cosine curve or straight line were also fitted were appropriate using GraphPad Prism version 
7 software, allowing period determination and comparison of the best model that fits the set of 
data best.  For the statistical comparison between the best fit of a cosinor curve and a straight 
line, indicating which model fits the set of data best, the threshold p value was set to 0.05.  
When p value was small, the simple model (the null hypothesis; straight line) was wrong and 
the more complicated model (cosinor curve) was accepted.  In case of high p value, the data did 
not present a compelling reason for rejecting the simpler model; hence was accepted.  The 
periodicity was set to 24 hours (estimated time for a complete cycle) in the cosinor model 
equation (see section 2.7.1.), allowing determination of circadian expression/ pattern among the 
different proteins were appropriate.  In addition, the adjusted R squared values were also taken 
into consideration for the comparison of the goodness of fit for regression models that contained 
different number of independent variables.  The R squared value was increase in presence of 
improve model fit, whereas was decrease when the term wasn’t improving the model fit.  Higher 
R square values were indeed observed in presence of cosinor curve fitting allowing period 
determination (24-hours) on the best fit.       
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2.13. Immunofluorescence and Confocal Microscopy 
To assess the cellular localisation of total BMAL1 protein (T-BMAL1) in time-dependent 
manner, immunofluorescence technique was used followed by confocal microscopy. A 
schematic diagram of detailed experimental protocols and procedure in shown in Figure 2.9. (at 
the end of this chapter). 
2.13.1. Slides preparation  
Glass coverslip slides (15 mm) (174969, ThermoFisher Scientific, Loughborough, UK) were 
cleaned with 70 % ethanol and autoclaved in order to become sterile.  Inside the culture hood, 
1.0 mg/ mL Poly-D-lysine (A-003-E; Sigma-Aldrich, Gillangham, UK) solution was diluted 
(1:10) with distilled H2O, aliquoted and stored at 4 °C for up to three months.  The coverslips 
were coated with Poly-D-lysine solution (5 µg/ cm2) for 5 minutes, in order to facilitate stronger 
cell adherence to the coverslips, and then washed with PBS and left to dry overnight at room 
temperature. The Poly-D-lysine coated-glass coverslips were then placed into a 12-well plate 
(one coverslip/ well), and each incubated with 0.02 % fibronectin/gelatin for 24 hours at 37 ºC 
with 5% CO2 (see section 2.3.3.1.). The following day, the fibronectin was aspirated and 
cultured spontaneous-contracting HL1-6 cells seeded (1.0 x 107 cells/ well) and incubated for 
24 hours at 37 ºC and 5 % CO2.  The cells were then observed microscopically (40x 
magnification, EVOS® microscope; ThermoFisher Scientific, Loughborough, UK) and washed 
twice with 1 mL PBS solution to remove non-adherent cells.  
2.13.2. Cell fixation, permeabilisation and blocking 
HL1-6 cells were synchronised with serum-shocked Claycomb medium (see section 2.4.) for 2 
hours at 37ºC with 5 % CO2, and then washed with 1 mL PBS solution. The PBS solution was 
replaced with fresh complete Claycomb medium (control) alone, or in combination with 1 nM 
ATXII in the absence or presence of 10 µM Ranolazine, 25 µM CAIP or 5 µM BAPTA-AM.  
The cells were fixed at specific timepoints 0; before serum-shock effect, 2; immediately after 
serum-shock, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 hours (Figure 2.9.) with 500µL cold 4 % 
paraformaldehyde dissolved in PBS (PFA; 30525-89-4, Santa Cruz Biotechnology, Texas, 
USA) for 20 minutes on ice.  Paraformaldehyde is an effective fixative that causes cross-linking 
of the proteins inside the cell, and has an advantage of long term storage as well as good cell 
penetration (Thavarajah et al., 2012).  Therefore, it was preferred as a fixation reagent compare 
to other alcohols. Cell permeabilisation will allow the antibodies to access and probe for 
intracellular structures.   HL1-6 fixed cells were then washed twice with 1 mL cold PBS solution 
(5 minutes each) and stored at 4 °C (fridge) overnight.  The following day the cells were 
permeabilised for 20 minutes with 0.1 % Triton x-100 (X100, Sigma-Aldrich, Gillangham, UK) 
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and 1 % Bovine Serum Albumin (BSA; A2153, Sigma-Aldrich, Gillangham, UK) dissolved in 
PBS.  Triton x-100 allows gentle permeabilisation of cell membrane, whereas, the BSA acts as 
a blocking agent minimising non-specific binding of proteins, hence improve the background 
fluorescence.  The cells were then washed twice with PBS solution (5 minutes each) and 
immunostained as explained next.  
 
Figure 2.9. Schematic flowchart of experimental protocol for HL1-6 atrial myocytes fixation time points for 
total Bmal1 (T-BMAL1) cellular localisation.  The HL1-6 cells were serum-shocked for 2 hours using 50 % 
FBS Claycomb medium, and then fixed every 4 hours for 48 hours, 12 hours following serum-shock 
synchronisation treatment in Claycomb medium (control) alone or in combination with 1 nM ATXII in the absence 
or presence of 10 µM Ranolazine, 25 µM CAIP or 5 µM BAPTA-AM. 
2.13.3. Antibody incubation 
Immunolabelling was based on incubation with a primary antibody that binds specifically to T-
BMAL1 protein.  This was followed by incubation with a secondary antibody carrying 
fluorochromes which exhibit intense and photostable fluorescence that target the primary T-
BMAL1 antibody. Fixed, permeabilised and blocked HL1-6 cells were incubated with the 
primary rabbit monoclonal anti-BMAL1 antibody in a humidified-chamber at 4 °C overnight 
(fridge). The primary anti-BMAL1 antibody used was raised against the rabbit, used at a 1:250 
dilution in blocking buffer (0.1 % Triton x-100 and 1 % BSA diluted in PBS; see Table 2.4.). 
The cells were washed three times with PBS solution (5 minutes each) at room temperature and 
then incubated with the secondary antibody; fluorescein isothiocyanate (FITC)/Alexa Fluor® 
488 goat anti-rabbit IgG (1:1000 dilution in blocking buffer) for 1 hour at room temperature in 
dark humidified-chamber (see Table 2.5.). The cells were then washed three times with PBS 
solution (5 minutes each), and cells were counter stained as explained next.  
2.13.4. Counter Staining and Mounting  
The coverslips were washed with PBS and then mounted using the fluorescence mounting 
medium Vectashield (H-1500, Vector Laboratories, California, USA) containing 4′,6-
diamidino-2-phenylindole (DAPI). DAPI is a fluorescent nuclear dye which allows the 
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visualisation the HL1-6 nuclei. A drop of Vectashield medium was added to clean 22 x 60 mm 
glass slide (174942, ThermoFisher Scientific, Loughborough, UK) and the coverslip 
(containing stained HL1-6 cells) was remove from the 12-well plate using tweezers, and 
inverted upside down on the glass slide. Each coverslip was then sealed using nail polish and 
each glass slide was labelled properly before stored in a dark slide box at 4 °C (fridge) for future 
viewing and acquisition using confocal microscopy. All glass slides were viewed within two 
weeks following preparation.  
2.13.5. Confocal microscopy 
The stained cell slides were first viewed, examined and imaged using Nikon A1M confocal 
microscope and DS-Qi1 wide-field camera on an Eclipse Ti-E microscope along with NIS 
elements acquisition software.  The microscope was fitted with lasers and suitable filter blocks 
for detection of blue fluorescence of 4',6-diamidino-2-phenylindole (DAPI; nucleic acid 
staining) and green fluorescence of fluorescein isothiocyanate (FITC/ Alexa Fluor® 488; T-
BMAL1 localisation), with excitation/emission wavelengths of 358/461 nm and 495/519 nm, 
respectively.  Slides were viewed under x20, x40 and x60 microscope objective magnifications, 
however only x40 magnification indicated in the result sections.   
2.13.6. Data acquisition and statistical analysis  
The IF stained cell images were examined using the Nikon NIS-Elements acquisition software 
(Melville, New York, USA).  Total (T-BMAL1) and nuclear (N-BMAL1) fluorescence were 
assigned by wavelength/colour to BMAL1 antibody detected by the software.  When each 
image scan was completed, using the 20x and/or 40x magnification images, the cellular and 
nuclear BMAL1 fluorescence of each cell was examined using the Region of Interest (ROI) 
tool found in the Image Adjust section of the Tool Palette, allowing specification of specific 
areas and shapes within the scan image.  For instance, for the quantification of BMAL1 nuclear 
localisation, the DAPI channel, which was used for staining purposes of HL1-6 
cardiomyocyte’s nuclei, was on allowing visualisation of the nuclear stained regions in the 
current images.  Then by selecting the single circle shape option provided in the ROI tool as an 
ROI boundary which will record the number of photons ascribed within the detected area, each 
visualised nucleus was selected. Once the ROI was selected and locked at the selected position, 
DAPI channel was turn off and FITC channel was turned on allowing visualisation of BMAL1 
fluorescent intensity in the marked nuclear regions. The ROI was further measured using the 
Measure ROI button which allowed visualisation of data for each selected nucleus.  Similarly, 
for the quantification of total BMAL1 cellular localisation each cell was selected separately 
using the free-draw option following adjustment in size of each cell surface area while FITC 
channel was on, allowing draw of areas within the scanned image where ROI is irregular or 
complex in shape.  The selected ROI were further measured using the Measure ROI button 
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which allowed visualisation of data for each selected HL1-6 FITC-stained cell.  Data were 
exported in a Microsoft Excel sheet format, from which the mean fluorescent intensity (MFI) 
of each ROI was used for the calculation and interpretation of BMAL1 relative fluorescent 
expression.  Data are presented as a total BMAL1, as well as a percentage (%) of nuclear MFI 
expression.   
The statistical analysis of data was conducted using GraphPad Prism version 7 software.  Two-
way ANOVA (analysis of variance) test was employed with the aim to test the overall 
divergence between the treated and the untreated (Control) cells and the effect of time (12-48 
hours), followed by post hoc analysis of significant main and interaction effects using 
Bonferroni multiple pairwise comparison test.  A Student’s t test (unpaired t test) was set at 
0.05; as a result, the p-values < 0.05 were interpreted as significant.  A cosine fit curve was also 
used, allowing period determination on the best fit of this curve (see section 2.7.1.).   
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Figure 2.9. Schematic representation of immunofluorescence experimental set-up.  HL1-6 atrial myocytes 
were seeded into 12-well plates pre-coated with Poly-D-lysine glass coverslips.  The following day the cells were 
synchronised with 50 % FBS cell culture medium for 2 hours, followed by slides fixation (4 % paraformaldehyde; 
PFA) and cell permeabilisation (0.2 % Triton & 5 % goat serum) 0, 2, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48hours 
post serum shock treatment (Control).  Cells were further subjected to several drug treatments to monitor changes 
in Bmal1 cellular localisation due to raised intracellular [Ca2+].  Slides were subjected to primary (1o) rabbit 
monoclonal anti-Bmal1 (1:250) for 24 hours and secondary (2o) goat anti-rabbit IgG Alexa 488 (1:1000) for 1 
hour.  For the visualisation of the nucleus in HL1-6 cells, Vectashield mounting medium containing DAPI was 
applied, followed by slides examination using confocal microscope.
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3.1. Introduction 
Circadian rhythms are rhythms in biological processes displaying endogenously driven 24-hour 
oscillations and are highly important for maintaining a variety of beneficial health effects in 
mammalian species and in humans (Schroder et al., 2015). Circadian rhythms are believed to have 
evolved in response to daily changes in the environment, and as part of that all mammalian 
species investigated express an intrinsic circadian (Harmer et al., 2001).  An internal circadian 
clock, is responsible for regulating these daily rhythms in all major organs, including various 
cell types in the heart.  The suprachiasmatic nucleus (SCN) located within the hypothalamus, 
acts as the principal, light-entrained circadian pacemaker in mammals and serves as the 
fundamental factor for creating and maintaining circadian rhythmicity; hence it is known as the 
central clock (Weaver et al., 1998). In addition, peripheral clocks are expressed in all organs 
across the body, and with respect to each location serve distinct roles in regulating circadian 
rhythmicity (Ralph et al., 1990; King et al., 2003).   The SCN, as the principal pacemaker, can 
coordinate all the peripheral clocks within the body, including the one found in the heart 
(Gachon et al., 2004).  However, even though the SCN synchronises several organs and tissues 
within the body, in vitro and ex vivo studies reveal that the peripheral clocks can function 
autonomously without cues from the SCN (Kowalska and Brown., 2007; Takeda and 
Maemura., 2011). SCN circadian rhythms are exclusively entrained (synchronised) by photic 
(light) stimuli, as well as non-photic (sleep/wake cycle, feeding times and hormonal levels) 
cues (Mistlberger and Skene., 2005).  The photosensitive retinal ganglionic cells (RGCs) 
located near the inner surface of the retina, receive light input via the optic nerve and send 
signals to the SCN via the retinohypothalamic tract (RHT), ensuring SCN entrainment to 
day/night cycles (Welsh et al., 2010).  The SCN will then projects these signals to various  
brain centres containing circadian clocks (including the heart) that direct behavioural, 
neuroendrocrine and autonomic circadian rhythms (Kohsaka et al., 2012).  Such signals 
include melatonin, cortisol and autonomic signalling, which in turn act as Zeitegebers (time-
keepers) for non-SCN clocks.  These clocks drive cellular-specific rhythms through gene-
expression that regulate critical physiological rhythms, including the heart  rate, blood 
pressure, sleep/wake cycle, body temperature and hormonal secretion (Aoyama et al., 2017; 
Hastings et al., 2003). 
Circadian clocks are constructed of a group of genes, that are feedback in a transcriptional-
translational feedback loop (TTFL) (Welsh et al., 2010).  In mammals, the basic TFFL involves 
the following genes: Bmal1, Clock, Per1-2, Cry1-2, Rev-erbα and Rorα (Yang et al., 2016).  
Circadian cycle in the SCN, and peripheral clocks, starts with heterodimerisation of the protein 
products of brain and muscle ARNT-like 1 (BMAL1; also known as ARNTL and MOP3) and 
circadian locomoter output cycles protein kaput (CLOCK) forming a CLOCK/BMAL1 
complex.  The CLOCK/BMAL1 complex binds to enhancer box (E-box) elements on the 
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promoter region of period (Per1 and Per2) and cryptochrome (Cry1 and Cry2) genes activating 
their transcription into PER and CRY proteins, which in turn form a large multimeric complex 
(PER/CRY) in the cytoplasm (Brown et al., 2005; Hofmann et al., 2006).   The PER/CRY 
complex will then enter the nucleus (along with casein kinase 1ε/δ; CK1ε/δ), where PER and 
CRY proteins inhibit their own synthesis by directly interacting with the CLOCK/BMAL1 
complex (Takahash et al., 2017; Gallego and Virshup., 2007).  Per and Cry mRNA levels 
decline, and degradation of the PER/CRY complex occurs through phosphorylation by CK1ε/δ; 
hence lowering PER and CRY protein levels.  Such degradation allows the cycle to start again 
after 24 hours following the previous transcriptional initiation. The cycle is stabilised by 
additional feedback loop in which CLOCK and BMAL1 drive related orphan receptor α 
(RORα) and REV-ERBα (also known as NR1D1) nuclear receptor E-box-mediated circadian 
expression, which in turn activate and supress Bmal1 transcription via REV response element 
(RRE), respectively (Preitner et al., 2002).  Therefore, any changes or mutations to the key 
proteins (i.e. BMAL1 or CLOCK) responsive for initiation of the circadian cycle directly 
affects the transcription and subsequent generation of core genes contributing to generation 
of normal circadian cycle.  
The prevalence of cardiovascular events in the morning is well documented therefore this could 
be a result of 24-hour variations in gene transcription that may impact the cardiac function and 
contribute to the morning peak in these events (Collins et al., 2010).  Diurnal rhythms (24-hour 
pattern) in timing of onset and tolerance of ventricular arrhythmic events, including myocardial 
infarction (MI), deadly ventricular arrhythmias and sudden cardiac death (SCD), have been 
reported to be more frequent in the morning (03:00 am) than at night hours (Muller et al., 1985; 
Tofler et al., 1995; Mahmoud et al., 2011). Whereas, diurnal patterning in atrial arrhythmias 
has not been fully studied, probably because of their relatively benign nature as compared to 
ventricular events.  Atrial arrhythmic events, including atrial fibrillation (AF) reported to 
exhibit a daily pattern with higher frequency between midnight and 02:00 am (Ripamonti et al., 
2017).  Such pattern may be driven by a circadian clock, hence highlighting possible 
involvement and/or contribution of clock genes in particular Bmal1, to its occurrence. 
The role of Bmal1, and various other clock genes, in the cardiovascular system has been 
investigated by a plethora of tissue-specific clock gene deletions (knockout), mutations or 
overexpression in rodents.  For instance, specific deletion of Bmal1 in mice ventricular 
cardiomyocytes, resulted in abnormal electrocardiography with prolonged RR and QRS 
intervals, signs of arrhythmogenesis, and diminished heart rate diurnal variations (Wang et al., 
2008; Schroder et al., 2013).  Also, deletion of Bmal1 in vascular smooth muscle cells and mice 
endothelial cells, abrogated blood pressure circadian rhythmicity accompanied with 
hypotension (reduced blood pressure) (Curtis et al., 2007; Westgate et al., 2008).  Furthermore, 
a study by Xie et al., (2015) showed that selective Bmal1 deletion in vascular smooth muscle 
cells, but not in cardiomyocytes, not only abolished the diurnal variations of constriction of 
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blood vessels (which subsequently increased the blood pressure), but also affected 
phosphorylation status of myosin filaments involved in the contractile machinery.  
Interestingly, overexpression of the ClockΔ19 (heterodimeric partner of Bmal1) allele in 
cardiomyocytes alters heart rate variability and contractility revealing a role of the peripheral 
circadian gene network in the heart (Bray et al., 2007).  Such findings are consistent with the 
presence and importance of intrinsic clocks in the heart and emphasise that any disruption of 
their molecular clock may result to detrimental end points (i.e. arrhythmias) (Jeyaraj et al., 
2012; Martino et al., 2008).  However, the role of molecular mechanism intrinsic to the 
cardiomyocyte (i.e. circadian clock) in cardiovascular disease is debatable and still under 
investigation.   
At the same time, various cardiovascular events reported to equally affect the expression and 
circadian rhythmicity of clock genes. For example, decreased amplitude of Bmal1 and Per2 
circadian expression was demonstrated in hypertrophic rat models (Mohri et al., 2003; Sole and 
Martino., 2009).  Also, circadian misalignments of Bmal1 and Clock genes were reported in rat 
hearts suffering from ischemia/reperfusion (I/R), due to decreased amplitudes in their 
oscillations, as well as, rapid and persistent peak expression when compare to control (Kung et 
al., 2007).  This further highlights the importance of investigating the association of clock genes 
(in particular Bmal1) with cardiovascular diseases.  However, most studies conducted so far 
investigating Bmal1 clock gene and its association with cardiac events were performed on 
ventricular myocytes (following its deletion or mutation), whereas less is known about its 
circadian expression in atrial cultured cells, as well as its association with the occurrence of 
atrial arrhythmias (including AF).   
Several factors contribute to the development of atrial arrhythmias, configuration of action 
potential due to alterations in ion channel activity and/or Ca2+ homeostasis (Tse., 2016).  The 
abnormal increase in intracellular Ca2+ concentration ([Ca2+]i) caused by sustain activation of 
persistent Na+ (NaP) channel results in prolong activation of action potential duration; hence 
generation of arrhythmias via early afterdepolarisations (EADs) (Weiss et al., 2010).  Anemonia 
sulcate toxin II (ATXII) is known to open NaP channels in atrial myocytes leading to sustained 
rise in [Ca2+]i, and was used as an in vitro model of AF in this thesis.  Intracellular [Ca
2+] is 
known to have diverse roles in the timing system by regulating the entrainment process, clock 
gene expression and output signalling (Hamada et al 1999; Lamia et al., 2009; Tanaka et al., 
2002; Aguilar-Roblero et al., 2007).  Periodic Ca2+ influx reported to be a critical process for 
the function of circadian pacemaker such as Per1 and Per2 in rodents (Lundkvist et al., 2005). 
Therefore, there is an assumption that Ca2+ signalling also regulated Bmal1 gene.  However, the 
correlation between altered Ca2+ homeostasis and Bmal1 clock gene circadian rhythms, is also 
far from clear. A study by Collins and Rodrigo (2010), demonstrated circadian variations in 
excitation contraction (E-C) coupling of rat ventricular myocytes in respect to Ca2+ 
homeostasis.  They reported that the basal systolic [Ca2+]i and contraction strength was lower
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in rat myocytes isolated during the active period (light) compare to resting period (dark). Such 
decrease in Ca2+ transient during the active period, was not attributable to a smaller L-type Ca2+ 
current, which was found to peak during the active period (Collins and Rodrigo, 2010).  
Interestingly, Boateng and Qi (2006) were able to show strong CLOCK protein localisation to 
the Z-disk of the cardiac myofilaments. Such presence of CLOCK protein within the 
cytoskeleton was dependent upon active cross-bridge cycling in these cells and increased Ca2+ 
cycling following raised contractile activity using 10 µM phenylephrine.  Thus, proposing that 
the expression of clock genes and their subcellular distribution can be influenced by 
intracellular activity (i.e. Ca2+ levels) in cardiac myocytes. 
In summary, given the benign nature of atrial arrhythmias and the lack of evidence regarding 
it’s circadian patterning (and the clock genes regulating it), triggers us to investigate the 
involvement of Bmal1 key clock gene in generation of atrial events via changes of Ca2+ 
homeostasis (rise of [Ca2+]i) through sustained activation of NaP channels (pro-arrhythmogenic 
factor).  
3.2. Aim 
Our overall aim is to test the hypothesis that changes in intracellular [Ca2+] ([Ca2+]i), as a model 
of atrial arrhythmias, has an effect on Bmal1 clock gene expression pattern and circadian 
rhythmicity in synchronised HL-1 clone 6 (HL1-6) atrial myocytes and primary mouse 
embryonic fibroblasts (pMEFs; comparable cell line) in vitro. 
3.3. Objectives 
1. Assess Bmal1 clock gene circadian rhythmicity and expression, in synchronised HL1-6 
atrial myocytes and primary mouse embryonic fibroblasts (pMEFs; comparable cell line) 
under control conditions, using Bmal1::Luc (mBmal1 promoter::luciferase) driven 
bioluminescence and RT-QPCR.  
2. Test whether raised intracellular [Ca2+] is associated with changes in Bmal1 expression, 
in synchronised HL1-6 atrial myocytes and pMEFs, using Bmal1::Luc driven 
bioluminescence and RT-QPCR.  This was achieved using the following conditions: 
i. ATXII (1 nM) alone, to raise intracellular [Ca2+] via sustain opening of NaP channels 
ii. ATXII (1 nM) in presence of Ranolazine (10 µM), to inhibit NaP channels 
iii. Ranolazine (10 µM), to assess involvement of Nap channels   
3. Determine the effects of raised intracellular [Ca2+] by ATXII treatment on Bmal1 
expression in synchronised HL1-6 cells and pMEFs, using MTS cell viability assay. 
      
Chapter 3. Bmal1 gene expression 
 
91 | P a g e  
 
4. Assess Ca2+ effects on Bmal1 expression under control and raised intracellular [Ca2+] 
conditions by ATXII (1 nM), in the presence of Ca2+ chelator (5 µM BAPTA-AM) in 
synchronised HL1-6 atrial myocytes, using Bmal1::Luc driven bioluminescence. 
5. Measure intracellular [Ca2+] level changes across time in synchronised HL1-6 atrial 
myocytes using Fura2-AM ratiometric fluorescent Ca2+ indicator, under the following 
conditions:  
i. culture medium (control conditions) 
ii. ATXII (1 nM) in absence and presence of Ranolazine (10 µM) 
iii. ATXII (1 nM) in presence of calcineurin autoinhibitory peptide (CAIP, 25 µM), a 
specific Ca2+/calmodulin dependent protein phosphatase calcineurin inhibitor 
3.4. Methods  
The experiments carried out in this section have been extensively described in chapter 2 (see 
sections 2.7-2.11.), but a brief description of the specific protocols is given here.  
3.4.1. Transfection of cells with Bmal1::Luc (mBmal1 promoter::luciferase) 
for circadian rhythms monitoring  
To monitor the presence of Bmal1 clock gene circadian rhythmicity, HL1-6 atrial myocytes and 
pMEFs were seeded (1 x 105 per 1 mL) in 35 mm dishes and transiently transfected for 24 hours 
with culture medium containing 6 x 1010 lentiviral particles with luciferase based reporter for 
Bmal1 promoter (Bmal1::Luc; see section 2.9.1.). Post transfection the cells were serum-
shocked for 2 hours (see section 2.9.2.) allowing synchronisation and resetting of the clock 
genes inside the cells.  Following serum-shock synchronisation, the cells were also treated with 
complete medium alone (control group) and/or in presence of [1 nM] ATXII alone or in 
combination with 10 µM Ranolazine (Nap (Nav1.5) channel blocker) or 5 µM BAPTA-AM 
(Ca2+ chelator).  The cells were then treated with bioluminescence culture medium containing 
0.1 mM Luciferin-EF™ endotoxin (see section 2.9.2.).  Bmal1::Luc bioluminescence 
recordings were then monitored using LumiCycle32-channel luminometer for 3-5 days and 
analysed for the determination of circadian characteristics (periodicity and amplitude).  A 
cosine curve was also fitted allowing period determination on the best fit of this cosine curve, 
prior to the different treatment conditions.  Periodicity, peak phase and amplitude between two 
groups was tested using T-test (significance p<0.05). 
3.4.2. Bmal1 mRNA expression determination, using RT-QPCR  
To determine mRNA expression and existence of circadian rhythmicity of Bmal1 clock gene, 
HL1-6 atrial myocytes and pMEFs were seeded in 6-well plates (2 x 105 cells/ well) for 24 
hours and then synchronised with serum-shock medium (see section 2.4.) for 2 hours.  
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Following serum-shock synchronisation, the cells were treated with complete medium alone 
(Control group) and/or in presence of NaP channel opener ATXII [1 nM].  The cells were then 
collected every 6 hours for 36 hours (HL1-6s) or every 4 hours for 48 hours (pMEFs) following 
trypsinisation and centrifugation at high speed (see section 2.4.1.).  RNA was extracted using 
RNeasy Mini Kit (QIAGEN; see section 2.4.) from each total cell lysate timepoint sample.  The 
RNA was purified by digesting DNA (see section 2.5.) allowing synthesis of cDNA samples.  
Triplicates of each timepoint cDNA sample was run for the determination of Bmal1 mRNA 
expression, by amplification of the target gene using RT-QPCR (see section 2.6.).  Experiments 
were performed in sample size of 3 technical replicates and Bmal1 clock gene mRNA 
expression was normalised to GAPDH expression that remained unaffected throughout time.  
Data were analysed using two-way ANOVA (analysis of variance) to test the overall divergence 
between ATXII-treated and untreated cells and the effect of time (12-48 hours), followed by 
post-hoc analysis of significant main and interaction effects using Bonferroni multiple pairwise 
comparison test.  A cosine curve was also fitted allowing period determination on the best fit 
of this curve.  Periodicity and peak phases between two groups was tested using T-test 
(significance p<0.05). 
3.4.3. MTS assay for the determination of cell viability  
To assess the true involvement of raised intracellular Ca2+ levels (due to 1 nM ATXII effect) 
on changes in Bmal1 circadian rhythmicity, HL1-6 cells and pMEFs were seeded in 96-well 
plates (1 x 105 cells/ well).  The following day the cells were synchronised for 2 hours with 
serum-shock medium (see section 2.10.) and then incubated with complete medium alone 
(Control group) and/or in presence of [1 nM] ATXII alone or in combination with 10 µM 
Ranolazine, and vehicles (1 % DMSO contained in ATXII and Ranolazine) for 1, 2, 3 days.  
After each day (day 1, day 2, day3), the cells were incubated with CellTiter96® Aqueous One 
Solution Reagent (MTS tetrazolium compound reduced to a coloured formazan product in 
metabolically active cells) for 1-2 hours and spectrophotometric absorbance was recorded at 
490 nm using a plate reader.  The quantity of formazan product measured was directly 
proportional to the number of living cells in culture. Experiments were performed in sample 
size of 3 technical replicates and the relative cell viability (%) was expressed as a percentage 
relative to the untreated control cells (serum-shocked medium).  This process was similarly 
followed for 3 subsequent days assessing the cytotoxic effect of variable treatments in cell 
survival during day 1, day 2 and day 3.     
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3.4.4. Measurement of intracellular [Ca2+] levels using the ratiometric Ca2+ 
ionophore Fura-2 AM 
To assess changes of intracellular [Ca2+] within 48 hours, HL1-6 cells were seeded (1.0 x 107) 
on 24-well plate for 24 hours.  The following day, the cells were synchronised with serum-
shocked Claycomb medium for 2 hours (see section 2.4.) allowing synchronisation and resetting 
of the clock genes inside the cells.  The cells were then incubated with complete Claycomb 
medium alone (Control group) and/or in presence of [1 nM] ATXII alone or in combination 
with 10 µM Ranolazine, or 25 µM CAIP (Ca2+- dependent protein phosphatase inhibitor).  
Following treatment, the cells were loaded in the dark every 4 hours for 48 hours (12 hours 
following serum-shock synchronisation), with 1 mM cell-permeable Fura 2-AM for 30 minutes 
(see section 2.11.).  The change in intracellular [Ca2+] was indicated as the ratio of Fura2-AM 
emission (510 nm) intensities for 340 nm and 380 nm excitation.  Experiments were performed 
in sample size of 3 technical replicates and the relative [Ca2+] was expressed as 340/380 ratio.  
Data were analysed using two-way ANOVA to test the overall divergence between treatment 
and untreated group and the effect of time (12-48 hours), followed by post-hoc analysis of 
significant main and interaction effects using Bonferroni multiple pairwise comparison test.  A 
cosine fit curve was also used, allowing period determination on the best fit of this curve.  
 
3.5. Results  
3.5.1. Bmal1::Luc driven bioluminescence and mRNA expression in 
synchronised HL1-6 atrial myocytes and pMEFs, under control conditions 
Profiles of Bmal1 driven bioluminescence over a period of 5 days (120 hours) after serum-
shock show very similar traces for each biological replicate within HL1-6 atrial myocytes (N=6) 
and primary mouse embryonic fibroblasts (pMEFs; N=6). Representative examples for each 
cell type are presented in Figure 3.1. Cosine fits to these traces reveal a significant difference 
in peak phase of bioluminescence rhythms, where the first peaks fall at 16.32 hours after serum 
shock in HL1-6 cells, whereas this is advanced in pMEFs which peak at 13.92 hours after serum 
shock (T-test, p<0.05). Irrespective of peak phase, the period of the bioluminescence rhythms 
did not differ between cell types (T-test, p>0.05), and are 26.09±0.78 [Mean±SEM] and 
25.22±0.26 hours, for HL1-6s and pMEFs, respectively. 
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Figure 3.1. Bmal1 clock gene bioluminescence recordings from HL1-6 atrial myocytes (A) and primary 
mouse embryonic fibroblasts (pMEFs; comparable cell line) (B) transduced with Bmal1::Luc (mBmal1 
promoter::luciferase) under control conditions, following serum-shock synchronisation with 50 % fetal 
bovine serum (FBS). Representative baseline subtracted recordings (N=6) of Bmal1::Luc bioluminescence are 
shown in black & cosinor curve fitted is shown in grey. Bmal1::Luc bioluminescence expressed as counts.min-1.  
 
Bmal1 clock gene mRNA expression was also assessed using RT-QPCR in both, HL1-6 cells 
(Figure 3.2., panel (A)) and pMEFs (Figure 3.2., panel (B)).  The levels of Bmal1 clock gene 
mRNA expression varied among the different timepoints in HL1-6 cells (panel (A)).  To 
investigate whether there is variation over time we looked at differences between mRNA 
expression during the several time points (time effect p=0.05).  The relative expression of 
Bmal1 was significantly high at 2 (9.77±0.38 [Mean±SEM]; N=3; p<0.01) and 18 hours 
(9.93±0.66; N=3; p<0.01) in comparison to the rest of timepoints.  Whereas, Bmal1 mRNA 
expression dropped at 12 (7.57±0.21; N=3; p<0.05) and 24 hours (8.81±0.09; N=3; p<0.05).  
Furthermore, from 24 hours-onwards, Bmal1 mRNA exhibit a constant, intermediate 
expression level until the end of the serum-shock effect.  To investigate the presence of 
circadian rhythms in the in the Bmal1 mRNA expression pattern, a cosinor curved was also 
fitted (shown in red).  The cosine curve revealed a period of 18.21±0.51 hours as calculated 
from peak-to-peak, hence the absence of a 24-hour circadian rhythm in HL1-6 atrial myocytes. 
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Figure 3.2. Bmal1 mRNA expression profile in HL1-6 atrial myocytes (A) and in primary mouse embryonic 
fibroblast cells (pMEFs; comparable cell line) (B) under control conditions, following serum-shock 
synchronisation with 50 % fetal bovine serum (FBS), using RT-QPCR.  Bmal1 mRNA expression was 
measured at 2, 6, 12, 16, 20, 24, 28, 32 and 36 hours (6-hour interval) in HL1-6 cells, and at 4, 8, 12, 16, 20, 24, 
28, 32, 36, 40, 44 and 48 hours (4-hour interval) in pMEFs.  Bmal1 mRNA expression peaked at 2, 18 and 36 
hours in HL1-6 cells (A), and at 8, 24 and 36 hours in pMEFs (B).  Bmal1 mRNA expression dropped at 12 and 
30 hours in HL1-6 cells (A), and at 16, 28 and 40 hours in pMEFs (B). The mRNA expression is normalised to 
GAPDH and expressed as arbitrary units. Values are Mean±SEM (N=3 for HL1-6 cells, N=4 for pMEFs). * 
p<0.05, ** p<0.01 
 
In pMEFs, the levels of Bmal1 clock gene mRNA expression varied among time (main effect 
p=0.05) (panel (B)).  The relative expression of Bmal1 was significantly high at 8 (7.25±0.97; 
N=4; p<0.05), 24 (7.79±0.80; N=4; p<0.05) and 36 hours (7.98±0.34; N=4; p<0.05) hours.  
Whereas, Bmal1 mRNA expression dropped at 16 (6.12±0.98; N=4), 28 (6.42±0.25; N=4) and 
40 hours (5.52±0.99; N=4).  Interestingly, from 40-48 hours Bmal1 exhibit low mRNA 
expression levels which they do not appear to differ from each other in terms of mRNA 
concentration.  The cosinor curve fitted to assessed whether Bmal1 mRNA expressed in a 
circadian manner showed a period of 20.08±0.14 hours, revealing the absence of 24-hour 
circadian rhythmicity in Bmal1 clock gene mRNA expression in pMEFs. 
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3.5.2. The effect of raised intracellular [Ca2+] on Bmal1::Luc driven 
bioluminescence and Bmal1 mRNA expression in synchronised HL1-6 atrial 
myocytes and pMEFs, using NaP channel opener 1 nM ATXII 
As a first observation, 1 nM ATXII treatment significantly disturbed Bmal1::Luc 
bioluminescent circadian rhythmicity in HL1-6 atrial myocytes,  but not in pMEFs (Figure 3.3., 
panel (A&B)).  Profiles of Bmal1::Luc driven bioluminescence after ATXII treatment, show 
significantly disturbed traces with tremendous fluctuations over the 5-day period, for each 
biological replicate (N=8 per cell type) within HL1-6 atrial myocytes, but not in pMEFs who 
showed very similar biological replicate traces (N=8).  Furthermore, the cosine fits to these 
traces reveal a significant difference in peak phase of bioluminescence rhythms, where the first 
peak falls at 17.04 hours in pMEFs, whereas this was advanced in ATXII-treated HL1-6 cells 
which peak at 14.16 hours after serum shock (T-test, p<0.05). The period of the 
bioluminescence rhythms was also significantly different (T-test, p>0.05) between cell types, 
which was 25.82±1.06 hours (N=8) and 17.05±1.07 hours (N=8), for HL1-6s and pMEFs 
respectively.  
In addition, the profiles of Bmal1::Luc driven bioluminescence recordings were no different in 
control and ATXII-treated pMEFs (interaction effect p>0.05; Figure 3.1., panel (B) & Figure 
3.3., panel (B)).  More specifically, Bmal1::Luc driven bioluminescence show very similar 
traces for each biological replicates (N=8) under ATXII treatment.  Such observation was also 
noted under control conditions.  Cosine fits to these traces reveal a significant difference in peak 
phase of bioluminescence rhythms, where the first peaks fall at 17.04 hours after ATXII 
treatment, whereas this is advanced under control conditions which peak at 13.92 hours after 
serum-shock (T-test, p<0.05).  Irrespective of peak phase, the period of the bioluminescence 
rhythms did not differ between the two conditions and are of 25.82±1.06 hours (N=8) and 
25.22±0.26 hours (N=6) for ATXII-treated and control cells, respectively (T-test, p>0.05) 
(Figure 3.7., panel (B1)). The change in the amplitude (Figure 3.7., panel (B2)) of the oscillation 
in bioluminescence in response to no treatment and 1 nM ATXII treatment was also quantified 
(interaction effect p<0.001).  Despite the absence of periodicity changes under control and 1 
nM ATXII treatment, significant decreased amplitude of Bmal1::Luc bioluminescence in 
pMEFs, was observed during 1 nM ATXII treatment (73.17±10.13 counts/min; N=8, p<0.001, 
when compared to control conditions (195.75±22.53 counts/min; N=6, p<0.001). 
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Figure 3.3. Bmal1 clock gene bioluminescence recordings from HL1-6 atrial myocytes (A) and primary 
mouse embryonic fibroblasts (pMEFs; comparable cell line) (B) transduced with Bmal1::Luc (mBmal1 
promoter::luciferase) under 1 nM ATXII treatment, following serum-shock synchronisation with 50 % fetal 
bovine serum (FBS). Representative baseline subtracted recordings (N=8) of Bmal1::Luc bioluminescence are 
shown in black and cosinor curve fitted is shown in red. Bmal1::Luc bioluminescence expressed as counts.min-1.  
 
Interestingly, the Bmal1::Luc driven bioluminescence recordings that received treatment with 
ATXII, were significantly different to the ones observed under control conditions (interaction 
effect p<0.05; Figure 3.1., panel (A) & Figure 3.3., panel (A)).  More specifically, the HL1-6 
cells exhibit Bmal1::Luc bioluminescence circadian rhythms under control conditions, with a 
period of 26.09±0.78 hours; N=6, p<0.05 (Figure 3.7., panel (A1)).  The period was extremely 
shortened following treatment with 1 nM ATXII, as Bmal1::Luc bioluminescence displayed 
periodicity of 17.05±1.07 hours; N=8, p<0.0001 in HL1-6 cells (Figure 3.7., panel (A1)).  The 
changes in Bmal1::Luc bioluminescence periodicity following ATXII treatment could also be 
interpreted as a shift in Bmal1 phase time by approximately 9 hours; a possible sign of raised 
intracellular [Ca2+] and arrhythmogenesis effects due to the more frequent diurnal rhythms 
recorded.  Furthermore, the cosine fits to these traces reveal a significant difference in peak 
phase of bioluminescence rhythms, where the first peaks falls at 16.32 hours after serum-shock 
in HL1-6 control cells, whereas this is delayed in cells treated with ATXII which peak at 14.16 
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hours after serum shock (T-test, p<0.05).  The change in the amplitude of the oscillation 
between control and ATXII-treated cells was also quantified (interaction effect p<0.0001) 
(Figure 3.7., panel (A2)). ATXII treatment significantly decreased the amplitude of the 
Bmal1::Luc bioluminescence oscillation in HL1-6 atrial myocytes (1.70±0.22 counts/min; 
N=8, p<0.0001), when compared to no treatment (15.69±2.15 counts/min; N=6, p<0.0001).   
Furthermore, Bmal1 clock gene mRNA expression changes following rise of [Ca2+]i via 1 nM 
ATXII treatment, was also assessed in HL1-6 atrial myocytes (but not in pMEFs) using RT-
QPCR.  The RT-QPCR showed that the levels of Bmal1 mRNA varied over time (time effect 
p=0.05) under treatment with 1 nM ATXII (Figure 3.4.).  The relative mRNA expression of 
Bmal1 was lower at 12 (8.68±0.19; N=3) and 30 (9.04±0.11; N=3) hours, and higher at 2 
(9.58±0.37; N=3, p<0.05) and 24 (9.96±0.54; N=3, p<0.05) hours.  Also, the cosine fit revealed 
a period of 22.10±0.09 hours as calculated from peak-to-peak; hence the absence of highly 
disturbed mRNA profile under ATXII treatment. 
 
 
 
 
 
 
 
 
 
Figure 3.4. Bmal1 mRNA expression profile in HL1-6 atrial myocytes under 1 nM ATXII treatment, 
following serum-shock synchronisation with 50 % fetal bovine serum (FBS), using RT-QPCR.  Bmal1 
mRNA expression was measured at 2, 6, 12, 16, 20, 24, 28, 32 and 36 hours (6-hour interval) in HL1-6 cells.  
Bmal1 mRNA expression peaked at 2 and 24 hours and dropped at 12 and 30 hours. The mRNA expression is 
expressed as arbitrary units (fold change from control). Values are Mean±SEM (N=3). * p<0.05 
 
Also, treating the HL1-6 cells with 1 nM ATXII affects the mRNA expression levels 
(interaction effect p=0.0408) and circadian pattern (time effect p=0.0420) of Bmal1 gene across 
time when compare to untreated (control) cells (Figure 3.2., panel (A) & Figure 3.4.).  In terms 
of difference in Bmal1 mRNA expression between ATXII-treated and control cells, was only 
observed during time points 12 and 24 hours.  HL1-6 cells showed higher relative Bmal1 mRNA 
expression in ATXII-treated cells at timepoints 12 (Control 7.57±0.21 vs ATXII 8.70±0.34; 
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N=3; p<0.05) and 24 hours (Control 8.81±0.09 vs ATXII 9.96±0.77; N=3; p<0.05) when 
compare to control cells.  Bmal1 mRNA expression during time points 2, 6, 18, 30 and 36 in 
ATXII-treated cells exhibit similar mRNA expression levels as under control conditions. 
Interestingly, Bmal1 peak expression time was shifted by 4 hours following treatment with 1 
nM ATXII which peaked at 22.10±0.09 hours, compare to a peak at 18.21±0.51 under control 
conditions. 
3.5.3. The effects of NaP channel inhibitor (10 µM Ranolazine) on Bmal1::Luc 
driven bioluminescence following treatment with 1 nM ATXII, in 
synchronised HL1-6 atrial myocytes and pMEFs 
The effect of NaP channel inhibitor (10 µM Ranolazine) following raised [Ca
2+]i after serum-
shock synchronisation, on Bmal1::Luc driven bioluminescence expression was assessed in 
HL1-6 atrial myocytes (Figure 3.5., panel (A)) and pMEFs (Figure 3.5., panel (B)).  
Representative baseline subtracted traces for Bmal1::Luc driven bioluminescence are shown 
for HL1-6 cells (panel (A); N=6) and pMEFs (panel (B); N=6).  As a first observation, 
Ranolazine treatment seems to restore the effects of raised [Ca2+]i by ATXII in HL1-6 atrial 
myocytes, and has no effect on pMEFs (Figure 3.5., panels (A&B)).  Profiles of Bmal1::Luc 
driven bioluminescence after ATXII treatment, show very similar traces for each biological 
replicate within HL1-6 atrial myocytes (N=6) and primary mouse embryonic fibroblasts 
(pMEFs; N=6).  Furthermore, the cosine fits to these traces reveal a significant difference in 
peak phase of bioluminescence rhythms, where the first peak falls at 15.32 hours in pMEFs, 
whereas this was delayed in HL1-6 cells which peak at 17.52 hours after serum shock (T-test, 
p<0.05).  Irrespective of peak phase, the period of the bioluminescence rhythms did not differ 
between cell types, and are of 26.10±1.19 hours and 25.32±0.97 hours for pMEFs and HL1-6 
atrial myocytes, respectively (T-test, p>0.05). 
In addition, the disturbed Bmal1::Luc driven bioluminescence expression phenotype observed 
in HL1-6 cells treated with ATXII alone was prevented in the presence of 10 µM Ranolazine 
(interaction effect p<0.0001) (Figure 3.3., panel (A) & Figure 3.5., panel (A)). More 
specifically, cosine fit to these traces reveal significant difference in peak phase of Bmal1::Luc 
driven bioluminescence rhythms between ATXII treatment alone (14.16 hours, T-test p>0.05) 
and in presence of Ranolazine (17.52 hours, T-test p>0.05).  Also, the period of the 
bioluminescence rhythms differs between the two conditions, and are of 17.05±1.07 hours 
(N=8) for ATXII-treated HL1-6 cells and 25.32±0.97 hours (N=6) for ATXII/Ranolazine 
treated cells (T-test, p<0.0001), hence revealing a shift in the phase time by approximately 9-
hours (Figure 3.7., panel (A1)).  Similar periodicity (26.09±0.78 hours, N=6, p>0.05) was also 
observed in control cells, meaning that it restored Ca2+ levels.  The change in the amplitude 
(Figure 3.7., panel (A2)) of the oscillation in bioluminescence in response to 1 nM ATXII 
treatment alone or in the presence of 10 µM Ranolazine was also quantified (interaction effect 
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p<0.0001). Ranolazine significantly increased the amplitude of the Bmal1::Luc 
bioluminescence oscillation in HL1-6 atrial myocytes (19.53±3.42 counts/min; N=6, 
p<0.0001), when compared to ATXII-treatment alone (1.70±0.22 counts/min; N=8, p<0.0001).   
Furthermore in pMEFs, Ranolazine in presence ATXII seem to have no effect on Bmal1::Luc 
bioluminescent rhythm patterns (time effect p>0.05), when compare to ATXII treatment alone 
(Figure 3.3., panel (B) & Figure 3.5., panel (B)).  More specifically, cosine fit to these traces 
reveal that Bmal1::Luc bioluminescence exhibit rhythmicity of 26.10±1.19 hours (N=6, 
p>0.05) following treatment with Ranolazine (in presence of ATXII), which was similar to 
pMEFs treated with ATXII alone (25.82±1.06 hours; N=8, p>0.05) (Figure 3.7., panel (B1)).  
Similar periodicity (25.22±0.26 hours; N=6, p>0.05) was also observed in control cells.  Also, 
cosine fit showed significant difference in peak phase of Bmal1::Luc driven bioluminescence 
rhythms between ATXII treatment alone (17.04 hours, T-test p<0.05) and in presence of 
Ranolazine (15.32 hours, T-test p<0.05).  In addition, despite the unaffected Bmal1::Luc 
bioluminescent periodicity, a change in the amplitude of the oscillation between ATXII-
treatment alone and Ranolazine (in presence of ATXII) was also observed (interaction effect 
p<0.05).  Ranolazine significantly increased the amplitude of the Bmal1::Luc driven 
bioluminescence oscillation in pMEFs (138.68±45.15 counts/min; N=6, p<0.05), when 
compared to ATXII-treatment alone (73.17±10.13 counts/min; N=6, p<0.05) (Figure 3.7., panel 
(B2)). 
Profiles of Bmal1 driven bioluminescence over a period of 5 days, show very similar traces for 
each biological replicate within HL1-6 atrial myocytes (N=6) and pMEFs (N=6).  
Representative examples for each cell type are presented in Figure 3.6. Cosine fits to these 
traces reveal a significant difference in peak phase of bioluminescence rhythms, where the first 
peaks fall at 18.48 hours in HL1-6 cells, whereas this was advanced in pMEFs which peak at 
15.12 hours (T-test, p<0.05). Irrespective of peak phase, the period of the bioluminescence 
rhythms did not differ between cell types (T-test, p>0.05), and are 25.12±0.51 hours for HL1-
6 cells and 25.67±1.02 hours; N=6 hours for pMEFs (Figure 3.7., panels (A1&B1)).   
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Figure 3.5. Bmal1 clock gene bioluminescence recordings from HL1-6 atrial myocytes (A) and primary 
mouse embryonic fibroblasts (pMEFs; comparable cell line) (B) transduced with Bmal1::Luc (mBmal1 
promoter::luciferase) under 1 nM ATXII + 10 µM Ranolazine treatment, following serum-shock 
synchronisation with 50 % fetal bovine serum (FBS).  Representative baseline subtracted recordings (N=6) of 
Bmal1::Luc bioluminescence are shown in black and cosinor curve fitted is shown in blue. Bmal1::Luc 
bioluminescence is expressed as counts.min-1.  
 
In addition, treating HL1-6 cells with 10 µM Ranolazine alone, showed approximately similar 
circadian pattern (25.12±0.51 hours; N=6, p>0.05), to the one observed under 10 µM 
Ranolazine in presence of 1 nM ATXII (25.32±0.97 hours; N=6, p>0.05) (Figure 3.7., panel 
(A1)).  This states the absence of changes in circadian rhythmicity following treatment with 10 
µM Ranolazine alone, in HL1-6 atrial myocytes and further supports the ATXII-induced effects 
on Bmal1::Luc bioluminescence traces observed.  In pMEFs Bmal1::Luc bioluminescence 
exhibit circadian pattern with period of 25.67±1.02 hours (N=6).  This was similar to the 
periodicity of Bmal1::Luc bioluminescence observed under 10 µM Ranolazine treatment in 
presence of 1 nM ATXII (26.10±1.19 hours, N=6, p>0.05), also stating the absence of changes 
in Bmal1 circadian rhythmicity (Figure 3.7., panel (B1)). 
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Figure 3.6. Bmal1 clock gene bioluminescence recordings from HL1-6 atrial myocytes (A) and primary 
mouse embryonic fibroblasts (pMEFs; comparable cell line) (B) transduced with Bmal1::Luc (mBmal1 
promoter::luciferase) under 10 µM Ranolazine treatment alone, following serum-shock synchronisation 
with 50 % fetal bovine serum (FBS).  Representative baseline subtracted recordings (N=6) of Bmal1::Luc 
bioluminescence are shown in black and cosinor curve fitted is shown in green. Bmal1::Luc bioluminescence 
expressed as counts.min-1. 
 
 
 
 
    
 
 
  
 
1 2 3 4 5
-1 1 0
-5 5
0
5 5
1 1 0
                                                              P o s t s y n c h ro n is a tio n  tim e  (h o u rs )
B
m
a
l1
 b
io
lu
m
in
e
s
c
e
n
c
e
(c
o
u
n
ts
.m
in
-
1
)
1 2 3 4 5
-4 0
-2 0
0
2 0
4 0
                                         P o s t s y n c h ro n is a tio n  t im e  (h o u rs )
B
m
a
l1
 b
io
lu
m
in
e
s
c
e
n
c
e
(c
o
u
n
ts
.m
in
-1
)
B
m
a
l1
 B
io
lu
m
in
es
ce
n
ce
 
C
o
u
n
ts
.m
in
-1
 
B
m
a
l1
 B
io
lu
m
in
e
sc
e
n
ce
 
C
o
u
n
ts
.m
in
-1
 
 
Post synchronisation time (days) 
 
Post synchronisation time (days) 
 
HL1-6s 
pMEFs 
A 
B 
0
1 0
2 0
3 0
P
e
ri
o
d
 (
h
o
u
rs
)
C
o
n
tr
o
l
1
n
M
 A
T
X
II
1
n
M
 A
T
X
II
/
1
0

M
 R
a
n
o
la
z
in
e
1
0

M
 R
a
n
o
la
z
in
e
0
1 0
2 0
3 0
A
m
p
li
tu
d
e
 (
c
o
u
n
ts
/m
in
)
C
o
n
tr
o
l
1
n
M
 A
T
X
II
1
n
M
 A
T
X
II
/
1
0

M
 R
a
n
o
la
z
in
e
1
0

M
 R
a
n
o
la
z
in
e
**** 
#### 
**** 
#### 
P
e
ri
o
d
 (
h
o
u
rs
) 
A
m
p
lit
u
d
e 
(C
o
u
n
ts
/m
in
) 
 
A2
F 
A1
E 
Chapter 3. Bmal1 gene expression 
 
103 | P a g e  
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Bioluminescence recording analysis from HL1-6 atrial myocytes and primary mouse embryonic 
fibroblast (pMEFs) transduced with Bmal1::Luc (mBmal1 promoter::luciferase) under control conditions 
and in presence of 1 nM ATXII alone or in combination with 10 µM Ranolazine, and in 10 µM Ranolazine 
treatment alone. (A1 & B1).  Bar graphs of the Bmal1::Luc diurnal period (hours) under the different 
interventions in HL1-6 cells and pMEFs, respectively.  The different treatments are indicated in different colours; 
Control (black), 1 nM ATXII (red), 1 nM ATXII + 10 µM Ranolazine (blue) and 10 µM Ranolazine (green). (A2 
& B2) Bar graphs of Bmal1::Luc amplitude oscillations (counts/min) recorded under all conditions (control 
(black), 1 nM ATXII (red), 1 nM ATXII + 10 µM Ranolazine (blue) and 10 µM Ranolazine (green)).  Values are 
Mean±SEM (N=6-8), # p<0.05, ** p<0.001, ####/**** p<0.00001  
 
In summary, Bmal1 clock gene expression is rhythmic in HL1-6 atrial cells however such 
expression patterns are significantly altered under increased levels of [Ca2+]i by 1nM ATXII 
treatment (Figure 3.8.; panels (A1-B1)).  The associated reduction in period (~10 hours) 
observed under ATXII treatment, and a striking loss of precision is rescued through the use of 
Ranolazine (10 µM) inhibitor, which seems to restore the effects of raised [Ca2+]i (Figure 3.8.; 
panel (C1)).  Whereas, Ranolazine alone showed approximately similar circadian pattern to the 
one observed under 10 µM Ranolazine in presence of 1 nM ATXII, which further supports the 
ATXII-induced effects on Bmal1::Luc bioluminescence traces observed (Figure 3.8.; panel 
(D1)).  Additionally, the circadian rhythmic patterns of Bmal1 driven bioluminescence in 
pMEFs, remained unaffected under raised intracellular [Ca2+] or through the use of several 
pharmacological interventions that inhibit Ca2+ signalling in the cell (Figure 3.8.; panels (A2-
D2)).    
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Figure 3.8. Summarised Bmal1 clock gene bioluminescence recordings from HL1-6 atrial myocytes (A1-D1) 
and primary mouse embryonic fibroblasts (pMEFs; comparable cell line) (A2-D2) transduced with 
Bmal1::Luc (mBmal1 promoter::luciferase) under control, 1 nM ATXII treatment alone and in presence of 
10 µM Ranolazine, and 10 µM Ranolazine treatment alone, following serum-shock synchronisation with 50 
% fetal bovine serum (FBS).  In HL1-6 atrial myocytes, Bmal1 expressed in a circadian manner under control 
(A1), Ranolazine treatment in presence of ATXII (C1) and Ranolazine treatment alone (D1).  Such expression was 
highly disrupted in presence of ATXII-induced raised [Ca2+]i.  In pMEFs, absence of Bmal1 disturbed circadian 
expression reported under all proposed interventions (A2-D2).  Bmal1::Luc bioluminescence expressed as 
counts.min-1. 
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3.5.4. Assessment of raised intracellular [Ca2+] effects on Bmal1::Luc driven 
bioluminescence circadian rhythmicity changes observed in HL1-6 atrial 
myocytes, using MTS cell viability assay 
Changes in Bmal1::Luc circadian rhythmicity after rise in intracellular [Ca2+] by ATXII, were assessed 
by MTS cell viability colorometric assay with 1 nM ATXII in the absence or presence of 10 µM 
Ranolazine, and vehicles (1 % DMSO contained in ATXII and Ranolazine) for 1, 2 and 3 days, in HL1-
6 atrial myocytes and primary mouse embryonic fibroblasts (pMEFs), following serum-shock 
synchronisation.  As a first observation 1 nM ATXII treatment alone, did not affect the viability of HL1-
6 cells (Figure 3.9., panel (A)).  A 2.3 % reduction in the number of HL1-6 viable cells was observed 
from day 1 to day 2, and a subsequent 4.2 % reduction from day 2 to day 3 following treatment with 
ATXII.  With a total 6.5 % reduction in the number of HL1-6 viable cells under ATXII treatment, a 
percentage not significant enough to report cytotoxicity involvement under the current treatment 
(p>0.05). Similarly, no significant reduction was observed in the number of HL1-6 cells under vehicle 
1 (1% DMSO contained in ATXII; 1.0 % reduction from day 1 to day 3) confirming the absence of 1 
nM ATXII treatment effect in HL1-6 cells viability. 
Under Ranolazine treatment (in presence of ATXII), a significant reduction (12.7 %) in the number of 
HL1-6 viable cells was observed from day 1 to day 2 (Figure 3.9., panel (A)).  However, such reduction 
was not enough to disrupt Bmal1::Luc bioluminescent rhythmicity, as the rhythm remained unaffected 
with approximately 24 circadian patterns (Figure 3.5., panel (A1)).  Indeed, the number of HL1-6 viable 
cells increased by 8.4 % from day 2 to day 3 under Ranolazine treatment in presence of ATXII, and 
possibly helped in avoiding the occurrence of cytotoxic effects.  Ranolazine treatment alone, increased 
the number of HL1-6 viable cells by 10 % (from day 1 to day 3), supporting the absence of cytotoxic 
effects on Bmal1 circadian rhythmicity (Figure 3.9., panel (A)).  The effect of 1 % DMSO contained 
into Ranolazine (vehicle 2) on cell viability was also reported, with an 8 % total reduction in HL1-6 cell 
number (from day 1 to day 3).  A percentage not significant enough to report cytotoxicity involvement 
under the current treatment (p>0.05).      
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Figure 3.9. Mean normalized HL1-6 atrial myocytes (panel (A)) and primary embryonic fibroblasts 
(pMEFs; panel (B)) viability (% control) after 1, 2, and 3 days.  Cells were incubated with control medium in 
presence of 1 nM ATXII alone, or in combination with 10 µM Ranolazine, or vehicles 1 and 2 (1 % DMSO used 
in ATXII and Ranolazine, respectively), following serum-shock synchronisation with 50 % FBS treatment.  The 
relative cell viability is expressed as a percentage (%) relative to the untreated control cells.  Values are 
Mean±SEM (N=3). 
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Furthermore, pMEFs treatment with 1 nM ATXII treatment alone or in the presence and absence of 10 
µM Ranolazine, is shown in Figure 3.9., panel (B).  As a first observation 1 nM ATXII treatment 
increased pMEFs viability on day 2 of treatment (Figure 3.9., panel (B)).  A 10.7 % increase in the 
number of viable pMEFs was observed from day 1 to day 2, followed by a 6.6 %-fold at day 3.  With a 
total 3.4 % reduction in the number of viable pMEFs under 1 nM ATXII treatment, a percentage not 
significant enough to report cytotoxicity involvement under the current treatment as the rhythms 
remained unaffected with approximately 24 circadian patterns (Figure 3.3., panel (B)).  Similarly, 
increased in pMEFs viability was observed on day 2 under vehicle 1 (1% DMSO contained in ATXII), 
followed by a 20.5 %-fold in cell viability on day 3.  This marks a total 6.1 % effect of DMSO on pMEFs 
viability (Figure 3.9., panel (B)).   
Similar pattern was also observed under Ranolazine treatment in presence of ATXII.  An increase of 
17.9 % was observed after 2 days of treatment followed by 9.1 % reduction in pMEFs viability on day 
3 (Figure 3.9., panel (B)).  With a total 7.2 % effect of 1 nM ATXII/ 10 µM Ranolazine treatment on 
Bmal1 rhythmicity, however not enough to disrupt its rhythmicity (see Figure 3.9., panel (B)).  The 
number of viable cells increased by 17.7 % (from day 1 to day 3) under 10 µM Ranolazine treatment 
alone, supporting the absence of Ranolazine effect on Bmal1 circadian rhythmicity in pMEFs (Figure 
3.9., panel (B)).  The effect of 1 % DMSO contained into Ranolazine (vehicle 2) on pMEFs viability 
was also reported, with a 23.3 % increase (from day 1 to day 2) in cell number, followed by a significant 
reduction on day 3 (13.4 %).  This marks a total of 6.7 % effect of DMSO on pMEFs viability, a 
percentage not significant enough to report cytotoxicity involvement under the current treatment 
(p>0.05). 
 
3.5.5. Assess raised intracellular [Ca2+] effects by ATXII on Bmal1::Luc 
driven bioluminescence using BAPTA-AM Ca2+ chelator, in synchronised 
HL1-6 atrial myocytes 
As a first observation, the Ca2+ chelator seems to restore the effects of raised [Ca2+]i by ATXII in HL1-
6 atrial myocytes (Figure 3.10.).  More specifically, under control conditions Bmal1::Luc 
bioluminescent recordings were significantly different to the ones observed under ATXII treatment 
alone in synchronised HL1-6 cells (interaction effect p<0.0001) (Figure 3.10., panels (A&B)). The 
Bmal1::Luc driven bioluminescence recordings observed during ATXII treatment alone, appeared with 
disturbing fluctuations to the signal during the 5-day recordings, leading to a loss of ‘smoothness’ of the 
signal due to loss of coherence in the measures, when compare to control (Figure 3.10., panels (A&B)).   
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Figure 3.10. Bmal1 clock gene bioluminescence recordings from HL1-6 atrial myocytes (A) transduced with 
Bmal1::Luc (mBmal1 promoter::luciferase) under control conditions (panel (A)), 1 nM ATXII treatment 
alone (panel (B)) and in presence of 5 µM BAPTA-AM Ca2+ chelator (panel (C)), following serum-shock 
synchronisation with 50 % fetal bovine serum (FBS). Representative baseline subtracted recordings (N=5-8) of 
Bmal1::Luc bioluminescence are shown in black and cosinor curve fitted is shown in grey (control), red (1 nM 
ATXI) and purple (1 nM ATXII + 5 µM BAPTA-AM). Bmal1::Luc bioluminescence expressed as counts.min-1 
 
Cosine fits to these traces reveal a significant difference in peak phase of bioluminescence rhythms, 
where the first peaks fall at 16.08 hours after serum shock (control group), whereas this was advanced 
in ATXII-treated cells which peak at 14.04 hours (T-test, p<0.05). Irrespective of peak phase, the period 
of the bioluminescence rhythms was also significantly different (T-test, p<0.001) between the two 
conditions (T-test, p>0.05), and are 25.82±1.06 hours (N=6) and 16.06±1.10 hours (N=8), for control 
and ATXII-treated cells, respectively (Figure 3.11., panel (A1)).  The changes in circadian rhythmicity 
during the presence of ATXII alone, could also interpreted as a shift in Bmal1 phase time by 
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approximately 10 hours; a possible sign of raised intracellular [Ca2+] effect, due to the more frequent 
diurnal rhythms recorded.  The change in the amplitude of the oscillation in bioluminescence in response 
to no treatment (control) and ATXII treatment alone was also quantified in HL1-6 cells (interaction 
p<0.01). The ATXII treatment significantly decreased (5.88±0.78 counts/min; N=8, p<0.01) 
Bmal1::Luc bioluminescence oscillation amplitude when compare to control (9.68±0.98 counts/min; 
N=6, p<0.01) (Figure 3.11., panel (A2)).     
 
 
 
 
 
 
 
 
Figure 3.11. Bioluminescence recording analysis from HL1-6 atrial myocytes transduced with Bmal1::Luc 
(mBmal1 promoter::luciferase) under control conditions (serum-shock effect) and in presence of 1 nM 
ATXII alone or in combination with 5 µM BAPTA-AM. (A1) Bar graphs of the Bmal1::Luc diurnal period 
(hours) under the different interventions in HL1-6 cells.  The different treatments are indicated in different colours; 
control (black), 1 M ATXII (red), 1 nM ATXII + 5 µM BAPTA-AM (purple). (A2) Bar graphs of Bmal1::Luc 
amplitude oscillations (counts/min) recorded under all conditions (control (black), 1 nM ATXII (red), 1 nM ATXII/ 
5 µM BAPTA-AM (purple) and 10µM Ranolazine.  Values are Mean±SEM (N=5-8), ** p<0.01, **** / #### 
p<0.0001. 
 
The effects of 5 µM BAPTA-AM Ca2+ chelator in Bmal1::Luc bioluminescence recordings, in presence 
of ATXII (1 nM) treatment, showed that the Ca2+ chelator prevented (interaction p<0.0001) the 
Bmal1::Luc driven bioluminescence expression phenotype observed under ATXII treatment alone, in 
HL1-6 cells (Figure 3.10., panel (C)).  More specifically, the cosine fit reveal that Bmal1::Luc 
bioluminescence exhibit approximately circadian rhythmicity of 25.91±0.54 hours in presence of 
BAPTA-AM Ca2+ chelator (in combination with 1 nM ATXII).  This suggests a shift in Bmal1::Luc 
bioluminescence phase time by approximately 10 hours, as a periodicity of 16.06±1.10 hours (N=8) was 
reported in ATXII-treated HL1-6 cells (Figure 3.11., panel (A1)).  Changes in the amplitude (interaction 
effect p<0.05) of the oscillation in Bmal1::Luc bioluminescence was also quantified (Figure 3.10., panel 
(A2)).  BAPTA-AM Ca2+ chelator slightly increased the amplitude of the Bmal1::Luc bioluminescence 
oscillation in HL1-6 atrial myocytes (6.62±0.84 counts/min; N=5, p<0.05), when compare to ATXII-
treatment alone (5.88±0.78 counts/min; N=8, p<0.05).  Additionally, it is worth stating that despite the 
significant difference (T-test, p<0.05) in peak phase of bioluminescence rhythms under BAPTA-AM 
(19.44 hours) and control conditions (16.08 hours), the period of the bioluminescence rhythms did not  
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differ between the two conditions, which are 25.82±1.06 hours and 25.91±0.54 hours for control and 
BAPTA-AM, respectively.  Thus, further supports the reversed action of BAPTA-AM Ca2+ chelator on 
ATXII-induced changes, as well as it highlights the involvement of Ca2+ in Bmal1::Luc changes.  
3.5.6. Intracellular [Ca2+] level changes in synchronised HL1-6 atrial 
myocytes within 48 hours, using Fura2-AM fluorescent Ca2+ indicator 
Following investigation of Bmal1 clock gene circadian expression and rhythmicity changes through rise 
in [Ca2+]i by 1 nM ATXII treatment, and prevention by 10 µM Ranolazine in HL1-6 atrial myocytes, we 
continued by assessing changes of intracellular [Ca2+] levels over 48 hours, following 50 % serum-shock 
synchronisation, using Fura2-AM (a ratiometric fluorescent Ca2+ indicator with high Ca2+ binding 
affinity).  Intracellular [Ca2+] was measured immediately after (2 hours) a synchronising serum-shock, 
and subsequently every 4 hours for 48 hours (from 12 hours onwards, avoiding serum-shock peak), 
under control conditions, 1 nM ATXII (to raise [Ca2+]i) in presence and absence of 10 µM Ranolazine 
(Nap inhibitor), or in presence of the most selective Ca2+-calmodulin serine/threonine protein 
phosphatase calcineurin inhibitor, 25 µM calcineurin autoinhibitory peptide (CAIP).  Values 
(Mean±SEM) are expressed as Fura2-AM fluorescence ratio (340/380 nm).  
As a first observation (Figure 3.12., panel (A1)), HL1-6 atrial myocytes expressed similar Ca2+ levels 
over time across the 48-hours under control conditions (time effect p>0.05) with no significant 
difference across the 48 hours.  The Ca2+ levels expressed similarly across the rest of the timepoints, 
until the end of the serum-shock effect.  Slightly higher Ca2+ levels were observed at 24 hours 
(0.97±0.03; N=3) and 40 hours (1.04±0.05; N=3, p>0.05), compare to lower Ca2+ levels at 2 (0.85±0.11; 
N=3) and 16 hours (0.87±0.04; N=3, p>0.05) post serum-shock synchronisation.  Despite the absence 
of significant difference of Ca2+ levels across the 48 hours, the cosine fit revealed a 20.01±0.10-hour 
rhythmic pattern (panel (A2)). 
 
 
 
 
 
 
 
Figure 3.12. Line graph showing average quantitative intracellular [Ca2+] ([Ca2+]i) levels (black; panel (A1)) 
and cosinor curve (grey; panel (A2)) in HL1-6 atrial myocytes over 48 hours, under control conditions 
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following serum-shock synchronisation with 50 % fetal bovine serum (FBS) using Fura2-AM (a ratiometric 
fluorescent Ca2+ indicator with high Ca2+ binding affinity).  [Ca2+]i was measured at the following time points: 
2 hours, 12 hours, 16 hours, 20 hours, 24 hours, 28 hours, 32 hours, 36 hours, 40 hours, 44 hours and 48 hours 
post serum-shock treatment.  The [Ca2+]i expressed as Fura2-AM fluorescence ratio (340/380 nm).  Values are 
Mean±SEM (N=6).       
 
We further continued assessing the effect of 1 nM ATXII on Ca2+ levels over time.  1 nM ATXII induced 
significant rise in Fura2-AM 340/380 nm ratio, an indicative of increased intracellular [Ca2+] when 
compared to control (Figure 3.13., panel (A1)).  Intracellular Ca2+ levels fluctuated across the 48-hours 
under 1 nM ATXII treatment (time effect p<0.0001).  The relative Ca2+ levels were significantly higher 
at timepoint 24 (2.24±0.15; N=6, p<0.0001) and 32 (2.33±0.41; N=6, p<0.0001) hours, marking the 
peaks of Ca2+ expression during the current treatment.  Significant difference was observed between 
timepoint 2 and 12 hours (0.98±0.02 vs 1.69±0.21; N=6, p<0.0001), 20 and 24 hours (1.58±0.10 vs 
2.24±0.15; N=6, p<0.0001), 24 and 28 hours (2.24±0.15 vs 0.95±0.05; N=6, p<0.0001), 28 and 32 hours 
(0.95±0.05 vs 2.33±0.41; N=6, p<0.0001), 32 and 36 hours (2.33±0.41 vs 1.66±0.17; N=6, p<0.0001), 
36 and 40 hours (1.66±0.17 vs 0.99±0.04; N=6, p<0.0001), 40 and 44 hours (0.99±0.04 vs 1.67±0.17; 
N=6, p<0.0001).  Lower Ca2+ levels were observed at timepoint 2 hours (0.98±0.02; N=6, p<0.05) right 
after serum-shock synchronisation, at 28 hours (0.98±0.02; N=6, p<0.001) and at 40 hours (0.99±0.04; 
N=6; p<0.05).  The cosine fit revealed a 16.32±0.32-hour pattern under ATXII-treatment (panel (A2)).  
 
 
 
 
 
 
 
Figure 3.13. Line graph showing average quantitative intracellular [Ca2+] ([Ca2+]i) levels (black; panel (A1)) 
and cosinor curve (red; panel (A2)) in HL1-6 atrial myocytes over 48 hours, under 1 nM ATXII treatment 
following serum-shock synchronisation with 50 % fetal bovine serum (FBS) using Fura2-AM (a ratiometric 
fluorescent Ca2+ indicator with high Ca2+ binding affinity).  [Ca2+]i was measured at the following time points: 
2 hours, 12 hours, 16 hours, 20 hours, 24 hours, 28 hours, 32 hours, 36 hours, 40 hours, 44 hours and 48 hours 
post serum-shock treatment.  The [Ca2+]i expressed as Fura2-AM fluorescence ratio (340/380 nm).  Values are 
Mean±SEM (N=6). *** p<0.0001       
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In terms of difference in Ca2+ levels between 1 nM ATXII-treated and control cells, was observed during 
time points 12 (Control 0.95±0.02 vs ATXII 1.69±0.21; N=6, p<0.0001), 16 (Control 0.87±0.04 vs 
ATXII 1.75±0.68; N=6, p<0.0001), 20 (Control 0.96±0.06 vs ATXII 1.58±0.10; N=6, p<0.0001), 24 
(Control 0.97±0.03 vs ATXII 2.25±0.15; N=6, p<0.0001), 32 hours (Control 0.94±0.04 vs ATXII 
2.33±0.41; N=6, p<0.0001), 36 (Control 0.99±0.04 vs ATXII 1.66±0.17; N=6, p<0.0001), 44 (Control 
1.00±0.09 vs ATXII 1.67±0.17; N=6, p<0.0001), with Ca2+ levels been significantly higher under 1 nM 
ATXII treatment compare to control conditions.  It is worth stating that the peak of Ca2+ levels at 24 
hours was similarly observed in ATXII-treated and control cells.   
Following treatment of HL1-6 cells with 1 nM ATXII, we continued by assessing changes in Ca2+ levels 
over time, in presence of 10 µM Ranolazine (Figure 3.14.).  As a first observation, the fluctuations 
observed at [Ca2+] levels with 1 nM ATXII, were restored by 10 µM Ranolazine in HL1-6 atrial 
myocytes (Figure 3.14., panel (A1)).  Ranolazine reduced Ca2+ levels following AXII treatment, 
however fluctuations in Ca2+ levels across the 48-hours were also observed (time effect p<0.01).  The 
relative Ca2+ levels were significantly higher at 2 hours (1.05±0.14; N=3, p<0.05), 20 hours (1.06±0.02; 
N=3, p<0.01) and 44 hours (1.14±0.01; N=3, p<0.001), marking the peaks of [Ca2+] levels during the 
current treatment.  Significant difference was also observed between timepoint 16 and 20 hours 
(0.89±0.03 vs 1.06±0.02; N=3, p=0.0047), 44 and 48 hours (1.14±0.01 vs 1.00±0.01; N=3, p=0.0346).  
Lower Ca2+ levels were observed at time points 16 hours (0.89±0.03; N=3, p<0.05) and at 32 hours 
(0.93±0.02; N=3, p<0.05).  Whilst there is a clear variation over time in Ca2+ levels, no circadian (24-
hour) rhythm was observed under 1 nM ATXII/ 10 µM Ranolazine treatment as calculated from trough 
to trough timepoints. To investigate the presence of circadian rhythms a cosine curve was fitted revealed 
a 18.02±0.12-hour pattern (Figure 3.14., panel (A1)).   
 
 
 
 
Figure 3.14. Line graph showing average quantitative intracellular [Ca2+] ([Ca2+]i) levels (black; panel (A1)) 
and cosinor curve (blue; panel (A2)) in HL1-6 atrial myocytes over 48 hours, under 1 nM ATXII/ 10 µM 
Ranolazine treatment following serum-shock synchronisation with 50 % fetal bovine serum (FBS) using 
Fura2-AM (a ratiometric fluorescent Ca2+ indicator with high Ca2+ binding affinity).  [Ca2+]i was measured 
at the following time points: 2 hours, 12 hours, 16 hours, 20 hours, 24 hours, 28 hours, 32 hours, 36 hours, 40 
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hours, 44 hours and 48 hours post serum-shock treatment.  The [Ca2+]i expressed as Fura2-AM fluorescence ratio 
(340/380 nm).  Values are Mean±SEM (N=3). * p<0.05, ** p<0.01  
 
In terms of difference (interaction effect p=0.0012) of Ca2+ levels between 1 nM ATXII and 1 
nM ATXII/ 10 µM Ranolazine treated cells, was observed at 12 hours (ATXII 1.69±0.21; N=6 
vs ATXII/Ranolazine 1.01±0.05; N=3, p=0.0092), 16 (ATXII 1.75±0.68; N=6 vs 
ATXII/Ranolazine 0.90±0.03; N=3, p=0.0002), 24 (ATXII 2.25±0.15; N=6 vs 
ATXII/Ranolazine 0.97±0.02; N=3, p<0.0001), 32 (ATXII 2.33±0.41; N=6 vs 
ATXII/Ranolazine 0.93±0.02; N=3, p<0.0001) and 36 hours (ATXII 1.66±0.17; N=6 vs 
ATXII/Ranolazine 0.99±0.01; N=3, p=0.0139), with Ca2+ levels been significantly higher under 
1 nM ATXII treatment.   
Significant difference was also observed between control and 1 nM ATXII/10 µM Ranolazine 
treated cells at 2 hours (Control 0.85±0.11; N=6 vs ATXII/Ranolazine 1.05±0.14; N=3, 
p=0.0002) and 44 hours (Control 1.00±0.09; N=6 vs ATXII/Ranolazine 1.14±0.01; N=3, 
p=0.0364).  Also, it is worth stating that the lower Ca2+ level pattern observed under control 
conditions, was similarly observed under ATXII/Ranolazine-treated cells, with no significant 
difference between most time points, proposing that the effect of ATXII was reversed in 
presence of 10 µM Ranolazine in HL1-6 atrial myocytes which expressed significantly different 
Ca2+ levels over time.  
We then continued by assessing the effect of 10 µM Ranolazine alone in the levels of Ca2+ over 
time.  As a first observation, Ca2+ levels seem expressed in a similar manner across the 48-hour 
period (Figure 3.15.).  A peak in relative Ca2+ levels was reported at 32 hours (1.58±0.02; N=3, 
p<0.001), whereas the Ca2+ levels remain roughly the same among the rest of the timepoints.  
Significant difference (main effect p<0.05) between Ca2+ levels was also observed between 
timepoint 28 hours and 32 hours (1.05±0.01 vs 1.58±0.02; N=3, p<0.0001), 32 and 36 hours 
(1.58±0.02 vs 1.00±0.02; N=3, p<0.0001), 44 and 48 hours (1.10±0.02 vs 0.73±0.02; N=3; 
p<0.0001).  Whilst there is variation over time in Ca2+ levels, however, no clearly observable 
circadian rhythm was demonstrated in the Ranolazine-treated cells, as no cosine curve was able 
to fit through the different timepoints. 
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Figure 3.15. Line graph showing average quantitative intracellular [Ca2+] ([Ca2+]i) levels (black) in HL1-6 
atrial myocytes over 48 hours, under 10 µM Ranolazine treatment alone following serum-shock 
synchronisation with 50 % fetal bovine serum (FBS) using Fura2-AM (a ratiometric fluorescent Ca2+ 
indicator with high Ca2+ binding affinity).  [Ca2+]i was measured at the following time points: 2 hours, 12 hours, 
16 hours, 20 hours, 24 hours, 28 hours, 32 hours, 36 hours, 40 hours, 44 hours and 48 hours post serum-shock 
treatment.  The [Ca2+]i expressed as Fura2-AM fluorescence ratio (340/380 nm).  Values are Mean±SEM (N=3). 
** p<0.01   
    
In terms of difference (interaction effect p<0.05) in Ca2+ levels between 1 nM ATXII/ 10 µM 
Ranolazine and 10 µM Ranolazine treated cells, was observed at 2 hours (ATXII/Ranolazine 
1.05±0.14 vs Ranolazine 0.91±0.01; N=3, p<0.0028), 12 hours (ATXII/Ranolazine 1.01±0.05 
vs Ranolazine 0.88±0.01; N=3, p<0.0080), 20 hours (ATXII/Ranolazine 1.06±0.02 vs 
Ranolazine 0.92±0.01; N=3, p<0.0022), 32 hours (ATXII/Ranolazine 0.93±0.02 vs Ranolazine 
1.58±0.02; N=3, p<0.0001) and 48 hours (ATXII/Ranolazine 1.00±0.01 vs Ranolazine 
0.73±0.02; N=3, p<0.0001).  Also, it is worth stating that the peak observed at 32 hours under 
Ranolazine treatment alone, was is complete opposite phase with the drop observed in 
ATXII/Ranolazine-treated cells.   
Ca2+ level changes were then also assessed in HL1-6 atrial myocytes following treatment with 
25 µM CAIP (calcineurin autoinhibitory peptide) in presence of 1 nM ATXII, to investigate 
possible effect of calcineurin.  As a first observation (Figure 3.16., panel (A1)), intracellular 
Ca2+ levels fluctuated across the 48 hours under CAIP treatment.  The relative Ca2+ levels were 
similar across the 48 hours exhibiting similar levels of expression until the end of the serum-
shock effect.  Peaks were observed at 2 hours (1.00±0.01; N=3), 24 hours (1.00±0.02; N=3), 28 
hours (1.02±0.01; N=3) and 36 hours (1.06±0.01; N=3), however, such differences could not 
be considered as significant (p>0.05).  Lower Ca2+ levels were observed at 12 hours (0.89±0.03; 
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N=3), 2 hours 0 (0.91±0.03; N=3) and 32 hours (0.89±0.03; N=3) post serum-shock 
synchronisation.  Despite the absence of significant changes of Ca2+ levels across time, the 
cosine curve fitted revealed a 16.11±0.12-hour pattern, as calculated from peak to peak 
timepoints (Figure 3.16., panel (A2)).     
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16. Line graph showing average quantitative intracellular [Ca2+] ([Ca2+]i) levels (black; panel A1) 
and cosinor curve (orange; panel (A2)) in HL1-6 atrial myocytes over 48 hours, under 1 Nm ATXII/ 25 µM 
CAIP treatment following serum-shock synchronisation with 50 % fetal bovine serum (FBS) using Fura2-
AM (a ratiometric fluorescent Ca2+ indicator with high Ca2+ binding affinity).  [Ca2+]i was measured at the 
following time points: 2 hours, 12 hours, 16 hours, 20 hours, 24 hours, 28 hours, 32 hours, 36 hours, 40 hours, 44 
hours and 48 hours post serum-shock treatment.  The [Ca2+]i expressed as Fura2-AM fluorescence ratio (340/380 
nm).  Values are Mean±SEM (N=3).       
 
We further continued assessing differences (interaction effect p<0.001) in Ca2+ levels between 
1 nM ATXII and 1 nM ATXII/ 25 µM CAIP – treated cells.  Significant difference was observed 
at time points 12 hours (ATXII 1.69±0.21; N=6 vs ATXII/CAIP 0.89±0.03; N=3, p<0.0006), 
16 (ATXII 1.75±0.68; N=6 vs ATXII/CAIP 0.97±0.01; N=3, p<0.0010), 20 (ATXII 1.58±0.10; 
N=6 vs ATXII/CAIP 0.91±0.03; N=3, p<0.0134), 24 (ATXII 2.25±0.15; N=6 vs ATXII/CAIP 
1.00±0.06; N=3, p<0.0001), 32 hours (ATXII 2.33±0.41; N=6 vs ATXII/CAIP 0.89±0.03; N=3, 
p<0.0001), 36 (ATXII 1.66±0.17; N=6 vs ATXII/CAIP 0.99±0.02; N=3; p<0.0126) and 44 
hours (ATXII 1.67±0.17; N=6 vs ATXII/CAIP 0.91±0.01; N=3; p<0.0016).  Also, it is worth 
stating that the lower Ca2+ level pattern observed under control conditions, was similarly 
observed under ATXII/CAIP-treated cells, with no significant difference between the different 
time points (p>0.05).   
In summary, under control conditions no significant difference was observed in intracellular 
[Ca2+] levels across time, despite the presence of an approximately 20-hour rhythmic pattern in
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HL1-6 atrial myocytes.  Such pattern was disrupted in less extend in the presence of 1 nMATXII 
(16-hour pattern) and intracellular [Ca2+] levels were significantly higher when compare to 
control.  The Ca2+ levels and pattern observed under ATXII treatment was restored in the 
presence of Ranolazine (18.5-hour pattern), whereas Ranolazine alone had no effects, with 
intracellular [Ca2+] levels experiencing similar levels of expression across time.  Also, 
intracellular [Ca2+] levels show some variation over time in presence of specific CaN protein 
phosphatase inhibitor (CAIP) under 1 nM ATXII treatment, with similarly low levels of 
expression as the ones observed under control conditions, highlighting the association of CaN 
with raised intracellular [Ca2+].   
3.6. Discussion 
3.6.1. Rhythmic Bmal1::Luc driven bioluminescence circadian expression in 
HL1-6 atrial myocytes  
Our results expose for the first time that Bmal1 clock gene expression is rhythmic in HL1-6 
atrial cells, and that these expression patterns are significantly altered when intracellular Ca2+ 
levels are increased through the sustained opening of Nap channels by ATXII.  The associated 
reduction in period (~10 hours), and a striking loss of precision is rescued through the use of 
several pharmacological interventions that inhibit Ca2+ signalling in the cell (Ranolazine & 
BAPTA-AM), suggesting that these pathways directly affect Bmal1 expression.  Given that 
ATXII treatment is a known model for atrial arrhythmia’s, our results strongly suggest that Ca2+ 
mediated changes in the cellular circadian clock are an integral part of the aetiology of atrial 
arrhythmia’s. This notion is also supported by the evidence that AF is mostly seen at specific 
timepoints of the day (between midnight and 02:00 am) hence highlighting the involvement of 
Bmal1 clock gene in the occurrence of such event (Ripamonti et al., 2017).   
The use of NaP channel opener ATXII, to assess the effects of pathologic intracellular [Ca
2+] on 
Bmal1 clock gene expression and circadian rhythmicity, proposed a novel way of assessing the 
expression of clock genes in a disease heart model using downstream molecular targets (i.e. 
abnormal increase in intracellular [Ca2+]) without pre-disturbing the molecular clock.  To 
emphasise the uniqueness of this new technical approach, so far the studies conducted to assess 
the association of clock genes with cardiovascular diseases, required the targeted 
cardiomyocyte-specific disruption of the molecular clock either through overexpression of a 
mutant CLOCK protein or through target deletion of Bmal1 clock gene (Bray et al., 2007, 
Durgan et al., 2011). Disrupted molecular clock in cardiomyocytes induce significant 
reductions in heart rate across all times of day, as well as altered substrate metabolism and 
contractile function.  This implies that such studies failed to investigate the roles of the clock 
mechanism in the heart without disturbing the central clock.   
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Furthermore, the observed significant impact of ATXII in the HL1-6 atrial myocytes, provide 
further evidence regarding the already known existence of NaP channels in HL1-6 cells (Strege 
et al., 2012).  Our data can be supported by a study from Schroder et al., (2013) who 
demonstrated loss of SCN5A gene circadian expression; the major contributor of Nav1.5. 
channel protein expression, after the use of inducible cardiac specific deletion of the Bmal1 
clock gene in murine ventricular myocytes.  An increase in Nav1.5. protein expression, is also 
a characteristic of NaP channel behaviour from this subtype, as the release of Ca
2+ occurs during 
the plateau phase of the action potential, were NaP channels are active.  Hence, further 
strengthen our findings, regarding the association of Bmal1 clock gene and raised [Ca2+]-
induced changes by ATXII following NaP channel opening. Additionally, the circadian 
rhythmic patterns of Bmal1 driven bioluminescence in pMEFs, remained unaffected under 
raised intracellular [Ca2+] supporting the reported absence of NaP channels in these cells (Strege 
et al., 2012).   
We further showed that by inhibiting Ca2+ signalling in the cells, in the presence of Ranolazine 
NaP channel inhibitor, the ATXII effects in HL1-6 atrial myocytes were highly reversed thus 
suggesting that the NaP/raised Ca
2+ arrhythmogenic pathway directly affects Bmal1 expression 
and further proposed the association of such clock gene with the occurrence of AF.  Even though 
Ranolazine exerts as a blocker of both rapid and sustained Na+ current (INa and INaL 
respectively), was also reported to inhibit (better than pure IKr blockers) K
+ current (IKr) and its 
recombinant equivalent “hERG” which appear to lead to a more favourable action on atrial 
repolarisation phase (Rajamani et al., 2008; Zaza et al., 2008; Rajamani et al., 2009; Kumar et 
al., 2009).  Therefore, our study strengthens the evidence of Ranolazine as suitable NaP channel 
inhibitor due to the complete restoration of ATXII effect in HL1-6 atrial myocytes.  
Interestingly, Ranolazine alone had no effects which further implies the activation of NaP 
channel in presence of raised [Ca2+]i.  On the other hand, Ranolazine alone had absolutely no 
effect in pMEFs hence further supporting the absence of NaP channels in fibroblast cells (Strege 
et al., 2012).  
The use of BAPTA-AM Ca2+ chelator in HL1-6 cells, provided further insights on the role of 
intracellular [Ca2+] in Bmal1::Luc circadian expression.  BAPTA-AM is highly selective for 
Ca2+ ions compare to EGTA or EDTA (EGTA derivative; high Mg2+ affinity) and could bind 
and release Ca2+ ions about 200-400 times faster than EGTA-AM, hence increasing the ability 
to inhibit Ca2+ diffusion in cells (Zheng et al., 2006).  Our study provided evidence that a 
reduction in intracellular [Ca2+] after the use of BAPTA-AM chelator, prevented ATXII-
induced Bmal1 period shortening.  Hence, further confirming the hypothesis that intracellular 
Ca2+ plays a role in the regulation of the rhythmicity of Bmal1 gene under ATXII-induced AF 
conditions.  In addition, a study by Yoshida et al., (2017) showed that Ca2+ influx inhibition by 
BAPTA-AM, disrupted the expression and phase of Bmal1 in non-cardiac cells (synovial cells). 
They also suggested that Bmal1 expression was strongly affected by Rorα and not Rev-
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erbα (Bmal1 transcriptional regulators) in the absence of Ca2+ influx, and that BAPTA-AM 
cancelled Bmal1 reported upregulation by TNF-α (intracellular Ca2+ enhancer). Thus, 
strengthening our hypothesis regarding Ca2+ mishandling and alteration in Bmal1 clock gene 
expression and rhythmicity.   
The changes in Bmal1 circadian rhythmicity in HL1-6 atrial myocytes (and pMEFs) by ATXII-
induced raised intracellular [Ca2+] (via sustain NaP opening), were also confirmed by MTS cell 
viability assay which reported a small reduction in the number of viable cells throughout the 3 
days.  Similarly, no significant overall reduction was observed in the number of viable HL1-6 
cells under Nap inhibitor (10 µM Ranolazine) treatment.  Thus, confirming the involvement of 
NaP channel opening and subsequently increased intracellular [Ca
2+] changes in Bmal1 
circadian rhythmicity, and further indicating a role for clock genes in atrial arrhythmias.  
Furthermore, the small reduction in pMEFs viability under all proposed treatments, further 
confirms the Bmal1 circadian patterns observed by bioluminescence recordings.  There is a 
plethora of assay methods that can be used for the estimation of the number of viable eukaryotic 
cells, including tetrazolium reduction (i.e. MTT, MTS), protease markers and ATP detection 
(Riss et al., 2013).  However, the MTS assay eliminates a liquid handling step during the assay 
procedure (the addition of a second reagent is not required to solubilise formazan precipitation), 
thus making the protocol more convenient and minimise extra steps that might increase the 
chances of contamination, as well as, induce mechanical stress which might affect their viability 
(Riss et al 2013). 
It is all worth stating that cosine curve fitting method is the simplest of many techniques 
available for analysis of bioluminescence time-series recordings, for the evaluation of circadian 
rhythmicity based on their periodicity and dependency of the size (amplitude).  Determination 
of period length is essential for a clear estimation of presence of circadian pattern in the cells, 
as well as for the estimation of rhythmicity changes under abnormal conditions.  In addition, 
periodicities can provide immediate and visual information about each outcome without a prior 
knowledge about the cyclic nature of the data or the clinical interventions used throughout the 
experiment.  Studies have also shown that period length is dependent on media containing 
serum concentrations of 5% and higher, resulting in compact bioluminescence waves which 
strongly support and emphasise the relevance of our findings (Nagoshi et al., 2004).  Therefore, 
a wider period length distribution manifests in a less efficient synchronisation and may also 
provide insights on the lower amplitude recordings during bioluminescence cycles.   
Furthermore, studies reported that the period of circadian rhythms is robust to external factors 
(i.e. temperature, CO2) in mammalian cell cultures across time, marking periodicity as an 
excellent criterion for investigation of circadian rhythms in HL1-6 and pMEFs (Kurosawa et 
al., 2017).  Whereas, studies have shown that in serum-shocked fibroblasts or tissue explants 
the amplitude of circadian rhythms tends to progressively decrease over time, despite the 
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unaffected periodicity (Nagoshi et al., 2004).  The rapid decrease may possibly be due to 
different frequencies of individual oscillators (dephasing) or due to progressive loss of 
amplitude in individual oscillations (damping); thus marking amplitude as a secondary criterion 
for commenting on bioluminescent recordings.  Additionally, due to the variability between cell 
lines, a considerable scatter of period length and amplitude throughout the 24-hour cycle should 
be expected.  However, no influence should be expected to any degree between each other’s 
rhythms within the same cell co-culture experiments, which further support the robustness of 
our results.  In addition, cells that are sensitive to irradiation (fluorescence excitation) won’t 
allow recording periods longer than 2 days, highlighting the use of the current cell lines in this 
set of experiments (Nagoshi et al., 2004).    
3.6.2. Bmal1 clock gene mRNA expression in HL1-6 atrial myocytes  
This study also reports an endogenous Bmal1 mRNA expression in HL1-6 atrial myocytes 
which was altered (in less extend than the one observed in bioluminescent model; ~ 6-hour shift 
in the peak expression time only) following treatment with ATXII, using RT-QPCR technique.  
Under such conditions, these cells showed varied Bmal1 expression over time, however it is 
arguable whether those changes are circadian.  The aberrant absence of these rhythms is in line 
with earlier observations by van der Veen et al., (2012) who provided evidence regarding Per2 
clock gene mRNA expression and rhythmicity in mouse atrial explant cells.  They showed that 
the ex vivo bioluminescence altered peak phase in the circadian rhythms of these cells, as a 
result of the time of sacrifice of the animal and subsequently their culture.  The peak phase of 
Per2::Luc bioluminescence rhythm in atrial tissue was very different between each of the four 
killing and culturing start times, compared to SCN and liver tissues which showed similar peaks 
during the different times of culturing.   
Findings suggest that mechanical stress shifts the circadian clock in cardiac cells.  Therefore, 
the aberrant circadian patterns observed in our data may be due to similar mechanical stress 
developed during the experimental steps prior to the cell lysis and collection procedure.  The 
large phase shifts may indicate a specific sensitivity of atria to mechanical stress that undergoes 
during the treatment. Such hypothesis is intriguing, when taking into account the mechanical 
nature of cardiac tissue and sensitivity of atrial cardiomyocytes to stretch. This hypothesis can 
also be adopted to explain the effects of timing of culturing (a mechanically stressful 
procedure), which also results in a larger range of phase shifts in the atrium.  Steps in the 
experimental procedure that may contribute to the development of mechanical stress in our cells 
are possibly the mechanical movement of the dishes during the media change, and/or serum 
content, or small changes in gas pressures when removing the dishes in and out of the 
incubators.  Similarly, opening the lid of the sealed cell culture dish to provide air exchange 
may also affect the phase shit, concluding that mechanical change (i.e. stress) highlights the 
possibility that increased cardiac activity might itself result in resetting of the circadian clock 
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in the atria.  Additionally, van der Veen et al., 2012 reported that following synchronisation 
under a certain period of time, clock genes start exhibiting dampened rhythmicity and 
significantly low levels of mRNA expression due to gradual loss of cell synchronisation.  The 
low Bmal1 mRNA expression may also be due to smaller number of cells lysed during 
collection process or further due to the steps in the experimental procedure that may contribute 
to the development of mechanical stress in our cells (i.e opening of incubator, changes in CO2 
levels etc), as previously stated. 
Furthermore, the absence of mRNA circadian pattern in HL1-6 atrial myocytes (using RT-
QPCR) may also be due to a possible interaction between Norepinephrine (NE) and serum 
shock cultured medium.  An exposure to a high concentration of serum has been related to 
induction of circadian mRNA accumulation for all clock genes that known to be expressed in a 
circadian fashion.  Serum alone, is considered as a Zeitgeber (external or environmental cue 
that entrains or synchronises) for the circadian clock in almost all cell types in culture, including 
the cardiomyocytes, due its composition (Nagoshi et al., 2005).  However, the use of NE is 
essential for the initiation and preservation of HL1-6 atrial myocytes beating in culture 
(Claycomb et al., 1998).  A study by Durgan et al., (2005) reported the effects of NE as a 
physiological Zeitgeber for the circadian clock within adult rat cardiomyocytes, as a 2-hour 
incubation of these cells in 10 µM of NE caused reactivation of the circadian clock within the 
cells which were also cultured in complete absence of serum throughout the whole experiment.  
Therefore, the combination of equally efficient Zeitgebers in HL1-6 atrial cells, may have 
caused their interaction and further affected cellular signalling pathways that might have helped 
in developing a 24-hour circadian pattern.   
In addition, an endogenous Bmal1 mRNA expression in pMEFs was also observed.  Similar 
mRNA expression pattern was also observed in a study by Sahar et al., (2010) who reported 
rhythmic expression of Bmal1 clock gene in wild type pMEFs synchronised with the 
glucocorticoid hormone analog dexamethasone (DEX; 100 nM).  Glucocorticoid hormones are 
secreted in a diurnal variation and the glucocorticoid receptor is expressed in most peripheral 
cell types excluding the SCN therefore glucocorticoids are considered as entraining signals, 
given that circadian gene expression has a different phase angle in the SCN and in peripheral 
tissue (Balsalobre et al., 2000).  In addition, similar to Sahar et al., (2010) we showed troughed 
Bmal1 mRNA expression timepoints at 12 and 40 hours, which further strengthens our findings.  
Also, we reported peaked mRNA expression at timepoints 8 and 36 hours, however is 
questionable whether such timepoints should be used for the true interpretation of Bmal1 
circadian expression in pMEFs.  That is because the first 12 hours should not be taken into 
account due to the continual effect of the serum-shock on pMEFs, as well as the cells collected 
towards the end (36-48 hours) of serum-shock might be completely out of phase or 
desynchronised as the effect of serum-shock fades away with time (Balsalobre et al, 1998).  
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On another note, the accuracy of such observations is critical considering the small number of 
samples.  For that reason, further experiments need to be done to confirm the above data.  The 
use of RT-PCR might also have its own limitations in detecting mRNA expression, such as 
possible crosslinking between the two probes or poor quality of mRNA.  Also, giving the 
evidence that the clock in the cells was shifted by the lysis treatment, the use of a more robust 
technique (such as Lentivirus bioluminescence), further supports our original findings.    
3.6.3. Oscillatory pattern of intracellular [Ca2+] over time in HL1-6 atrial 
myocytes 
It has been reported that intracellular [Ca2+] plays diverse roles as a component of the timing 
system by regulating the entrainment process, clock gene expression and output signalling 
(Tanaka et al., 2002; Aguilar-Roblero et al., 2007; Lamia et al., 2009).  A study by Lundkvist 
et al., (2005) reported that periodic Ca2+ influx is a critical process for the function of circadian 
pacemaker such as Per1 and Per2 genes in rodents.  In this study we also showed that Ca2+ 
signalling regulates Bmal1 clock gene expression and circadian rhythmicity in HL1-6 in vitro 
cell culture model.  Following validation of Bmal1 clock gene circadian expression and 
rhythmicity changes under atrial arrhythmias through rise in intracellular [Ca2+] by 1 nM ATXII 
treatment and prevention by 10 µM Ranolazine in HL1-6 atrial myocytes, we continued by 
investigating changes of intracellular Ca2+ levels over 48 hours, under the current conditions.   
We showed that the Ca2+ levels fluctuated across the 48-hour timeline under physiological 
conditions however with an approximately 20-hour rhythmic pattern.  This might also be in line 
the Bmal1::Luc driven bioluminescent pattern observed earlier in our study, as similar 
periodicity was reported under control conditions.  Following that, intracellular Ca2+ levels 
significantly rise under ATXII-induced atrial arrhythmias.  In addition, clear variation (different 
to control conditions) in Ca2+ levels over time was observed due to heavy fluctuations that have 
been reported in a non-circadian manner, proposing the involvement of Ca2+ changes under 
ATXII-induced treatment, and subsequent effect on Bmal1 circadian rhythmicity.  Interestingly 
Ca2+ levels under ATXII treatment revealed an approximately 16-hour rhythmic pattern which 
happens to be in line with the Bmal1::Luc driven bioluminescent expression pattern observed 
earlier in our study.  Hence, further supports possible association of periodic Ca2+ influx and 
Bmal1 clock gene expression.  ATXII reported to cause the induction of Ca2+ waves in many 
myocytes, which is consistent with an effect of ATXII to cause intracellular Ca2+ overload and 
delayed afterdepolarisations (Song et al., 2008).  In addition, a study by Wanke et al (2009), 
who reported marked changes in Ca2+ cycling in intact hearts by 1 nM ATXII, have shown that 
such changes were also prevented or reversed by Ranolazine treatment (Wanke et al., 2009).      
Lower levels of [Ca2+]i were observed across time in presence of Ranolazine, which supports 
the reported activity of such Nap channel inhibitor.  The effects of Ranolazine, have been 
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confirmed in hearts/myocytes from several species including mouse, rat, guinea pig, rabbit and 
human with no significant difference in its potency among the different species, eliminating 
variation among its mode of action (Hale et al., 2008).  The Ranolazine concentration used in 
the experiments described, is at the upper end of the range of recommended therapeutic 
concentration (2-10 µM), however was used in numerous studies (Wasserstrom et al., 2009).  
Ca2+ level variations over time were observed in an approximately 24-hour circadian pattern 
under Ranolazine treatment, similarly observed under physiological conditions, implying that 
Ranolazine recovered Ca2+ levels after ATXII-induced atrial arrhythmias.  We interpret these 
findings to indicate that Ranolazine inhibition of increased INaP induced by ATXII antagonises 
the changes in time-dependent Ca2+ cycling induced by the toxin.  Presumably, the increase in 
Na+ current that developed during increased INaP current is responsible for the Ca
2+ cyclic 
changes observed over time, hence the block of such current will allow Na+ and Ca2+ levels 
restitution to return to normal levels.  Therefore, our results in the present study are consistent 
with the known effect of Ranolazine to block INaP and suggesting that interventions that promote 
INaP and subsequent time-dependent changes in Ca
2+ cycling could be antagonised by 
Ranolazine action, making Ranolazine a good anti-arrhythmic model to use for future studies.  
It is worth also worth stating that Ranolazine alone had no effects, with Ca2+ levels experiencing 
similar levels of expression across time, marking the importance of ATXII-induced raised Ca2+ 
changes over time, as well as the activation of Nap channels in presence of high Ca2+ levels.   
In addition, intracellular Ca2+ levels show some variation over time in presence of specific 
calcineurin protein phosphatase inhibitor, which emphasise the association of calcineurin with 
raised [Ca2+]i.  In a heathy heart calcineurin is inactive and unresponsive to high frequency Ca
2+ 
waves that drive contraction, whereas upon raised intracellular [Ca2+] calcineurin gets activated 
and subsequently binds to a Ca2+/calmodulin (CaM) complex to drive various signalling 
pathways that have been linked to the progression of cardiac arrhythmias (Wilkins and 
Molkentin., 2004).  Elevated levels of intracellular [Ca2+] and CaM, are shown to be associated 
with atrial arrhythmias in animals and chronic AF in patients due to calcineurin activation (Jabr 
et al., 2016).  Activated calcineurin reported to lead to dephosphorylation of Inhibitor 1 (I1) at 
threonine 35 (Thr35) target site and initiate its dissociation from protein phosphatase 1 (PP1).  
PP1 activation will then cause dephosphorylation of gap junctional proteins known as 
connexins.  In particular, PP1 reported to cause dephosphorylation of phosphorylated Cx43 at 
Serine 365 (pCx43-Ser365) which in turn will enhanced the phosphorylation of Cx43 at Ser368 
site, by protein kinase C (PKC) (Jabr et al., 2016).  This will lead to reduced gap junction 
electrical conductance, a well-known pro-arrhythmic factor, as changes in gap junctional 
proteins were also reported to disturbed conduction of electrical activity across the heart which 
will lead to arrhythmias.  Therefore, our findings are in line with the literature, considering that 
CAIP inhibits calcineurin activation in presence of raised [Ca2+]i, hence prevent the facilitation 
of an arrhythmic event.   
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4.1. Introduction  
Atrial arrhythmias, including atrial fibrillation (AF), are characterised by rapid and irregular 
beating of the heart (>200 bpm vs 60 bpm on healthy individual). Disruption in circadian 
rhythm may be a potential factor for the occurrence of arrhythmogenic events, as it was 
reported that mammalian diurnal rhythms contribute to the existence of patterned atrial 
arrhythmias (Standberg et al., 2010; Remme and Bezzina., 2010).  Circadian rhythmicity and 
involvement of clock genes have been proposed in atrial arrhythmias by van der Veen et al., 
(2012), who reported that peripheral clock genes, Per1 and Per2, were expressed in mouse 
atrial explant culture cells, with the Per2 exhibiting circadian expression and rhythmicity.  
Thus, proposing the importance of further investigation of protein expression and rhythmicity 
of more clock genes in the atria, as well as their contribution in atrial arrhythmias.  BMAL1 
have gain great interest considering that is the one of the two key proteins driving the 
mammalian circadian clock, however less in known about its expression in the heart and more 
specifically in the atria.  Our preliminary findings (see Chapter 3) provided evidence for 
Bmal1 mRNA expression and circadian rhythmicity in cultured HL1-6 immortal atrial 
cardiomyocytes, with periodicity of approximately 24 hours.  Such expression and 
rhythmicity was highly disrupted by raised intracellular [Ca2+] ([Ca
2+]i) using ATXII, hence 
suggesting a possible correlation between BMAL1 clock gene and increased intracellular 
[Ca2+] triggered by sustained activation of persistent Na+ (NaP) channels.  Therefore, this 
provides a prospect to assess the behaviour of BMAL1 clock gene protein expression under 
electrophysiological and pathophysiological conditions (raised [Ca2+]i).   
Atrial arrhythmias are known to be associated with raised intracellular [Ca2+]; the trigger of 
contractile mechanism in the heart (Grandi et al, 2012).  In order to, maintain synchronous 
beating of the myocardium, propagation of electrical activity (action potential; AP) between 
cardiomyocytes is essential. The process of electrical activation of cardiomyocytes which 
leads to initiation of contraction is known as excitation-contraction coupling (E-C coupling) 
(Bers., 2014).  The bridge between cardiac myocyte membrane depolarisation (excitation of 
cells) and initiation of contraction is achieved by intracellular Ca2+ entry during plateau phase 
(phase 2) of the AP, and the further triggered Ca2+ release from the sarcoplasmic reticulum 
(SR; Ca2+ intracellular stores).  The Ca2+ entry during plateau phase is caused by opening of 
dihydropyridine receptors (DHPR) which form a hemichannel once activated by AP.  This 
results to further activation of another set of receptors known as type 2 ryanodine receptors 
(RyR2) located on the SR, which cause SR opening leading to rapid Ca2+ release into the 
cytoplasm, a process referred to as Ca2+-induced Ca2+ release (CICR).  CICR will prevent 
further influx of Ca2+ after binding of Ca2+ to DHPR, in addition to activation of myofilaments 
responsible for contraction of the heart (Bers., 2014).  Interestingly, recent findings proposed 
opening of NaP channels during the plateau phase, contributing to cellular Ca
2+ entry and 
facilitation of contraction via E-C coupling (Chadda et al., 2017).  After contraction, Na+/Ca2+ 
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exchanger (NCX) brings intracellular [Ca2+] to pre-contraction levels by exchanging 3 Na+ 
ions with 1 Ca2+ ion, hence highlighting its importance in facilitating relaxation through Ca2+ 
removal from the cytoplasm (Delbridge et al., 1996). 
On the other hand, intracellular [Ca2+] overload can lead to derangements in signalling and 
electrochemical function of the heart, which reported to be associated with atrial arrhythmic 
events (Balke and Shorofsky et al., 1998).  Therefore, the ability of the heart to maintain Ca2+ 
levels within a physiological range (200 nM intracellular [Ca2+] and 1.8 mM extracellular 
[Ca2+]) under resting conditions is essential to prevent deterioration to pathological 
conditions, such as seen in arrhythmias.  Raised intracellular [Ca2+] associated with atrial 
arrhythmias is multifactorial and complexed, however, the resultant rise in Ca2+ reported to 
play a role in maintaining the abnormal electrical activity of the heart.  Sustained activation 
and prolonged opening of NaP channels during plateau phase (phase 2) of the action potential, 
reported to be associated with abnormal excitation of electrical activity across the heart 
leading to development of atrial arrhythmias.  Sustained and elevated activation of these 
channels (NaP), stimulates overload of intracellular [Na
+] which leads to reduction of the 
electrochemical gradient for Ca2+ extrusion by the NCX, causing overload of cellular Ca2+ 
facilitation, contractile dysfunction and subsequent facilitation of arrhythmias (Grandi and 
Pandit., 2012).  The resulting Na+ current from these events is referred to as late or persistent 
Na+ current (INaP) and its selective inhibition reported to prevent the emergence of 
arrhythmogenic action potentials (Maltsev et al., 1998; Moreno and Clancy 2012; Yang et al., 
2012; Shryock et al., 2013).  Gain of function mutations of SCN5A gene that encodes the 
major Na+ channel in the heart (Nav1.5.) leads to increased INaP current which results in 
prolongation of action potential, a reported arrhythmogenic factor (Rivolta et al., 2001).  
However, regulation of such current at a molecular level, has not been investigated in depth 
in cardiomyocytes and therefore is not yet fully understood.  Even though INaP current was 
clearly measured in the Nav1.5. channel, specific inhibition of Nav1.8. (SCN10A) channel, 
which is not a major Na+ channel in the heart leading to increased INaP current, has shown to 
reduce INaP current in the heart (Mishra et al., 2011; Yang et al., 2012).  This implies that even 
the identity of the key channels subunits for INaP in cardiomyocytes is still unclear.   
In addition, immunocytochemical experiments by Maier et al., (2004) showed that Nav1.1. 
and Nav1.6. channels are present in the transverse tubules, and may have a role in the 
coordination and synchronisation of the conduction of the action potential, from the cell 
surface of the myocyte into the interior via the transverse tubules, leading to contraction. 
Therefore, play a role in regulating cellular [Ca2+] which is highly associated with cardiac 
contractile mechanism.  Also, Nav1.6. channel is reported to generate INaP current in 
ventricular myocytes (Purkinje cells), hence its mutation can similarly cause defects in NaP 
channel inactivation gating leading to generation of arrhythmias (Eijkelkamp et al., 2012). 
Furthermore, although persistent activation of NaP channels contributes to the Ca
2+-mediated 
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atrial arrhythmogenesis, may also contribute to the maintenance of such arrhythmic events.  
A study by Wagner et al., (2006) reported that the Ca2+/calmodulin (CaM)-dependent protein 
kinase II (CaMKII) interacts with and phosphorylates the cardiac Na+ channel in mouse and 
rabbit ventricular myocytes, leading to its steady state inactivation which further reduce INa in 
the heart. However, they have also reported that CaMKII greatly increased INaP levels (via 
hyperphosphorylating the NaP channel) in the heart, which would be a gain-of-function and 
mimic ventricular arrhythmias.   
Furthermore, less in known about the circadian expression of NaP channel components in the 
heart, and whether their expression change when BMAL1 clock gene expression is 
interrupted.  A study by Schroder et al., (2013) demonstrated loss of SCN5A gene (encodes 
the Nav1.5. channel) circadian pattern after the use of inducible cardiac specific deletion of 
the Bmal1 clock gene in murine ventricular myocytes. They also reported reduced 
cardiomyocyte Nav1.5. channel expression and microscopic INa after Bmal1 clock gene 
deletion (Schroder et al., 2013).  Whereas, a study by Han et al., (2012) reported reduced 
amplitude of circadian rhythms in SCN1A gene (encoded the Nav1.1. channel) following 
Bmal1 knockout, which further strengthen the link between various Na+ channel components 
and circadian expression.      
Additionally, raised intracellular [Ca2+] may also contribute to the generation of atrial 
arrhythmias, through abnormal propagation of action potential due to slowed conduction 
velocity.  This abnormality can occur from structural remodelling of the gap junctional serine-
rich phosphoproteins known as connexins (Cxs) (Zhu et al., 2016; Jabr et al., 2016).  Studies 
have proposed that reduction in Cxs distribution, abundance and therefore performance are 
associated with decreased conduction velocity which induces AF, this suggests a tight 
correlation between Cxs expression and electrical conductance (Jennings., 2013; Dhillon et 
al., 2014).  Atrial gap junctions composed mainly Cx43 and Cx40 isoforms, and in less extent 
Cx45 (Vozzi et al, 1999).  The relative atrial quantity and distribution of Cx43 under 
physiological conditions, contributes to increased gap junction conductance and ordered 
propagation of action potential.  In comparison, under pathological conditions reduced Cx43 
protein expression was reported to be associated with low gap junction conductance and 
subsequent cardiac arrhythmias (Glukhov et al, 2012).  Increased Cx40 protein expression has 
shown to be associated with atrial arrhythmic events (i.e. AF) in humans, thus consolidating 
the importance of the role of connexins in the disease (Polontchouk et al, 2001).         
Phosphorylation status of Cxs determines their function in regulating the gap junction (Kato., 
2012).  There are different types of protein kinases (i.e. PKC, PKA) and protein phosphatases 
(i.e. PP1, PP2A, Calcineurin; CaN) involved in targeting specific sites for Cx43 
phosphorylation and dephosphorylation.  The majority of Cx43 phosphorylation occurs on 
serine residues, with the most widely studied been Serine 365 (Ser365) and Serine 368 
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(Ser368) (Dhillon et al., 2014).  Under physiological conditions, Cx43 is phosphorylated at 
Ser365 maintaining the function of Ser368 by inhibiting its phosphorylation from protein 
kinase C (PKC) (Solan et al., 2007).  This activates gap junction and allows them to remain 
open resulting in normal electrical conductance.  Whereas, under raised intracellular [Ca2+] 
pathological conditions, Cx43 is phosphorylated at Ser368 site by PKC resulting in closure of 
gap junctions, which decreases cellular communication and inhibits electrical conductance 
(Solan and Lampe., 2005).  Furthermore, it was shown that Ser365 site acts as a gate keeper 
of Ser368 that exerts mechanisms to prevent pathological conditions such as AF (Solan et al., 
2007).  Elevated levels of intracellular [Ca2+] and CaM, which are shown to be associated with 
atrial arrhythmias in animals and chronic AF in patients, can induce calcineurin (CaN; 
Ca2+/CaM dependent protein phosphatase 3) activation which cause dephosphorylation of 
inhibitor 1 (I1) at Threonine 35 (Thr35) site (Jabr et al., 2016).  Dephosphorylation of I1 will 
facilitate protein phosphatase 1 (PP1) dissociation from I1, which under control conditions 
are found as a complex.  This further results in activation of PP1 to dephosphorylate Cx43 at 
Ser365 site, exposing the Ser368 residue to PKC-induced phosphorylation, hence reduce gap 
junction conductance which is considered arrhythmogenic (Jabr et al., 2016).  This study also 
showed that Cx43-Ser368 phosphorylation by PKC is equally mediated by protein 
phosphatase 2A (PP2A) via initial Cx43-Ser365 dephosphorylation.  Increased Cx43 
phosphorylation effects at Ser368 site were reversed in presence of chelerythrine (PKC 
inhibitor), whereas tautomycin (PP1 inhibitor) prevented Cx43 dephosphorylation at Ser365 
and phosphorylation at Ser368 (PP2A had no effect) (Jabr et al., 2016).  In addition, alterations 
in connexin protein expression which are Ca2+-dependent and are modulated by CaN-
dependent pathways, require calcineurin inhibition by Calcineurin Autoinhibitory Peptide 
(CAIP); a peptide sequence corresponding to the autoinhibitory domain of CaN, where it binds 
and inhibits CaN phosphatase activity (Terada et al., 2003).   
Furthermore, a study by Chaldoupi et al., (2009), provided evidence regarding changes in 
Cx40 phosphorylation status equally leads to disruption of gap junctional electrical 
conductance.  The study suggests that phosphorylation of Cx40 by cAMP-dependent 
pathways and alterations in channel properties (i.e. electrophoretic mobility) are likely to be 
mediated by protein kinase A (PKA), but other kinases and/or phosphatases may also play 
key role in regulating Cx40 channel function in the heart.  On this note, Hatch et al., (2015) 
showed that raised intracellular [Ca2+] increased Cx40 phosphorylation levels and such 
change was solely mediated by calcineurin with partial involvement of PP2A.  This suggests 
that Cxs phosphorylation is possible by various protein phosphatases and kinases, in addition 
understanding these proteins also allows insight on the pathologies that their dysfunction 
harbours.  In addition, the reported involvement of circadian rhythms in occurrence of atrial 
arrhythmias, hints the linkage of disrupted circadian rhythm being a potential cause of 
disrupted connexin expression (Remme and Bezzina., 2010).  A study by Tong et al., (2016) 
investigated total Cx40 and Cx43 expression in the mouse heart using suprachiasmatic nucleus 
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(SCN) lesion and pharmacological ANS block mouse.  They reported significant circadian 
variations in the expression of total Cx40 and Cx43 in the SCN lesion mouse.  However, the 
two connexin gene expressions lost rhythms in the ANS mouse, and the circadian rhythmicity 
of Bmal1 clock gene was also dampened significantly, suggesting that Cx40 and Cx43 gene 
expressions have clear circadian rhythm and might be regulated by the central clock in the 
SCN through ANS.  The existence of clear circadian patterns (and the clock genes regulating 
it) in total Cx43 indicates the possibilities for phosphorylated Cx43 (major cause of 
unregulated action potential conduction), being responsible for the circadian variations of AF. 
Moreover, the role of raised intracellular [Ca2+] on BMAL1 clock genes function is still under 
investigation.  Interestingly, the study by Petrzilka et al, (2009) showed that TNF-α 
(intracellular Ca2+ enhancer)–induced expression of Per1 and Dbp clock genes, was cancelled 
by inhibition of Ca2+ influx in NIH3T3 mouse fibroblast cells, implying that elevated 
intracellular [Ca2+] acts as a metabolic sensor capable of coordinating the circadian clockwork 
of peripheral oscillators, and may equally modulate Bmal1 expression.  PER1 protein has been 
shown to be a positive regulator of BMAL1 expression allowing to cycle whilst the level of 
its partner CLOCK remains constant.  Therefore, high levels of Ca2+ resulting in PER1 
degradation further result in depressed Bmal1 transcription and generation of circadian 
abnormalities hence further strengthens our initial findings.   
Rhythmic phosphorylation (at specific sites) of clock proteins appears to be a crucial step for 
regular clock function and gene/protein circadian expression (Tamaru et al., 2003; Tomita et 
al., 2005; Tamaru et al., 2009).  BMAL1 is known to phosphorylated by a variety of protein 
kinases and phosphatases. For example, CK1ε/δ reported to induce BMAL1 phosphorylation, 
however the phospho-acceptor sites of BMAL1 have not yet been identified (Eide et al., 2002).  
On the other hand, CK1ε/δ also shown to cause high phosphorylation of PER proteins 
phosphorylation, by targeting them for proteasomal degradation upon high accumulation in 
the cytoplasm.  Such process was shown to be negatively regulated by Ca2+- independent PP1-
mediated dephosphorylation affecting its circadian oscillatory expression pattern (Gallego et 
al., 2006; Vanselow et al., 2006).  Disruption of PP1 in CK1ε/δ deficient cells, resulted in 
PER phosphorylation (Lee et al., 2011).  Whereas, the disruption of another Ca2+-independent 
protein phosphatase (PP2A), which is also known to induce PER dephosphorylation, had no 
effect on PER expression (Sathyanarayanan et al., 2004)  Interestingly, inhibition of PP1 was 
reported to also affect BMAL1, hence suggesting that PP1 may not only act on PER protein 
accumulation but also alter BMAL1 expression levels perhaps via epigenetic modifications 
on the transcriptional machinery (Koshibu et al., 2009; Schmutz et al., 2011).  However, the 
association of Ca2+-dependent protein phosphatases with BMAL1 expression is unknown 
considering the lack of studies available.         
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In addition, the targeted phosphorylation sites on BMAL1 are of great importance, as they are 
highly associated with the transcriptional function and signalling of the protein, which is also 
essential for the regulation of circadian clock.  Studies provided evidence of BMAL1 rhythmic 
phosphorylation at Serine 42 (Ser42) residue by S6 protein kinase 1 (S6K1) in mouse 
embryonic fibroblasts, which affected its protein transcriptional activity and reported to be 
essential for the stimulation of BMAL1 protein synthesis (Dang et al., 2016; Lipton et al., 
2015). On the other hand, Tamaru et al., (2015) reported that CK2α rhythmically 
phosphorylates BMAL1 at Serine 90 (Ser90) (in mouse embryonic fibroblasts) and promotes 
its nuclear entry, which is essential for regulating the mammalian circadian clock.  Thus, 
underlying the fact that multiple kinases and phosphatases affect BMAL1 expression and 
circadian rhythmicity, yet the molecular mechanisms underlying phosphorylation of BMAL1 
mammalian clock protein (and the phosphorylated target site) in the heart remains elusive.   
In summary, given the activation of PP1 by Ca2+-dependent calcineurin (following raised 
intracellular [Ca2+] levels), and the indirect association of PP1 with BMAL1 protein 
accumulation suggests possible involvement of enhanced intracellular [Ca2+] affecting 
BMAL1 protein expression and phosphorylation in atrial arrhythmic events.  However, the 
relationship between BMAL1 expression and its circadian oscillation in the atria in response 
to the intracellular mechanisms underlying AF, such as increased INaP current, raised 
intracellular [Ca2+], altered Cx40 and Cx43 expression, and increased Cx43-Ser368 
phosphorylation, are far from clear.     
4.2. Aim 
Our overall aim is to investigate the effects of raised intracellular [Ca2+] by 1 nM ATXII, on 
the protein expression of BMAL1 (Total and phosphorylated; pBMAL1-Ser42), connexins 
(Total Cx40, Total Cx43 and phosphorylated; pCx43-Ser368), and NaP channel components 
(Nav1.1, Nav1.5 and Nav1.6), in synchronised HL1 clone 6 (HL1-6) total cell lysates within 
48 hours, using SDS-page and western blotting techniques.     
4.3. Objectives 
1. Investigate the effects of raised [Ca2+]i  and calcineurin on Total BMAL1 (T-BMAL1) 
and phosphorylated BMAL1 at Serine 42 residue (pBMAL1-Ser42) protein expression and 
pattern within 48 hours, in synchronised HL1-6 total cell lysate using SDS-page and 
western blotting technique.  This was achieved using the following conditions: 
iv. Control (serum-shock effect)  
v. ATXII (1 nM) alone, to raise intracellular [Ca2+] via sustain opening of NaP channels 
vi. ATXII (1 nM) in presence of Ranolazine (10 µM), to inhibit NaP channels              
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vii. ATXII (1 nM) in presence of calcineurin autoinhibitory peptide (CAIP, 25 µM), a 
specific Ca2+/CaM-dependent protein phosphatase calcineurin inhibitor 
2. Investigate the effects of raised [Ca2+]i and calcineurin on Total connexin 43 (T-Cx43), 
phosphorylated Cx43 at Serine 368 residue (pCx43-Ser368), and Total connexin 40 (T-
Cx40) gap junctional proteins’ expression and pattern in synchronised HL1-6 total cell 
lysate across 48 hours, using SDS-page and western blotting technique.  This was achieved 
using the following conditions: 
i. Control (serum-shock effect) 
ii. ATXII (1 nM) alone 
iii. ATXII (1 nM) in presence of Ranolazine (10 µM) 
iv. ATXII (1 nM) in presence of CAIP (25 µM)  
3. Investigate the effects of raised [Ca2+]i on the NaP channel components (Nav1.1, Nav1.5 
and Nav1.6) protein expression and pattern in synchronised HL1-6 total cell lysate within 
48 hours, using SDS-page and western blotting technique.  This was achieved using the 
following conditions: 
i. Control (serum-shock effect) 
ii. ATXII (1 nM) alone 
iii. ATXII (1 nM) in presence of Ranolazine (10 µM) 
4.4. Methods and experimental protocols 
The experimental protocol, methodology and images analysis used in this section have been 
extensively described in chapter 2 (see section 2.12.), but a brief description of the specific 
protocols and an overview of the rationale are given here.  
4.4.1. SDS-page and Western blotting 
HL1-6 atrial myocytes were seeded (1.0 x 107 per mL) on T25 cm2 culture flasks and once 
reached 85-90 % confluence were synchronised at selected time points (every 4 hours for 48 
hours) with 50 % serum-shocked Claycomb medium (see section 2.4.), for 2 hours.  At the 
end of incubation time, the serum-shock medium was replaced with fresh complete Claycomb 
medium. Then the synchronised cells will either be kept in the control medium (control group) 
or treated with ATXII (1 nM) alone, to raise [Ca2+]i; or ATXII in combination with either 
Ranolazine (10 µM) or CAIP (25 µM).  Cell lysates were then prepared (using RIPA lysis 
buffer/ MS-SAFEä protease and phosphatase inhibitor cocktail, see section 2.12.1.) at 0 (pre-
synchronisation), 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 hours. Total protein was then 
extracted and quantified for the assessment of protein expression changes following western 
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blotting method (see section 2.12.2.).  Total cell lysate protein samples of 30 μg were loaded 
in SDS-polyacrylamide gels along with a pre-stained molecular weight (MW 10-250 kDa) 
protein ladder.  Proteins on SDS-polyacrylamide gels were transferred on PVDF membranes 
and then blocked using Odyssey® blocking buffer to minimise non-specific protein binding 
on the membrane.  The PVDF membranes were washed and probed with primary antibodies 
(targeting protein of interest and GAPDH protein as a loading control) diluted in Odyssey® 
blocking buffer and 1 % BSA (see Table 2.4.) for 1-2 hours at room temperature on an orbital 
shaker.  The membranes were then washed and incubated for 1 hour at room temperature 
(covered in foil) with the appropriate horseradish peroxidase (HRP) conjugated secondary 
antibodies diluted in Odyssey® blocking buffer and 1 % BSA (see Table 2.5).  The probed 
membranes were finally washed, and immediately scanned using ODYSSEY®CLx imager 
scanner system (LI-COR) to quantify the resolved protein bands.  
The intensity of each protein band was analysed using Image Studio (IS) 13.1 software.  Each 
protein band intensity (phosphorylated or total form) was normalised to its corresponding 
GAPDH band intensity, using Microsoft Office Excel 2016 software.  The normalised 
phosphorylated protein form was further divided with the normalised total protein form and 
presented as a ratio.  An average of the normalised protein (total or phosphorylated form) 
expression was obtained at each time point from technical triplicates and expressed as Mean 
± standard error of the mean (SEM) using GraphPad Prism version 7 software.  The protein 
expression levels presented from 12 hours onwards, as any time points before were not taken 
into consideration due to apparent effects of serum-shock on the cells which affect the protein 
expression levels.  Data were analysed using two-way ANOVA (analysis of variance) to test 
the overall divergence between the treated and the untreated (control) groups and the effect of 
time (12-48 hours), followed by post-hoc analysis of significant main and interaction effects 
using Bonferroni multiple pairwise comparison test.  
Tables throughout this chapter indicate the values obtained from the statistical comparison 
between the best fit of a cosinor curve and a straight line, indicating which model fits the set 
of data best.  When p value was small, the simple model (the null hypothesis; straight line) 
was wrong and the more complicated model (cosinor curve) was accepted.  The threshold p 
value was set to 0.05.  In case of high p value, the data did not present a compelling reason 
for rejecting the simpler model; hence was accepted.  The periodicity was set to 24 hours 
(estimated time for a complete cycle) in the cosinor model equation, allowing determination 
of circadian expression/ pattern among the different proteins were appropriate.  In addition, 
the adjusted R squared values were also taken into consideration for the comparison of the 
goodness of fit for regression models that contained different number of independent 
variables.  The R squared value was increase in presence of improve model fit, whereas was 
decrease when the term wasn’t improving the model fit.  Higher R square values were indeed 
observed in presence of cosinor curve fitting allowing period determination on the best fit.        
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4.5. Results 
4.5.1. Assessment of clock gene protein expression in synchronised total cell 
lysates of HL1-6 atrial cardiomyocytes 
One of the major components of circadian cycle, and hence key contributor to the maintenance 
of atrial rhythmic events, is BMAL1.  This section will focus on assessment of the effects of 
ATXII treatment (and therefore raised [Ca2+]i due to sustained NaP channel activation; hence 
atrial arrhythmogenesis) and Ca
2+/CaM activated calcineurin (CaN) on the total and 
phosphorylation status of BMAL1 across two circadian cycles (48 hours), in the absence and 
presence of NaP channel inhibitor (10 µM Ranolazine), as well as, calcineurin autoinhibitory 
peptide (CAIP, 25 µM).  Attention will be given on the total and phosphorylation status of 
Serine 42 (pBMAL1-Ser42) by using an antibody selective to the phosphorylated form.  This 
will be achieved through western blotting experiments using serum-shocked synchronised 
HL1-6 total cell lysate.  Data are presented as mean changes of total BMAL1 (T-BMAL1) 
normalised to GAPDH and as a ratio of normalised pBMAL1-Ser42 / T-BMAL1 to 
investigate whether there is really an effect of treatments on BMAL1 phosphorylation status.    
4.5.1.1. Effects of raised intracellular [Ca2+] and Ca2+-activated calcineurin on 
Total BMAL1 (T-BMAL1) protein expression, in synchronised HL1-6 total cell 
lysates 
In synchronised total HL1-6 cell lysates, T-BMAL1 protein expression changes were 
observed under control conditions, raised intracellular [Ca2+] by ATXII treatment alone and 
in presence of 10 µM Ranolazine.  Figure 4.1. shows representative western blots indicating 
the changes in T-BMAL1 protein expression via change of band intensity and Figure 4.2. 
shows line graphs demonstrating the trend of oscillation observed in the mean normalised T-
BMAL1 values under all treatment conditions mentioned above across the 48 hours.  T-
BMAL1 protein expression bands were observed at 78 kDa (upper blots; green bands), along 
with GAPDH expression (37 kDa; lower blots, red bands) which was used as a loading control 
to normalised T-BMAL1 protein bands.  The intensity of T-BMAL1 bands varied and 
oscillated across time under all conditions (Figure 4.1.).  For example, under control 
conditions (Figure 4.1., panel A; time effect p<0.05), T-BMAL1 band intensity increased at 
12 hours and then decreased from 16 up to 24 hours.  Band intensities increased at 28 hours 
and remained increased up to 40 hours, whereas from 44 hours onwards T-BMAL1 band 
intensity decreased.  Following raised intracellular [Ca2+] under ATXII treatment (Figure 4.1., 
panel B; time effect p<0.05), T-BMAL1 band intensity increased at 16 hours and then dropped 
at 24 hours until it increased again at 32 hours.  From 32 hours onwards, T-BMAL1 band 
intensity gradually dropped until the end of 48 hours.  To further confirm the ATXII action 
on T-BMAL1 protein expression, Ranolazine effect was tested in the presence of ATXII.  As 
Figure 4.1., panel C shows the intensity of T-BMAL1 bands varied and oscillated across time, 
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with low band intensity at 12 hours followed up by higher band intensities from 16 hours up 
to 24 hours, and subsequent drop at 28 hours.  T-BMAL1 band intensity increased again at 36 
hours and then dropped until the end of 48 hours.  Importantly, the change in T-BMAL1 
expression was not accompanied by changes in GAPDH band intensity, which reported 
similar levels of expression across time under all treatment conditions (Figure 4.1.; lower 
blots, red bands). 
 
 
 
 
 
 
 
 
Figure 4.1. Total BMAL1 (T-BMAL1) protein expression in synchronised HL1-6 total cell lysates (30 
µg/µL) at different timepoints post-synchronisation, under control, 1 nM ATXII, and 1 nM ATXII/10 µM 
Ranolazine conditions. Western blot representative figures depicting the protein expression levels of T-BMAL1 
(78 kDa; green colour) and GAPDH (37 kDa; red colour) from 0 to 48 hours (4-hour interval) under control 
(panel A), 1 nM ATXII (panel B), and 1 nM ATXII/10 µM Ranolazine (panel C) conditions. GAPDH was used 
as a loading control (lower blots).  
 
In addition, mean T-BMAL1 protein expression levels were quantified and presented in 
Figure 4.2.  T-BMAL1 protein expression levels under control conditions (Figure 4.2., panel 
A) indicate peaks at 12 (0.320.06; N=7, p<0.05), 28 (0.370.07; N=7, p<0.05) and 40 
(0.350.06; N=7) hours, and troughs at 16 (0.260.05; N=7, p<0.05), 36 (0.330.07; N=7) 
and 48 (0.270.05; N=7, p<0.05) hours.  Interestingly, T-BMAL1 protein expression levels 
start increasing after 24 hours of serum-shock, however towards the end (from 44-48 hours) 
protein expression levels drop indicating that the cells started to lose synchrony and the effect 
of serum shock is gone.  T-BMAL1 protein levels show variation in a time-dependent manner 
(time effect p<0.05) with an almost circadian periodicity (22.12±0.12 hours).  Such 
observation is also summarised in Table 4.1., which indicates the statistical comparison 
between the cosinor curve and the straight line and supports that the preferred model with the 
higher adjusted R square value was the cosinor fitting and p value < 0.05, confirming the 
presence of a circadian pattern under control conditions.  
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ATXII treatment alone lowered T-BMAL1 protein levels (interaction effect p=0.05; ATXII 
vs Control) when compare to control conditions (Figure 4.2., panel D).  Lowering of T-
BMAL1 protein levels yields to changes of the dynamics of the circadian clock hence changes 
in its peaking expression time.  Indeed, T-BMAL1 protein expression under ATXII treatment 
alone peaked at 16 (0.320.06; N=7, p<0.05) and 32 (0.360.10; N=7, p<0.05) hours, with 
the later proposing a 4-hour shift in the peaking expression time when compare to control 
conditions, which reported a peak at 28 hours (p=0.05; ATXII vs Control) (Figure 4.2., panel 
D). Furthermore, T-BMAL1 protein expression under ATXII treatment was lower at 
timepoint 24 (0.260.04; N=7, p<0.05) and 44 (0.300.06; N=7, p<0.05) hours.  This suggests 
a 20-hour rhythmic pattern within the expression, and absence of circadian rhythmicity due to 
the fit of straight line as the best model with the highest adjected R square value and with a p 
value > 0.05 (Table 4.1.).  Furthermore, similarly to control conditions towards the end of 
serum-shock (from 40-48 hours) T-BMAL1 protein expression levels drop even more 
indicating cell desynchrony and loss of serum-shock effect (Figure 4.2., panel B).  Also, the 
mean normalised T-BMAL1 protein levels in HL1-6 cell lysate treated with ATXII showed 
different pattern as the control profile, suggesting that the raised intracellular [Ca2+] could 
disrupt the expression of T-BMAL1 clock gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Mean normalised Total BMAL1 (T-BMAL1) protein expression levels in synchronised HL1-6 
total cell lysates at different timepoints post-synchronisation, under control, 1 nM ATXII, and 1 nM 
ATXII/10 µM Ranolazine conditions.  Normalised T-BMAL1 protein expression levels against GAPDH 
A B 
C D 
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expression (T-BMAL1/GAPDH) line graphs (B; red colour) and cosine curve fit graphs (A; black colour and C; 
blue colour) to assess the presence of circadian rhythmicity (24-hour pattern).  Data are presented from 12 hours 
following serum-shock synchronisation, up to 48 hours (4-hour interval).  (A) Under control conditions, T-
BMAL1 protein expression levels peaked at 12 and 28 hours, and troughed at 16, 36 and 48 hours (N=7, * 
p<0.05).  (B) Following treatment with 1 nM ATXII, T-BMAL1 protein expression levels peaked at 16 and 32 
hours, and troughed at 12, 24 and 48 hours (N=7, * p<0.05).  (C) In presence of 10 µM Ranolazine, T-BMAL1 
protein expression levels peaked at 16, 24 and 36 hours, and troughed at 12, 28 and 48 hours (N=7, * p<0.05).  
(D) Summarised line graphs of T-BMAL1 protein expression levels under control (black), ATXII (red) and 
ATXII/Ranolazine (blue). Significant difference following the different treatments is reported with # (Control 
vs ATXII/Ranolazine), † (ATXII vs ATXII/Ranolazine).  Data are presented as Mean ± SEM.  † p<0.05, ## 
p<0.01  
 
Furthermore, under ATXII/Ranolazine treatment the overall levels of T-BMAL1 protein 
expression dropped compare to the control group (interaction effect p<0.05; 
ATXII/Ranolazine vs Control) (Figure 4.2., panel D).  As Figure 4.2., panel B shows T-
BMAL1 protein expression levels peaked at 16 (0.280.11; N=7, p<0.05), 24 (0.270.09; 
N=7) and 36 (0.290.11; N=7, p<0.05) hours, and troughed at 12 (0.240.09; N=7), 28 
(0.200.07; N=7, p<0.05) and 48 (0.210.08; N=7, p<0.05) hours.  Interestingly, the trough 
observed under ATXII/Ranolazine at 28 hours, is opposite to the peak observed at that time 
under control conditions (Control 0.370.07; N=7 vs ATXII/Ranolazine 0.200.07; N=7, 
p<0.01) (Figure 4.2., panel D).  In addition, at timepoint 32 hours, where T-BMAL1 protein 
expression levels peaked under ATXII treatment alone, whereas in presence of Ranolazine a 
clear trough was observed instead (ATXII 0.360.10; N=7 vs ATXII/Ranolazine 0.250.08; 
N=7, p<0.05) (Figure 4.2., panel D).  Furthermore, whilst there is a clear variation over time 
in the expression of T-BMAL1 under ATXII/Ranolazine treatment (time effect p<0.05), an 
almost circadian rhythm was also demonstrated (23.900.16 hours) (Figure 4.2., panel B).  
Such observation is also summarised in Table 4.1., which supports that the preferred model 
with the higher adjusted R square was the cosinor fitting with a p value < 0.05.  Interestingly, 
the mean normalised T-BMAL1 protein levels in HL1-6 cell lysate treated with Ranolazine 
showed similar pattern as the control profile (apart from timepoint 28 hours) proposing 
restoration of ATXII – induced T-BMAL1 protein expression changes. 
The role of calcineurin (CaN; Ca2+/CaM dependent protein phosphatase) in the observed Ca2+-
induced changes on T-BMAL1 protein expression was also assessed, by testing the effects of 
calcineurin selective inhibitor (calcineurin autoinhibitory peptide; CAIP, 25 µM) in presence 
and absence of 1 nM ATXII treatment.  The western blot representation (Figure 4.3., panel A) 
indicates that the intensity of T-BMAL1 bands varied and oscillates across time, under 25 µM 
CAIP treatment in presence of 1 nM ATXII.  T-BMAL1 band intensity was low at 12 hours 
and then increased at 16 hours.  From 20 hours and up to 24 hours band intensities were low, 
until they increased again at 28 hours.  At 32 hours T-BMAL1 band intensity was again low 
and remain low up to 40 hours, whereas from 44 up to 48 hours T-BMAL1 levels increased 
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again for the last time.  The effect of 25 µM CAIP treatment alone was also investigated to 
test for possible contribution of calcineurin effect alone under control conditions.  The western 
blot representation (Figure 4.3., panel B) indicates that the intensity of T-BMAL1 bands did 
not oscillate as much compare to the rest of the treatment groups.  Similar T-BMAL1 band 
intensities were observed from 12 to 20 hours, followed by a slight increase at 24 and 28 
hours, whereas from 32 to 48 hours T-BMAL1 band intensities were similar to the ones 
observed from 12 to 20 hours.  The changes in T-BMAL1 expression were not accompanied 
by changes in GAPDH band intensity under 25 µM CAIP treatment alone or in presence of 1 
nM ATXII, which reported similar levels of expression across time (Figure 4.3., red blots).   
 
 
 
 
 
 
Figure 4.3. Total BMAL1 (T-BMAL1) protein expression in synchronised HL1-6 total cell lysates (30 
µg/µL) at different timepoints post-synchronisation, under 25 µM calcineurin autoinhibitory peptide 
(CAIP) in presence and absence of 1 nM ATXII treatment. Western blot representative figures depicting the 
protein expression levels of T-BMAL1 (78 kDa; green colour) and GAPDH (37 kDa; red colour) from 0 to 48 
hours (4-hour interval), under 1 nM ATXII/25 µM CAIP (panel A) and 25 CAIP µM treatment alone (panel B). 
GAPDH was used as a loading control (lower blots). 
   
The T-BMAL1 band intensities were quantitated, normalised (to GAPDH) and presented in 
Figure 4.4.  As panel C shows, under ATXII/CAIP treatment T-BMAL1 protein expression 
oscillatory pattern was different to the one observed under control or ATXII treatment alone. 
T-BMAL1 protein expression appears to have the most fluctuations in terms of peaking 
expression time under ATXII/CAIP treatment, when compare to control and ATXII treatment 
alone, stating a bigger effect of treatment during the current timepoints.  Under ATXII/CAIP 
treatment, peaks were observed at 16 (0.390.08; N=3, p<0.01), 28 (0.390.14; N=3, p<0.01) 
and 44 (0.480.15; N=3, p<0.01) hours, whereas troughs were observed at 20 (0.250.04; 
N=3, p<0.05) and 32 (0.250.08; N=3, p<0.05) hours (Figure 4.4., panel A).  Interestingly, 
the peak observed at 28 hours under ATXII/CAIP treatment, was similarly observed under 
control conditions (Figure 4.4., panel C).  However, the peak observed at 16 hours under 
ATXII/CAIP treatment was opposite to a trough observed under control conditions.  
A 78 kDa T-BMAL1 
 
 
37 kDa GAPDH 
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Furthermore, T-BMAL1 protein expression levels start increasing following 40 hours of 
serum-shock synchronisation under ATXII/CAIP treatment (Figure 4.4., panel A).  T-BMAL1 
protein expression at 44 hours, under ATXII/CAIP treatment, was significantly different to 
the control and ATXII treatment alone were a drop in protein expression levels was observed 
instead (Figure 4.4., panel C).  In addition, CAIP partially recovers the effects of ATXII 
treatment suggesting possible calcineurin effect.    
In presence of 25 CAIP µM treatment alone, the overall T-BMAL1 protein expression levels 
increased compare to the rest of the treatments where lower T-BMAL1 protein expression 
levels were observed (Figure 4.4., panel C).  In addition, under 25 µM CAIP treatment alone 
T-BMAL1 protein expression peaked at 12 (0.440.12; N=7, p<0.05) and 28 (0.440.14; 
N=7, p<0.05), whereas it troughed at 20 (0.360.13; N=7, p<0.05) and 40 (0.340.10; N=7, 
p<0.05) hours (Figure 4.4., panel B).  In addition, at 24 hours T-BMAL1 protein expression 
under 25 CAIP µM treatment alone was significantly higher than the control and ATXII/CAIP 
groups (CAIP 0.430.13; N=7 vs Control 0.290.06; N=7, p<0.01; CAIP 0.430.13; N=7 vs 
ATXII/CAIP 0.280.09; N=3, p<0.01) (Figure 4.4., panel C).  Whereas, similar troughs at 20 
hours were observed under all treatment groups, with different levels of expression (CAIP 
0.360.11; N=7 vs Control 0.290.04; N=7, p<0.05; CAIP 0.360.11; N=7 vs ATXII/CAIP 
0.250.04; N=3, p<0.05) (Figure 4.4., panel C).  Also, it seems that T-BMAL1 under CAIP 
treatment alone presented similar pattern of expression as the one observed under control 
conditions, suggesting the absence of calcineurin effect alone.  At the same time, no obvious 
circadian rhythmic pattern could be confirmed for T-BMAL1 protein expression under CAIP 
treatment alone or in presence of ATXII, due to the absence of 24-hour periodicity following 
straight line fitting as the preferred model (p>0.05; Table 4.1.).   
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Figure 4.4. Mean normalised Total BMAL1 (T-BMAL1) protein expression levels in synchronised HL1-6 
total cell lysates at different timepoints post-synchronisation, under control, 1 nM ATXII, 1 nM ATXII/25 
µM CAIP and 25 µM CAIP conditions.  Normalised T-BMAL1 protein expression levels against GAPDH 
expression (T-BMAL1/GAPDH) line graphs (A; orange colour and B; green colour) to assess the presence of 
circadian rhythmicity (24-hour pattern).  Data are presented from 12 hours following serum-shock 
synchronisation, up to 48 hours (4-hour interval).  (A) Under 1 nM ATXII/25 µM CAIP treatment, T-BMAL1 
protein expression levels peaked at 16, 28 and 44 hours, and troughed at 12, 20, 32 and 48 hours (N=3, * p<0.05, 
** p<0.01).  (B) Following 25 µM CAIP treatment alone, T-BMAL1 protein expression levels peaked at 12 and 
28 hours, and troughed at 20 and 40 hours (N=7, * p<0.05). (C) Summarised line graphs of T-BMAL1 protein 
expression levels under control (black), ATXII (red), ATXII/CAIP (orange) and CAIP (green). Significant 
difference following the different treatments is reported with * (Control vs CAIP), # (ATXII vs ATXII/CAIP), 
≠ (CAIP vs ATXII/CAIP).  Data are presented as Mean ± SEM.  */≈ p<0.05, **/##/≠≠ p<0.01 
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Table 4.1. Statistical comparison between cosinor curve and straight line model for total BMAL1 (T-
BMAL1) protein expression levels in synchronised HL1-6 total cell lysates under control, 1 nM 
ATXII alone and in presence of 10 µM Ranolazine or 25 µM CAIP.  The goodness of the fit for the 
regression models was indicated with the adjusted R squared values; the higher the R squared value the 
improved the fit.  Under control and Ranolazine treatments, T-BMAL1 protein expression reported 
circadian rhythmicity with a p<0.05, whereas for all other interventions, the straight line resulted to be the 
best model to fit (p>0.05).     
 
 
 
 
 
 
 
 
 
 
 
 
4.5.1.2. Effects of raised intracellular [Ca2+] and Ca2+-activated calcineurin on 
phosphorylated BMAL1-Ser42 (pBMAL1-Ser42) protein expression, in 
synchronised HL1-6 total cell lysates  
In synchronised total HL1-6 cell lysates, phosphorylated BMAL1-Ser42 (pBMAL1-Ser42) 
protein expression changes were observed under control conditions, raised intracellular [Ca2+] 
by ATXII treatment alone and in presence of 10 µM Ranolazine.  Figure 4.5. shows 
representative western blots indicating the changes in pBMAL1-Ser42 under all treatment 
conditions mentioned above across the 48 hours.  pBMAL1-Ser42 protein expression bands 
were observed at 78 kDa (upper blots; green bands), along with GAPDH expression (37 kDa; 
lower blots, red bands).  Under control conditions (Figure 4.5., panel A), pBMAL1-Ser42 
band intensities were roughly the same throughout the 48 hours with very small oscillations 
across time.  pBMAL1-Ser42 bands were low from 12 up to 16 hours and then slightly 
increased at 20 hours, following that timepoint the bands appeared to express with similar 
intensities (Figure 4.5., panel A).  Following raised intracellular [Ca2+] under ATXII treatment 
(Figure 4.5., panel B; time effect p<0.05), pBMAL1-Ser42 band intensities increased at 16 
hours followed by a drop at 20 hours until it increased again at 32 and 36 hours. pBMAL1-
Ser42 band intensities dropped again from 40 hours until the end of 48 hours.  To further 
confirm the ATXII action on pBMAL1-Ser42 protein expression, Ranolazine effect was tested 
in the presence of ATXII.  As Figure 4.5., panel C shows the intensity of pBMAL1-Ser42 
bands slightly oscillates across time under Ranolazine treatment.  At 12 hours pBMAL1-Ser42 
band intensity was low and then start increasing with stronger bands at 20 and 24 hours.  This 
was followed by a decrease at 28 hours and then increase again from 32 to 40 hours.  From 
44 to 48 hours lower pBMAL1-Ser42 band intensities were observed.  The changes in 
Total BMAL1 protein expression   
Straight 
line 
Cosinor 
Curve 
Treatment  Period p value Adjusted R square 
Control  22 0.050 -0.008049 -0.007649 
ATXII 20 0.2206 -0.01169 -0.003889 
ATXII/RANOLAZINE  24 0.050 -0.03217 -0.02018 
ATXII/CAIP 17 0.2030 0.03944 -0.1904 
CAIP    20 0.5231 -0.006486 -0.02035 
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pBMAL1-Ser42 protein expression were not accompanied by changes in GAPDH band 
intensity, which reported similar levels of expression across time under all treatment 
conditions (Figure 4.5., red bands). 
 
 
 
 
 
 
 
 
 
Figure 4.5. Phosphorylated BMAL1-Serine 42 (pBMAL1-Ser42) protein expression in synchronised HL1-
6 total cell lysates (30 µg/µL) at different timepoints post-synchronisation, under control, 1 nM ATXII, 
and 1 nM ATXII/10 µM Ranolazine conditions. Western blot representative figures depicting the protein 
expression levels of pBmal1-Ser42 (78 kDa; green colour) and GAPDH (37 kDa; red colour) from 0 to 48 hours 
(4-hour interval) under control (panel A), 1 nM ATXII (panel B), and 1 nM ATXII/10 µM Ranolazine (panel C) 
conditions.  GAPDH was used as a loading control (lower blots).  
 
In addition, pBMAL1-Ser42 band intensities were quantified, normalised to T-BMAL1 and 
presented in Figure 4.6.  As panel A shows, under control conditions, low pBMAL1-Ser42 
protein expression levels were observed throughout the 48-hour period, with a peak 
expression at 20 hours (1.080.62; N=6, p<0.05).  However, no obvious pBMAL1-Ser42 
protein fluctuations were observed across the remaining timepoints, reporting the absence of 
circadian rhythmic pattern under control conditions (Figure 4.6., panel A), as well as the effect 
of time (p>0.05).  Such observation is also summarised in Table 4.2., which indicates the 
statistical comparison between the cosinor curve and the straight line, and supports that the 
preferred fit model with the higher adjusted R square was the straight line.  It is worth stating 
that a gradual increase in protein expression levels was reported following 36 hours of serum-
shock synchronisation under control conditions. Furthermore, Figure 4.6., panel B shows that 
ATXII treatment is changing the overall levels of pBMAL1-Ser42 protein expression over 
time (drug effect p<0.05). Such intervention significantly increased the amount of BMAL1 
that was phosphorylated at Ser42 (ATXII vs Control; interaction effect p=0.05) compared to 
control conditions (Figure 4.6., panel D).  A shift in the peaking expression time of pBMAL1-
Ser42 was observed (compare to control conditions) at 24 (1.150.52; N=6), 36 (1.120.49; 
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N=6) and 48 (1.340.64; N=6) hours under ATXII treatment.  Also, pBMAL1-Ser42 protein 
expression levels dropped at 16 (0.980.36; N=6), 32 (1.060.48; N=6) and 40 (1.090.49; 
N=6) hours (Figure 4.6., panel B).  The mean normalised pBMAL1-Ser42 protein expression 
pattern under ATXII treatment alone was different to the one observed under control 
conditions throughout the 48 hours, suggesting that the raised intracellular [Ca2+] could 
possibly disrupt the expression of pBMAL1 at Ser42 residue.  In addition, our results show 
that under ATXII treatment, pBMAL1-Ser42 protein expression oscillate with a 20-hour 
period, which accounts for the absence of 24-hour circadian pattern.  The absence of circadian 
expression of pBMAL1-Ser42 upon ATXII treatment is also summarised in Table 4.2. with 
the straight line been the preferred model to fit its expression upon the two circadian cycles 
(p>0.05).   
 
Figure 4.6. Mean normalised phosphorylated BMAL1-Serine 42 (pBMAL1-Ser42) protein expression 
levels in synchronised HL1-6 total cell lysates at different timepoints post-synchronisation, under control, 
1 nM ATXII, and 1 nM ATXII/10 µM Ranolazine conditions.  Normalised pBMAL1-Ser42 protein 
expression levels against GAPDH expression (pBMAL1-Ser42/GAPDH) line graphs (A; black colour, B; red 
colour and C; blue colour), to assess the presence of circadian rhythmicity (24-hour pattern).  Data are presented 
from 12 hours following serum-shock synchronisation, up to 48 hours (4-hour interval). (A) Under control 
conditions, pBMAL1-Ser42 protein expression levels peaked at 24 and 48 hours, and troughed at 12 and 44 
hours (N=6, * p<0.05).  (B) Following treatment with 1 nM ATXII, pBMAL1-Ser42 protein expression levels 
A B 
C D 
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peaked at 12 and 32 hours, and troughed at 20 and 40 hours (N=6).  (C) In presence of 10 µM Ranolazine, 
pBMAL1-Ser42 protein expression levels peaked at 20 28 and 44 hours, and troughed at 24, 32 and 40 hours 
(N=7).  (D) Summarised line graphs of pBMAL1-Ser42 protein expression levels under control (black), ATXII 
(red) and ATXII/Ranolazine (blue). Significant difference following the different treatments is reported with # 
(Control vs ATXII/Ranolazine), † (ATXII vs ATXII/Ranolazine).  Data are presented as Mean ± SEM.  ##/†† 
p<0.01 
 
Ranolazine effect was also tested in the presence of ATXII, following 2 hours of serum-shock 
synchronisation.  Figure 4.6., panel D shows that under ATXII/Ranolazine treatment the mean 
pBMAL1-Ser42 protein expression levels significantly decreased throughout the 48 hour-
period, when compare to control and ATXII treatment alone (ATXII vs ATXII/Ranolazine; 
interaction effect p<0.001, Control vs ATXII/Ranolazine; interaction effect p<0.001).  In 
addition, no significant difference was observed among the different timepoints as similar 
levels of expression were reported across time, reporting the absence of Ranolazine to reverse 
ATXII effects following raised [Ca2+]i.  The absence of circadian expression and rhythmicity 
is also indicated by the fit of straight line as the best model, with a p value > 0.05 (Table 4.2.).  
Significant difference between ATXII treatment alone and ATXII/Ranolazine treatment was 
observed throughout the various timepoints following 20 hours of serum-shock 
synchronisation (p<0.01; Figure 4.6., panel D).  In addition, significant difference was also 
observed between ATXII/Ranolazine and control conditions at 20 hours (ATXII/Ranolazine 
0.390.22; N=7 vs Control 1.080.62; N=6, p<0.01) (Figure 4.6., panel D).  It is also worth 
stating that such pattern was significantly different to the pattern observed under control and 
ATXII treatment alone, proposing the inability of Ranolazine to reverse ATXII effects on 
pBMAL1-Ser42.   
The role of calcineurin in the observed Ca2+-induced changes on pBMAL1-Ser42 protein 
expression was also assessed, by testing the effects of 25 µM CAIP in presence and absence 
of 1 nM ATXII treatment.  The western blot representation (Figure 4.7., panel A) indicates 
that pBMAL1-Ser42 band intensity was similarly high at 12 and 16 hours, and then decreased 
at 20 hours under ATXII/CAIP treatment.  Whereas, from 24 hours up to 32 hours pBMAL1-
Ser42 band intensity increases and then start decreasing until the end of 48 hours. The effect 
of 25 µM CAIP treatment alone was also investigated, for possible contribution of calcineurin 
effect alone under control conditions, indicating that pBMAL1-Ser42 protein band intensity 
was low from 12 up to 20 hours, and only increased at 24 and 28 hours.  While, from 32 hours 
onwards, similar band intensities were observed.  The changes in pBMAL1-Ser42 expression 
were not accompanied by changes in GAPDH band intensity under 25 µM CAIP treatment 
alone or in presence of 1 nM ATXII, which reported similar levels of expression across time 
(Figure 4.7., red blots).   
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Figure 4.7. Phosphorylated BMAL1-Serine 42 (pBMAL1-Ser42) protein expression in synchronised HL1-
6 total cell lysates (30 µg/µL) at different timepoints post-synchronisation, under 25 µM calcineurin 
autoinhibitory peptide (CAIP) in presence and absence of 1 nM ATXII treatment. Western blot 
representative figures depicting the protein expression levels of pBMAL1-Ser42 (78 kDa; green colour) and 
GAPDH (37 kDa; red colour) from 0 to 48 hours (4-hour interval) under 1 nM ATXII/25 µM CAIP (panel A) 
and 25 CAIP µM treatment alone (panel B).  GAPDH was used as a loading control (lower blots).  
 
The intensity of pBMAL1-Ser42 bands under ATXII/CAIP or CAIP treatment alone was 
quantitated and presented in Figure 4.8.  ATXII/CAIP treatment affected pBMAL1-Ser42 
protein expression due to oscillation observed over time (drug effect p<0.05) (Figure 4.8., 
panel A).  pBMAL1-Ser42 protein expression oscillated in a circadian manner (24.110.21 
hours) as calculated from trough (16 hours; 0.810.14; N=3) to trough (40 hours; 0.870.30; 
N=3) timepoints following cosinor curve fit (Figure 4.8., panel A).  This is also supported in 
Table 4.2. were higher R square value was reported for the cosinor curve as the best fit model 
for pBMAL1-Ser42 protein expression (p<0.05).  In addition, pBMAL1-Ser42 protein 
expression levels significantly increased under ATXII/CAIP treatment when compare to 
control and ATXII treatment alone (interaction effect p=0.05) (Figure 4.8., panel C).  Peak 
expression levels under ATXII/CAIP treatment were observed at 24 (1.240.19; N=3, 
p<0.01), 32 (1.630.23; N=3, p<0.01) and 40 hours (0.870.31; N=3, p<0.01), whereas it 
troughed at 16 hours (0.810.14; N=3) aswell as during the end of serum-shock effect (40- 48 
hours).  Interestingly, similar peak expression time (at 24 hours) was also observed during 
ATXII treatment alone (Figure 4.8., panel C).  Despite the increase in phosphorylated BMAL1 
levels, significant difference was observed between ATXII/CAIP and control conditions 
throughout both circadian cycles (p<0.0001; Figure 4.8., panel C).   
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In addition, the overall pBMAL1-Ser42 protein expression levels under 25 µM CAIP 
treatment alone were significantly lower when compare to ATXII/CAIP treatment (p=0.05; 
CAIP vs ATXII/CAIP) throughout the 48-hour period (Figure 4.8., panel C).  pBMAL1-Ser42 
protein expression levels peaked at 12 (0.810.24; N=6), 24 (0.800.26; N=6) and 36 
(0.790.27; N=6) hours, and troughed at 16 hours (0.680.24; N=6) and 40 (0.690.23; N=6) 
hours (Figure 4.8., panel B).  pBMAL1-Ser42 protein expression levels gradually decrease 
with time (from 32 hours onwards) indicating possible desynchrony of the cells; hence further 
supporting the absence of circadian pattern in the current treatment.  The absence of circadian 
expression and rhythmicity is also indicated by the fit of straight line as the best model, with 
a p value > 0.05 (Table 4.2.).  Significant difference in pBMAL1-Ser42 protein expression 
levels was also observed between CAIP treatment alone and AXII/CAIP treatment among all 
timepoints (p<0.0001; Figure 4.8., panel C).  Furthermore, pBMAL1-Ser42 protein 
expression levels followed similar pattern as the one observed under control conditions, 
suggesting the absence of calcineurin effect alone.   
 
 
 
 
 
 
Figure 4.8. Mean normalised phosphorylated BMAL1-Serine 42 (pBMAL1-Ser42) protein expression 
levels in synchronised HL1-6 total cell lysates at different timepoints post-synchronisation, under control, 
1 nM ATXII, and 1 nM ATXII/10 µM Ranolazine conditions.  Normalised pBMAL1-Ser42 protein 
expression levels against GAPDH expression (pBMAL1-Ser42/GAPDH) line graphs (B; green colour) and 
A B 
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cosine curve fit graphs (A; orange colour) to assess the presence of circadian rhythmicity (24-hour pattern).  Data 
are presented from 12 hours following serum-shock synchronisation, up to 48 hours (4-hour interval).  (A) Under 
1 nM ATXII/25 µM CAIP treatment, pBMAL1-Ser42 protein expression levels peaked at 32 and troughed at 16 
and 40 hours (N=3, ** p<0.01). (B) Following 25 µM CAIP treatment alone, pBMAL1-Ser42 protein expression 
levels peaked at 24, 36 and 44 hours, and troughed at 16, 28 and 40 hours.  (C) Summarised line graphs of T-
BMAL1 protein expression levels under control (black), ATXII (red), ATXII/CAIP (orange) and CAIP (green). 
Significant difference following the different treatments is reported with # (ATXII vs ATXII/CAIP), ≠ (CAIP 
vs CAIP/ATXII).  Data are presented as Mean ± SEM. #/≠ p<0.05, ##/≠≠ p<0.01 
 
Table 4.2. Statistical comparison between cosinor curve and straight line model for phosphorylated 
BMAL1-Serine 42 (pBMAL1-Ser42) protein expression levels in synchronised HL1-6 total cell lysates 
under control, 1 nM ATXII alone and in presence of 10 µM Ranolazine or 25 µM CAIP.  The goodness 
of the fit for the regression models was indicated with the adjusted R squared values; the higher the R 
squared value the improved the fit.  Under CAIP treatment in presence of ATXII, pBMAL1-Ser42 protein 
expression reported circadian rhythmicity with a p<0.05 and the highest adjusted R squared value, whereas 
for all other interventions, the straight line resulted to be the best model to fit.    
 
 
 
 
 
 
 
Furthermore, the difference between total and phosphorylated form of BMAL1 was also 
investigated.  Absence of total and phosphorylated BMAL1 circadian patterns were observed 
following serum-shock synchronisation of HL1-6 cell lysates, despite the reported oscillatory 
protein expression.  Under control conditions, the proportion of T-BMAL1 protein expression 
increased progressively until the peaking time (28 hours) (Figure 4.2., panel A).  Interestingly, 
the pBMAL1-Ser42 showed a different pattern, with much earlier peak expression at 20 hours 
(Figure 4.6., panel A).  It is also worth stating that the total and phosphorylated BMAL1 levels 
showed similar decrease in expression following 32 hours of serum-shock synchronisation 
under control conditions (Figure 4.2., panel A & Figure 4.6., panel A).  In presence of ATXII 
treatment, much higher pBMAL1-Ser42 levels were observed in comparison to T-BMAL1 
levels of expression (Figure 4.2., panel B & Figure 4.6., panel B).  Despite the difference in 
levels of expression across the two circadian cycles, antiphasic peaking expression pattern 
was also observed between total and phosphorylated BMAL1.  When T-BMAL1 expression 
troughed at 24 hours, the pBMAL1-Ser42 expression was peaking for the first time, and when 
Phosphorylated BMAL1 – Serine 42 protein 
expression   
Straight 
line 
Cosinor 
Curve 
Treatment  Period p value Adjusted R square 
Control  28 0.5244 -0.009031 -0.01459 
ATXII 20 0.5630 -0.01346 -0.03293 
ATXII/RANOLAZINE  14 0.9072 -0.02283 -0.05008 
ATXII/CAIP  24 0.0046 -0.03555 3.517 
CAIP   11  0.8830 -0.01130 -0.02267 
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the T-BMAL1 expression peaked at 32 hours, pBMAL1-Ser42 expression troughed (Figure 
4.2., panel B & Figure 4.6., panel B).  Additionally, elevation in pBMAL1-Ser42 expression 
was observed towards the end of serum-shock synchronisation (40-48 hours), whereas T-
BMAL1 expression was progressively decreasing across time (Figure 4.2., panel B & Figure 
4.6., panel B).  In presence of Ranolazine, unlike T-BMAL1, the phosphorylated BMAL1 
levels did not change or oscillated during the two circadian cycles, reporting the absence of 
Ranolazine in reversing ATXII effect (Figure 4.2., panel C & Figure 4.6., panel C). Whereas, 
T-BMAL1 showed similar levels of expression as the ones observed under control condition, 
proposing a possible contribution of raised [Ca2+]i in affecting total, but not BMAL1 
phosphorylated protein expression levels. 
The difference between total and phosphorylated form of BMAL1 was also investigated under 
ATXII/CAIP or CAIP treatment alone.  Overall, the phosphorylated form of BMAL1 showed 
higher levels of expression under ATXII/CAIP treatment, compare to total form of BMAL1 
(Figure 4.4., panel A & Figure 4.8., panel A).  In addition, T-BMAL1 protein expression levels 
peaked at 16 and 28 hours, whereas pBMAL1-Ser42 showed a different pattern, with much 
later peaks at 24 and 36 hours under ATXII/CAIP treatment (Figure 4.4., panel A & Figure 
4.8., panel A).  Interestingly, the proportion of T-BMAL1 protein expression increased 
progressively following 32 hours of serum-shock synchronisation under ATXII/CAIP 
treatment.  This is different to pBMAL1-Ser42 who reported gradual decreasing levels 
following that time point.  In presence of CAIP treatment alone, similar levels of expression 
were observed between total and phosphorylated form of BMAL1 (Figure 4.4., panel B & 
Figure 4.8., panel B).  However, difference in the peak/through expression timepoints was 
observed.  For example, a 4-hour shift in the trough expression of BMAL1 was reported, with 
pBMAL1-Ser42 showing decreased expression at 16 and 28 hours, whereas T-BMAL1 
demonstrated trough levels of expression at 20 and 32 hours (Figure 4.4., panel B & Figure 
4.8., panel B).  Additionally, absence of total and phosphorylated BMAL1 circadian patterns 
was reported, despite the observed oscillation in the levels of expression under the above 
interventions.   
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4.5.3. Assessment of connexin protein expression in synchronised total cell 
lysates of HL1-6 atrial cardiomyocytes 
One of the major contributors of the intracellular mechanisms underlying AF is the altered 
connexin expression, due to changes to their phosphorylation status and gating properties.  
This section will focus on assessment of the effects of raised [Ca2+]i by ATXII-induced NaP 
channel activation and Ca2+/CaM activated calcineurin (CaN) on the total (Cx43 & Cx40) and 
phosphorylation status of Cx43, across two circadian cycles (48 hours), in the absence and 
presence of 10 µM Ranolazine, as well as, 25 µM CAIP.  Attention will be given on the total 
(Cx43 & Cx40) and phosphorylation status of Serine 368 (pCx43-Ser368) by using an 
antibody selective to the phosphorylated form.  This will be achieved through western blotting 
experiments using serum-shocked synchronised HL1-6 total cell lysate.  Data are presented 
as mean changes of total Cx43 or Cx40 (T-Cx43 or T-Cx40) normalised to GAPDH, and as a 
ratio of normalised pCx43-Ser368 / T-Cx43 to investigate whether there is really an effect of 
treatments on Cx43 phosphorylation status.    
4.5.3.1. Effects of raised intracellular [Ca2+] and Ca2+-activated calcineurin on 
Total Cx43 (T-Cx43) protein expression, in synchronised HL1-6 total cell lysates 
In synchronised total HL1-6 cell lysates, T-Cx43 protein expression changes were observed 
under control conditions, raised intracellular [Ca2+] by ATXII treatment alone and in presence 
of 10 µM Ranolazine.  Figure 4.9. shows representative western blots indicating the changes 
in T-Cx43 protein expression via change of band intensity and Figure 4.9. shows line graphs 
demonstrating the trend of oscillation observed in the mean normalised T-Cx43 values under 
all treatment conditions mentioned above across the 48 hours.  T-Cx43 protein expression 
bands were observed at 43 kDa (upper blots; green bands), along with GAPDH expression 
(37 kDa; lower blots, red bands) which was used as a loading control to normalised T-Cx43 
protein bands.  The intensity of T-Cx43 bands under control conditions varied across time, 
with a higher T-Cx43 band intensity at 12 hours and a lower band intensity at 16 hours, until 
it increased again at 20 hours (Figure 4.9., panel A).  Whereas, from 24 hours onwards T-
Cx43 band intensities were similarly observed.  In addition, as panel B shows, ATXII 
treatment is changing the overall T-Cx43 band intensities.  For example, T-Cx43 band 
intensity was high from 12 up to 28 hours, followed by a decrease at 32 hours and a slight 
increase at 36 hours.  Also, from 36 hours onwards, the T-Cx43 band intensities were similarly 
low.  In presence of Ranolazine Nap channel inhibitor in combination with ATXII, T-Cx43 
band intensities were similarly high from 12 hours up to 28 hours and slightly lower band 
intensities from 32 hours onwards.  The changes in T-Cx43 expression were not accompanied 
by changes in GAPDH band intensity, which reported similar levels of expression across time 
under all treatment conditions (Figure 4.9.; lower blots, red bands).   
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Figure 4.9. Total Cx43 (T-Cx43) protein expression in synchronised HL1-6 total cell lysates (30 µg/µL) at 
different timepoints post-synchronisation, under control, 1 nM ATXII, and 1 nM ATXII/10 µM 
Ranolazine conditions. Western blot representative figures depicting the protein expression levels of T-Cx43 
(43 kDa; green colour) and GAPDH (37 kDa; red colour) from 0 to 48 hours (4-hour interval) under control 
(panel A), 1 nM ATXII (panel B), and 1 nM ATXII/10 µM Ranolazine (panel C) conditions.  GAPDH was used 
as a loading control (lower blots).  
 
In addition, mean T-Cx43 protein expression levels were quantified and presented in Figure 
4.10.  Under control conditions, T-Cx43 show variation in its protein expression levels in a 
time-dependent manner (drug effect p<0.05), however such expression could not be 
considered as circadian due to the absence of 24-hour period following straight line fitting 
(18.01±0.12 hours).  Such observation is also summarised in Table 4.3., which indicates the 
statistical comparison between the cosinor curve and the straight line, and supports that the 
preferred model with the higher adjusted R square was the straight line (p>0.05).  In addition, 
T-Cx43 protein expression peaked at 20 (0.300.07; N=9, p<0.01) and slightly at 32 
(0.210.03; N=9) hours, and troughed at 16 (0.190.03; N=9, p<0.05) and 36 (0.180.03; 
N=9, p<0.05) hours (Figure 4.10., panel A).  Also, T-Cx43 protein expression levels start 
decreasing after 28 hours of serum-shock, indicating that the HL1-6 cells started to lose 
synchrony and the effect of serum-shock is gradually gone.  
In presence of raised [Ca2+]i by ATXII treatment, T-Cx43 protein expression levels show 
oscillation across time (time effect p<0.05) with peaks at 16 (0.280.05; N=9, p<0.05) and 36 
(0.240.03; N=9) hours, and troughs at 12 (0.240.03; N=9) and 32 (0.190.02; N=9, p<0.05) 
hours (Figure 4.10., panel B).  This suggest a rhythmic 20-hour T-Cx43 protein expression 
under ATXII treatment.  Similarly, to control conditions, such expression could not be 
considered as circadian due to the absence of circadian curve fit as the preferred model 
(p>0.05; Table 4.3.).  Also, the mean normalised T-Cx43 protein levels in HL1-6 cell lysate 
treated with ATXII showed different pattern as the control profile, suggesting that the raised 
intracellular [Ca2+] could possibly disrupt T-Cx43 protein expression.  
A 
43 kDa T-Cx43 
37 kDa GAPDH 
0 4 8 12 16 20 24 28 32 36 40 44 48 (hours)  
B 
43 kDa T-Cx43 
37 kDa GAPDH 
C 
43 kDa T-Cx43 
37 kDa GAPDH 
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In order to, further confirm the ATXII action on T-Cx43 protein expression, Ranolazine effect 
was tested in the presence of ATXII. As Figure 4.10. panel C shows, ATXII/Ranolazine 
treatment is changing the overall levels of T-Cx43 protein expression (drug effect p<0.05). 
Significant difference between the different timepoints was also observed, stating that there is 
variation over time.  The ATXII/Ranolazine treatment show similar protein expression pattern 
as the control group, with peaks at 20 (0.250.05; N=9, p<0.05) and 32 (0.210.02; N=9) 
hours, and trough at 16 (0.190.02; N=9, p<0.05), 24 (0.170.02; N=9, p<0.05) (different to 
control), 36 (0.180.02; N=9, p<0.05) and 48 hours (0.140.02; N=9, p<0.05) (different to 
control) (Figure 4.10., panel D).  In addition, no obvious T-Cx43 circadian expression patterns 
could be confirmed due to absence of 24-hour periodicity, represented with the fit of the 
straight line as a preferred model based on the highest R square value (p>0.05; Table 4.3.).  
Furthermore, Ranolazine plausible effect on recovering ATXII effect on T-Cx43 mean 
normalised protein levels, may be due to similar oscillatory pattern observed under control 
conditions.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Mean normalised Total connexin 43 (T-Cx43) protein expression levels in synchronised HL1-
6 total cell lysates at different timepoints post-synchronisation, under control, 1 nM ATXII, and 1 nM 
ATXII/10 µM Ranolazine conditions.  Normalised T-Cx43 protein expression levels against GAPDH 
expression (T-Cx43/GAPDH) line graphs (A; grey colour, B; red colour and C; blue colour) to assess the 
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presence of circadian rhythmicity (24-hour pattern).  Data are presented from 12 hours following serum-shock 
synchronisation, up to 48 hours (4-hour interval). (A) Under control conditions, T-Cx43 protein expression levels 
peaked at 20 hours, and troughed at 16 and 36 hours (N=9, * p<0.05, ** p<0.01).  (B) Following treatment with 
1 nM ATXII, T-Cx43 protein expression levels peaked at peaked at 16 and 36 hours, and troughed at 12 and 32 
hours (N=9, * p<0.05).  (C) In presence of 10 µM Ranolazine, T-Cx43 protein expression levels peaked at 20, 
32 and 44 hours, and troughed at 16, 24, 36 and 48 hours (N=9, * p<0.05).  (D) Summarised line graphs of T-
Cx43 protein expression levels under control (black), ATXII (red) and ATXII/Ranolazine (blue). Data are 
presented as Mean ± SEM.  
 
To investigate the role of calcineurin 25 µM CAIP selective inhibitor was used in in presence 
and absence of 1 nM ATXII treatment.  The western blot representation (Figure 4.11., panel 
A) indicates that T-Cx43 band intensity was high at 12 hours followed by a decrease in 
fluorescent intensity at 16 hours and then increased again at 20 hours. Whereas, from 24 up 
to 48 hours the intensity of T-Cx43 bands was roughly the same.  In presence of 25 µM CAIP 
treatment alone, T-Cx43 band intensity was high from 12 up to 20 hours followed by a 
decrease at 24 hours and increased again at 28 hours (Figure 4.11., panel B).  Similar lower 
band intensities were observed from 32 up to 36 hours, while increased fluorescence intensity 
was observed from 40 up to 48 hours.   
 
 
 
 
 
 
Figure 4.11. Total connexin 43 (T-Cx43) protein expression in synchronised HL1-6 total cell lysates (30 
µg/µL) at different timepoints post-synchronisation, under 25 µM calcineurin autoinhibitory peptide 
(CAIP) in presence and absence of 1 nM ATXII treatment. Western blot representative figures depicting the 
protein expression levels of T-Cx43 (43 kDa; green colour) and GAPDH (37 kDa; red colour) from 0 to 48 hours 
(4-hour interval) under 1 nM ATXII/25 µM CAIP (panel A) and 25 CAIP µM treatment alone (panel B).  
GAPDH was used as a loading control (lower blots).  
 
In addition, our results show that under ATXII/CAIP conditions the overall T-Cx43 protein 
expression levels was significantly lower in comparison to control and ATXII treatment 
groups (interaction effect; p<0.01) (Figure 4.12., panel C).  T-Cx43 protein expression levels 
peaked at 12 (0.130.05; N=3, p<0.05), 20 (0.140.05; N=3, p<0.05), 32 (0.120.05; N=3) 
and 48 (0.140.06; N=3, p<0.05) hours, and troughed at 16 (0.090.03; N=3, p<0.05) and 36 
(0.090.04; N=3, p<0.05) hours (Figure 4.12., panel A).  Such expression could not be 
considered as circadian due to the absence of circadian curve fit as the preferred model 
(p>0.05; Table 4.3.).  Interestingly, under ATXII treatment alone, T-Cx43 protein expression 
A 
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37 kDa GAPDH 
0 4 8 12 16 20 24 28 32 36 40 44 48 (hours)  
B 
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showed early peaked expression at 16 hours, compared to ATXII/CAIP treatment (20 hours) 
suggesting initial effects of CAIP treatment on T-Cx43 protein expression at such timepoint 
(Figure 4.12., panel C).  Significant difference between ATXII/CAIP treatment and ATXII 
treatment alone on T-Cx43 protein expression, was observed at 20 hours (ATXII/CAIP 
0.140.05; N=3 vs ATXII 0.270.04; N=9, p<0.01), 24 hours (ATXII/CAIP 0.110.03; N=3 
vs ATXII 0.230.03; N=9, p<0.01), 36 hours (ATXII/CAIP 0.090.04; N=3 vs ATXII 
0.240.03; N=9, p<0.01) and 40 hours (ATXII/CAIP 0.090.04; N=3 vs ATXII 0.230.03; 
N=9, p<0.01) (Figure 4.12., panel C).  Interestingly, T-Cx43 protein expression levels 
followed similar oscillatory pattern as the one observed under control conditions, suggesting 
possible effect of calcineurin on T-Cx43 protein expression ATXII-induced changes.     
Furthermore, CAIP treatment alone affected T-Cx43 protein expression levels in a time-
dependent manner (drug effect; p=0.05) (Figure 4.12., panel B).  Even though under CAIP 
treatment alone T-Cx43 protein expression peaked at 12 (0.300.11; N=6, p<0.01), 28 
(0.170.03; N=6, p<0.05) and 44 (0.180.09; N=6, p<0.05) hours, and troughed at 24 
(0.130.04; N=6, p<0.05) and 40 (0.190.01; N=6, p<0.05) hours, absence of circadian 
rhythm was reported due to the absence of 24-hour periodicity following straight line fit as 
the preferred model with the higher adjusted R square value (p>0.05; Table 4.3.).  
Additionally, CAIP treatment alone gradually decrease T-Cx43 protein expression throughout 
the 48 hours.  In addition, significant difference was observed between CAIP treatment alone 
and ATXII/CAIP at timepoint 12 (CAIP 0.300.11; N=6 vs ATXII/CAIP 0.130.05; N=3, 
p<0.01), 16 (CAIP 0.270.11; N=6 vs ATXII/CAIP 0.100.03; N=3, p<0.01) and 20 hours 
(CAIP 0.260.12; N=6 vs ATXII/CAIP 0.140.05; N=3, p<0.01) (Figure 4.12., panel C).  
Also, it seems that CAIP treatment alone, presented different pattern as the one observed under 
control conditions, suggesting a possible effect of calcineurin alone. 
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Figure 4.12. Mean normalised Total connexin 43 (T-Cx43) protein expression levels in synchronised HL1-
6 total cell lysates at different timepoints post-synchronisation, under control, 1 nM ATXII, 1 nM 
ATXII/25 µM CAIP and 25 µM CAIP conditions.  Normalised T-Cx43 protein expression levels against 
GAPDH expression (T-Cx43/GAPDH) line graphs (A; orange colour and B; green colour) to assess the presence 
of circadian rhythmicity (24-hour pattern).  Data are presented from 12 hours following serum-shock 
synchronisation, up to 48 hours (4-hour interval). (A) Under 1 nM ATXII/25 µM CAIP treatment, T-Cx43 
protein expression levels peaked at 12, 20, 32 and 48 hours, and troughed at 16, 24 and 36 hours (N=3, * p<0.05).  
(B) Following 25 µM CAIP treatment alone, T-Cx43 protein expression levels peaked at 12, 28 and 44 hours, 
and troughed at 24 and 40 hours (N=6, * p<0.05, ** p<0.01).  (C) Summarised line graphs of T-BMAL1 protein 
expression levels under control (black), ATXII (red), ATXII/CAIP (orange) and CAIP (green).  Significant 
difference following the different treatments is reported with # (ATXII vs ATXII/CAIP), ≠ (CAIP vs 
ATXII/CAIP).  Data are presented as Mean ± SEM. ##/≠≠p<0.01  
 
 
 
 
 
8 12 16 20 24 28 32 36 40 44 48 52
0.0
0.1
0.2
0.3
0.4
0.5
CAIP
Post synchronisation time (hours)
N
o
rm
a
li
s
e
d
 T
C
x
4
3
p
ro
te
in
 e
x
p
re
s
s
io
n **
* *
*
8 12 16 20 24 28 32 36 40 44 48 52
0.0
0.1
0.2
0.3
ATXII/CAIP
Post synchronisation time (hours)
N
o
rm
a
li
s
e
d
 T
C
x
4
3
p
ro
te
in
 e
x
p
re
s
s
io
n
*
*
*
*
*
8 12 16 20 24 28 32 36 40 44 48 52
0.0
0.1
0.2
0.3
0.4
0.5
Control
ATXII
ATXII/CAIP
CAIP



##
##
## ##
Post synchronisation time (hours)
N
o
rm
a
li
s
e
d
 T
C
x
4
3
p
ro
te
in
 e
x
p
re
s
s
io
n
A B 
C 
  Chapter 4.  Phosphorylated Cx43 protein expression 
153 | P a g e  
 
Table 4.3. Statistical comparison between cosinor curve and straight line model for total connexin 43 
(T-Cx43) protein expression levels in synchronised HL1-6 total cell lysates under control, 1 nM 
ATXII alone and in presence of 10 µM Ranolazine or 25 µM CAIP.  The goodness of the fit for the 
regression models was indicated with the adjusted R squared values; the higher the R squared value the 
improved the fit.  For all interventions, the straight line resulted to be the best model to fit T-Cx43 protein 
expression, with the highest adjusted R squared values.   
 
 
 
 
 
 
4.5.3.2. Effects of raised intracellular [Ca2+] and Ca2+-activated calcineurin 
on phosphorylated Cx43-Serine 368 (pCx43-Ser368) protein expression, in 
synchronised HL1-6 total cell lysates 
In synchronised total HL1-6 cell lysates, phosphorylated Cx43-Ser368 (pCx43-Ser368) 
protein expression changes were observed under control conditions, raised intracellular [Ca2+] 
by ATXII treatment alone and in presence of Ranolazine.  Figure 4.13. shows representative 
western blots indicating the changes in pCx43-Ser368 protein expression via change of band 
intensity and Figure 4.14. shows line graphs demonstrating the trend of oscillation observed 
in the mean normalised pCx43-Ser368 values under all treatment conditions mentioned above 
across the 48 hours.  pCx43-Ser368 protein expression bands were observed at 43 kDa (upper 
blots; green bands), along with GAPDH expression (37 kDa; lower blots, red bands) which 
was used as a loading control to normalise pCx43-Ser368 protein bands.  As Figure 4.13. 
panel A shows, under control conditions lower pCx43-Ser368 intensity bands were observed 
at 12 and 16 hours, and then increased from 20 hours up to 28 hours.  Whereas from 32 hours 
onwards, lower pCx43-Ser368 intensity bands were observed.  Under ATXII treatment 
(Figure 4.13. panel B), increased pCx43-Ser368 band intensity was observed at 12 hours, 
followed by a decrease form 16 up to 20 hours, and then increase again from 24 up to 36 
hours.  Whereas, from 40 hours onwards, lower pCx43-Ser368 band intensities were observed.  
To further confirm the ATXII action on pCx43-Ser368 protein expression, Ranolazine effect 
was tested in the presence of ATXII.  Figure 4.13. panel B shows, pCx43-Ser368 band 
intensity was low from 12 up to 16 hours, and then increased at 20 up to 28 hours.  From 32 
up to 40 hours the band intensity was gradually decreasing, until it increased again at 44 hours.  
The changes in pCx43-Ser368 expression were not accompanied by changes in GAPDH band 
intensity, which reported similar levels of expression across time under all treatment 
conditions (Figure 4.13.; lower blots, red bands).     
Total Cx43 protein expression   
Straight 
line 
Cosinor 
Curve 
Treatment  Period p value Adjusted R square 
Control  20 0.2130 0.01551 -0.008534 
ATXII 20 0.2291 0.02283 0.01085 
ATXII/RANOLAZINE  12 0.1944 0.008841 -0.008104 
ATXII/CAIP  12 0.5526 -0.03292 -0.05702 
CAIP  18 0.1744 0.06991 -0.01785 
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Figure 4.13. Phosphorylated Cx43-Serine 368 (pCx43-Ser368) protein expression in synchronised HL1-6 
total cell lysates (30 µg/µL) at different timepoints post-synchronisation, under control, 1 nM ATXII, and 
1 nM ATXII/10 µM Ranolazine conditions. Western blot representative figures depicting the protein 
expression levels of pCx43-Ser368 (43 kDa; green colour) and GAPDH (37 kDa; red colour) from 0 to 48 hours 
(4-hour interval) under control (panel A), 1 nM ATXII (panel B), and 1 nM ATXII/10 µM Ranolazine (panel C) 
conditions.  GAPDH was used as a loading control (lower blots).  
 
In addition, mean pCx43-Ser368 protein expression levels were quantified and presented in 
Figure 4.14.  Under control condition, pCx43-Ser368 protein expression levels change in a 
time-dependent manner indicating that there is variation over time (drug effect p<0.05).  
pCx43-Ser368 protein expression levels were significantly high under control treatment, with 
peaks at 20 (0.880.27; N=4, p<0.05), 28 (0.920.22; N=4, p<0.05) and 36 hours (0.830.19; 
N=4, p<0.05), and troughs at 12 (0.530.11; N=4), 24 (0.670.17; N=4) and 40 (0.480.11; 
N=4) hours (Figure 4.14., panel A).  It is also worth stating that after 28 hours, pCx43-Ser368 
protein expression levels are followed by a significant drop until its trough point (40 hours) 
and then rise back again where it peaks for the last time (44 hours). pCx43-Ser368 protein 
expression under control conditions, did not oscillate in a circadian manner due to the absence 
of 24-hour periodicity (Figure 4.14., panel A).  Such observation is also summarised in Table 
4.4., which indicates the statistical comparison between the cosinor curve and the straight line 
and supports that the preferred model with the higher adjusted R square was the straight line 
(p>0.05).   
ATXII treatment alone is changing the overall levels of pCx43-Ser368 by not only 
significantly lowering its protein expression levels throughout the 48 hours, but also causing 
changes in the dynamics of the circadian clock hence changes in its peaking expression time 
(drug effect p<0.01, time effect p<0.01) (Figure 4.14., panel B).  Indeed, due to pCx43-Ser368 
levels consistently decreased under ATXII treatment, a shift in the peaking expression time 
was also observed at 32 hours (0.490.12; N=4, p<0.05), compared to a 20-hour peak 
observed under control conditions (Figure 4.14., panel D). Also, under ATXII conditions 
pCx43-Ser368 show variation in its protein expression in a time-dependent manner, with a 
A 
43 kDa pCx43-Ser368 
37 kDa GAPDH 
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24-hour periodicity after cosinor curve fitting (Figure 4.14., panel B).  Such observation is 
also summarised in Table 4.4., which indicates the statistical comparison between the cosinor 
curve and the straight line and supports that the preferred model with the higher adjusted R 
square was the cosinor curve (p<0.05).  In addition, pCx43-Ser368 protein expression pattern 
under ATXII treatment alone was different to the one observed under control conditions 
(ATXII vs Control; interaction effect p=0.05), suggesting possible effect of raised intracellular 
[Ca2+] on Cx43 phosphorylation status.  Interestingly, significant difference between ATXII 
treatment and control conditions was observed at 20 (ATXII 0.230.05; N=4 vs Control 
0.880.27; N=4, p<0.001) and 28 hours (ATXII 0.390.09; N=4 vs Control 0.920.22; N=4, 
p<0.001) (Figure 4.14., panel D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14. Mean normalised phosphorylated connexin 43 – Serine 368 (pCx43-Ser368) protein 
expression levels in synchronised HL1-6 total cell lysates at different timepoints post-synchronisation, 
under control, 1 nM ATXII, and 1 nM ATXII/10 µM Ranolazine conditions.  Normalised T-Cx43 protein 
expression levels against GAPDH expression (pCx43-Ser368/GAPDH) line graphs (A; grey colour and C; blue 
colour) and cosine curve fit graphs (B; red colour) to assess the presence of circadian rhythmicity (24-hour 
pattern).  Data are presented from 12 hours following serum-shock synchronisation, up to 48 hours (4-hour 
interval).  (A) Under control conditions, pCx43-Ser368 protein expression levels peaked at 20, 28 and 36 hours, 
and troughed at 12, 24 and 40 hours (N=4, * p<0.05). (B) Following treatment with 1 nM ATXII, pCx43-Ser368 
protein expression levels peaked at peaked at 12, 32 and 48 hours, and troughed at 20 and 40 hours (N=4, * 
A B 
C D 
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p<0.05).  (C) In presence of 10 µM Ranolazine, pCx43-Ser368 protein expression levels peaked at 12, 20 and 
28 hours, and troughed at 16, 32 and 40 hours (N=4, * p<0.05).  (D) Summarised line graphs of pCx43-Ser368 
protein expression levels under control (black), ATXII (red) and ATXII/Ranolazine (blue). Significant difference 
following the different treatments is reported with * (Control vs ATXII), # (Control vs ATXII/Ranolazine).  Data 
are presented as Mean ± SEM. ## p<0.01, *** p<0.001 
 
Furthermore, Ranolazine treatment managed to restore pCx43-Ser368 protein expression 
pattern after ATXII treatment as it follows similar protein expression pattern as the one 
observed in control conditions (Figure 4.14., panel D).  Also, the overall pCx43-Ser368 
protein expression levels were significantly lower throughout the 48 hours, under Ranolazine 
treatment compared to the control conditions (interaction effect; p<0.01) (Figure 4.14., panel 
D). Under ATXII/Ranolazine conditions pCx43-Ser368 protein expression levels peaked at 
20 hours (0.540.30; N=4, p<0.05) and 28 hours (0.560.27; N=4, p<0.05) followed by a 
significant drop at 40 hours (0.130.02; N=4, p<0.05) (Figure 4.14., panel C).  Significant 
difference between control and ATXII/Ranolazine conditions was observed at 32 
(ATXII/Ranolazine 0.280.04; N=4 vs Control 0.800.19; N=4, p<0.01) and 36 hours 
(ATXII/Ranolazine 0.320.12; N=4 vs Control 0.830.19; N=4, p<0.01) (Figure 4.14., panel 
D).  A 20-hour cycle was also observed following straight line fit as the best model for pCx43-
Ser368 protein expression with the highest adjusted R square value (Table 4.4.).  Furthermore, 
a shift in the peaking expression time between ATXII treatment alone (32 hours) and 
ATXII/Ranolazine treatment (20 hours) reported, indicating Ranolazine involvement in 
partially reversing ATXII effects.   
Calcineurin effect was also assessed using 25 µM CAIP selective inhibitor in combination 
with 1 nM ATXII.  The western blot representation (Figure 4.15., panel A) indicates that the 
intensity of pCx43-Ser368 bands varied and oscillates across time.  pCx43-Ser368 high band 
intensities were observed from 12 up to 24 hours, and decrease from 28 hours up to 40 hours, 
following that it increased at 44 hours.  The effect of 25 µM CAIP treatment alone was also 
investigated to test for possible contribution of calcineurin under control conditions.  As 
Figure 4.15., panel B shows, pCx43-Ser368 band intensity was high at 12 hours, followed by 
a decrease from 16 up to 20 hours.  This was followed by similar increased band intensities 
from 24 hours up to 36 hours, which decreased at 40 hours.  Whereas, at 44 hours, high pCx43-
Ser368 band intensity was observed followed by another decrease at 48 hours.  pCx43-Ser368 
high band intensities were quantitated, normalised (to GAPDH) and presented in Figure 4.16. 
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Figure 4.15. Phosphorylated connexin 43 – Serine 368 (pCx43-Ser368) protein expression in synchronised 
HL1-6 total cell lysates (30 µg/µL) at different timepoints post-synchronisation, under 25 µM calcineurin 
autoinhibitory peptide (CAIP) in presence and absence of 1 nM ATXII treatment. Western blot 
representative figures depicting the protein expression levels of pCx43-Ser368 (43 kDa; green colour) and 
GAPDH (37 kDa; red colour) from 0 to 48 hours (4-hour interval) under 1 nM ATXII/25 µM CAIP (panel A) 
and 25 CAIP µM treatment alone (panel B).  GAPDH was used as a loading control (lower blots).  
 
Our results show that under ATXII/CAIP treatment pCx43-Ser368 protein expression levels 
oscillated in a circadian manner due to the presence of 24-hour periodicity (Figure 4.16., panel 
A).  Such observation is also summarised in Table 4.4., which indicates the statistical 
comparison between the cosinor curve and the straight line, and supports that the preferred 
model with the higher adjusted R square was the cosinor curve (p<0.05).  pCx43-Ser368 
protein expression levels change in a time-dependent manner indicating that there is variation 
over time (time effect p<0.05), as well as, effect of ATXII/CAIP treatment due to higher levels 
of expression compare to Control and ATXII treatment alone (ATXII/CAIP vs ATXII vs 
Control; interaction effect p=0.05) (Figure 4.16., panel C).  Under ATXII/CAIP conditions 
higher pCx43-Ser368 protein expression levels were observed at 28 hours (1.340.38; N=3, 
p<0.05).  Whereas, lower levels of expression were reported at 16 (1.010.04; N=3), 40 
(0.780.08; N=3, p<0.05) and 48 hours (0.730.16; N=3, p<0.05) (Figure 4.16., panel A).  
Significant difference between ATXII/CAIP and ATXII treatment alone, was observed at 20 
(ATXII/CAIP 1.050.18; N=3 vs ATXII 0.230.05; N=4, p<0.01), 28 (ATXII/CAIP 
1.340.38; N=3 vs ATXII 0.390.09; N=4, p<0.01), 32 (ATXII/CAIP 1.170.30; N=3 vs 
ATXII 0.490.12; N=4, p<0.01) and 40 hours (ATXII/CAIP 0.770.09; N=3 vs ATXII 
0.290.09; N=4, p<0.05) (Figure 4.16., panel C).  In addition, ATXII/CAIP treatment 
managed to restore pCx43-Ser368 protein expression pattern after ATXII treatment, as it 
follows very similar oscillatory pattern as the one observed under control conditions, 
suggesting possible effect of calcineurin on pCx43-Ser368 protein expression ATXII-induced 
changes. 
A 43 kDa pCx43-Ser368 
37 kDa GAPDH 
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In presence of CAIP treatment alone, pCx43-Ser368 protein expression levels change in a 
time-dependent manner indicating that there is variation over time (time effect p<0.05).  
Similar to ATXII/CAIP treatment, higher levels of expression were observed under CAIP 
treatment alone in comparison to Control and ATXII treatments (CAIP vs ATXII vs Control; 
interaction effect p=0.05).  pCx43-Ser368 protein expression levels peaked at 12 (1.170.40; 
N=4) and 44 (1.520.64; N=4, p<0.01) hours and were the lowest at 16 (0.810.29; N=4), 28 
(0.880.27; N=4), 40 (0.890.16; N=4) and 48 (0.920.23; N=4) hours.    In addition, pCx43-
Ser368 followed gradual similar levels of expression from 20 up to 40 hours indicating 
possible cell desynchrony due to gradual loss of serum shock effect (Figure 4.16., panel B).  
Absence of circadian pattern was observed under CAIP treatment alone, indicated with a fit 
of a straight line as the preferred model for pCx43-Ser368 protein expression, with the highest 
adjusted R square value (Figure 4.16., panel B & Table 4.4.).  Furthermore, CAIP treatment 
alone presented different pattern as the one observed under control conditions, suggesting 
possible effect of calcineurin alone on pCx43-Ser368 protein expression.    
 
 
 
 
 
 
 
Figure 4.16. Mean normalised phosphorylated connexin 43 – Serine 368 (pCx43-Ser368) protein 
expression levels in synchronised HL1-6 total cell lysates at different timepoints post-synchronisation, 
under control, 1 nM ATXII, 1 nM ATXII/25 µM CAIP and 25 µM CAIP conditions.  Normalised pCx43-
A B 
C 
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Ser368 protein expression levels against GAPDH expression (pCx43-Ser368/GAPDH) line graphs (B; green 
colour) and cosine curve fit graphs (A; orange colour) to assess the presence of circadian rhythmicity (24-hour 
pattern).  Data are presented from 12 hours following serum-shock synchronisation, up to 48 hours (4-hour 
interval).  (A) Under 1 nM ATXII/25 µM CAIP treatment, pCx43-Ser368 protein expression levels peaked at 
12, 28 and 44 hours, and troughed at 16 and 40 hours (N=3, * p<0.05, ** p<0.01).  (B) Following 25 µM CAIP 
treatment alone, pCx43-Ser368 protein expression levels peaked at 12 and 44 hours, and troughed at 16, 28, 40 
and 48 hours (N=4, ** p<0.01).  (C) Summarised line graphs of pCx43-Ser368 protein expression levels under 
control (black), ATXII (red), ATXII/CAIP (orange) and CAIP (green).  Significant difference following the 
different treatments is reported with # (ATXII vs ATXII/CAIP).  Data are presented as Mean ± SEM. # p<0.05, 
## p<0.01 
 
Table 4.4. Statistical comparison between cosinor curve and straight line model for phosphorylated 
Cx43 – Ser368 (pCx43-Ser368) protein expression levels in synchronised HL1-6 total cell lysates 
under control, 1 nM ATXII alone and in presence of 10 µM Ranolazine or 25 µM CAIP.  The goodness 
of the fit for the regression models was indicated with the adjusted R squared values; the higher the R 
squared value the improved the fit.  Under ATXII treatment alone or in presence of 25 µM CAIP, pCx43-
Ser368 protein expression reported circadian rhythmicity allowing cosinor curve fitting, whereas for all 
other interventions, the straight line resulted to be the best model to fit its expression with the highest 
adjusted R squared value. 
 
 
 
 
 
Furthermore, the difference between total and phosphorylated form of Cx43 was also 
investigated.  Absence of total and phosphorylated Cx43 circadian patterns were observed 
following serum-shock synchronisation of HL1-6 cell lysates, despite the reported oscillatory 
protein expression.  Under control conditions, the proportion of T-Cx43 protein expression 
gradually decrease following its peak expression timepoint (20 hours) (Figure 4.10., panel A).  
Interestingly, even though the pCx43-Ser368 showed a different pattern, with much higher 
levels of expression throughout the two circadian cycles compare to T-Cx43 protein 
expression, similar peak expression at 20 hours was also observed (Figure 4.14., panel A).  
Additionally, similar pattern of expression were also observed during the first 24 hours, 
whereas the two significant drops in levels of phosphorylated form of Cx43 were not observed 
for the total Cx43 form.  In presence of ATXII treatment, similar total and phosphorylated 
Cx43 overall levels of expression were observed (Figure 4.10., panel B & Figure 4.14., panel 
B).  Despite the similar levels of expression across the two circadian cycles, antiphasic 
peaking expression pattern was also observed between total and phosphorylated Cx43.  When 
Phosphorylated Cx43 – Serine 368 
protein expression   
Straight 
line 
Cosinor 
Curve 
Treatment  Period p value Adjusted R square 
Control  16 0.3644 -0.01282 -0.002095 
ATXII 24 0.0256 -0.02012 0.06407 
ATXII/RANOLAZINE  12 0.3737 0.01510 -0.01302 
ATXII/CAIP  24 0.050 -0.006255 0.01171 
CAIP 12  0.2123 -0.01495 -0.03408 
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T-Cx43 expression troughed at 20 hours, the pCx43-Ser368 expression was peaked, and when 
the T-Cx43 expression troughed at 32 hours, pCx43-Ser368 expression peaked for the first 
time (Figure 4.10., panel B & Figure 4.14., panel B).  Additionally, gradual decrease in pCx43 
expression was observed following 32 hours of serum-shock synchronisation, whereas T-
Cx43 expression was progressively increasing across time (Figure 4.10., panel B & Figure 
4.14., panel B).  In presence of Ranolazine, unlike T-Cx43 levels of expression, significantly 
high phosphorylated Cx43 levels of expression were observed compare to control and ATXII 
treatment alone.  It is also worth stating that total and phosphorylated form of Cx43 following 
similar pattern of expression for at least 36 hours post serum-shock synchronisation despite 
their difference in levels of expression (Figure 4.10., panel C & Figure 4.14., panel C).  
However, the significant drop in pCx43-Ser368 levels of expression observed under 
Ranolazine treatment, was not reported in T-Cx43 pattern of expression.  Additionally, total 
and phosphorylated Cx43 showed similar patterns of expression as the ones observed under 
control condition, proposing a possible contribution of raised [Ca2+]i in affecting Cx43 protein 
expression levels. 
The difference between total and phosphorylated form of Cx43 was also investigated under 
ATXII/CAIP or CAIP treatment alone.  Overall, the phosphorylated form of Cx43 showed 
higher levels of expression under ATXII/CAIP treatment, compare to total form of Cx43 
(Figure 4.12., panel A & Figure 4.16., panel A).  In addition, T-Cx43 protein expression levels 
peaked at 20 and 48 hours, whereas pCx43-Ser42 showed a different pattern, with much later 
peaks at 28 and 44 hours under ATXII/CAIP treatment (Figure 4.12., panel A & Figure 4.16., 
panel A).  Interestingly, the proportion of pCx43-Ser368 protein expression decreased 
progressively following 32 hours of serum-shock synchronisation under ATXII/CAIP 
treatment.  This is different to T-Cx43 who reported almost similar levels of expression across 
time with no major fluctuations in expression levels across the two circadian cycles.  In 
presence of CAIP treatment alone, similar pattern of expression was observed between total 
and phosphorylated form of Cx43 during the second circadian cycle (from 24 up to 48 hours) 
(Figure 4.12., panel B & Figure 4.16., panel B).  Whereas during the first circadian cycle, 
pCx43-Ser368 showed lower levels of expression at 16 hours compare to a much later drop 
in T-Cx43 protein expression levels at 24 hours, suggesting difference in total and 
phosphorylated form of Cx43 expression pattern across time.  This implies possible 
involvement of Ca2+/Calcineurin activated pathway in driving such changes.    
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4.5.3.3. Effects of raised intracellular [Ca2+] and Ca2+-activated calcineurin 
on Total Cx40 (T-Cx40) protein expression, in synchronised HL1-6 total cell 
lysates 
In synchronised total HL1-6 cell lysates, T-Cx40 protein expression changes were observed 
under control conditions, raised intracellular [Ca2+] by ATXII treatment alone and in presence 
of Ranolazine.  Figure 4.17. shows representative western blots indicating the changes in T-
Cx40 protein expression via change of band intensity and Figure 4.18. shows line graphs 
demonstrating the trend of oscillation observed in the mean normalised T-Cx40 values under 
all treatment conditions mentioned above across the 48 hours.  T-Cx40 protein expression 
bands were observed at 40 kDa (upper blots; green bands), along with GAPDH expression 
(37 kDa; lower blots, red bands) which was used as a loading control to normalised T-Cx40 
protein bands.  Under control condition (Figure 4.17., panel A), equally high intensity of T-
Cx40 bands was observed across most of the different timepoints, with slightly lower band 
intensity observed at 40 and 44 hours.   
Following raised intracellular [Ca2+]i by ATXII treatment (Figure 4.17., panel B), a trend of 
oscillation was observed across the 48 hours (time effect p>0.05).  As panel B shows, T-Cx40 
band intensity increased at 12 hours, followed by a decrease at 16 hours and a subsequent 
increase at 20 hours.  From 24 up to 44 hours, similar lower band intestines were observed, 
followed by an increase at 48 hours.  In presence of ATXII and Ranolazine NaP inhibitor, the 
intensity of T-Cx40 bands varied and oscillated across time (Figure 4.17., panel C).  For 
example, T-Cx40 band intensity was low at 12 hours and then increased from 16 hours up to 
24 hours, until it dropped again at 28 hours.   Higher T-Cx40 band intensity was observed 
from 32 hours up to 48 hours.  In addition, the changes in T-Cx40 expression were not 
accompanied by changes in GAPDH band intensity, which reported similar levels of 
expression across time (Figure 4.17.; lower blots, red bands).      
   
 
 
 
 
 
Figure 4.17. Total Cx40 (T-Cx40) protein expression in synchronised HL1-6 total cell lysates (30 µg/µL) 
at different timepoints post-synchronisation, under control, 1 nM ATXII, and 1 nM ATXII/10 µM 
Ranolazine conditions. Western blot representative figures depicting the protein expression levels of T-Cx40 
A 40 kDa T-Cx40 
37 kDa GAPDH 
0 4 8 12 16 20 24 28 32 36 40 44 48 (hours)  
B 40 kDa T-Cx40 
37 kDa GAPDH 
40 kDa T-Cx40 
37 kDa GAPDH 
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(40 kDa; green colour) and GAPDH (37 kDa; red colour) from 0 to 48 hours (4-hour interval) under control 
(panel A), 1 nM ATXII (panel B), and 1 nM ATXII/10 µM Ranolazine (panel C) conditions.  GAPDH was used 
as a loading control (lower blots).  
 
The T-Cx40 band intensities were quantitated, normalised (to GAPDH) and presented in 
Figure 4.18. As panel A illustrates, under control conditions T-Cx40 protein expression levels 
appeared to be similarly expressed with no significant difference across time (p>0.05).  
Slightly higher T-Cx40 protein expression levels were observed at 16 (0.320.11; N=6), 28 
(0.320.10; N=6) and 40 hours (0.320.10; N=6).  Similarly, low T-Cx40 protein expression 
levels were observed at 12 (0.240.03; N=6), 20 (0.280.09; N=6), 32 (0.280.09; N=6) and 
48 hours (0.270.07; N=6) (Figure 4.18., panel A).  Furthermore, panel B shows that ATXII 
is affecting T-Cx40 protein expression, by not only lowering the protein expression levels but 
also by causing changes in the dynamics of the circadian clock hence changes in its peaking 
expression time (Figure 4.18., panel B).  Indeed, ATXII treatment affected T-Cx40 protein 
expression peak times at 20 (0.270.15; N=3, p<0.05), 36 (0.290.12; N=3, p<0.05) and 48 
hours (0.340.18; N=3) p<0.05) when compare to control conditions (peaks; 16, 28 and 40 
hours), suggesting a 4-8 hour shift in the peak expression time (ATXII vs Control; interaction 
effect p=0.05) (Figure 4.18., panel D).  Significant difference in T-Cx40 protein expression 
levels was also observed between ATXII and control treatment at 16 hours (ATXII 0.170.07; 
N=3 vs Control 0.320.11; N=6, p<0.05), where T-Cx40 levels peaked under control 
conditions and troughed under ATXII treatment (Figure 4.18., panel D).  Also, T-Cx40 protein 
expression pattern under ATXII treatment alone was different to the one observed under 
control conditions, suggesting a possible contribution of raised intracellular [Ca2+] in changes 
of T-Cx40 protein expression. 
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Figure 4.18. Mean normalised Total Cx40 (T-Cx40) protein expression levels in synchronised HL1-6 total 
cell lysates at different timepoints post-synchronisation, under control, 1 nM ATXII, and 1 nM ATXII/10 
µM Ranolazine conditions.  Normalised T-Cx40 protein expression levels against GAPDH expression (T-
Cx40/GAPDH) line graphs (A; black colour, B; red colour and C; blue colour) to assess the presence of circadian 
rhythmicity (24-hour pattern).  Data are presented from 12 hours following serum-shock synchronisation, up to 
48 hours (4-hour interval).  (A) Under control conditions, T-Cx40 protein expression levels peaked at 16, 28 and 
40 hours, and troughed at 12, 20, 32 and 48 hours (N=6, * p<0.05).  (B) Following treatment with 1 nM ATXII, 
T-Cx40 protein expression levels peaked at 12, 20, 36 and 48 hours, and troughed at 16, 24 and 44 hours.  (N=3, 
* p<0.05).  (C) In presence of 10 µM Ranolazine, T-Cx40 protein expression levels peaked at 20, 32 and 48 
hours, and troughed at 12 and 28 hours (N=3, * p<0.05).  (D) Summarised line graphs of T-Cx40 protein 
expression levels under control (black), ATXII (red) and ATXII/Ranolazine (blue). Significant difference 
following the different treatments is reported with # (Control vs ATXII/Ranolazine), * (Control vs ATXII). Data 
are presented as Mean ± SEM.  */# p<0.05 
 
In addition, as Figure 4.18., panel C shows, the mean normalised T-Cx40 protein expression 
levels decreased under Ranolazine treatment, in comparison to control and ATXII-treatment 
alone.  Under ATXII/Ranolazine treatment T-Cx40 protein expression levels peaked at 20 
hours (0.250.16; N=3) followed by a drop at 28 hours (0.200.09; N=3) and then rise back 
again at 32 hours (0.260.14; N=3).  From 32 hours and up to 48 hours, similarly high levels 
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of expression were observed (Figure 4.18., panel C).  Additionally, absence of significant 
difference reported across the different timepoints under Ranolazine treatment in presence of 
ATXII (drug effect p>0.05).  Significant difference between ATXII/Ranolazine and control 
conditions was observed at 28 hours (ATXII/Ranolazine 0.200.09; N=3 vs Control 
0.320.10; N=6, p<0.05), where T-Cx40 levels peaked under control conditions but troughed 
under ATXII/Ranolazine treatment (Figure 4.18., panel D). The T-Cx40 protein expression 
oscillatory pattern observed under ATXII/Ranolazine treatment was different to the one 
observed under control conditions, possibly indicating Ranolazine inability to fully reverse 
ATXII effects.  
Interestingly, no obvious circadian rhythmic pattern could be confirmed for T-Cx40 protein 
expression under all mentioned interventions (control, ATXII treatment alone or in presence 
of Ranolazine), due to the absence of 24-hour periodicity following straight line fitting as the 
preferred model for all tested interventions (p>0.05; Table 4.5.).   
 
 
Table 4.5. Statistical comparison between cosinor curve and straight line model for Total Cx40 (T-
Cx40) protein expression levels in synchronised HL1-6 total cell lysates under control, 1 nM ATXII 
alone and in presence of 10 µM Ranolazine or 25 µM CAIP.  The goodness of the fit for the regression 
models was indicated with the adjusted R squared values; the higher the R squared value the improved the 
fit.  For all interventions, the straight line resulted to be the best model to fit T-Cx40 protein expression, 
with the highest adjusted R squared values. 
 
 
 
 
 
To assess the role of calcineurin in the observed Ca2+-induced changes on T-Cx40 protein 
expression, we tested the effects of 25 µM CAIP in combination with 1 nM ATXII.  The 
western blot representation (Figure 4.19., panel A) indicates oscillatory T-Cx40 band intensity 
pattern across the 48 hours.  T-Cx40 band intensity was low at 12 hours and then increased at 
16 hours, whereas from 20 up to 24 hours it decreased again.  At 28 hours T-Cx40 band 
intensity increased followed by a decrease at 32 hours and remain low up to 36 hours, whereas 
from 40 up to 48 hours T-Cx40 band intensities increased.  The intensity of T-Cx40 bands 
under 25 µM CAIP treatment alone was roughly the same across the different timepoints, with 
similar band intensities observed from 12 up to 48 hours (Figure 4.19., panel B).  The changes 
Total Cx40 protein expression   
Straight 
line 
Cosinor 
Curve 
Treatment  Period p value Adjusted R square 
Control   12 0.8944 -0.01435 -0.02922 
ATXII  16 0.2589 -0.006121 -0.07157 
ATXII/RANOLAZINE  16 0.2335 -0.005442 -0.04747 
ATXII/CAIP  12 0.3579 0.01726 -0.04908 
CAIP  42 0.9176 -0.01269 -0.0257 
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in T-Cx40 expression were not accompanied by changes in GAPDH band intensity, which 
reported similar levels of expression across time (Figure 4.19.; lower blots, red bands). 
 
 
 
 
 
Figure 4.19. Total Cx40 (T-Cx40) protein expression in synchronised HL1-6 total cell lysates (30 µg/µL) 
at different timepoints post-synchronisation, under 25 µM calcineurin autoinhibitory peptide (CAIP) in 
presence and absence of 1 nM ATXII treatment. Western blot representative figures depicting the protein 
expression levels of T-Cx40 (40 kDa; green colour) and GAPDH (37 kDa; red colour) from 0 to 48 hours (4-
hour interval) under 1 nM ATXII/25 µM CAIP (panel A) and 25 CAIP µM treatment alone (panel B).  GAPDH 
was used as a loading control (lower blots).  
 
Additionally, the mean normalised T-Cx40 protein expression levels under ATXII/CAIP were 
significantly higher compared to control and ATXII treatment alone (interaction effect 
p=0.05; ATXII/CAIP vs ATXII, p=0.05; ATXII/CAIP vs Control) (Figure 4.20., panel C). 
The ATXII/CAIP treatment significantly affected T-Cx40 protein expression levels, as 
oscillatory pattern was observed between the timepoints (time effect p<0.05) (Figure 4.20., 
panel A).  The T-Cx40 protein expression levels peaked at 16 hours (ATXII/CAIP 0.360.12; 
N=3 vs ATXII 0.170.07; N=3, p<0.01), 28 hours (ATXII/CAIP 0.460.17; N=3 vs ATXII 
0.230.09; N=3, p<0.01) and 40 hours (ATXII/CAIP 0.480.13; N=3 vs ATXII 0.280.16; 
N=3, p<0.01).  Lower T-Cx40 levels were observed at 12 (0.220.06; N=3), 24 (0.280.10; 
N=3), 36 (0.310.09; N=3) and 48 hours (0.400.20; N=3) hours (Figure 4.20., panel C).  In 
addition, ATXII/CAIP treatment seem to restore T-Cx40 protein expression pattern after 
ATXII treatment, as it seems to follow similar oscillatory protein expression pattern as the 
one observed under control conditions (peaks; 16, 28 and 40 hours), suggesting possible effect 
of calcineurin on T-Cx40 protein expression ATXII-induced changes.  
Under CAIP treatment alone, the overall T-Cx40 protein expression levels dramatically 
dropped compare to the rest of the treatment groups (CAIP vs Control; interaction effect 
p<0.0001, CAIP vs ATXII/CAIP; interaction effect p<0.0001) (Figure 4.20., panel C).  Figure 
4.20., panel B illustrates no significant difference between the different timepoints (time effect 
p>0.05) indicating the absence of calcineurin effect on T-Cx40 protein expression.  Significant 
difference between CAIP treatment alone and ATXII/CAIP also reported at 16 hours 
(ATXII/CAIP 0.360.12; N=3 vs CAIP 0.120.04; N=4, p<0.01), 24 hours (ATXII/CAIP 
A 40 kDa T-Cx40 
37 kDa GAPDH 
0 4 8 12 16 20 24 28 32 36 40 44 48 (hours)  
B 40 kDa T-Cx40 
37 kDa GAPDH 
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0.280.10; N=3 vs CAIP 0.130.04; N=4, p<0.05), 28 hours (ATXII/CAIP 0.460.17; N=3 
vs CAIP 0.120.04; N=4, p<0.001), 36 hours (ATXII/CAIP 0.310.09; N=3 vs CAIP 
0.120.04; N=4, p<0.05) and 40 hours (ATXII/CAIP 0.480.13; N=3 vs CAIP 0.130.03; 
N=4, p<0.001) (Figure 4.20., panel C).  Absence of T-Cx40 circadian rhythmic pattern 
reported under CAIP treatment alone or in presence of ATXII, due to no obvious 24-hour 
periodicity following straight line fitting as the preferred model for all tested interventions 
(p>0.05; Table 4.7.).   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20. Mean normalised T-Cx40 protein expression levels in synchronised HL1-6 total cell lysates at 
different timepoints post-synchronisation, under control, 1 nM ATXII, 1 nM ATXII/25 µM CAIP and 25 
µM CAIP conditions.  Normalised T-Cx40 protein expression levels against GAPDH expression (T-
Cx40/GAPDH) line graphs (A; black colour, B; red colour and C; blue colour) to assess the presence of circadian 
rhythmicity (24-hour pattern).  Data are presented from 12 hours following serum-shock synchronisation, up to 
48 hours (4-hour interval).  (A) Under 1 nM ATXII/25 µM CAIP treatment, T-Cx40 protein expression levels 
peaked at 16, 28 and 40 hours, and troughed at 12, 24, 36 and 48 hours (N=3, *p<0.05, ** p<0.01).  (B) Following 
25 µM CAIP treatment alone, absence of peaks and trough timepoints were observed (N=4).  (C) Summarised 
line graphs of T-Cx40 protein expression levels under control (black), ATXII (red), ATXII/CAIP (orange) and 
CAIP (green).  Significant difference following the different treatments is reported with # (ATXII vs 
ATXII/CAIP), ≠ (CAIP vs ATXII/CAIP).  Data are presented as Mean ± SEM. ≠ p<0.05, ##/≠≠ p<0.01, ≠≠≠ 
p<0.001            
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4.5.4. Assessment of persistent sodium channel subtypes protein expression 
in synchronised total cell lysates of HL1-6 atrial cardiomyocytes 
One of the major contributors of the intracellular mechanisms underlying AF is the raised 
intracellular Ca2+ concentration due to sustain opening of persistent Na channels (NaP).  This 
section will focus on assessment of the effects of raised [Ca2+]i on various NaP subtypes, 
including  Nav1.1., Nav1.5. and Nav1.6., across two circadian cycles (48 hours), in the 
absence and presence of 10 µM Ranolazine NaP activator.  Attention will be given on the total 
status of Nav1.1., Nav1.5 and Nav1.6 by using antibodies selective to their total form.  This 
will be achieved through western blotting experiments using serum-shocked synchronised 
HL1-6 total cell lysate.  Data are presented as mean changes of total Nav1.1., Nav1.5 or 
Nav1.6. protein expression normalised to GAPDH.  
4.5.4.1. Effects of raised intracellular [Ca2+] on persistent sodium channel 
subtypes (Nav1.1, Nav1.5, Nav1.6) protein expression, in synchronised 
HL1-6 total cell lysates 
In synchronised total HL1-6 cell lysates, the protein expression changes of persistent sodium 
channel subtypes 1.1, 1.5 and 1.6 (Nav1.1., Nav1.5 and Nav1.6.) was assessed under control 
conditions, raised intracellular [Ca2+] by ATXII treatment alone and in presence of Ranolazine 
NaP channel inhibitor across the 48 hours.   
As Figure 4.21., panel A shows Nav1.1. protein expression bands were observed at 33 kDa 
(lower blots; green bands), along with GAPDH expression (37 kDa; upper blots, red bands) 
which was used as a loading control to normalise Nav1.1. protein bands.  Under control 
conditions, Nav1.1. bands intensity was similar from 12 up to 24 hours, followed by an 
increase at 28 hours and then gradually decrease from 32 up to 44 hours.  Following raised 
intracellular [Ca2+] by ATXII treatment, Nav1.1. bands intensity was similar between 12 and 
20 hours, and then increased at 24 hours, followed by a decrease at 28 hours and a gradual 
increase up to 48 hours.  Whereas in presence of 10 µM Ranolazine in combination with 1 
nM ATXII, the intensity of Nav1.1. bands varied across time, with similar high band 
intensities from 12 up to 36 hours, followed by a decrease at 40 hours and then increase again 
at until the end of 48 hours.  The Nav1.1. bands were quantitated, normalised (to GAPDH) 
and presented in Figure 4.22.  
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Figure 4.21. Total persistent sodium channel 1.1. (Nav1.1.) protein expression in synchronised HL1-6 total 
cell lysates (30 µg/µL) at different timepoints post-synchronisation, under control, 1 nM ATXII, and 1 nM 
ATXII/10 µM Ranolazine conditions. Western blot representative figures depicting the protein expression 
levels of Nav1.1. (33 kDa; green colour) and GAPDH (37 kDa; red colour) from 0 to 48 hours (4-hour interval) 
under control (panel A), 1 nM ATXII (panel B), and 1 nM ATXII/10 µM Ranolazine (panel C) conditions.  
GAPDH was used as a loading control (upper blots).  
 
Our results showed that under control conditions Nav1.1. protein expression levels varied and 
oscillated in a time-dependent manner (Figure 4.22., panel A). Significant difference was 
observed between the different timepoints, revealing that there is variation over time under 
control conditions (time effect p<0.01).  High mean normalised Nav1.1 protein expression 
levels were observed at 28 (0.530.02; N=3, p<0.05) and 48 (0.480.08; N=3) hours, whereas 
lower levels were observed at 20 (0.410.02; N=3) and 44 (0.360.03; N=3, p<0.01) hours, 
suggesting a 24-hour cycle under control conditions.  Such observation is also summarised in 
Table 4.6., which indicates the statistical comparison between the cosinor curve and the 
straight line and supports that the preferred model with the higher adjusted R square was the 
cosinor fitting (p<0.05). 
However, ATXII treatment is changing the overall Nav1.1. protein expression by not only 
lowering its expression levels, when compare to control conditions (ATXII vs Control; 
interaction effect p=0.05), but also cause changes in the dynamics of the circadian clock hence 
changes in its peaking expression time (Figure 4.22., panel D).  Indeed, due to Nav1.1 protein 
expression levels consistently decreased under ATXII treatment, a shift in the peaking 
expression time was also observed at 24 hours, in comparison to the peak observed at 28 hours 
under control conditions (Control 0.530.02; N=3 vs ATXII 0.280.08; N=3, p<0.01) (Figure 
4.22., panel D).  Also, under ATXII treatment, Nav1.1 protein expression levels peaked at 24 
(0.370.09; N=3, p<0.05) and 40 (0.460.16; N=3, p<0.01) hours (20-hour cycle), and 
troughed at 28 (0.280.08; N=3) and 48 (0.390.17; N=3) hours (20-hour cycle), suggesting 
absence of circadian rhythmicity (Figure 4.22., panel B). As Table 4.6. shows, the preferred 
model to fit was the straight line with a p>0.05.  In addition, Nav1.1. protein expression pattern 
was different to the one observed under control conditions, suggesting possible effects of 
A 37 kDa GAPDH 
 
33 kDa Nav1.1. 
 
0 4 8 12 16 20 24 28 32 36 40 44 48 (hours)  
B 37 kDa GAPDH 
 
33 kDa Nav1.1. 
 C 37 kDa GAPDH 
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raised intracellular [Ca2+] on Nav1.1. protein expression.  On the other hand, Figure 4.22. 
panel C & D indicates that Ranolazine did not managed to restore Nav1.1. protein levels after 
ATXII treatment, with the overall Nav1.1. protein expression levels been significantly lower 
for at least 40 hours, compare to control and ATXII-treatment alone (Control vs 
ATXII/Ranolazine; interaction effect p=0.05, ATXII vs ATXII/Ranolazine; interaction effect 
p=0.05).  Also, no clear Nav1.1. protein expression peaks were observed throughout 
Ranolazine treatment, confirming the absence of circadian pattern following fitting of a 
straight line as the best model (p>0.05) (Figure 4.22., panel C & Table 4.6.).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22. Mean normalised persistent sodium channel 1.1. (Nav1.1.) protein expression levels in 
synchronised HL1-6 total cell lysates at different timepoints post-synchronisation, under control, 1 nM 
ATXII, and 1 nM ATXII/10 µM Ranolazine conditions.  Normalised Nav1.1. protein expression levels against 
GAPDH expression (Nav1.1./GAPDH) line graphs (B; red colour and C; blue colour) and cosine curve fit graphs 
(A; black colour) to assess the presence of circadian rhythmicity (24-hour pattern).  Data are presented from 12 
hours following serum-shock synchronisation, up to 48 hours (4-hour interval). (A) Under control conditions, 
Nav1.1. protein expression levels peaked at 28 and 48 hours, and troughed at 20 and 44 hours (N=3, * p<0.05, 
** p<0.01).  (B) Following treatment with 1 nM ATXII, Nav1.1. protein expression levels peaked at 24 and 40 
hours, and troughed at 28 and 44 hours.  (N=3, * p<0.05, ** p<0.01).  (C) In presence of 10 µM Ranolazine, 
absence of peak and trough Nav1.1 protein expression levels were observed (N=3, * p<0.05).  (D) Summarised 
line graphs of Nav1.1. protein expression levels under control (black), ATXII (red) and ATXII/Ranolazine 
(blue). Significant difference following the different treatments is reported with * (Control vs ATXII) # (Control 
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vs ATXII/Ranolazine), † (ATXII vs ATXII/Ranolazine). Data are presented as Mean ± SEM.  †/# p<0.05, ##/** 
p<0.01 
 
 
Interestingly, Nav1.1. trough expression at 28 (0.270.09; N=3) hours under 
ATXII/Ranolazine treatment was completely different to the peak observed under control 
conditions (Control 0.530.02; N=3 vs ATXII/Ranolazine 0.270.09; N=3, p<0.01) (Figure 
4.22., panel D).  Furthermore, Nav1.1. trough expression during timepoint 40 (0.260.15; 
N=3) hours under ATXII/Ranolazine treatment is also completely opposite to the peak 
observed under ATXII treatment alone (ATXII 0.460.16; N=3 vs ATXII/Ranolazine 
0.260.15; N=3, p<0.05).  Significant difference in Nav1.1. protein expression levels between 
control and ATXII/Ranolazine conditions from 12 hours up to 24 hours (p<0.05) was also 
observed (Figure 4.22., panel D). The Nav1.1. protein expression oscillatory pattern under 
ATXII/Ranolazine treatment was different to the one observed under control conditions, 
indicating Ranolazine inability to fully reverse ATXII effects in Nav1.1 channel. 
 
Table 4.6. Statistical comparison between cosinor curve and straight line model for persistent sodium 
channel 1.1. (Nav1.1.) protein expression levels in synchronised HL1-6 total cell lysates under control, 
1 nM ATXII alone and in presence of 10 µM Ranolazine.  The goodness of the fit for the regression 
models was indicated with the adjusted R squared values; the higher the R squared value the improved the 
fit.  Under control conditions, Nav1.1. protein expression reported circadian rhythmicity with a p<0.05, 
whereas for all other interventions, the straight line resulted to be the best model to fit with the highest 
adjusted R square value. 
 
 
 
 
 
 
 
 
 
 
Nav1.5. protein expression levels were also investigated across two circadian cycles.  Figure 
4.23. shows representative western blots of Nav1.5. protein expression changes across the 48 
hours, under control conditions (panel A), raised intracellular [Ca2+] by ATXII treatment alone 
(panel B) and in presence of Ranolazine NaP channel inhibitor (panel C).  Nav1.5. protein 
expression bands were observed at 168 kDa (upper blots; green bands), along with GAPDH 
expression (37 kDa; lower blot, red bands) which was used as a loading control to normalise 
Nav1.5. protein bands.  Nav1.5. band intensity was low at 12 hours, followed by an increase 
at 16 and 20 hours, until it decreased again at 24 hours.  This was followed by an increase at 
28 hours and a decrease at 32 hours.  Similar Nav1.5 band intensities from 32 up to 48 hours 
were observed. As Panel B (ATXII treatment alone) indicates, Nav1.5. band intensity was 
similarly high between 12 and 24 hours, followed by a decrease at 28 hours and then increased
Nav1.1. protein expression  Straight 
line 
Cosinor 
Curve 
Treatment  Period p value Adjusted R square 
Control  24 0.0077 0.04719 0.244 
ATXII 20 0.3467 0.003524 -0.04729 
ATXII/Ranolazine 12 0.2971 0.006985 -0.09695 
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again at 32 hours.  The Nav1.5. band intensities were also similarly high from 32 up to 40 
hours, followed by a decrease at 44 hours and increased again at 48 hours.  In presence of 
Ranolazine following ATXII treatment (panel C), the intensity of Nav1.5. bands varied and 
oscillate across time, with similar band intensities from 12 up to 16 hours, followed by a 
decrease at 20 hours and then gradually increase until 28 hours.  This was followed by similar 
band intensities from 32 up to 48 hours.  Nav1.5. band intensities were quantitated, normalised 
(to GAPDH) and presented in Figure 4.24.   
 
 
 
 
 
 
 
Figure 4.23. Total persistent sodium channel 1.5. (Nav1.5.) protein expression in synchronised HL1-6 total 
cell lysates (30 µg/µL) at different timepoints post-synchronisation, under control, 1 nM ATXII, and 1 nM 
ATXII/10 µM Ranolazine conditions. Western blot representative figures depicting the protein expression 
levels of Nav1.5. (168 kDa; green colour) and GAPDH (37 kDa; red colour) from 0 to 48 hours (4-hour interval) 
under control (panel A), 1 nM ATXII (panel B), and 1 nM ATXII/10 µM Ranolazine (panel C) conditions.  
GAPDH was used as a loading control (lower blots).  
 
As Figure 4.24., panel A shows, under control conditions, Nav1.5 show fluctuations in its 
protein expression levels (drug effect p<0.01).  Low overall Nav1.5. protein expression levels 
were observed under control conditions; however, significant difference was observed 
between the different timepoints indicating that there is variation over time (time effect 
p<0.05).  Nav1.5. protein expression levels peaked at 16 (0.100.02; N=5, p<0.05), 28 
(0.090.01; N=5, p<0.05), 36 (0.070.02; N=5) and 48 (0.060.01; N=5) hours, and troughed 
at 12 (0.060.01; N=5), 24 (0.060.01; N=5), 32 (0.060.01; N=5) and 44 (0.050.01; N=5) 
hours (Figure 4.24., panel A).  In addition, Figure 4.24., panel B shows that ATXII treatment 
is changing the overall levels of Nav1.5. protein expression (drug effect p<0.05).  Nav1.5. 
protein expression levels follow roughly higher expression pattern, as the one observed under 
control conditions, with a 4-hour advanced peak on its expression time at 24 (0.110.04; N=5, 
p<0.05), 32 (0.090.03; N=5) and 40 (0.070.03; N=5) hours compare to control conditions 
A 168 kDa Nav1.5. 
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(Figure 4.24., panel D).  Additionally, Nav1.5. protein expression decreased at 28 (0.050.01; 
N=5, p<0.05) and 44 (0.050.02; N=5, p<0.05) hours (Figure 4.24., panel B). The mean 
normalised Nav1.5. protein levels in HL1-6 cell lysate treated with ATXII showed different 
pattern as the control profile, suggesting that the raised intracellular [Ca2+] could disrupt the 
expression of Nav1.5. channel.  
 
 
 
 
Figure 4.24. Mean normalised persistent sodium channel 1.5. (Nav1.5.) protein expression levels in 
synchronised HL1-6 total cell lysates at different timepoints post-synchronisation, under control, 1 nM 
ATXII, and 1 nM ATXII/10 µM Ranolazine conditions.  Normalised Nav1.5. protein expression levels against 
GAPDH expression (Nav1.5./GAPDH) line graphs (A; black colour, B; red colour and C; blue colour) to assess 
the presence of circadian rhythmicity (24-hour pattern).  Data are presented from 12 hours following serum-
shock synchronisation, up to 48 hours (4-hour interval).  (A) Under control conditions, Nav1.5. protein 
expression levels peaked at 16, 28, 36 and 48 hours, and troughed at 12, 24, 32 and 44 hours (N=5, * p<0.05). 
(B) Following treatment with 1 nM ATXII, Nav1.5. protein expression levels peaked at 24, 32 and 48 hours, and 
troughed at 28 and 44 hours (N=5, * p<0.05). (C) In presence of 10 µM Ranolazine, Nav1.5. protein expression 
levels peaked at 12, 28, 40 and 48 hours, and troughed at 20, 32 and 44 hours (N=5, * p<0.05). (D) Summarised 
line graphs of Nav1.5. protein expression levels under control (black), ATXII (red) and ATXII/Ranolazine 
(blue). Significant difference following the different treatments is reported with # (Control vs 
ATXII/Ranolazine), † (ATXII vs ATXII/Ranolazine). Data are presented as Mean ± SEM. # p<0.05, †† p<0.01 
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The mean normalised Nav1.5. protein expression levels under ATXII/Ranolazine conditions 
significantly increased across the 48 hours (drug effect p<0.01), in comparison to control and 
ATXII treatment alone (interaction effect p<0.001) (Figure 4.24., panel D).  Significant 
difference between the different timepoints was also observed under ATXII/Ranolazine, 
stating that there is variation over time (time effect; p<0.05).  In addition, Nav1.5. protein 
expression levels peaked at 12 (0.110.04; N=5), 28 (0.140.04; N=5, p<0.05), 40 (0.130.02; 
N=5) and 48 (0.120.03; N=5) hours, and troughed at 20 (0.090.02; N=5, p<0.05), 32 
(0.110.02; N=5) and 44 (0.100.02; N=5, p<0.05) hours (Figure 4.24., panel C).  Significant 
difference was observed between ATXII/Ranolazine treatment and control conditions from 
24 up to 48 hours (p<0.05) (Figure 4.24., panel D). Significant difference was also observed 
between ATXII/Ranolazine and ATXII treatment alone at 28 (ATXII/Ranolazine 0.140.04; 
N=5 vs ATXII 0.050.01; N=5, p<0.01), 36 (ATXII/Ranolazine 0.120.04; N=5 vs ATXII 
0.060.02; N=5, p<0.01), 40 (ATXII/Ranolazine 0.130.02; N=5 vs ATXII 0.070.03; N=5, 
p<0.01), 44 (ATXII/Ranolazine 0.100.02; N=5 vs ATXII 0.050.02; N=5, p<0.01) hours 
(Figure 4.24., panel D).  Ranolazine plausible effect on recovering ATXII effect on Nav1.5. 
channel, may be due to similar pattern observed under control and ATXII/Ranolazine 
conditions.   
Furthermore, data originated from western blots indicated that HL1-6s did not show a 
rhythmic Nav1.5. protein expression pattern upon all treatment conditions mentioned above 
following serum-shock synchronisation.  As Table 4.7. shows, the straight line was the 
preferred model to fit for all tested interventions, with p>0.05.  All tested free running periods 
were far from the accepted 24-hour periodicity, indicating absence of Nav1.5. circadian 
rhythmicity in the current experiments.   
Table 4.7. Statistical comparison between cosinor curve and straight line model for persistent sodium 
channel 1.5. (Nav1.5.) protein expression levels in synchronised HL1-6 total cell lysates under control, 
1 nM ATXII alone and in presence of 10 µM Ranolazine.  The goodness of the fit for the regression 
models was indicated with the adjusted R squared values; the higher the R squared value the improved the 
fit.  For all the interventions mentioned above, the straight line resulted to be the best model to fit Nav1.5. 
protein expression with the highest adjusted R square value.  
 
 
 
 
 
               
Nav1.5. protein expression  Straight 
line 
Cosinor 
Curve 
Treatment  Period p value Adjusted R square 
Control  12 0.5848 0.06934 -0.0412 
ATXII 16 0.2365 -0.003606 -0.02401 
ATXII/Ranolazine 12 0.7809 -0.01424 -0.0341 
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Nav1.6. protein expression changes were also observed under control conditions, raised 
intracellular [Ca2+] by ATXII treatment alone and in presence of Ranolazine, in synchronised 
total HL1-6 cell lysates.  Figure 4.25. shows representative western blots and Figure 4.26 
demonstrates line graphs indicating the trend of oscillation observed in the mean normalised 
Nav1.6. values under all conditions mentioned above across the 48 hours.  Nav1.6. protein 
expression bands were observed at 220 kDa (upper blots; green bands), along with GAPDH 
expression (37 kDa; lower blots, red bands) which was used as a loading control to normalise 
Nav1.6. protein bands (Figure 4.25.).  As the western blot representation in panel A (control 
conditions) indicates, similar Nav1.6. band intensities were observed from 12 up to 20 hours 
and increased at 24 hours, this is followed by a decrease at 28 hours up to 32 hours.  Similar 
Nav1.6. band intensities were also observed from 36 up to 48 hours.  Under ATXII treatment, 
similar Nav1.6. band intensities were reported throughout the different timepoints.  Whereas, 
under Ranolazine treatment in presence of ATXII, the intensity of Nav1.6. bands varied across 
time, with similar band intensities from 12 up to 16 hours, followed by a slight increase at 20 
hours and then gradually decrease with similar band intensities up to 48 hours.  The Nav1.6. 
band intensities were quantitated, normalised (to GAPDH) and presented in Figure 4.26.  
  
 
 
 
 
 
 
Figure 4.25. Total persistent sodium channel 1.6. (Nav1.6.) protein expression in synchronised HL1-
6 total cell lysates (30 µg/µL) at different timepoints post-synchronisation, under control, 1 nM 
ATXII, and 1 nM ATXII/10 µM Ranolazine conditions. Western blot representative figures depicting 
the protein expression levels of Nav1.6. (220 kDa; green colour) and GAPDH (37 kDa; red colour) from 0 
to 48 hours (4-hour interval) under control (panel A), 1 nM ATXII (panel B), and 1 nM ATXII/10 µM 
Ranolazine (panel C) conditions.  GAPDH was used as a loading control (lower blots).  
 
Under control conditions Nav1.6. protein expression levels oscillated across the 48 hours.  
Low overall Nav1.6 protein expression levels were observed under control conditions with 
peaks at 24 (0.040.02; N=4, p<0.05) and 36 (0.040.02; N=4, p<0.05) hours (Figure 4.26., 
panel A).  The effects of raised intracellular [Ca2+], by ATXII treatment, on Nav1.6. protein 
A 220 kDa Nav1.6. 
 
 
37 kDa GAPDH 
 
0 4 8 12 16 20 24 28 32 36 40 44 48 (hours)  
B 
220 kDa Nav1.6. 
 
 
37 kDa GAPDH 
 
C 220 kDa Nav1.6. 
 
 
37 kDa GAPDH 
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expression in synchronised HL1-6 total cell lysate showed similarly low Nav1.6 protein 
expression levels throughout the different timepoints (time effect p>0.05) (Figure 4.26., panel 
B). Thus, suggesting the inability of ATXII a subsequently raised intracellular [Ca2+], to affect 
Nav1.6. protein expression.  In addition, the overall Nav1.6. protein expression levels under 
ATXII/Ranolazine conditions were the highest throughout the 48 hours in comparison to 
control and ATXII treatment alone (interaction effect; p=0.05) (Figure 4.26., panel D).  Our 
results also indicate that under ATXII/Ranolazine treatment, Nav1.6. show variation in its 
protein expression in a time-dependent manner, with peaks at 20 (0.070.01; N=4) and 44 
(0.050.01; N=4) hours following serum-shock synchronisation (Figure 4.26., panel C).  Such 
peak times were marked as significantly different to the peaking expression times observed 
under control group, as well as ATXII treatment alone, (p<0.05) (Figure 4.26., panel D).  
Significant difference was also observed between ATXII/Ranolazine treatment and control 
conditions at 32 hours (Control 0.040.02; N=4 vs ATXII/Ranolazine 0.050.01; N=4 
p<0.05) (Figure 4.26., panel D). The Nav1.6. oscillatory expression pattern observed under 
ATXII/Ranolazine treatment was different to the one observed under control conditions, 
indicating Ranolazine inability to fully reverse ATXII effects in Nav1.6. channels.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26.  Mean normalised persistent sodium channel 1.6. (Nav1.6.) protein expression levels in 
synchronised HL1-6 total cell lysates at different timepoints post-synchronisation, under control, 1 nM
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ATXII, and 1 nM ATXII/10 µM Ranolazine conditions.  Normalised Nav1.6. protein expression levels against 
GAPDH expression (Nav1.6./GAPDH) line graphs (A; black colour, B; red colour and C; blue colour) to assess 
the presence of circadian rhythmicity (24-hour pattern).  Data are presented from 12 hours following serum-
shock synchronisation, up to 48 hours (4-hour interval).  (A) Under control conditions, Nav1.6. protein 
expression levels peaked at 24 and 36 hours, and troughed at 20, 32 and 48 hours (N=4, * p<0.05). (B) Following 
treatment with 1 nM ATXII, absence of peaks and troughs were observed (N=4).  (C) In presence of 10 µM 
Ranolazine, Nav1.6. protein expression levels peaked at 20 and 44 hours, and troughed at 12, 28 and 40 hours 
(N=4, * p<0.05). (D) Summarised line graphs of Nav1.6. protein expression levels under control (black), ATXII 
(red) and ATXII/Ranolazine (blue). Significant difference following the different treatments is reported with # 
(Control vs ATXII/Ranolazine). Data are presented as Mean ± SEM. # p<0.05 
 
At the same time, no obvious circadian rhythmic pattern could be confirmed for Nav1.6. 
protein expression under control, ATXII treatment alone or in presence of Ranolazine, due to 
the absence of 24-hour periodicity following straight line fitting as the preferred model for all 
tested interventions (Table 4.8.; p>0.05).   
 
Table 4.8. Statistical comparison between cosinor curve and straight line model for persistent sodium 
channel 1.6. (Nav1.6.) protein expression levels in synchronised HL1-6 total cell lysates under control, 
1 nM ATXII alone and in presence of 10 µM Ranolazine.  The goodness of the fit for the regression 
models was indicated with the adjusted R squared values; the higher the R squared value the improved the 
fit.  For all the interventions mentioned above, the straight line resulted to be the best model to fit Nav1.6. 
protein expression with the highest adjusted R square value.   
Nav1.6. protein expression  
Straight 
line 
Cosinor 
Curve 
Treatment  Period p value Adjusted R square 
Control  12 0.3363 -0.01342 -0.05265 
ATXII 12 0.3593 -0.02215 -0.05357 
ATXII/Ranolazine 20 0.5434 0.04422 -0.01521 
 
 
4.6. Discussion 
4.6.1. Total BMAL1 (T-BMAL1) and phosphorylated BMAL1-Ser42 
protein expression and rhythmicity under raised intracellular [Ca2+] in 
synchronised HL1-6 total cell lysate  
The occurrence of AF at certain time of the day hints the linkage of circadian rhythmicity (and 
the clock genes driving it), in the aetiology of AF.  However, the expression of clock genes in 
atria and their involvement in possible intracellular mechanisms underlying AF is currently 
unknown.  Our results showed for the first time rhythmic expression of Bmal1 clock gene in 
HL1-6 atrial myocytes (Chapter 3).  Such expression was highly disturbed (reduction in 
period) following raised intracellular [Ca2+] by ATXII (a model for atrial arrhythmias via 
sustain activation of Nap channels) and fully reversed in presence of NaP channel inhibitor, as 
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well as, selective Ca2+ chelator.  Thus, further emphasising that the involvement of Ca2+ 
mediated changes in cellular circadian clock are part of the occurrence of such events.  In 
addition, given the known contribution of Ca2+ activated calcineurin pathway in the generation 
of atrial arrhythmias (due to slow conduction velocity and abnormal propagation of action 
potential), the results indicated in this chapter proposed possible involvement of calcineurin 
driving the Total BMAL1 (T-BMAL1) protein expression changes observed under ATXII 
treatment, in the aetiology of AF signalling pathway.    
More specifically, we started by showing an oscillatory pattern of T-BMAL1 protein expression under 
control conditions with peaks observed at 12, 24 and 40 hours post serum-shock effect.  This is also in 
line with the study by Tamaru et al., (2003), which reported high T-BMAL1 nuclear protein expression 
at similar timepoints in mouse embryonic fibroblasts cells.   Such pattern was disturbed following 
raised intracellular [Ca2+] by ATXII, as lower T-BMAL1 protein expression levels were observed 
across time.  Raised intracellular [Ca2+] also changed the dynamics of the circadian clock by 
affecting its peak expression time, proposing a 4-hour delay when compare to control 
conditions, thus suggesting that the changes in intracellular [Ca2+] are associated with the 
changes observed in T-BMAL1 protein expression across time.  Ca2+ is a ubiquitous second 
messenger intrinsic to the dynamic regulation of a wide range of physiological functions 
inducing the process of excitation-contraction coupling in cardiac myocytes (Bers., 2014). 
Therefore, the ability of the heart to maintain Ca2+ levels within a physiological range (200 
nM intracellular [Ca2+] and 1.8 mM extracellular [Ca2+]) under resting conditions is essential 
to prevent deterioration to pathological conditions, such as seen in arrhythmias.  Rise in 
intracellular [Ca2+] 320-560 nM reported to be arrhythmogenic and associated with changes 
in gap junction conductance; one of the major factors contributing to the generation of AF 
events.  Studies have shown that 5 nM ATXII, significantly increased intracellular [Ca2+] to 
380 – 400 nM in rabbit left atrial cells, following NaP channel sustain significant increase, 
whereas 9 µM Ranolazine reduced the Ca2+ overload observed (Fraser et al., 2007; Luo et al., 
2013).  Thus, supporting that the suggested pathologic alterations in Ca2+ cycling observed 
during ATXII-induced arrhythmias in HL1-6 atrial cells, should be taken into consideration 
as predispose factors that possibly drive and/or affect T-BMAL1 circadian patterns changes.  
In addition, the 20-hour cycle observed within the expression aligns with the circadian rhythm 
within the protein expression of T-BMAL1 clock gene following cosine fit.  Interestingly, the 
use of NaP inhibitor, Ranolazine, in presence of ATXII treatment showed similar T-BMAL1 
expression pattern as the one observed under control conditions.  Thus, proposing restoration 
of ATXII-induced T-BMAL1 protein expression changes due to the subsequent activation of 
NaP channel.  In addition, lower T-BMAL1 levels were observed under Ranolazine treatment 
which is line with the reported activity of Ranolazine to inhibit the sustained and elevated 
activation of NaP channels, and subsequently the Ca
2+ overload, contractile dysfunction and 
generation of arrhythmias.   
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We also showed that T-BMAL1 level changes with the use of CAIP (specific calcineurin 
inhibitor), revealing a possible involvement of calcineurin activity driving these changes.  In 
a heathy heart calcineurin is inactive and unresponsive to high frequency Ca2+ waves that 
drive contraction, whereas upon raised intracellular [Ca2+] calcineurin gets activated and 
subsequently binds to a Ca2+/CaM complex to drive various signalling pathways (Wilkins and 
Molkentin., 2004).  T-BMAL1 protein expression following ATXII treatment in the presence 
of CAIP (calcineurin inhibitor) appeared to have multiple fluctuations indicating changes in 
the levels of its expression across time.  Such changes could not consider as circadian due to 
the absence of a 24-hour circadian pattern under CAIP treatment.  This is line with the study 
by Sachan et al., (2011) who reported reduction of the regulator of calcineurin 1 on the exon 
4 isoform (Rcan1.4) circadian oscillation in presence of Cyclosporine A (CsA) calcineurin 
inhibitor.  Rcan1.4, is one of the many target genes activated by calcineurin and in vivo studies 
have shown that its expression is extremely responsive to calcineurin changes in the heart as 
well as other tissues, therefore altered Rcan1.4 transcript levels can be used as a sensitive 
indicator of changes in calcineurin activity (Yang et al., 2014).  Interestingly CAIP treatment 
alone presented similar pattern of expression as the one observed under control conditions, 
suggesting the absence of calcineurin effect alone in absence of raised intracellular Ca2+ 
concentration.  However, despite the similar pattern (between control and CAIP treatment 
alone) high T-BMAL1 protein expression levels were reported.  This is opposite to the known 
Ca2+/calcineurin activated pathway considering the absence of raised intracellular [Ca2+] at 
this point, thus suggesting a possible link between calcineurin and T-BMAL1 independent of 
Ca2+ activation.  Therefore, further experiments need to be conducted to validate the signalling 
pathway through which calcineurin affects T-BMAL1 protein expression.   
In addition, considering that BMAL1 phosphorylation regulates its fate and transcriptional 
activity, and all is dependent on the protein kinase and phosphatase action, hence the 
phosphorylation site targeting BMAL1.  BMAL1 reported to be phosphorylated on Serine 42 
(Ser42), as well as, at Serine 90 (Ser90) sites, and mutation and/or deletion of either site was 
reported to affect its circadian expression (Tamaru et al.; 2009; Lipton et al., 2015; Tamaru et 
al., 2015; Dang et al., 2016;).  In our study, we investigated the protein expression and 
circadian pattern of phosphorylated BMAL1 at Serine 42 residue (pBmal1-Ser42).  Low 
pBMAL1-Ser42 protein expression levels were observed under control conditions, with a 28-
hour expression pattern across time.  Under raised intracellular [Ca2+] by ATXII treatment, 
pBMAL1-Ser42 protein expression levels significantly increased and presented a 20-hour 
rhythmic pattern.  This was different to the one observed under control conditions, suggesting 
that the raised intracellular [Ca2+] might possibly affect T-BMAL1 expression by affecting its 
phosphorylation levels at Ser42 residue.  In addition, ATXII-induced effects not only 
disturbed pBMAL1-Ser42 protein expression levels across time, but also disrupted its 
rhythmicity by shortening its period which might link to the AF frequency to occur at certain 
time of the day.    
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Also, such pattern was highly disrupted in the presence of NaP inhibitor, Ranolazine, which 
significantly lowered pBMAL1-Ser42 protein expression levels when compare to control and 
ATXII treatments alone.  However, it is not clear whether Ranolazine reversed the ATXII 
effects, possibly due to cell desynchronisation as the effect of serum-shock was lost (van der 
Veen et al, 2012). During serum-shock, these cells are highly synchronised and expressed as 
a ratio at given times, however, with time this dampens and the clock gene, as well as the 
protein become no longer synchronised.  Even though the gene itself is expressed when it 
fades away, the protein expression could equally follow a similar pattern.  To strengthen this, 
it has been reported that following synchronisation under a certain period of time, clock genes 
start exhibiting dampened rhythmicity due to gradual loss of cell synchronisation (van der 
Veen et al., 2012).  Furthermore, significantly high pBMAL1-Ser42 protein expression was 
reported under CAIP treatment (in presence of ATXII). This is different to the literature, 
considering that CAIP inhibits calcineurin activation and subsequently lowering Ca2+ levels; 
hence it was expected to lower pBMAL1-Ser42 protein expression levels.  Such pattern was 
indeed observed under CAIP treatment alone.  Despite the increased expression levels under 
CAIP treatment in presence of ATXII, pBMAL1-Ser42 protein expression oscillated in a 
circadian manner, whereas in presence of CAIP treatment alone pBMAL1-Ser42 presented a 
non-rhythmic pattern with various oscillations across time.   
Thus, taken together our findings from these experiments, the T-BMAL1 protein expression 
changes observed by Ca2+-activated calcineurin, suggests its possible involvement in 
mediating BMAL1 expression in occurrence of AF.  However, further experiments need to be 
conducted for the identification of possible calcineurin phosphorylation target sites on T-
BMAL1, despite the Ser42 residue due to the enhanced levels of expression of BMAL1 
phosphorylated form. Also, considering the lack of studies assessing T-BMAL1 expression in 
the heart, might require further experiments to validate our findings.  Studies performed so far 
in different cell lines, assessed total and phosphorylated BMAL1 expression via 
immunoprecipitation experiments, and reported that BMAL1 expression detected in different 
extend in the nuclear and cytoplasmic compartments (Kondratov et al., 2003; Dang et al., 
2016).  Hence, this can provide further insight in our study considering that higher T-BMAL1 
protein expression levels were reported in the nucleus in comparison to the cytoplasmic 
compartment of the cell.       
4.6.2. Connexins protein expression and rhythmicity under raised 
intracellular [Ca2+] in synchronised HL1-6 total cell lysate  
Atrial arrhythmias, including AF are generated by abnormalities in action potential (AP) 
propagation and conduction.  The gap junctional proteins (Cx43 and Cx40) are vital in the 
regulation of AP propagation, hence key AF contributors (Beauchamp et al., 2006; Jennings 
et al., 2013).  The effects of raised intracellular [Ca2+] on Total Cx43 have been well studied 
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in the ventricles, showing that it facilitates reduction in AP conduction velocity hence, 
decreasing gap junction conductance (Jabr et al., 2016).  Raised intracellular [Ca2+] reduced 
AP conduction velocity, was also reported to reduce Cx43 phosphorylation at Ser365 and 
increased phosphorylation at Ser368 (Jabr et al., 2016).  In addition, the discovery of AF 
circadian variations, suggest the existence of biological clocks in these gap junction proteins 
(Viskin et al., 1999).  Therefore, considering that Cx40 and Cx43, as the predominantly 
expressed proteins in atrial gap junctions, playing a key role in maintaining a regular cardiac 
rhythm, gain of great interest to investigate their circadian involvement in relation to 
occurrence of AF.  
Our results show that T-Cx43 protein expression levels under control conditions are changing 
across time and oscillated with a 20-hour rhythm.  This suggests alterations (increase or 
decrease) of the electrical conductance at gap junctions of atrial myocytes and thus ease of 
cardiac AP propagation through cardiac tissues at different times of the day.  Thus, further 
implying potential diurnal variation in the occurrence of such actions, which is also supported 
in the literature (Bollmann et al, 2000).  Furthermore, these results imply that at the specific 
times, in a distinct period of time when lower gap junction conductance occurs, in our case 
during timepoints 16 and 36 hours following sample serum-shock synchronisation, the AP 
conduction velocity decreased; a predisposing AF risk factor.  Reduced T-Cx43 protein 
expression was observed from 28 hours onwards, which might be a sign that the effect of 
serum-shock starts fading away causing the HL1-6 atrial myocytes to lose their 
synchronisation and subsequently clock gene and protein expression desynchrony.  Clock 
genes were reported to exhibit dampened rhythmicity following synchronisation under a 
certain period of time, due to gradual loss of cell synchronisation (van der Veen et al., 2012).  
Therefore, this suggests that due to the poor synchronisation and the dampening of signals, T-
Cx43 protein expression levels are indeed under the control of clock genes, which further 
supports our hypothesis.  Moreover, ATXII caused a disruption in the T-Cx43 protein 
expression pattern with a 4-hour earlier peak and trough points when compare to control.  This 
can propose that increased intracellular [Ca2+] disrupted the regular T-Cx43 expression 
pattern, as it was shown to oscillate differently when compare to control, providing evidence 
of opening of Nap channel under ATXII treatment and disruption of its potential circadian 
rhythmicity.  The assumption that this is an important factor contributing to the generation of 
AF, is the interference of Bmal1 clock genes rhythmicity in controlling molecular mechanism 
such as T-Cx43 protein expression in atrial gap junctions.  Such pattern was reversed in 
presence of NaP channel inhibitor, Ranolazine, as T-Cx43 experience similar pattern under 
control conditions.  This suggests that Ranolazine reversed the disruptive effects of ATXII 
and partially recovers T-Cx43 protein expression levels, providing evidence that the ATXII-
induced changes in T-Cx43 protein expression were due to raised intracellular [Ca2+].  In 
addition, the use of Ranolazine to modulate the levels of intracellular [Ca2+] and maintain T-
Cx43 rhythmicity in HL1-6 atrial myocytes, further supports the link between atrial 
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electrophysiology and clock gene circadian rhythmicity. Interestingly, Ranolazine, also 
lowered T-Cx43 protein expression when compare to control and ATXII treatment alone.  It 
appears that blocking of the NaP channel, consequently reduces intracellular [Ca
2+] levels but 
also further reduces T-Cx43 expression levels in atrial gap junctions.  However, considering 
that Ranolazine also acts on other ion channels as well (Na+, NaP and K
+), meaning that it 
alters other mechanistic pathways which might have an effect on T-Cx43 life spam, 
trafficking, formation and expression (Dias, et al. 2014).   
The role of calcineurin on T-Cx43 protein expression was also investigated when intracellular 
[Ca2+] was raised by ATXII and decreased by specific calcineurin inhibitor (CAIP), hence 
suggests a potential role for calcineurin, whereas CAIP alone had no effect.  Our data are 
consisted with the reported calcineurin-induced Cx43 phosphorylation (at Ser368) activity 
under raised intracellular [Ca2+] (Jabr et al., 2016).  Jabr et al., (2016) reported calcineurin role 
in Cx43 phosphorylation at Ser365, leading to Cx43 dephosphorylation at Ser68 in raised 
intracellular [Ca2+] ventricular myocardium.  In addition, even though the T-Cx43 protein 
expression observed across time revealed a non-circadian pattern under CAIP treatment (in 
presence of ATXII), the 4-hour shift observed in the peak expression time of T-Cx43 reflects 
a possible contribution of CAIP in reversing ATXII-effects changes.   
Most studies performed investigate the expression of Cx43 as a total protein, like the study 
performed by Tong et al., (2016) who demonstrated T-Cx43 and T-Cx40 circadian 
rhythmicity in atrial and ventricular myocytes. Therefore, our study is also the first to 
investigate the rhythmicity and circadian expression of phosphorylated Cx43 (pCx43-
Ser368), in atrial HL1-6 cell lysates.  Our results showed that pCx43-Ser368 protein 
expression expressed in an almost circadian manner (20 hours) under control conditions, 
suggesting the possible involvement of circadian rhythms in regulating their expression.  In 
addition, low levels of pCx43-Ser368 protein expression were reported under control 
conditions, support the use of a healthy model throughout the experiment.  This is in line with 
the literature as low levels of pCx43-Ser368 protein were reported under healthy physiological 
conditions, whereas high levels of pCx43-Ser368 are known to reduce gap junction 
conductance, a phenomenon observed under pathological conditions (Solan et al., 2007).   
Activation of NaP channels by ATXII, resulted in circadian oscillation of pCx43-Ser368 
protein expression when compare to control conditions.  However, lower pCx43-Ser368 
expression levels were observed when compare to control conditions, thus suggesting that 
raised intracellular [Ca2+] did not increase pCx43-Ser368 amount in atrial cells, but increase 
pCx43-Ser368 percentage.  This is different to the reported high pCx43-Ser368 expression 
observed under pathologic conditions (i.e. raised intracellular [Ca2+]).  Increased pCx43-
Ser368 protein levels reported to reduce cell-to-cell coupling and promote slow AP 
conduction velocity (Lampe et al., 2000).  Raised intracellular [Ca2+] was also reported to be 
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associated with reduced Cx43 phosphorylation at Ser365 site, and increased at Ser368 site 
(Jabr et al., 2016).  In addition, the lack of studies investigating pCx43-Ser368 protein 
expression levels across different timepoints, might require further experiments to validate 
our findings as time has proven to be a crucial factor affecting Cx43-Ser368 phosphorylation 
status.  Furthermore, Ranolazine treatment managed to restore pCx43-Ser368 protein 
expression levels and circadian pattern after ATXII treatment, as it follows similar protein 
expression pattern as the one observed in control conditions, validating the ATXII-effects 
observed earlier.  In addition, lower levels pCx43-Ser368 protein levels following Ranolazine 
treatment strengthen our findings considering the inhibitory activity of Ranolazine against NaP 
channel.   
The investigated effects of CAIP on pCx43-Ser368 protein expression, revealed calcineurin 
involvement in mediating the ATXII-effects observed as it managed to restore pCx43-Ser368 
protein expression levels and circadian pattern.  Raised intracellular [Ca2+] reduced AP 
conduction velocity, was shown to reduce Cx43 phosphorylation at Ser365 site and increased 
phosphorylation at Ser368 site (Jabr et al., 2016).  Such changes were also reversed in 
presence of CAIP and cyclosporine (CysA), calcineurin inhibitors, hence further supporting 
our findings as low pCx43-Ser368 protein expression levels under CAIP treatment.  In 
presence of CAIP alone, pCx43-Ser368 followed almost similar levels of expression across 
time with absence of circadian rhythmicity pattern, further supporting the absence of 
calcineurin effect alone.   
Furthermore, so far, no evidence of inducible arrhythmias were reported in Cx40 wild-type 
models, as studies available revealed increased susceptibility to atrial arrhythmias following 
Cx40 knock-out in mice (Verheule et al., 1999; Hagendorff et al., 1999).  Therefore, our study 
is the first to provide evidence regarding, Cx40 protein expression in relation to AF atrial 
arrhythmias, using HL1-6 atrial myocytes in an in vitro model.  We showed that under control 
conditions, higher T-Cx40 protein expression levels were observed throughout the 48 hours 
when compare to ATXII treatment alone or in presence of NaP inhibitor, Ranolazine.  Similar 
T-Cx40 and T-Cx43 levels were observed following quantification of fluorescent bands under 
control conditions.  This is in line with immunohistochemical staining studies of healthy 
atrium in animals who reported similar expression of Cx40 and Cx43 under physiological 
conditions (Gros et al., 1994; Verheule et al., 1997; van der Velden et al., 1998).  In addition, 
T-Cx40 protein expressed in a 12-hour cycle supporting the absence of circadian rhythmicity 
under control conditions.        
Raised intracellular [Ca2+], changed the overall T-Cx40 expression, by not only slightly 
lowering its protein expression levels but also by causing changes in the dynamics of the 
circadian clock; hence changes in its peaking expression time when compare to control 
conditions.  T-Cx40 protein expression pattern under ATXII treatment alone was different to 
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the one observed under control conditions, suggesting that the raised intracellular [Ca2+] by 
ATXII-induced arrhythmias could disrupt the expression of T-Cx40.  On another note, 
increased Cx40 protein levels and distribution is also correlated with an increased stability of 
AF and the occurrence of structural changes in atrial myocytes, suggesting that the process of 
gap junctional remodelling is involved in AF stabilisation (van der Velden et al., 2000).  With 
increasing time of AF, lower levels of T-Cx40 protein observed, therefore, in future studies 
for true interpretation of T-Cx40 in AF model a shorter time range of ATXII -induced AF 
could be used to complete the picture.  The overall T-Cx40 protein expression levels under 
Ranolazine treatment reduced across time, with absence of circadian pattern observation. 
However, the T-Cx40 protein expression pattern observed was different to the one observed 
under control conditions, indicating Ranolazine inability to fully reverse ATXII effects, which 
further supports its known activity on other ion channels.   
The use of CAIP calcineurin inhibitor (in presence of ATXII), showed that T-Cx40 protein 
expression levels significantly increased when compare to control and ATXII treatment alone.  
However, T-Cx40 protein expression pattern under ATXII/CAIP treatment was partially 
restored in a non-circadian manner over time, as similar protein expression pattern was 
observed under control conditions.  This is in line with Hatch et al., (2015) who showed that 
raised intracellular [Ca2+] increased Cx40 phosphorylation levels and such change was solely 
mediated by calcineurin with partial involvement of PP2A, thus proposing similar pathway 
driving T-Cx40 expression.  However, the low levels observed under ATXII treatment alone 
might suggests further experiments to be conducted in order to support such statement, as well 
as, for the true interpretation of calcineurin effect on the T-Cx40 protein expression.  Also, 
CAIP treatment alone, had no effect on T-Cx40 expression as similar levels where observed 
across time, possibly due to absence of HL1-6 cells synchronisation by serum-shock.   
Furthermore, considering that HL1-6 cells were from mouse atrial tissue, further experiments 
using human atrial tissue samples (obtained from atrial biopsy) will allow strong validation of 
our findings in humans.  Analytical methods to western blot analysis, such as confocal 
microscopy imaging can also be used to investigate possible alterations of cellular connexin 
protein expression localisation, as well as, indication of the degree of connexin 
phosphorylation levels.  Finally, multielectrode arrays (MEAs) can be used to correlate 
connexin lateralisation with action potential conduction velocity measurements across the 48 
hours, hence link possible action potential changes at specific time with connexin levels. 
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4.6.3. Nav1.1., Nav1.5 and Nav1.6 persistent Na+ channels subtypes; protein 
expression and rhythmicity under raised intracellular [Ca2+] in 
synchronised HL1-6 total cell lysate 
The involvement of persistent Na+ (NaP) channels in generation of atrial arrhythmias, 
including AF, are key to improve better understanding of the aetiology of this pathology.  The 
different NaP channel subtypes (Nav1.1., Nav1.5. and Nav1.6.) used in these set of 
experiments show different protein expression oscillatory patterns across time following 
raised intracellular [Ca2+] using ATXII, hence suggesting differing roles in AF occurrence.  In 
addition, the presence of circadian rhythms in these channels will provide further insights of 
the NaP channel ionic behavior (INaP) characterising an action potential that dictates cardiac 
contraction.   
Our findings regarding Nav1.1. channel under control conditions shown promising results 
regarding the protein expression profile of this subtype coinciding with a 20-hour rhythm over 
the 48-hour cycle.  Even though the rhythms observed were maintained by the effect of serum 
and not any other source (i.e. light entrainment, which is also not feasible in in vitro studies), 
proposed that the presence of rhythmically expressed Nav1.1. protein has an endogenous free-
running period which implies the presence of circadian rhythmicity.  A study by I Han et al., 
(2012) reported the presence of Nav1.1. circadian pattern in wild-type mouse model which 
was disturbed (reduced amplitude circadian rhythms) in SCN1A gene (encoding for Nav1.1 
channel) knockout mouse model.  Raised intracellular [Ca2+] induced by ATXII, disturbed 
Nav1.1. channel periodicity and reduced its protein expression levels when compare to 
control.  This is different to the reported mechanism of NaP channel activation, as raised 
intracellular [Ca2+] could be due to NCX exchanger activity which allows Ca2+ influx due to 
cellular Na+ abundance caused by activation of NaP channels, thus suggesting that ATXII was 
unable to fully activate the certain NaP channel subtype.  Also, Nav1.1. expression profile in 
presence of Ranolazine, showed different profile (lower expression) to the one observed under 
control conditions, indicating Ranolazine inability to fully reverse ATXII effects.  
Furthermore, Nav1.1 antibody used detected bands at 33kDa; where Nav1.1. β subunit 
reported to be present, however, other bands were also reported by studies at higher molecular 
weight (Catterall et al., 2010).  Therefore, the lack of availability of specific antibodies to 
probe for Nav subunits is critical in order to be able to provide accurate contribution of each 
subunit to the function of these channels.   
Our findings regarding Nav1.5. channel under control conditions, showed variation over time 
with multiple fluctuations indicating changes in the levels of its protein expression.  Such 
changes could not consider as circadian due to the absence of a 24-hour rhythmic pattern.  
This absence of a circadian pattern might be due to the different processes (post-translational 
modifications; PTMs) involved to produce a protein.  Studies provided evidence that there is 
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a slight difference in time between PTMs and actual protein synthesis, as there are factors (i.e. 
protein stability, half-life) that might interfere with accurate measurement of these 
experiments (Lodish et al., 2000; Vogel and Marcotte., 2012).  Nav proteins in cardiac 
myocytes have extended half-lives (~35 hours), thus the formation and trafficking of these 
channels is expected to have critical impact on overall function of the channel 
(Maltsev et al., 2008).  Additionally, the mammalian rate of mRNA transcription compared 
to protein translation is low (2 mRNAs/ 1 hour), resulting in many protein outcomes which 
could possibly contribute to different levels of expression across the different times (Jansen 
and Pfaffelhuber., 2013).  Nav1.5. protein levels, follow higher expression pattern after 
treatment with ATXII, hence suggesting that raised intracellular [Ca2+] affects SCN5A gene 
expression which governs Nav1.5. channel protein expression.  An increase in Nav1.5. protein 
expression, is also a characteristic of NaP channel behaviour from this subtype, as the release 
of Ca2+ occurs during the plateau phase were NaP channels are active.  Nav1.5. expression 
pattern observed with a 4-hour advanced peak compare to the control conditions providing 
further insights on the mechanism involved between intracellular [Ca2+] level changes and 
clock genes.  The high Nav1.5. expression observed in the presence of Ranolazine following 
ATXII treatment, with similar peaks and troughs as the control group suggests plausible 
antagonistic effect of Ranolazine on recovering ATXII effects.   
The Nav1.6. channel subtype showed that under control conditions, protein expressed over 
time in a non-circadian manner.  This is due to variation in Nav1.6. levels which makes unable 
the protein expression to follow the Nav1.6. gene pattern.  The ATXII treatment alone had no 
effect on Nav1.6. protein expression as similar levels where observed across time.  The 
absence of ATXII effect on Nav1.6. circadian expression in HL1-6 cells might be due to cells 
desynchrony from loss of serum-shock effect, as well as channel subtype specificity in 
different types of cells (Rush et al., 2005; Chen et al., 2008).  A study by Raman et al., (1997) 
showed that in isolated SCN8A (gene encode for Nav1.6. channel) null mice Purkinje cells, a 
70 %-fold reduction in NaP current was observed when compare to wild-type.  However, the 
literature is limited when it comes to atrial cells.  Also, Nav1.6. expression profile under 
ATXII treatment in presence of Ranolazine show oscillations across time in a circadian 
manner (period of 24-hours).  This is different to the pattern observed under control 
conditions, indicating Ranolazine inability to fully reverse ATXII effects.  Also, the absence 
of rhythmic pattern under ATXII treatment alone, makes it unable to fully conclude any 
possible outcomes regarding NaP activation in these channels.   
Further experiments need to be conducted considering the small number of sample replicates, 
which could further support our findings, as well as, contribute to a true conclusion regarding 
the involvement of these current subtypes in AF occurrence. To provide a holistic 
understanding of the behaviour of the channels, functionality tests can be used such as a 
voltage patch clamp technique, whereby the voltage of the cellular membrane is controlled, 
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and the resulting current is recorded, and/or current patch clamp technique where the current 
pass through the controlled cellular membrane and action potential is recorded (Nowotny and 
Marra., 2015).  Thus, providing further information of the association of such currents with 
disturbed propagation of action potential observed in AF events.    
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5.1. Introduction  
Synchronisation of independent/individual molecular clocks of peripheral organs, such as the 
heart, are managed by the suprachiasmatic nucleus, located within the hypothalamus. 
Peripheral clocks display circadian fluctuations of Ca2+ levels in the cytoplasm. However, it 
is uncertain how these changes in Ca2+ levels are related to the circadian transcriptional clock. 
In addition, studies have shown that Ca2+ influx is critical for Per1 and Per2 clock genes 
circadian function in rodents (Lundkvist et al., 2005). Furthermore, CLOCK was reported to 
be phosphorylated by Ca2+-dependent protein kinase C (PKC) inducing Per expression 
following dimerisation with BMAL1 during clock resetting in serum-shocked fibroblasts 
(Shim et al., 2007). Whereas inhibition of Ca2+ influx reported to disrupt upregulation of 
Bmal1 clock gene, and subsequent its protein expression levels in rheumatoid synovial cells 
(Yoshida et al., 2017). Thus, providing further evidence of clock genes association with Ca2+ 
signalling.  
Ca2+ mishandling is a hallmark of cardiac pathologies, including arrhythmias. Raised 
intracellular [Ca2+] mediated by several mechanisms including sustain activation 
(hyperphosphorylation) of persistent Na+ (NaP) channels. Such rise in intracellular [Ca
2+] is 
associated with prolonged action potential duration (APD), early afterdepolarisations (EADS; 
which are considered arrhythmogenic), as well as with direct/indirect effects on gap junctional 
connexin proteins phosphorylation, gap junction electrical conductance and slowed action 
potential conduction velocity. In addition, protein phospathase calcineurin and other several 
Ca2+ responsive signalling pathways have shown to be related to the evolution/development 
of cardiac arrhythmias. Raised intracellular [Ca2+] causes calcineurin activation after its 
binding to a Ca2+ calmodulin (CaM) complex. Calcineurin (Ca2+-CaM dependent serine-
threonine protein phosphatase) activation leads to dephosphorylation of Inhibitor 1 (I1) at 
threonine 35 (Thr35) target site initiating its dissociation from protein phosphatase 1 (PP1), 
which under control conditions are found expressed as a complex, leading to PP1 activation. 
PP1 then causes dephosphorylation of phosphorylated Cx43-Serine 365 (pCx43-Ser365) 
enhanced phosphorylation of Cx43-Ser368 by protein kinase C (PKC), leading to reduced gap 
junction electrical conductance and subsequent facilitation of atrial arrhythmic events. The 
occurrence of atrial arrhythmias reported diurnal pattern, hence suggesting possible 
association with circadian variations (with the clock genes driving it). 
Positive and negative feedback loops at the transcriptional and posttranscriptional level 
influence the molecular core of circadian clocks function and rhythmicity. Driving these daily 
rhythms are the Bmal1 and Clock genes, the two main components of the circadian clock 
molecular machinery (Stow and Gumz., 2011). Upon their cytoplasmic translation, BMAL1 
and CLOCK proteins aggregate as a heterodimer (BMAL1/CLOCK), and directly and 
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indirectly affect the positive and negative feedback loops of the circadian cycle. Following 
translocation of the BMAL1/CLOCK heterodimer into the nucleus, E-box elements are 
activated and a subsequent increase of the transcriptional rates of the period (Per1 and Per2) 
and cryptochrome (Cry1 and Cry2) genes are observed (Ko and Takahashi., 2006; Kondratov 
et al., 2007). Both PER and CRY proteins aggregate (PER/CRY complex) and inhibit the pro-
transcriptional effect of the BMAL1/CLOCK heterodimer in the nucleus, thus decreasing 
Bmal1 transcription rates and create a major negative transcriptional feedback loop. In 
addition, the BMAL1/CLOCK heterodimer induce transcription of Rev-erbα and Rorα genes, 
which have an opposite effect on Bmal1 transcription rate, after their binding to related orphan 
receptor (ROR) elements on Bmal1 promoter region (Ko and Takahashi., 2006). REV-ERBα 
protein will hinder the transcription of Bmal1 (instigating a small negative feedback loop), 
whereas Rorα will activate it (Ko and Takahashi., 2006; Kondratov et al., 2007). Also, the 
circadian clock mechanism is positively regulated by mPER2, reported to hold a positive 
effect on Bmal1 transcription when REV-ERBa inhibition is absent (Shearman et al., 2000). 
In addition, positive feedback loop may result from the de-repression of Bmal1 transcription 
(and eventually stimulation/activation), which arises with possible declining transcription of 
Per, Cry and Rev-erba negative regulators due to absence or decrease in BMAL1/CLOCK 
heterodimers (Reppert and Weaver., 2002).  
Given the above, BMAL1 protein expression and function are essential control features for 
the facilitation of circadian rhythms. The function of clock proteins is regulated and dependent 
on their cellular localisation, stability and break down by ubiquitisation. Interestingly, 
BMAL1 cellular localisation has shown to be tissue type dependent.  For instance, in mouse 
embryonic fibroblasts BMAL1 reported to be mainly localised in the nuclear compartment of 
the cell (Tamaru et al.,2003). Whereas, in hepatocytes moderate BMAL1 expression was 
reported in both, nuclear and the cytoplasmic cellular compartments (Dang et al., 2016).  In 
non-cardiac cells BMAL1 reported to cycle between the nucleus and cytoplasm, in order to 
facilitate CLOCK accumulation in the nucleus (Kondratov et al., 2003; Kwon et al. 2006). 
However, little is known about BMAL1 intracellular localisation and nucleocytoplasmic 
shuttle cycling in cardiac myocytes.  Interestingly, Boateng and Qi (2006) were able to show 
strong CLOCK protein localization in the cardiac myofilaments in correspondence of the Z-
disk. After the generation of contraction in these cells, facilitated by raised intracellular Ca2+, 
an active cross-bridge cycling occurred leading to the presence of CLOCK protein within the 
cytoskeleton. Increased contractile activity with phenylephrine treatment was enough to 
induce enhanced CLOCK protein expression and nuclear translocation, whereas a decrease in 
contractile activity resulted in reduced CLOCK protein nuclear cycling. This proposes that 
the intracellular activity in cardiac myocytes can influence the expression and the subcellular 
distribution of CLOCK protein. In the current case it could definitely be argued that the effect 
on BMAL1 is indirect since the effects of altered metabolic or mechanical activity on BMAL1 
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are unknown in the heart. However, CLOCK heterodimerise with BMAL1 to induce the 
transcription of their target genes after biding to their E-box, therefore, similar decreased 
nuclear translocation may be observed after inhibiting contractile activity and subsequently 
Ca2+ levels in atrial myocytes.   
Rhythmic phosphorylation (at specific sites) of clock proteins appears to be a crucial step for 
regular clock function (Tamaru et al., 1999; Tamaru et al., 2003; Tomita et al., 2005; Tamaru 
et al., 2009). Among the different clock proteins, BMAL1 is the only one that undergoes an 
extensive repertoire of posttranslational modifications (PTMs) including phosphorylation (at 
a specific sites), ubiquitination and acetylation (Hirayama et al., 2007; Mehra et al., 2009; Lee 
et al., 2001). Supposedly, the BMAL1/CLOCK dimerisation induces the phosphorylation, 
facilitating their nuclear localisation and certainly leading to the degradation of each protein. 
On further mutational analysis BMAL1 was shown to contain highly conserve functional 
nuclear localization signals (NLS) in its N-terminal and a nuclear export signal (NES) in its 
PAS domain, allowing it to shuttle across the nuclear membrane to permit the nuclear 
accumulation of CLOCK (Kwon et al., 2006). This process was shown to regulate BMAL1 
shuttling between the nucleus and the cytoplasm, which is crucial for the BMAL1/CLOCK 
circadian function and for the transcription of their target genes (i.e. Per, Cry).  In addition to 
the findings on circadian regulation, heterodimerisation and nuclear translocation of 
BMAL1/CLOCK can be rapidly induced within one hour by serum shock synchronisation 
stimulus (Balsalobre et al., 1998; Shim et al., 2007). Also, BMAL1 phosphorylation and 
dephosphorylation cellular localisation varies among cell types. For example, in fibroblasts 
it’s been shown that BMAL1 phosphorylation and/or dephosphorylation are restricted to the 
nucleus, only whereas BMAL1 in the cytoplasm is not subjected to PTMs by phosphorylation 
(Tamaru et al.,2003).  On the other hand, in mouse liver, BMAL1 reported to be similarly 
phosphorylated in both, nuclear and cytoplasmic cellular compartments (Lee et al., 2001; 
Dang et al., 2016).  
Phosphorylation of BMAL1 regulates its fate, transcriptional activity and cellular localisation, 
and all is dependent on the protein kinase action; hence the targeted BMAL1 phosphorylation 
site. Up to date, BMAL1 found to be phosphorylated (at different serine and/or threonine 
residues) in vitro by several kinases which cause changes to its cellular distribution, including 
casein kinase 2α (CK2α), protein kinase B (Akt) and casein kinase 1ε/δ (CK1ε/δ) (Eide et al., 
2002; Tamaru et al., 2015; Robles et al.; 2010). A study by Tamaru et al., (2015) reported that 
CK2α rhythmically phosphorylates BMAL1 at Ser90 and promotes its nuclear entry, essential 
for regulating the mammalian circadian clock. Interestingly, CK2α hyperphosphorylation of 
BMAL1 protein in CRY-deficient mice, propose that BMAL1 modification might be 
contributed to CRY proteins (Lee et al., 2001; Tamaru et al., 2003).  The alteration and/or 
reduction of CK2alpha phosphorylation site on BMAL1 (ser90) have an adverse effect on the 
nuclear BMAL1 circadian accumulation and results in a loss of circadian rhythmicity (Tamaru 
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et al.; 2009). Yet, the molecular mechanism underlying rhythmic phosphorylation of 
mammalian clock proteins remains elusive.  In contrast Dang et al., (2016) provide evidence 
that BMAL1 transcriptional activity is regulated by insulin, through a reduction of BMAL1 
nuclear accumulation. The nuclear accumulation is altered via AKT-mediated Serine 42 
(Ser42) phosphorylation in the liver; hence promoting BMAL1 accumulation in the cytosol 
and facilitation of protein synthesis. Moreover, a recent study by Young et al., (2017) showed 
that genetic disruption of the cardiomyocyte circadian clock resulted in subsequent changes 
in gene and protein expression of multiple insulin signalling components, leading to a chronic 
activation of the Akt/mTOR/S6K signalling, elevated BMAL1 protein synthesis in the cytosol 
and cardiac size, hence subsequent circadian disruption. 
In addition, even though CK1ε/δ was reported to induce BMAL1 phosphorylation and 
mediated transcription after nuclear entry, the phospho-acceptor sites of BMAL1 have not yet 
been identified (Eide et al., 2002).  Furthermore, CK1ε/δ are essential PER kinases, causing 
PER phosphorylation and targeting them for proteasomal degradation.  Such process is 
negatively regulated by PP1-mediated dephosphorylation (Gallego et al., 2006).  In CK1ε/δ 
deficient cells, the phosphorylation of PER was nonrhythmic and severely compromised. 
Moreover, the PER proteins were mainly localised in the cytoplasm. However, upon PP1 
disruption, a significant increase of PER phosphorylation speed was; such an effect could not 
be observed upon PP2A disruption (Lee et al., 2011). Inhibition of PP1 accelerated PER 
degradation results in BMAL1 overexpression, due to mishandling of BMAL1 acetylation and 
repression of the negative feedback loop. Additionally, a further study by Schmutz et al., 
(2011) reported a modest effect of PP1 inhibition on BMAL1 nuclear accumulation, 
demonstrating that PP1 may affect BMAL1 concentrations. PP1 may induce epigenetic 
modifications on the transcriptional machinery resulting in changes of BMAL1 levels. In all 
studies mentioned above it is obvious that the identity of protein kinases and phosphatases 
modulating BMAL1 phosphorylation are far from clear. In addition, the phosphorylation 
cellular sites and hence function of BMAL1 in cardiac myocytes is still unknown.  On that 
note, PP1 is known to be activated by Ca2+ independently through calcineurin mediated 
pathways.  Jabr et al., (2016) showed, that under raised intracellular [Ca2+] levels, calcineurin 
gets activated and cause dephosphorylation on Inhibitor 1 (I1) at Thr35. This results in PP1 
dissociation from I1, which under control conditions are found in close proximity, and 
subsequent activation. PP1 activation modulate action potential conduction, by decreasing gap 
junction electrical conductance which is considered a proarrhythmic factor. Therefore, 
considering that BMAL1 phosphorylation and dephosphorylation cellular localisation varies 
among cell types and the fact that it shuttles between cytoplasm and nucleus, and that’s under 
the influence of kinases (CK1ε/δ, CK2 etc) and PP1 indirectly, we thought that it was possible 
that there could be an interaction between BMAL1 and calcineurin, leading to or mediating 
atrial arrhythmic events, such as AF.            
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In summary, the mRNA and protein levels of BMAL1 in peripheral clock cells, as well as in 
the SCN, reported robust oscillation in a circadian manner via direct or indirect regulation of 
its own expression though feedback loops (Abe et al., 1998; Oishi et al., 2000; Tamaru et al., 
2000., Tamaru et al., 2003; Tamaru et al., 2010).  However, the molecular events that cause 
these fundamental feedback loops to oscillate in a stable manner with an approximate 24-hour 
periodicity are still unclear.  Additionally, immediate complete arrhythmic wheel-running 
activity reported in Bmal1 knockout (-/-) mice in constant darkness, implying that BMAL1 is 
an essential and non-redundant component in the mammalian molecular clock (Bunger et al., 
2000).  This suggests that the regulatory events that control its localisation and/or activation 
are key components that possibly drive circadian’s clock stable 24-hour periodicity.  BMAL1 
shuttling oscillatory pattern inside the nuclear and/or cytoplasmic cellular compartments can 
therefore provide further insights. Finally, considering that temporal regulation of the 
subcellular localisation and phosphorylation of the BMAL1 protein, served as crucial time-
delay events, it gain great interest of investigating whether Ca2+ homeostasis changes during 
AF occurrence, and subsequent changes in gap junctional connexin phosphorylation status, as 
well as, activation of Ca2+-related phosphoproteins (i.e. calcineurin), are linked with changes 
in BMAL1 subcellular localisation and/or nucleocytoplasmic shuttling.  Such changes will 
further imply direct effect on BMAL1 phosphorylation status allowing it to oscillate in a stable 
or non-stable circadian manner in serum-shocked HL1-6 cardiac myocytes.  A possible impact 
on BMAL1 subcellular localisation may also provide further insights of the timing that AF 
occurs and the location of BMAL1 during that time, as well as, its involvement in the 
development of possible Ca2+-activated feedback loop during atrial arrhythmias.        
5.2. Aim 
To investigate the effect of raised intracellular Ca2+ concentration ([Ca2+]i) by 1 nM ATXII 
on Total BMAL1 (T-BMAL1) and nuclear cellular localisation in synchronised HL1-6 atrial 
myocytes within 48 hours, using immunofluorescence and confocal microscopy techniques.  
5.3. Objectives 
1. Investigate nuclear cellular localisation of Total BMAL1 (T-BMAL1) protein 
expression under control conditions in synchronised HL1-6 cells within 48 hours using 
immunofluorescence and confocal microscopy. 
2. Assess the effects of raised [Ca2+]i conditions on T-BMAL1 protein nuclear cellular 
localisation in synchronised HL1-6 cells within 48 hours using immunofluorescence 
and confocal microscopy.  This was achieved by quantifying T-BMAL1 protein 
expression under the following conditions: 
i. ATXII (1 nM), to raise [Ca2+]i            
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ii. ATXII (1 nM) in presence of Ranolazine (10 µM), to inhibit NaP channels 
iii. ATXII (1 nM) in presence of BAPTA-AM (5 µM), Ca2+ chelator 
3. Assess the effects of calcineurin (CaN) in control and raised [Ca2+]i conditions on T-
BMAL1 protein nuclear cellular localisation in synchronised HL1-6 cells within 48 
hours.  This was achieved by quantifying T-BMAL1 protein expression using the most 
selective calcineurin autoinhibitory peptide (CAIP, 25 µM) inhibitor, in presence and 
absence of 1 nM ATXII. 
5.4. Methods and experimental protocols 
The experimental protocol, methodology, confocal acquisition and images analysis used in 
this section have been extensively described in chapter 2 (see section 2.12.), but a brief 
description of the specific protocols and an overview of the rationale are given here.  
5.4.1. Total BMAL1 (T-BMAL1) nuclear localisation using 
immunofluorescence and confocal microscopy 
HL1-6 atrial myocytes were seeded (1.0 x 107 cells/well) on Poly-D-lysine coated-glass 
coverslips (placed on a 12-well plate) for 24 hours prior to experimental day.  The next day 
the cells were synchronised for 2 hours with serum-shocked Claycomb medium (see section 
2.4.) (Control group), which was then replaced with complete Claycomb medium.  The cells 
were fixed with PBS solution containing 4 % paraformaldehyde, just before serum-shock 
effect (0 hours), immediately after serum-shock synchronisation (2 hours) and every 4 hours 
for 48 hours (from 12 hours onwards, avoiding serum-shock peak which based on our previous 
experiments shown to appear between 8-12 hours post serum-shock treatment).  The cells 
were then permeabilised and blocked with PBS containing 0.1 % Triton x-100 and 1 % Bovine 
Serum Albumin (BSA).  Immunolabelling was based on cells incubation with the primary 
rabbit monoclonal anti-BMAL1 antibody (1:250 dilution in blocking buffer) for 24 hours at 4 
ºC (fridge), and with goat anti-rabbit IgG secondary antibody (FITC)/Alexa Fluor® 488 
(green fluorescent label; 1:1000 dilution in blocking buffer) for 1 hour at room temperature in 
humidified-chamber.  The cells were then washed with PBS and counter stained with nuclear 
dye using a drop of Vectashield mounting medium containing DAPI allowing nuclear 
visualisation (blue fluorescent label).  Each glass coverslip was sealed using nail polish on a 
glass slide and stored in the dark at 4°C. Similar protocol was used on cells (from similar 
passages used in control) treated with 1 nM ATXII alone or in combination with 10 µM 
Ranolazine or 5 µM BAPTA-AM or 25 µM CAIP.  
The prepared slides were then examined and imaged using Nikon A1M confocal microscope 
with NIS elements acquisition software.  The microscope was fitted with lasers and suitable 
filter blocks for detection of blue fluorescence of DAPI (nucleic acid staining; 358/461 nm) 
and green fluorescence of FITC (T-BMAL1 cellular localisation; 495/519 nm).  The slides
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were viewed under x20, x40 and x60 microscope objective magnifications, however only x40 
magnification pictures are presented.  Total and nuclear BMAL1 fluorescence was assigned 
by wavelength/colour to BMAL1 antibody detected (mean fluorescent intensity (MFI)).  
BMAL1 was expressed as a Total, as well as a percentage (%) of nuclear fraction expression.  
Data were analysed using two-way ANOVA (analysis of variance) to test the overall 
divergence between the treated and the untreated (control) groups and the effect of time (0-48 
hours), followed by post-hoc analysis of significant main and interaction effects using 
Bonferroni multiple pairwise comparison test.  A cosine curve was also fitted allowing period 
determination on the best fit of this cosine curve, by fitting data of 24 hour (estimated time 
for a complete cycle) prior to the different treatment conditions.  
 
5.5. Results 
5.5.1. Nuclear localisation of Total BMAL1 (T-BMAL1) in synchronised 
HL1-6 atrial myocytes 
In synchronised HL1-6 cells, Total BMAL1 (T-BMAL1) protein fluorescence intensity was 
investigated in the nuclear compartment of the cell.  The levels of T-BMAL1 fluorescent 
expression fluctuated across time following serum-shock synchronisation.  Lower nuclear T-
BMAL1 fluorescent intensity reported prior serum-shock synchronisation (0 hours), and 
immediately after the end of serum-shock (2 hours) incubation time, increased fluorescent 
intensity was observed.  Similarly, high T-BMAL1 fluorescent intensity levels were observed 
between 12 and 20 hours post serum-shock synchronisation (see representative confocal 
image in Figure 5.1.), whereas reduced nuclear localisation reported at 24 hours followed by 
increased T-BMAL1 nuclear localisation at 28 hours.  32 hours following serum-shock effect, 
T-BMAL1 nuclear localisation was reduced followed by a fluorescent rise at 36 hours.  
Whereas, similarly, high levels of fluorescent expression were reported from 40 hours until 
the end (48 hours) of serum-shock effect (Figure 5.1.).   
 
 
 
 
 
 
 
 
 
Figure 5.1. Nuclear localisation of Total BMAL1 (T-BMAL1) in synchronised HL1-6 atrial myocytes 
under control conditions.  Representative immunofluorescent confocal laser scanning microscopic images of 
HL1-6 cells showing T-BMAL1 protein expression and cellular localisation at specific times, following 50 % 
serum-shock synchronisation.  The cells were immunostained with the T-BMAL1 primary antibody (rabbit 
20 hours 
24 hours 
16 hours 40 hours 44 hours 
50 µm 50 µm 50 µm 50 µm 
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monoclonal anti-BMAL1 antibody; 1:250) and visualised with the secondary antibody goat anti-rabbit IgG 
secondary antibody (FITC 1:1000, green)/Alexa Fluor® 488.  Nuclei were visualised with the nuclear stain, 
DAPI (blue).  High nuclear BMAL1 localisation was observed at 16 and 20 hours, and lower nuclear BMAL1 
localisation at 40 and 44 hours following serum-shock synchronisation.  
 
We then continued by assessing the total cellular localisation of T-BMAL1 protein expression 
in cultured synchronised HL1-6 cells.  The mean quantified T-BMAL1 fluorescence intensity, 
was calculated after specific times following cell synchronisation (0, 2, 12, 16, 20, 24, 28, 32, 
40, 44 and 48 hours).  The starting time was chosen to be 12 hours at which the serum-shock 
effects are minimal on cellular signalling pathways and all peripheral clock genes, including 
Bmal1 are ensured to be synchronised.  As Figure 5.2. shows, the mean T-BMAL1 cellular 
fluorescence intensity under control condition exhibits peaks and trough levels.  T-BMAL1 
expression oscillatory pattern did not exhibit circadian rhythmicity (12.12±0.32 hours) 
following cosine curve fitting (Figure 5.2.).  The one-way ANOVA test show significant 
overall time effect (p<0.0001) under control conditions, with clear oscillations in mean T-
BMAL1 cellular fluorescent intensity under control conditions. T-BMAL1 cellular 
localisation protein expression peaks were observed at 16 (2524.38±25.58; p<0.05), 24 
(3080.27±19.50; p<0.01), 32 (3045.34±17.75; p<0.01) and 44 (2875.66±27.89; p<0.05) 
hours.  Whereas, obvious drops were observed at 20 (2126.66±14.95) and 28 (2030.26±13.06) 
hours. T-BMAL1 cellular localisation levels declined following 36 hours serum-shock 
synchronisation and similar levels were observed until the end of the serum-shock effect (48 
hours).  Interestingly, significant difference (p<0.0001) was observed prior serum-shock 
treatment (0 hours) and post synchronisation at 2 hours revealing initial effects of serum-shock 
synchronisation.  
 
 
 
 
 
 
 
 
* 
** ** * 
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Figure 5.2. Mean fluorescence intensity (MFI) of total cellular BMAL1 (T-BMAL1) in synchronised HL1-
6 atrial myocytes, under control conditions.  Mean T-BMAL1 fluorescence intensity (line graph; black colour) 
was calculated at various time points, starting from 12 hours following serum-shock synchronisation. A cosine 
curve (grey colour) was also fitted to assess the presence of circadian rhythmicity. Data expressed as 
Mean±SEM; N=3 cells. * p<0.05, ** p<0.01 
 
Given the observed oscillatory pattern of the T-BMAL1 fluorescence intensity (Figure 5.2.), 
we have further investigated its nuclear distribution within 48 hours following serum-shock 
synchronisation (Figure 5.3.).  This was achieved by quantifying the fluorescence intensity 
(from acquired confocal images) of BMAL1 in the nucleus following the use of specific 
nuclear staining dye; DAPI.  Such expression was then normalised to its total intensity and 
expressed as a percentage (%) of fluorescence intensity of T-BMAL1.  As Figure 5.3. shows, 
BMAL1 started to become more visible in the nucleus at 16 hours (61.61±5.11%) and at 20 
hours (nuclear 60.21±4.09%) based on the quantified fluorescent intensity.  At 24 hours 
BMAL1 nuclear fluorescent intensity significantly decreased for the first time (47.59±2.85%), 
whereas its fluorescent intensity rise again 4 hours later (28 hours; 60.80±3.69%).  Despite 
the second nuclear BMAL1 localisation drop at 32 hours (49.26±2.85%), towards the end of 
serum-shock effect (from 36 hours up to 44 hours) high BMAL1 localisation inside the nuclear 
cellular compartment was clearly stated.  Also, 48 hours post serum-shock synchronisation, 
BMAL1 fluorescent intensity was as low (51.36±2.06%) as the one observed during 24 and 
32 hours.  
 
 
 
 
 
 
 
 
Figure 5.3. Quantification analysis of time-dependent nuclear BMAL1 protein expression in synchronised 
HL1-6 atrial myocytes, under control conditions.  Mean percentage (%) of HL1-6 cells showing nuclear 
staining as indicated in bar chart.  The BMAL1-expressing cells were analysed by NIS elements acquisition 
software.  Nuclear fraction expression of BMAL1 localisation is presented as (%) Mean±SEM of total fraction 
expression.    
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5.5.2. Effects of ATXII on nuclear localisation of Total BMAL1 (T-BMAL1) 
in synchronised HL1-6 atrial myocytes 
The effect of raised intracellular [Ca2+]i by NaP channel opener ATXII on Total BMAL1 (T-
BMAL1) cellular localisation following serum-shock synchronisation was further assessed.  
T-BMAL1 protein fluorescence intensity observed in the cell, was affected by the time Bmal1 
treated with 1 nM ATXII, following 50 % serum-shock synchronisation.  In particular, as the 
representative confocal images of immunostained HL1-6 show (Figure 5.4.), T-BMAL1 was 
highly localised into the nuclear cellular compartment from 2 hours up to 24 hours of treatment 
with ATXII.  At 28 hours T-BMAL1 nuclear fluorescent intensity significantly reduced and 
was the lowest for the first time since ATXII treatment, followed by a rapid increase of 
fluorescent intensity at 32 hours up until 44 hours.  Towards the end of ATXII treatment effect 
(48 hours), T-BMAL1 nuclear fluorescent intensity was again significantly reduced for the 
second time.  
 
 
 
 
 
 
 
 
Figure 5.4. Nuclear localisation of Total BMAL1 (T-BMAL1) in synchronised HL1-6 atrial myocytes 
under 1 nM ATXII.  Representative immunofluorescent confocal laser scanning microscopic images of serum-
shocked synchronised HL1-6 cells showing T-BMAL1 protein expression and cellular localisation at specific 
times following ATXII treatment.  The cells were immunostained with the T-BMAL1 primary antibody (rabbit 
monoclonal anti-BMAL1 antibody; 1:250) and visualised with the secondary antibody goat anti-rabbit IgG 
secondary antibody (FITC 1:1000, green)/Alexa Fluor® 488.  Nuclei were visualised with the nuclear stain, 
DAPI (blue).  Lower nuclear BMAL1 localisation observed at 2 and 12 hours, and high nuclear BMAL1 
localisation reported at 20 and 24 hours following serum-shock synchronisation. 
 
We then continued by assessing the total cellular localisation of T-BMAL1 protein expression 
in cultured synchronised HL1-6 cells following treatment with ATXII.  Figure 5.5. shows the 
effect of ATXII on the mean T-BMAL1 cellular fluorescence intensity (reflecting its 
localisation) for 48 hours. The mean quantified T-BMAL1 fluorescence intensity, was 
calculated and presented after specific times (0, 2, 12, 16, 20, 24, 28, 32, 40, 44 and 48 hours) 
following cell treatment.  In ATXII treated cells, the mean total T-BMAL1 protein expression 
showed variation in a time-dependent manner (Figure 5.5.).  However, such variation could 
not be considered as circadian due to the absence of 24-hour periodicity following cosine fit 
(10.98±0.45 hours).  Furthermore, a 4-hour later peak (at 20 hours) was observed under 1 nM 
20 hours 24 hours 2 hours 12 hours 
50 µm 50 µm 50 µm 50 µm 
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ATXII in T-BMAL1 cellular localisation when compared to the untreated cells (at 16 hours). 
The one-way ANOVA test show significant overall time effect (p<0.0001) under 1 nM ATXII 
treatment.  For example, the mean T-BMAL1 fluorescence intensity peaked at timepoints 20 
(2315.18±18.66; p<0.05) and 28 (3929.70±19.14; p<0.001) hours, with the later peak been 
significantly higher compare to its first peak.  Following that, the T-BMAL1 cellular 
localisation expression significantly dropped at 32 (2280.48±16.54) hours and kept at lower 
levels until the end of 48 hours.  Interestingly, significant difference was observed prior 
serum-shock treatment (0 hours, 2207.11±2656; p<0.0001) and post synchronisation at 2 
hours (1914.99±21.63; p<0.0001) revealing initial effects of serum-shock synchronisation.  
Whereas, no significant difference (p>0.05) was observed between 2 and 12 hours under 
ATXII treatment, as observed under control conditions. 
The effects of ATXII compare to control conditions on T-BMAL1 cellular localisation at 
tested times were assessed using two-way ANOVA test, where both time and drug effects 
were assessed as to simultaneously occurring variables (interaction effect p<0.0001).  In terms 
of difference of T-BMAL1 cellular localisation between ATXII-treated and untreated 
(control) cells, was observed at 2 (immediately after synchronisation), 12, 16, 20, 24, 28, 32, 
36, 40, 44 and 48 hours (post-synchronisation). Additionally, when T-BMAL1 cellular 
localisation expression peaked in control cells at 16 hours it troughed under ATXII treatment 
(Control 2524.38±SEM vs ATXII 1842.90±SEM; p<0.0001).  Similar observation was 
reported at 24 hours (Control 3080.27±235.65 vs ATXII 1876.05±134.22; p<0.0001).  On the 
other hand, when T-BMAL1 cellular localisation peaked at 28 hours in ATXII-treated cells it 
troughed under control conditions (Control 2030.26±SEM vs ATXII 3929.70±SEM; 
p<0.0001).  Similarly, opposite T-BMAL1 cellular localisation expression levels between the 
two treatments was reported from 32 hours up to 48 hours (Figure 5.10.).   
* 
**
* 
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Figure 5.5. Mean fluorescence intensity (MFI) of total cellular BMAL1 (T-BMAL1) in synchronised HL1-
6 atrial myocytes, under 1 nM ATXII treatment.  Mean T-BMAL1 fluorescence intensity (line graph; black 
colour) was calculated at various time points, starting from 12 hours following serum-shock synchronisation. A 
cosine curve (red colour) was also fitted to assess the presence of circadian rhythmicity. Data expressed as 
Mean±SEM; N=3. * p<0.05, *** p<0.001 
 
Given the observed oscillatory pattern of the T-BMAL1 fluorescence intensity under ATXII 
treatment (Figure 5.5.), we then continued to test the differential cellular BMAL1 fluorescence 
intensity and localisation in the nuclear compartment of the cell (Figure 5.6.).  In presence of 
NaP channel opener ATXII, nuclear BMAL1 localisation showed a different pattern, when 
compare to untreated control cells.  Significantly higher BMAL1 fluorescent intensity levels 
reported in the nuclear cellular compartment under ATXII treatment throughout the two 
circadian cycles (48 hours) in comparison to serum-shock effect alone (control conditions).  
More specifically, extremely high BMAL1 fluorescent intensity was observed in the nucleus 
for up to 24 hours following ATXII treatment.  Interestingly BMAL1 nuclear localisation was 
also the highest at 24 hours among the different timepoints (69.20±43.76%).  Four hours later 
(at 28 hours), a rapid decrease in BMAL1 nuclear fluorescent intensity was observed 
(50.22±3.00%).  This is opposite to the untreated (control) cells, were lower nuclear BMAL1 
localisation was observed at 24 hours (47.49±3.19%) followed by an increase in BMAL1 
fluorescent intensity at 28 hours (60.80±3.69%) (Figure 5.3.).     
Following the rapid drop of BMAL1 nuclear localisation at 28 hours, BMAL1 nuclear 
fluorescent intensity increased at 32 hours (58.72±5.41%) under ATXII treatment.  Similarly, 
high nuclear fluorescent intensities were also reported for at least 8 more hours of treatment 
(36-44 hours).  Towards the end of serum-shock effect (48 hours), significantly low BMAL1 
nuclear localisation was observed (48.92±4.58%).  Also, it is worth stating that similarly low 
nuclear localisation was reported at 28 hours (50.22±3.00%), were BMAL1 was the lowest 
for the first time.  
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Figure 5.6. Quantification analysis of time-dependent nuclear Total BMAL1 (T-BMAL1) protein 
expression in synchronised HL1-6 atrial myocytes, under 1 nM ATXII treatment.  Mean percentage (%) of 
HL1-6 cells showing nuclear staining as indicated in bar chart graph.  The BMAL1-expressing cells were 
analysed by NIS elements acquisition software. Nuclear fraction expression (blue) BMAL1 localisation is 
presented as (%) Mean±SEM of total fraction expression.  
 
In order to, test whether Ranolazine may reverse or prevent the ATXII-induced disruption of 
T-BMAL1 nuclear cellular localisation, HL1-6 cells were treated with 1 nM ATXII in 
combination with 10 µM Ranolazine, following 50 % serum-shock synchronisation.  At 0 
horus (prior serum-shock synchronisation), high nuclear T-BMAL1 localisation was observed 
followed by a reduced fluorescent intensity after 2 hours of serum-shock synchronisation and 
beginning of treatment with ATXII/Ranolazine.  From 12 hours and up to 20 hours post 
ATXII/Ranolazine treatment, similar T-BMAL1 protein fluorescent intensity was observed 
(Figure 5.7.), followed by reduced fluorescent intensity at 24 hours.  Whereas from 28 hours 
and up to 48 hours post treatment time, increased T-BMAL1 fluorescent intensity reported in 
the nucleus with peak nuclear localisation at 40 hours.   
 
 
 
 
 
Figure 5.7. Nuclear localisation of Total BMAL1 (T-BMAL1) in synchronised HL1-6 atrial myocytes, 
under 1 nM ATXII treatment in combination with 10 µM Ranolazine.  Representative immunofluorescent 
50 µm 50 µm 
44 hours 
50 µm 
Chapter 5. BMAL1 nuclear localisation 
 
201 | P a g e  
 
confocal laser scanning microscopic images of serum-shocked synchronised HL1-6 cells showing T-BMAL1 
protein expression and cellular localisation at specific times following 1 nM ATXII/10 µM Ranolazine 
treatment.  The cells were immunostained with the T-BMAL1 primary antibody (rabbit monoclonal anti-BMAL1 
antibody; 1:250) and visualised with the secondary antibody goat anti-rabbit IgG secondary antibody (FITC 
1:1000, green)/Alexa Fluor® 488.  Nuclei were visualised with the nuclear stain, DAPI (blue).  High nuclear 
BMAL1 localisation observed at 20 hours and lower BMAL1 localisation reported at 2, 12 and 44 hours 
following serum-shock synchronisation.  
 
We then continued by assessing the total cellular localisation of T-BMAL1 protein expression 
under 1 nM ATXII treatment in presence of 10 µM Ranolazine.  Figure 5.8. shows the effect 
of ATXII/Ranolazine, on the mean T-BMAL1 cellular fluorescence intensity (reflecting its 
localisation) for 48 hours.  The mean T-BMAL1 protein expression showed variation in a 
time-dependent manner, however, such variation could not be considered as circadian due to 
the absence of 24-hour periodicity after cosine curve fitting (10.65±0.67 hours) (Figure 5.8.).    
One-way ANOVA test show significant overall time effect (p<0.0001) under 1 nM ATXII/ 
10 µM Ranolazine treatment.  Mean T-BMAL1 cellular fluorescence intensity peaked at 24 
(3168.54±27.00; p<0.001), 32 (2063.89±22.93; p<0.05) and 40 (2186.92±30.15; p<0.05) 
hours, with 8-hour difference respectively and the 24-hour peak been the highest among the 
other two ones (Figure 5.8.). Mean T-BMAL1 cellular fluorescence intensity troughed at 12 
(1964.97±16.51), 28 (1891.85±20.57) and 44 (1984.13±18.74) hours.  Similarly, to control 
and ATXII-treated cells, significant difference was observed prior serum-shock treatment and 
2 hours post synchronisation (p<0.0001) (Figure 5.10.).   
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Figure 5.8. Mean fluorescence intensity (MFI) of total cellular BMAL1 (T-BMAL1) in synchronised 
HL1-6 atrial myocytes, under 1 nM ATXII treatment in combination with 10 µM Ranolazine.  Mean 
T-BMAL1 fluorescence intensity (line graph; black colour) was calculated at various time points, starting 
from 12 hours following serum-shock synchronisation. A cosine curve (blue colour) was also fitted to assess 
the presence of circadian rhythmicity. Data expressed as Mean±SEM; N=3. * p<0.05, *** p<0.001 
 
In addition, the presence of Ranolazine has indeed minimised and almost prevented the ATXII 
effects on the mean total cellular T-BMAL1 fluorescence intensity for at least 28 hours when 
compared to control (Figure 5.10.).  The levels of T-BMAL1 cellular fluorescence intensity 
varied among the two conditions, as well as, time points (interaction effect p<0.0001).  In 
terms of difference of T-BMAL1 cellular localisation between control and ATXII/Ranolazine-
treated cells, was observed at 0 (pre-synchronisation), 2 (immediately after synchronisation), 
12, 16, 20, 28, 32, 36, 40, and 44 hours (post-synchronisation).  Up to 28 hours the two 
treatments reported similar T-BMAL1 cellular fluorescence intensity pattern, whereas from 
32 hours (Control 3045.34±17.75 vs ATXII/Ranolazine 2063.89±22.93; p<0.0001), 36 hours 
(Control 2507.44±24.04 vs ATXII/Ranolazine 1723.40±17.43; p<0.0001), 40 hours (Control 
2615.94±14.15 vs ATXII/Ranolazine 2186.92±30.15; p<0.0001) up to 44 hours (Control 
2875.67±27.89 vs ATXII/Ranolazine 1984.13±18.74; p<0.0001) T-BMAL1 showed higher 
cellular fluorescence intensity under control conditions when compared to ATXII/Ranolazine 
treatment (Figure 5.10.).  
Also, the levels of T-BMAL1 cellular fluorescence intensity varied among 1 nM ATXII 
treatment alone and in presence of 10 µM Ranolazine, as well as, time points (interaction 
effect p<0.0001). Two-way ANOVA test showed significant difference between ATXII and 
ATXII/Ranolazine-treated T-BMAL1 cellular fluorescence intensity at 0, 2, 16, 20, 24, 28, 
32, 40, 44 and 48 hours.  Interestingly, when T-BMAL1 cellular localisation expression 
peaked in ATXI/Ranolazine-treated cells at 16 hours (ATXII 1842.90±13.67 vs 
ATXII/Ranolazine 2428.46±22.76; p<0.0001) and 24 hours (ATXII 1876.05±11.11 vs 
ATXII/Ranolazine 3168.54±27.00; p<0.0001), it troughed under ATXII treatment alone 
(Figure 5.10.).  Whereas, ATXII-treated cells experience higher T-BMAL1 cellular 
fluorescence intensity at 28 hours (ATXII 3929.69±19.14 vs ATXII/Ranolazine 
1891.85±20.57; p<0.0001), and this is opposite to ATXII/Ranolazine treated cells were T-
BMAL1 cellular fluorescence intensity troughed.  Similar T-BMAL1 cellular localisation 
expression pattern between the two treatments was reported from 32 hours up to 48 hours 
(Figure 5.10.).   
Given the observed oscillatory pattern of the T-BMAL1 fluorescence intensity under 
ATXII/Ranolazine treatment (Figure 5.8.), we then continued to test the differential cellular 
BMAL1 fluorescence intensity and localisation in the nuclear compartment of the cell (Figure 
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5.9.). Significantly high BMAL1 fluorescent intensity levels were reported in the nuclear 
cellular compartment under Ranolazine treatment at most timepoints post-synchronisation, 
similarly to ATXII treatment.  As Figure 5.9. shows, high BMAL1 fluorescent intensity was 
reported in the nuclear cellular compartment at 0 hours (pre-synchronisation timepoint), 
whereas immediately after synchronisation (2 hours), a significant drop in BMAL1 nuclear 
localisation was reported for the first time (32.74±6.75%). This is different to BMAL1 
localisation under control and ATXII-treated cells, which reported high nuclear localisation 
immediately after serum-shock effect (Figure 5.3. & Figure 5.6.).   
Following that, similarly high nuclear BMAL1 localisation was observed at timepoints 12, 
16, 20, 28, 32, 36, 40 and 44 hours, followed by a drop in BMAL1 fluorescent intensity 
towards the end of treatment time (48 hours; 57.01±5.45%) (Figure 5.9.).  Interestingly, at 24 
hours nuclear BMAL1 localisation was the lowest for the second time (48.15±4.83%).  Similar 
drop in BMAL1 nuclear fluorescent intensity was also observed in control treated-cells, 
however, this is different to ATXII-treated cells were high nuclear BMAL1 localisation was 
reported (Figure 5.3. & Figure 5.6.).   
 
 
 
 
 
 
 
Figure 5.9. Quantification analysis of time-dependent nuclear Total BMAL1 (T-BMAL1) protein 
expression in synchronised HL1-6 atrial myocytes, under 1 nM ATXII treatment in combination with 10 
µM Ranolazine.  Mean percentage (%) of HL1-6 cells showing nuclear staining as indicated in bar chart graph.  
The BMAL1-expressing cells were analysed by NIS elements acquisition software.  Nuclear fraction expression 
BMAL1 localisation is presented as (%) Mean ± SEM of total fraction expression.         
 
In summary, T-BMAL1 nuclear fluorescent intensity pattern under ATXII/Ranolazine 
treatment, was similarly observed in control-treated cells (for at least one circadian cycle; 0-
24 hours) providing evidence that T-BMAL1 localisation level changes were restored 
following raised [Ca2+]i levels by ATXII treatment (Figure 5.10., panels A&B).  In more 
details, the low T-BMAL1 fluorescent intensity levels observed in the nucleus prior serum-
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shock synchronisation (0 hours) were similarly observed under control and ATXII/Ranolazine 
treatment.  Immediately after the end of serum-shock (2 hours) incubation time, increased 
fluorescent intensity reported in untreated and ATXII/Ranolazine treated cells (Figure 5.10., 
panel (A)).  This was different to ATXII-treated cells which reported similar levels of nuclear 
localisation during those timepoints.   Increased T-BMAL1 fluorescent intensity levels were 
observed from 2 up to 20 hours of treatment with the above interventions (control and 
ATXII/Ranolazine), followed by similar reduced nuclear fluorescent intensity at 24 hours 
(Figure 5.10., panel (A)).  This was also different to ATXII treatment alone which reported 
delayed reduced fluorescent intensity levels 4 hours later, at 28 hours of treatment.  On the 
other hand, increased nuclear fluorescent intensity levels were similarly observed at 28 hours 
under control and ATXII/Ranolazine treated cells (Figure 5.10., panel (A).  Whereas, quite 
similar increased nuclear fluorescent intensity levels were observed from 32 and up to 48 
hours of treatment under all mentioned interventions, with slightly reduced levels of 
expression towards the end of serum-shock effect (48 hours) in ATXII-treated cells.  
In addition, under control conditions, T-BMAL1 nuclear localisation exhibit variation across 
time with significant peaks at 24 and 32 hours and troughs at 20 and 28 hours (Figure 5.10., 
panel B).  The ATXII-treated cells experience disturbed T-BMAL1 nuclear localisation with 
lower levels of expression and earlier peaks at 20 and 28 hours.  Such pattern was partly 
reversed in the presence of 10 µM Ranolazine, which reported similar (to control) levels and 
pattern of expression up to 28 hours, whereas from 32 hours onwards even though similar 
pattern to control conditions was observed lower T-BMAL1 levels were reported under 
Ranolazine treatment (Figure 5.10., panel B).  Thus suggesting a possible role of raised [Ca2+]i 
ATXII effects (via sustain activation of NaP channels) on T-BMAL1 cellular localisation.   
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Figure 5.10. Nuclear localisation and mean fluorescence intensity (MFI) of Total cellular BMAL1 (T-
BMAL1) in synchronised HL1-6 atrial myocytes, under control conditions, 1 nM ATXII treatment alone, 
or in combination with 10 µM Ranolazine. (A) Representative immunofluorescent confocal laser scanning 
microscopic images of serum-shocked synchronised HL1-6 cells showing T-BMAL1 protein expression and 
nuclear cellular localisation at specific times following control, 1 nM ATXII treatment alone or in presence of 
10 µM Ranolazine. (B) Mean T-BMAL1 fluorescence intensity was calculated at various time points, starting 
from 12 hours following serum-shock synchronisation. Data expressed as Mean±SEM; N=3.  Significant 
difference following the different treatments is reported with * (Control vs ATXII), # (Control vs 
ATXII/RANOLAZINE), † (ATXII vs ATXII/RANOLAZINE).  */#/† p<0.0001  
 
5.5.3. Effects of BAPTA-AM on ATXII-induced changes in Total BMAL1 
(T-BMAL1) cellular localisation in synchronised HL1-6 atrial myocytes  
 
In order to confirm a possible role of raised [Ca2+]i associated with ATXII and mediating the 
ATXII-induced changes in T-BMAL1 cellular localisation, HL1-6 cells were treated with the 
membrane permeable Ca2+-chelator BAPTA-AM in combination with ATXII. Prior serum-
shock synchronisation (0 hours), lower nuclear T-BMAL1 localisation was observed followed 
by immediate increase in fluorescent intensity after the end of serum-shock (2 hours) 
incubation time and beginning of BAPTA-AM treatment.  High nuclear T-BMAL1 
localisation was observed up to 28 hours, with extremely high protein fluorescence intensity 
noted at 20 hours, followed by a reduction at 32 hours (see representative images in Figure 
5.11.).  A subsequent rise of nuclear T-BMAL1 fluorescent intensity was observed at 36 hours.  
Similar levels of fluorescence were reported from 36 up to 48 hours, marking the end of 
BAPTA-AM treatment with high nuclear localisation.   
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Figure 5.11. Nuclear localisation of Total BMAL1 (T-BMAL1) in synchronised HL1-6 atrial myocytes, 
under 1 nM ATXII treatment in combination with 5 µM BAPTA-AM.  Representative immunofluorescent 
confocal laser scanning microscopic images of serum-shocked synchronised HL1-6 cells showing T-BMAL1 
protein expression and cellular localisation at specific times following 1 nM ATXII/5 µM BAPTA-AM 
treatment.  The cells were immunostained with the T-BMAL1 primary antibody (rabbit monoclonal anti-BMAL1 
antibody; 1:250) and visualised with the secondary antibody goat anti-rabbit IgG secondary antibody (FITC 
1:1000, green)/Alexa Fluor® 488.  Nuclei were visualised with the nuclear stain, DAPI (blue).  High nuclear 
BMAL1 localisation observed at 28 hours and lower BMAL1 localisation reported at 12, 44 and 48 hours 
following serum-shock synchronisation.  
 
We further assess the total cellular localisation of T-BMAL1 protein expression under 1 nM 
ATXII treatment in combination with 5 µM BAPTA-AM.  Figure 5.12. shows the effect of 1 
nM ATXII in combination with 5 µM BAPTA-AM, on the mean T-BMAL1 cellular 
fluorescence intensity (reflecting its localisation) for 48 hours.  The mean quantified total T-
BMAL1 cellular (cytoplasm and nucleus) fluorescence intensity, was calculated and presented 
after specific times (0, 2, 12, 16, 20, 24, 28, 32, 40, 44 and 48 hours) following HL1-6 cells 
treatment.   
The mean T-BMAL1 protein expression showed variation in a time-dependent manner (time 
effect p<0.0001).  However, such variation could not be considered as circadian due to the 
absence of 24-hour periodicity following cosine curve fitting (8.97±0.21 hours).  In addition, 
the T-BMAL1 protein expression was lower (trough points) at timepoint 0 (1561.72±16.59; 
p<0.05) (post synchronisation time), 12 (1949.16±25.22; p<0.05) and 44 (2126.47±26.33; 
p<0.05) hours.  Similarly, high T-BMAL1 protein expression was observed from timepoint 
16 up to 40 hours, with no clear observation of peaks (due to similar T-BMAL1 cellular 
protein expression levels) 
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Figure 5.12. Mean fluorescence intensity (MFI) of total cellular BMAL1 (T-BMAL1) in synchronised 
HL1-6 atrial myocytes, under 1 nM ATXII treatment in combination with 5 µM BAPTA-AM.  Mean T-
BMAL1 fluorescence intensity (line graph; black colour) was calculated at various time points, starting from 12 
hours following serum-shock synchronisation. A cosine curve (purple colour) was also fitted to assess the 
presence of circadian rhythmicity.  Data expressed as Mean ± SEM; N=3. * p<0.05   
 
The levels of T-BMAL1 cellular fluorescence intensity varied between 1 nM ATXII treatment 
alone and in presence of 5 µM BAPTA-AM, as well as, timepoints (interaction effect 
p<0.0001) (Figure 5.14., panel B). Two-way ANOVA test showed significant difference 
between ATXII and ATXII/BAPTA-AM-treated T-BMAL1 cellular fluorescence intensity at 
0, 2, 16, 20, 24, 28, 32, 36, 40 and 48 hours.  Additionally, when T-BMAL1 cellular 
localisation expression peaked in BAPTA-AM-treated cells at 24 hours, it troughed under 
ATXII treatment (ATXII 1876.05±11.11 vs ATXII/BAPTA-AM 2619.02±29.75; p<0.0001).  
Whereas when T-BMAL1 peaked under ATXII-treated cells at 28 hours, it troughed under 
BAPTA-AM treatment (ATXII 3929.70±19.14 vs ATXII/BAPTA-AM 2520.10±34.39; 
p<0.0001).  Also, opposite T-BMAL1 cellular localisation expression patterns between the 
two treatments was reported from 32 hours up to 40 hours (Figure 5.14., panel B).  
Furthermore, similarly low T-BMAL1 cellular localisation expression levels were observed 
under control and ATXII/BAPTA-AM conditions, suggesting a possible role of raised [Ca2+]i 
associated with ATXII, and BAPTA-AM mediating the ATXII-induced changes in T-BMAL1 
cellular localisation. 
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Given the observed oscillatory pattern of the mean T-BMAL1 fluorescence intensity 
(representing its localisation) under ATXII/BAPTA-AM treatment (Figure 5.12.), we then 
continued to test the differential cellular BMAL1 fluorescence intensity and localisation in the 
nuclear compartment of the cell (Figure 5.13.).  Under ATXII/BAPTA-AM treatment, 
BMAL1 nuclear localisation varied across the two circadian cycles with various fluctuations 
in intensity levels among the different timepoints. More specifically, lower BMAL1 
localisation levels were reported at 0 hours (pre-synchronisation time), however, following 2 
hours of serum-shock synchronisation BMAL1 fluorescent intensity levels increased and 
remained high for up to 20 hours, where it was the highest for the first time in that certain 
compartment (70.36±7.25%). A drop in BMAL1 nuclear localisation was reported at 24 hours 
(52.32±5.86%), followed by a subsequent rise at 28 hours (62.52±7.03%).  At 32 hours, 
BMAL1 fluorescent intensity levels were the lowest for the last time (40.87±5.01%), whereas 
from that timepoint onwards (36 hours - 48 hours) BMAL1 nuclear localisation levels were 
progressively increasing.  Interestingly, similarly high BMAL1 nuclear localisation intensity 
was observed at timepoint 44 hours (68.19±8.93%) and 48 hours (68.08±8.10%).  In addition, 
T-BMAL1 nuclear pattern under ATXII/BAPTA-AM treatment, was similarly observed in 
control-treated cells, providing evidence that T-BMAL1 localisation level changes were 
restored by BAPTA-AM Ca2+ chelator following raised [Ca2+]i levels by ATXII treatment 
(Figure 5.3. & Figure 5.13).   
 
 
 
 
 
 
 
 
 
 
Figure 5.13. Quantification analysis of time-dependent nuclear Total BMAL1 (T-BMAL1) protein 
expression in synchronised HL1-6 atrial myocytes, under 1 nM ATXII treatment in combination with 5 
µM BAPTA-AM.  Mean percentage (%) of HL1-6 cells showing nuclear staining as indicated in bar chart graph.  
The BMAL1-expressing cells were analysed by NIS elements acquisition software.  Nuclear fraction expression 
(blue) BMAL1 localisation is presented as (%) Mean±SEM of total fraction expression.   
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In summary, T-BMAL1 nuclear fluorescent intensity pattern under ATXII/BAPTA-AM 
treatment, was similarly observed in control-treated cells providing evidence that T-BMAL1 
localisation level changes were restored following raised [Ca2+]i levels by ATXII treatment 
(Figure 5.14., panels A&B).  In more details, the low T-BMAL1 fluorescent intensity levels 
observed in the nucleus prior serum-shock synchronisation (0 hours) were similarly observed 
under control and ATXII/BAPTA-AM treatment (Figure 5.14., panel (A)).  Immediately after 
the end of serum-shock (2 hours) incubation time, increased fluorescent intensity reported in 
untreated and ATXII/BAPTA-AM treated cells.  This was different to ATXII-treated cells 
which reported similar levels of nuclear localisation during those timepoints.   Increased T-
BMAL1 fluorescent intensity levels were observed from 2 up to 20 hours of treatment with 
the above interventions (control and ATXII/BAPTA-AM), followed by similar reduced 
nuclear fluorescent intensity at 24 hours (Figure 5.14., panel (A)). This was also different to 
ATXII treatment alone which reported delayed reduced fluorescent intensity levels 4 hours 
later, at 28 hours of treatment.  Finally, increased nuclear fluorescent intensity levels were 
similarly observed from 32 and up to 48 hours under control and ATXII/BAPTA-AM treated 
cells (Figure 5.14., panel (A)).  
In addition, under control conditions, T-BMAL1 cellular localisation exhibit variation across 
time with significant peaks at 24 and 32 hours and troughs at 20 and 28 hours (Figure 5.14., 
panel (B)).  ATXII-treated cells experience disturbed T-BMAL1 cellular localisation with 
lower levels of expression and earlier peaks at 20 and 28 hours (Figure 5.14., panel (B)).  Such 
phenomenon was partly reversed in the presence of BAPTA-AM Ca2+ chelator, as similarly 
low control-pattern was observed, suggesting a possible role of BAPTA-AM in mediating the 
ATXII-induced changes on T-BMAL1 cellular localisation hence supporting the effects 
observed under ATXII treatment.   
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Figure 5.14. Nuclear localisation and mean fluorescence intensity (MFI) of Total cellular BMAL1 (T-
BMAL1) in synchronised HL1-6 atrial myocytes, under control conditions, 1 nM ATXII treatment alone, 
or in combination with 5 µM BAPTA-AM.  (A) Representative immunofluorescent confocal laser scanning 
microscopic images of serum-shocked synchronised HL1-6 cells showing T-BMAL1 protein expression and 
nuclear cellular localisation at specific times following control, 1 nM ATXII treatment alone or in presence of 5 
µM BAPTA-AM. (B) Mean T-BMAL1 fluorescence intensity was calculated at various time points, starting 
from 12 hours following serum-shock synchronisation. Data expressed as Mean±SEM; N=3. Significant 
difference following the different treatments is reported with # (ATXII vs ATXII/BAPTA-AM), # p<0.0001 
 
5.5.4. Effects of calcineurin autoinhibitory peptide on ATXII-induced 
changes on Total BMAL1 (T-BMAL1) cellular localisation in synchronised 
HL1-6 atrial myocytes 
Raised [Ca2+]i induced by ATXII treatment showed a significant role in ATXII effects on total 
cellular TBMAL1 expression and its nucleocytoplasmic shuttling.  Given that T-BMAL1 
shuttling is governed by the level of BMAL1 phosphorylation which is turn regulated by 
protein kinases and phosphatases.  We chose to test for the contribution of Ca2+-calmodulin 
dependent protein phosphatase calcineurin (CaN) to the observed ATXII effects on T-BMAL1 
differential cellular distribution in synchronised HL1-6 atrial myocytes for 48 hours period. 
The most selective calcineurin inhibitor; calcineurin autoinhibitory peptide (CAIP; 25 µM) 
was used in this study.   
Prior (0 hours) and immediately after (2 hours) serum-shock synchronisation, T-BMAL1 
appeared in the nuclear compartment of the cell.  Similarly, increased T-BMAL1 nuclear 
fluorescent intensity levels were observed from 16 hours (see representative image in Figure 
5.15.) up to 24 hours following ATXII/CAIP treatment.  Alike reduced T-BMAL1 protein 
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fluorescence intensity was observed during the second circadian cycle among the rest of the 
timepoints (from 28 up to 48 hours), with a slight increase at 44 hours of ATXII/CAIP 
treatment.   
 
 
 
 
 
 
 
 
 
Figure 5.15. Nuclear localisation of Total BMAL1 (T-BMAL1) in synchronised HL1-6 atrial myocytes, 
under 1 nM ATXII in combination with 25 µM calcineurin autoinhibitory peptide (CAIP).  
Representative immunofluorescent confocal laser scanning microscopic images of serum-shocked synchronised 
HL1-6 cells showing T-BMAL1 protein expression and cellular localisation at specific times following 1 nM 
ATXII/25 µM CAIP treatment.  The cells were immunostained with the T-BMAL1 primary antibody (rabbit 
monoclonal anti-BMAL1 antibody; 1:250) and visualised with the secondary antibody goat anti-rabbit IgG 
secondary antibody (FITC 1:1000, green)/Alexa Fluor® 488.  Nuclei were visualised with the nuclear stain, 
DAPI (blue).  High nuclear BMAL1 localisation observed at 16 and 20 hours, and lower nuclear BMAL1 
localisation reported at 28 and 36 hours following serum-shock synchronisation.  
 
The total cellular localisation of T-BMAL1 protein expression under with 1 nM ATXII 
treatment in combination with 25 µM CAIP was further assessed.  Figure 5.16. shows the 
effect of 1 nM ATXII in combination with 25 µM CAIP, on the mean T-BMAL1 cellular 
fluorescence intensity (reflecting its localisation) for 48 hours.  The mean quantified T-
BMAL1 cellular (cytoplasm and nucleus) fluorescence intensity, was calculated and presented 
after specific times (0, 2, 12, 16, 20, 24, 28, 32, 40, 44 and 48 hours) following HL1-6 cells 
synchronisation.  The T-BMAL1 protein expression in HL1-6 cells showed variation in a 
time-dependent manner (time effect p<0.0001).  However, such variation could not be 
considered as circadian due to the absence of 24-hour periodicity following cosine curve 
fitting (16.02±0.23 hours).  This is also different to control and ATXII treatment alone, which 
reported a rhythm of approximately 10 hours.  A 4-hour earlier peak was also observed under 
ATXII/CAIP treatment (at 16 hours) when compare to ATXII-treatment alone (at 20 hours) 
(Figure 5.22.). 
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Figure 5.16. Mean fluorescence intensity (MFI) of total cellular BMAL1 (T-BMAL1) in synchronised 
HL1-6 atrial myocytes, under 1 nM ATXII treatment in combination with 25 µM calcineurin 
autoinhibitory peptide (CAIP).  Mean T-BMAL1 fluorescence intensity (line graph; black colour) was 
calculated at various timepoints, starting from 12 hours following serum-shock synchronisation.  A cosine curve 
(orange colour) was also fitted to assess the presence of circadian rhythmicity.  Data expressed as Mean±SEM; 
N=3. * p<0.05 
 
In addition, treating of HL1-6 cells with 1 nM ATXII in the presence of 25 µM CAIP was 
able to restore cellular localisation of T-BMAL1 protein expression, as similar pattern was 
observed in control (untreated) cells (Figure 5.22.).  For example, similar T-BMAL1 cellular 
localisation protein expression pattern was observed from timepoint 0 to 12 hours, and from 
timepoint 32 to 48 hours between control and ATXII/CAIP treatment.  However, T-BMAL1 
cellular localisation protein levels were significantly higher under ATXII/CAIP treatment 
when compare to control conditions (interaction effect p<0.0001).  In addition, the T-BMAL1 
protein localisation peaks observed at 16 hours and 32 hours under ATXII/CAIP treatment, 
were similarly observed under control conditions (Figure 5.22.). Whereas, not so steep drop 
in T-BMAL1 cellular localisation expression was observed at 28 hours under ATXII/CAIP 
treatment (2717.24±21.97; p<0.0001) when compare to control group (2030.26±13.06; 
p<0.0001). 
Furthermore, two-way ANOVA analysis showed significant difference (interaction effect 
p<0.0001) between the levels, as well as timepoints, of T-BMAL1 cellular localisation under 
ATXII treatment alone and in presence of CAIP across the 48 hours.  Opposite effect on T-
BMAL1 cellular localisation expression was observed at 16 hours, with ATXII treatment 
causing a peak and ATXII/CAIP treatment causing a trough on its cellular localisation 
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expression (ATXII 1842.89±13.67 vs ATXII/CAIP 3307.51±19.17; p<0.0001).  Not so steep 
drop was observed at 28 hours, with ATXII (3929.70 ±19.14; p<0.0001) treatment alone 
causing major dampening on T-BMAL1 cellular localisation expression, when compare to 
ATXII/CAIP (2717.24±21.97; p<0.0001) treatment.  At 32 hours similar opposite effect on 
T-BMAL1 cellular localisation expression was observed, with ATXII/CAIP treatment 
causing higher localisation expression and ATXII treatment alone lowering it (ATXII 
2280.48±16.54 vs ATXII/CAIP 3168.38±42.60; p<0.0001).  At 40 hours, T-BMAL1 cellular 
localisation expression pattern was significantly higher under ATXII/CAIP treatment 
compare to ATXII treatment alone (ATXII 1788.69±18.79 vs ATXII/CAIP 2402.61±24.78; 
p<0.0001). 
Given the observed oscillatory pattern of the T-BMAL1 fluorescence intensity (representing 
its localisation) under ATXII/CAIP treatment (Figure 5.16.), we then continued to test the 
differential cellular BMAL1 fluorescence intensity and localisation in the nuclear 
compartment of the cell (Figure 5.17.).  High BMAL1 fluorescent intensity was observed up 
to 24 hours post serum-shock synchronisation, with peak nuclear localisation levels at 16 
hours (61.48±5.72%), 20 hours (63.36±5.72%) and 24 hours (62.02±6.12%).  Whereas, lower 
BMAL1 fluorescent intensity was reported from 32 hours (43.37±6.71%) until the end of the 
two circadian cycles, with slightly higher localisation at timepoint 40 hours (48.21±7.32%).  
Interestingly, the drop in BMAL1 fluorescent intensity at 32 hours was similarly observed 
under control conditions.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17. Quantification analysis of time-dependent nuclear Total BMAL1 (T-BMAL1) protein 
expression in synchronised HL1-6 atrial myocytes, under 1 nM ATXII treatment in combination with 25 
µM calcineurin autoinhibitory peptide (CAIP).  Mean percentage (%) of HL1-6 cells showing nuclear staining 
as indicated in bar chart graph.  The BMAL1-expressing cells were analysed by NIS elements acquisition 
software.  Nuclear fraction expression (blue) BMAL1 localisation is presented as (%) Mean±SEM of total 
fraction expression.   
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The effect of 25 µM CAIP treatment alone was also investigated to test if calcineurin may 
affect T-BMAL1 cellular localisation under our control recording conditions.  Similarly, high 
T-BMAL1 fluorescent intensity levels in the nuclear compartment of the cell were observed 
up to 24 hours post serum-shock synchronisation (see representative images in Figure 5.18.).  
Interestingly, towards the beginning of the second circadian cycle and until its end (from 28 
hours up to 48 hours) T-BMAL1 protein fluorescent intensity was radically decreasing 
presenting similarly low levels of nuclear localisation.   
 
 
 
 
 
 
 
Figure 5.18. Nuclear localisation of Total BMAL1 (T-BMAL1) in synchronised HL1-6 atrial myocytes, 
under 25 µM calcineurin autoinhibitory peptide (CAIP) treatment alone.  
Representative immunofluorescent confocal laser scanning microscopic images of serum-shocked synchronised 
HL1-6 cells showing T-BMAL1 protein expression and cellular localisation at specific times following 25 µM 
CAIP treatment.  The cells were immunostained with the T-BMAL1 primary antibody (rabbit monoclonal anti-
BMAL1 antibody; 1:250) and visualised with the secondary antibody goat anti-rabbit IgG secondary antibody 
(FITC 1:1000, green)/Alexa Fluor® 488.  Nuclei were visualised with the nuclear stain, DAPI (blue).  High 
nuclear BMAL1 localisation was observed at 16 hours.  
 
The total cellular localisation of T-BMAL1 protein expression under 25 µM CAIP alone was 
further assessed.  Figure 5.19. shows the effect of 25 µM CAIP alone, on the mean T-BMAL1 
cellular fluorescence intensity (reflecting its localisation) for 48 hours.  The total cellular 
localisation of T-BMAL1 protein expression peaked at 24 (3168.54±27.00; p<0.01), 32 
(3296.12±40.88; p<0.01) and 48 (3059.95±31.42; p<0.01) hours (8 and 16-hour difference 
respectively), with the 32-hour peak been the highest among the other two ones.  Following 
that, troughs of the T-BMAL1 cellular localisation expression were observed at timepoint 20 
(2185.27±23.42) and 36 (2114.99±17.79) hours, with a 16-hour interval aswell, presenting in 
that way a rhythmic expression pattern.  Even though the overall Total BMAL1 cellular 
localisation showed variation in a time dependent manner (time effect p<0.0001) manner 
under 25 µM CAIP treatment, such changes could not be considered as circadian due to the 
absence of 24-hour periodicity following cosine curve fitting (19.12±0.22 hours).  Also, the 
levels of T-BMAL1 cellular localisation expression exhibit increasing trend from 36 hours 
until the end of 48-hours. 
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Figure 5.19. Mean fluorescence intensity (MFI) of total cellular BMAL1 (T-BMAL1) in synchronised 
HL1-6 atrial myocytes, under 25 µM calcineurin autoinhibitory peptide (CAIP) treatment alone.  Mean 
T-BMAL1 fluorescence intensity (line graph; black colour) was calculated at various timepoints, starting from 
12 hours following serum-shock synchronisation. A cosine curve (green colour) was also fitted to assess the 
presence of circadian rhythmicity.  Data expressed as Mean±SEM; N=3, p<0.01 
 
Furthermore, the levels of T-BMAL1 cellular localisation expression varied between CAIP 
treatment alone and ATXII/CAIP (interaction effect p<0.0001). Significant difference was 
observed across the 48 hours.  In addition, similar peak at 16 hours was observed under both 
treatments, however, CAIP treatment alone lowered T-BMAL1 expression in the cells (Figure 
5.21., panel (B)).  Furthermore, similar T-BMAL1 cellular localisation expression pattern was 
observed between control and CAIP treatment alone, which suggests the absence of CAIP 
effect on our control conditions, even though different T-BMAL1 expression levels were 
observed between the two treatments (Figure 5.21., panel (B)). 
In addition, given the observed oscillatory pattern of the T-BMAL1 fluorescence intensity 
(representing its localisation) under 25 µM CAIP treatment alone (Figure 5.19.), we then 
continued to test the differential cellular BMAL1 fluorescence intensity and localisation in the 
nuclear compartment of the cell (Figure 5.20.).  Similarly, to CAIP treatment in presence of 
ATXII, enhanced BMAL1 localisation levels were observed from 2 up to 24 hours 
(61.15±7.47%) post serum-shock synchronisation, following CAIP treatment alone.  
Whereas, from 28 hours onwards (up to 48 hours), significantly lower BMAL1 fluorescent 
intensity was observed in the nucleus (43.67±5.46%).  Alike levels of localisation were 
reported at timepoint 40 (53.51±6.97%) and 48 hours (51.81±6.38).  
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Figure 5.20. Quantification analysis of time-dependent nuclear Total BMAL1 (T-BMAL1) protein 
expression in synchronised HL1-6 atrial myocytes, under 25 µM calcineurin autoinhibitory peptide 
(CAIP) treatment alone.  Mean percentage (%) of HL1-6 cells showing nuclear staining as indicated in bar 
chart graph.  The BMAL1-expressing cells were analysed by NIS elements acquisition software.  Nuclear 
fraction expression (blue) BMAL1 localisation is presented as (%) Mean±SEM of total fraction expression.   
 
In summary, T-BMAL1 nuclear fluorescent intensity pattern under ATXII/CAIP treatment, 
was similarly observed in control-treated cells (up to 28 hours) further enhancing evidence of 
T-BMAL1 protein shuttle-calcineurin mediating effects (Figure 5.21., panels A&B).  In more 
details, immediately after the end of serum-shock (2 hours) incubation time, increased 
fluorescent intensity reported in untreated and ATXII/CAIP-treated cells (Figure 5.21., panel 
(A)).  Increased T-BMAL1 fluorescent intensity levels were observed from 2 up to 20 hours 
of treatment during the above interventions (control and ATXII/CAIP), followed by similar 
reduced nuclear fluorescent intensity at 24 hours.  This was different to ATXII treatment alone 
which reported delayed reduced fluorescent intensity levels 4 hours later, at 28 hours of 
treatment (Figure 5.21., panel (A)).  In addition, the reduction in T-BMAL1 nuclear 
localisation at 32 hours was similarly observed under control and ATXII/CAIP-treated cells.  
Finally, increased nuclear fluorescent intensity levels were similarly observed towards the end 
of serum-shock effect (44 hours), under control and ATXII/BAPTA-AM treated cells.  On the 
other hand, CAIP treatment alone did not have any effects in control conditions suggesting 
the absence of calcineurin effects alone.  That is due to the fact that high T-BMAL1 
fluorescent intensity levels were observed in the nuclear compartment of the cell during the 
first circadian cycle (0-24 hours), whereas during the second circadian cycle (28-48 hours) T-
BMAL1 protein fluorescent intensity levels were radically decreasing presenting similarly 
low levels of nuclear localisation.   
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In addition, under control conditions, T-BMAL1 cellular localisation exhibit variation across 
time with significant peaks at 24 and 32 hours and troughs at 20 and 28 hours (Figure 5.21., 
panel (B)).  ATXII-treated cells experience disturbed T-BMAL1 cellular localisation with 
lower levels of expression and earlier peaks at 20 and 28 hours.  Such phenomenon was partly 
reversed or prevented in the presence of CAIP calcineurin inhibitor, suggesting a possible role 
of calcineurin in mediating the ATXII-induced changes on T-BMAL1 cellular localisation.  
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Figure 5.21. Nuclear localisation and mean fluorescence intensity (MFI) of Total cellular BMAL1 (T-
BMAL1) in synchronised HL1-6 atrial myocytes, under control conditions, 1 nM ATXII treatment alone, 
or in combination with 25 µM CAIP, and 25 µM CAIP treatment alone.                                                                                      
(A) Representative immunofluorescent confocal laser scanning microscopic images of serum-shocked 
synchronised HL1-6 cells showing T-BMAL1 protein expression and nuclear cellular localisation at specific 
times following control, 1 nM ATXII alone or in presence of 25 µM CAIP, and 25 µM CAIP alone. (B) Mean 
T-BMAL1 fluorescence intensity was calculated at various time points, starting from 12 hours following serum-
shock synchronisation. Data expressed as Mean±SEM; N=3. Significant difference following the different 
treatments is reported with * (Control vs CAIP), † (ATXII vs ATXII/CAIP), # (ATXII vs ATXII/CAIP). */#/† 
p<0.0001 
 
5.6. Discussion  
5.6.1. Cellular localisation of Total BMAL1 (T-BMAL1) in synchronised 
HL1-6 atrial myocytes across 48 hours 
The cellular localisation and shuttle cycling of T-BMAL1 in cardiac myocytes, and more 
specifically in atrial cells is currently unknown.  The cyclic transcription of clock genes 
revealed that PER1/2 and CRY1/2 proteins undergo near synchronous circadian patterns of 
nuclear abundance in rodents (Field et al., 2000).  Hence, the timing of entry, as well as the 
residence time of core clock proteins into the nucleus, is a critical step in maintaining the 
correct pace of the circadian clock. 
In our study we monitored the real-time circadian rhythmicity of BMAL1 subcellular 
localisation in HL1-6 atrial myocytes synchronised by treatment with 50 % fetal bovine serum 
(FBS), a strong inducer of circadian expression in cultured models.  We found that in HL1-6 
cells, BMAL1 undergoes progressive nuclear accumulation.  More specifically, in serum-
shocked HL1-6 cells, BMAL1 protein progressively accumulates in the nucleus with peaks 
observed at 16-20 hours after serum-shock synchronisation.  This was followed by a 
diminishment in the nuclear protein levels at 24 hours.  Thereafter, the nuclear BMAL1 levels 
exhibit a significant increase between 28 and 44 hours of serum-shock synchronisation.  
Whereas towards the end of serum-shock effect BMAL1 nuclear expression was dramatically 
reduced, increasing the chances of cell desynchrony due to diminishment of serum-shock 
effect.   Unsynchronised HL1-6 cells were also used to investigate priori assumptions about 
when during the circadian cycle BMAL1 enters and peaks inside the nuclear compartment of 
the cell.  Interestingly, BMAL1 found to be less expressed in the nucleus prior serum-shock 
synchronisation, whereas significantly increased localisation levels were observed following 
serum-shock synchronisation time (2 hours) reporting the importance of synchronisation 
effect on localisation of clock genes.  However, because we have used unsynchronised cells, 
which likely would anyway not be rhythmic any assumptions could not be taken into 
consideration considering the circadian effect of serum on clock gene localisation (Stokes et 
al., 2017).  In addition, we also observed that the mean total BMAL1 protein expression levels 
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in synchronised HL1-6 cells peaked at 16, 24, 32 and 44 hours, whereas lower BMAL1 protein 
expression levels were observed at 20, 28, 36 and 48 hours, which supports the absence of a 
circadian (24 hours) pattern and the presence of an approximately 10-hour rhythmic cycle.        
BMAL1 acceleration in the nuclear region of the cell is consistent with Lee et al., (2006) who 
reported nuclear BMAL1 localisation alone or upon its heterodimerisation with CLOCK.   In 
addition, this is in line with the observation that circadian oscillations of the nuclear 
accumulation of CLOCK depended on BMAL1, as CLOCK found to be highly expressed in 
the cytoplasm (Kondratov et al., 2003).  Another study by Lee et al., (2001) reported that in 
mouse liver, BMAL1 does not accumulate significantly in the cytoplasm before its nuclear 
entry, suggesting that BMAL1 may be subjected to similar posttranslational regulatory 
mechanisms in the molecular clockworks of different cell types.  However, further analysis is 
required to adequately define the circadian regulatory mechanisms that drive BMAL1 
subcellular localisation in HL1-6 atrial myocytes.   
These observations indicate that the BMAL1 protein undergoes temporally regulated 
subcellular localisation in atrial cells with functional circadian clock.  This is supported by the 
fact that BMAL1 protein subcellular localisation in CRY-deficient fibroblasts lacking a 
functional circadian clock, do not change over time (Lee et al., 2001).  Nevertheless, another 
recent report has suggested that cardiomyocytes shared similar circadian gene expression 
profiles to the SCN, which further supports the use of HL1-6 atrial myocytes as a model for 
the central circadian clock (Umemura et al., 2017).  Our immunocytochemical analysis shows 
that in HL1-6 cells, BMAL1 protein levels oscillate in a non-circadian manner after its nuclear 
entry.  These data constitute the first immunocytochemical evidence for the temporal 
regulation of endogenous BMAL1 localisation under control conditions, suggesting that 
BMAL1 nuclear export is largely dependent on the circadian clock.   
The BMAL1 nuclear shuttling observations are supported by the presence of nuclear 
localisation signals (NLS) in the N-terminal region and the basic-helix-loop-helix (bHLH) 
region of the BMAL1 protein, in addition to two nuclear export signals (NES) in its PAS 
domain region (Seaz and Young., 1996; Yagita et al., 2001).  The NLS and NES were reported 
to allow BMAL1 shuttling between the cytoplasm and the nucleus, and further permit CLOCK 
nuclear accumulation.  Studies reported that NLS1 is the functional NLS unit essential for 
nuclear BMAL1 localisation, as any mutation on NLS1 shown to abolish its nuclear 
accumulation (Bedard et al., 2006).  BMAL1 protein has intrinsic nuclear import ability, but 
nevertheless some exogenously expressed BMAL1 remains localised in the cytoplasm due to 
additional domains on its C-terminal region (Tamaru et al., 2003).  However, further studies 
are required to investigate its distribution in the cytoplasmic cellular compartment across time 
so that true comparisons can be made.  
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5.6.2. Effects of raised intracellular [Ca2+] on Total BMAL1 (T-BMAL1) 
cellular localisation in synchronised HL1-6 atrial myocytes across 48 hours 
There has been significant progress in our understanding of the Ca2+ molecular mechanisms 
mediating atrial arrhythmias.  However, little is known about the association of Ca2+ signalling 
with the diurnal occurrence of atrial arrhythmic events, and to a greater extend with clock 
genes expression and cycling (in particular Bmal1).  So far, the studies conducted 
investigating the involvement of clock mechanism in cardiac events, are particularly 
associated with clock gene knockouts/mutations or overexpression of clock proteins (Bray et 
al., 2007, Durgan et al., 2011).  However, we choose to use downstream molecular targets (i.e. 
abnormal increase in intracellular [Ca2+]), hence avoiding pre-disturbing the molecular clock 
as well as proposing a new model for studying circadian clock function and localisation in the 
heart.   
Our results showed that raised intracellular [Ca2+] by ATXII (NaP channel opener) is 
associated with disturbed Bmal1 clock gene circadian rhythm in synchronised HL1-6 cells 
and T-BMAL1 protein expression in total synchronised HL1-6 cell lysate (Chapter 3 & 4).  
Moreover, the results indicated in this chapter reveal that increased intracellular [Ca2+] also 
affect the nuclear shuttling of T-BMAL1 protein due to a difference in the pattern observed 
under control conditions.  To assess the effects of raised Ca2+ levels on BMAL1 shuttling, 
HL1-6 cells were subjected to 1 nM ATXII, following serum-shock synchronisation which 
allow resetting of the clock genes for the true evaluation of circadian changes (Stokes et al., 
2017).  Firstly, our results show that T-BMAL1 protein progressively accumulates in the 
nucleus up to 24 hours following raised intracellular [Ca2+] levels.  This was followed by a 
diminishment in the nuclear protein levels, possibly due to concomitant increase of 
cytoplasmic T-BMAL1 protein accumulation in the cell, at 28 hours.  Significantly enhanced 
T-BMAL1 protein levels in the nuclear compartment of the cells were observed up to 44 
hours.  This was different to the nuclear shuttle pattern observed under control conditions, as 
T-BMAL1 recuced localisation timepoint was reported at 24 hours before it increase again at 
28 hours.  In addition, the mean total BMAL1 protein expression under raised intracellular 
[Ca2+] peaked at 20 and 28 hours (10-hour rhythmic pattern), compare to 16 and 24 hours 
observed under control conditions, indicating a 4-hour delay in the T-BMAL1 protein 
expression, as well as, the absence of a circadian pattern.        
The lack of studies investigating the effects of pathological Ca2+ levels (in vivo and in vitro) 
on T-BMAL1 protein nuclear shuttling marks the importance and uniqueness of our findings.  
A study investigating the changes in CLOCK protein localisation following increased 
contractile activity (and subsequently Ca2+ levels) with 10 µM phenylephrine reported 
enhanced CLOCK protein expression and nuclear translocation in cardiac myofilaments, thus 
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proposing the involvement of intracellular activities in cardiac myocytes (Boateng and Qi., 
2006).  Similarly, enhanced nuclear T-BMAL1 accumulation (and less nuclear shuttling) was 
reported in HL1-6 atrial myocytes following treatment with ATXII, when compare to control 
conditions.  The use of ATXII to mimic atrial arrhythmic events, via sustain opening of 
persistent Na+ (NaP) channels and subsequently rise in intracellular [Ca
2+], is well 
documented.  Further experiments also reported that ATXII markedly increases the force and 
prolongs action potential duration inducing arrhythmic events in various experimental models 
including canine atrial and ventricular myocytes, rat isolated hearts, as well as strips of rat 
skeletal muscle tissue, providing further evidence of its actions on NaP channels and 
subsequently raised intracellular [Ca2+] levels in HL1-6 atrial myocytes (Luo et al., 2013; 
Waldo et al., 2008; Fraser et al., 2006).   
We further continued assessing whether the ATXII-induced disruption of T-BMAL1 cellular 
localisation could be reversed or prevented in presence of Ranolazine (10 µM) inhibitor.  We 
previously showed that Ranolazine reversed the disturbed rhythm of Bmal1 clock gene in 
synchronised HL1-6 cells and T-BMAL1 protein expression in total synchronised HL1-6 cell 
lysate, following raised intracellular [Ca2+] by ATXII (Chapter 3 & 4).  Ranolazine, an anti-
anginal drug, is reported to have opposite effects on cardiac myocytes as it has been shown to 
reverse the sustained rise in diastolic and systolic Ca2+ caused by ATXII by inhibiting INaP 
current, thus preventing cellular Na+ overload by blocking the NCX reverse mode leading to 
decreased intercellular [Ca2+] levels and Ca2+ loading in sarcoplasmic reticulum (Hayashida 
et al., 1994; Song et al., 2004; Fraser et al., 2006; Sossalla et al., 2007).  Experiments from 
canine to guinea pig cardiac myocytes, reported that Ranolazine is 38-fold more potent at 
inhibiting the concentration, voltage and frequency of NaP current (INaP), showing that it is 
specific to these types of channels (Antzelevitch et al., 2004), thereafter possibly mediating 
ATXII-induced effects on T-BMAL1 cellular localisation.   
In this chapter, our results show that the T-BMAL1 nuclear shuttling pattern observed under 
Ranolazine treatment, was similarly detected in control cells, providing evidence that T-
BMAL1 protein shuttle cycle was restored following raised [Ca2+]i levels by ATXII treatment.  
Under Ranolazine treatment, T-BMAL1 protein progressively accumulates in the nucleus 
from 12 up to 20 hours.  This was followed by a diminishment in the T-BMAL1 nuclear 
protein levels (and possibly concomitant increase of T-BMAL1 protein in the cytoplasm at 24 
hours), similar to control conditions.  From 28 hours up to end of treatment time (48 hours), 
T-BMAL1 protein levels became extremely visible in the nuclear compartment of the cell, 
with high localisation levels.  However, slightly lower nuclear T-BMAL1 levels were reported 
when compare to control conditions in Ranolazine-treated HL1-6 cells.  Interestingly, Boateng 
and Qi., (2006) demonstrate that a decrease in contractile activity (by 10 μM verapamil; Ca2+ 
channel blocker) resulted in reduced CLOCK protein expression in the nucleus and 
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cytoskeleton of cardiac myofilaments, thus suggesting that expression of clock proteins, as 
well as their nuclear distribution are highly associated with changes in Ca2+ levels.   
In addition, the presence of Ranolazine minimised and almost prevented the ATXII effects on 
the mean total BMAL1 protein expression for at least 28 hours when compared to control 
conditions, whereas from 32 hours onwards even though similar pattern to control conditions 
was observed, lower T-BMAL1 levels were reported under Ranolazine treatment.  Thus 
suggesting a possible role of raised [Ca2+]i ATXII effects (via sustain activation of NaP 
channels) on T-BMAL1 cellular localisation.  On the other hand, the inability of Ranolazine 
to fully reversed ATXII-induced effects on T-BMAL1 cellular localisation throughout the 48 
hours, may be partially due to the non-exclusive action of Ranolazine on sodium channels 
(and INaP current), as studies reported its association with potassium channels aswell (Gupta 
et al., 2015; Rayner‐Hartley and Sedlak., 2018).  Also, other NaP blockers currently available 
(such as, tetrodoxin (TTX), lidocaine, mexiletine and flecainide), reported to have greater 
potency of blocking the cardiac INaP current (Heinemann et al., 1992; Le Grand et al., 2008).  
However, a study by Antao et al., (2014) showed that in comparison to the left ventricular 
myocytes in rabbits, an increased in INaP current density, as well as enhanced sensitivity to 
ATXII and Ranolazine, was observed in left atrial myocytes hence supporting the use of HL1-
6 atrial cells and the current treatments to investigate possible effects on T-BMAL1 cellular 
localisation.      
The BAPTA-AM Ca2+-chelator (in combination with ATXII) was also used to confirm the 
role of raised intracellular [Ca2+] associated with ATXII and mediating the ATXII-induced 
changes in T-BMAL1 cellular localisation, in synchronised HL1-6 cells.  Our results show 
that the disturbed Bmal1 clock gene circadian rhythm in HL1-6 atrial myocytes, was reversed 
(24-hour circadian rhythm) in presence of 5 µM BAPTA-AM in synchronised HL1-6 atrial 
myocytes in vitro (Chapter 3).  Moreover, the results indicated in this chapter reveal that the 
T-BMAL1 nuclear shuttling pattern observed under BAPTA-AM treatment, was similarly 
detected in control cells, thus confirming the role of raised intracellular [Ca2+] associated with 
ATXII on T-BMAL1 protein shuttle changes.  In BAPTA-AM-treated HL1-6 cells, T-
BMAL1 was mostly observed in the nuclear compartment of the cell throughout the 48 hours, 
with nuclear diminishment localisation at 32 hours (similarly observed under control 
conditions).   
In addition, the presence of BAPTA-AM Ca2+ chelator partially reverse the ATXII effects on 
the mean total BMAL1 protein expression in synchronised HL1-6 cells, as similarly low T-
BMAL1 protein levels were observed under control conditions.  Interestingly, the absence of 
a 24-hour pattern was observed, suggesting the non-circadian T-BMAL1 shuttling under 
BAPTA-AM treatment.  Also, Yoshida et al., (2018) showed that inhibition of Ca2+ influx by 
BAPTA-AM chelator, disrupted the phase and expression of Bmal1 gene in non-cardiac cells 
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(synovial cells).  They also reported that BAPTA-AM cancelled Bmal1 gene expression up-
regulation by TNF-α, which is known to enhance intracellular [Ca2+] in myocytes (White et 
al., 2006).  Furthermore, Petrzilka et al., (2009) reported that TNF-α – induced expression of 
Per1 gene, was similarly cancelled by Ca2+ influx inhibition in NIH3T3 mouse fibroblast cells.  
Therefore, taken together these studies (even though they were conducted in non-cardiac 
cells), as well as our findings, enhanced intracellular [Ca2+] is highly associated and clearly 
modulate the expression and localisation of BMAL1 protein in HL1-6 atrial cells.  However, 
considering the use of an in vitro model (cultured HL1-6 atrial myocytes) to investigate 
BMAL1 nuclear shuttling changes, raise the point that more interventional clinical trials may 
be required to clarify the relationship between clock proteins and atrial arrhythmias.   
5.6.3. Effects of calcineurin autoinhibitory peptide on ATXII-induced 
changes on Total BMAL1 (T-BMAL1) cellular localisation, in synchronised 
HL1-6 atrial myocytes 
In a healthy heart, Ca2+-dependent serine/threonine protein phosphatase calcineurin is thought 
to be inactive and unresponsive to high Ca2+ waves that drive contraction. Calcineurin is 
activated in response to stress, presumably when intracellular Ca2+ exceeds a required 
threshold (Sachan et al., 2011).  Increased activity of calcineurin reported in cardiac 
arrhythmias in response to raised intracellular [Ca2+] levels (Wolk et al., 2003; Wilkins and 
Molkentin., 2004; Jabr et al., 2016).  Enhanced intracellular [Ca2+] levels were shown to 
activate calcineurin to cause dephosphorisation of Inhibitor 1 (I1; endogenous inhibitor of 
Ca2+-independent PP1) at Thr35 residue, and its dissociation from PP1 (Jabr et al., 2016).  
Once PP1 dissociated from I1, it gets activated and cause Cx43 dephosphorylation at Ser365, 
as well as enhance its phosphorylation at Ser368 by PKC which further results in 
arrhythmogenic reduced gap junction electrical conductance (Jabr et al., 2016).  Various Ca2+ 
independent – protein phosphatases and kinases were reported to affect T-BMAL1 cellular 
localisation and nucleocytoplasmic shuttling, however little is known about its association 
with calcineurin hence marking the importance and uniqueness of our findings (Eide et al., 
2002; Robles et al., 2010; Tamaru et al., 2015).   
The effects of calcineurin on T-BMAL1 protein localisation were assessed using the most 
selective calcineurin inhibitor (calcineurin autoinhibitory peptide; CAIP, 25 µM) in the 
presence and absence of 1 nM ATXII.  We previously showed that CAIP alone did not have 
any effects in control conditions, but partially prevented ATXII effects on T-BMAL1 protein 
expression in total synchronised HL1-6 cell lysate (Chapter 4).  In this chapter, our results 
show that the T-BMAL1 nuclear shuttling pattern observed under CAIP treatment (in presence 
of ATXII), was different to the one observed under ATXII treatment alone, but partially 
similar to the one observed under control conditions, thus providing evidence of calcineurin 
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activity on T-BMAL1 protein cellular shuttling though its dephosphorylation action.  Under 
CAIP treatment (in presence of ATXII), T-BMAL1 was mostly observed in the nuclear 
compartment of the cell throughout the 48 hours, with nuclear diminishment at 32 (similar to 
control conditions) and 44 hours (different to control conditions) post synchronisation.   
Interestingly, slightly higher nuclear T-BMAL1 protein levels were observed when compare 
to control conditions.  This is in line with a study by Schmutz et al., (2011) who reported, 
slightly higher levels of nuclear BMAL1 protein accumulation in I1 (PP1 endogenous 
inhibitor) mutant mice (when compare to control wildtype mice), indicating that PP1 affects 
BMAL1 levels and influences its subcellular localisation.  Therefore, considering the fact that 
calcineurin activates PP1 (indirectly) under raised intracellular [Ca2+], and the fact that similar 
nuclear T-BMAL1 protein levels were observed in our in vitro model, suggests a possible 
calcineurin-PP1 dephosphorylation signalling pathway mediating T-BMAL1 nuclear 
shuttling in synchronised HL1-6 cells.  However, further studies need to be conducted to 
confirm such association, possibly using phosphorylated BMAL1 antibody to check for 
calcineurin dephosphorylation effects and possible phosphorylation site on T-BMAL1. 
In addition, the Ca2+-activated calcineurin shown to have several substrates including the 
nuclear factor of activated T cells (NFATc) through which it influences long term changes in 
gene expression associated with pathological cardiac remodelling (Dyar et al., 2015).  
Dephosphorylation of NFATc by calcineurin, allows its translocation to the nucleus where it 
binds to and activates calcineurin regulator isoform 4 gene (Rcan1.4) (Beals et al., 1997).  At 
the same time, serine/threonine casein kinase 2 (CK2) reported to enhance the affinity of the 
CIC motif on RCAN1 (calcineurin inhibitor) for calcineurin and initiate the inhibition towards 
calcineurin – NFAT pathway activation (Dyar et al., 2015).  Tamaru et al., (2009) showed that 
any mutation and/or depletion of CK2-phosphorylation site on BMAL1 (Ser90), resulted in 
impaired nuclear BMAL1 circadian accumulation.  Thus, proposing possible calcineurin 
association with T-BMAL1 cellular shuttling, following phosphorylation of BMAL1 at Ser90. 
Furthermore, the presence of CAIP (in combination with ATXII) partially reversed the ATXII 
effects on the mean total BMAL1 protein expression in synchronised HL1-6 cells, as similar 
T-BMAL1 protein expression pattern (but slightly higher levels of expression up to 20 hours 
post synchronisation) was observed throughout the 48 hours under control conditions.  Thus, 
further providing evidence of the association of T-BMAL1 and calcineurin (via tis 
dephosphorylating activity), leading to or mediating atrial arrhythmias, following raised 
intracellular [Ca2+].  In addition, CAIP alone did not have any effects in control conditions as 
similar mean total BMAL1 protein expression pattern was observed, highlighting the absence 
of calcineurin effect alone.       
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6.1. General Discussion  
6.1.1. Bmal1 clock gene circadian rhythmicity in HL1-6 cells  
The present study is the first to report Bmal1 clock gene expression in HL1-6 atrial myocytes. 
Our results also expose that Bmal1 clock gene expression is rhythmic in these cells under 
control conditions using lentivirus bioluminescence technique, hence supporting the presence 
of a circadian pattern of this gene in atria. The reported presence of Bmal1 gene in HL1-6 
cells, which is a well-documented in vitro model for studying atrial physiology and 
pathophysiology (due to their similar phenotype to adult cardiomyocytes), further supports 
our findings, as well as, proposed their use for future experiments regarding circadian 
electrophysiology (Claycomb et al., 1998). Interestingly, the reported intracellular Ca2+ 
circadian rhythmicity in HL1-6 cells under control conditions, was in line (similar periodicity) 
with the circadian rhythm of Bmal1 gene observed, hence supports an association of Ca2+ 
contributing and possibly driving its circadian expression in atrial myocytes. In addition, 
Bmal1 mRNA expression was also reported in these cells, with absence of circadian 
rhythmicity, possibly due to involvement of mechanical stress of the cells during the lysis 
process (for RT-QPCR experiment). Mechanical stress is known to shift the circadian clock 
in cardiac cells, which can explain the aberrant circadian patterns observed in our data, which 
further supports the use of lentivirus bioluminescence as a more robust technique for the 
investigation of circadian characteristics (van der Veen et al., 2012).  
Raised intracellular [Ca2+], the well-known contributor of atrial arrhythmias, significantly 
altered Bmal1 gene expression and circadian phenotype, through the sustained opening of NaP 
channels by ATXII. Given then known function of ATXII driving similar mechanisms as the 
ones observed under arrhythmic conditions (NaP opening and intracellular Ca
2+ overload), our 
results strongly suggest that Ca2+ mediated changes in the cellular circadian clock are an 
integral part of the aetiology of atrial arrhythmia’s (Song et al., 2008). Interestingly, 
intracellular Ca2+ circadian rhythm was also disturbed in a similar way in presence of ATXII, 
and the 16-hour oscillatory pattern observed was in line with the Bmal1 gene expression 
pattern under ATXII, which further supports the association of periodic Ca2+ influx with 
Bmal1 gene circadian rhythmicity. The observed significant impact of ATXII in the HL1-6 
atrial myocytes, supports the known existence of NaP channels in these cells which strengthens 
their use as a good in vitro model for AF (Strege et al., 2012). Our study, also propose a new 
technical approach to assess the involvement of clock genes in cardiovascular diseases without 
pre-disturbing the molecular clock, as most studies conducted so far required targeted 
cardiomyocyte-specific disruption of the molecular clock either through overexpression of a 
mutant CLOCK protein or through target deletion of Bmal1 clock gene (Bray et al., 2007, 
Durgan et al., 2011).  
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The disruptive effects of raised intracellular Ca2+ on Bmal1 gene expression and circadian 
pattern, were prevented in presence of several pharmacological interventions that inhibit Ca2+ 
signalling in the cell (Ranolazine; NaP channel inhibitor & BAPTA-AM Ca2+ chelator). Thus, 
further suggesting that the NaP/raised Ca
2+ arrhythmogenic pathway directly affects Bmal1 
expression in atria which strengthens its association in AF occurrence. Additionally, we 
proposed that Ranolazine is a suitable NaP channel inhibitor (despite its inhibitory activity on 
other ion channels) due to the complete restoration of ATXII effect in HL1-6 cells (Rajamani 
et al., 2009; Strege et al., 2012). This again show that HL1-6 cell line is a good in vitro model 
for the investigation of atrial related events, such as AF, as well as for the investigation of 
circadian characteristics of clock genes such as, Bmal1.  
6.1.2. BMAL1 protein expression in HL1-6 cells  
We also report that Total BMAL1 (T-BMAL1) protein expression exhibits a trend of 
oscillation across time, with an approximately 20-hour rhythmic pattern under control 
conditions. The T-BMAL1 oscillatory pattern, as well as, its levels of expression were 
similarly disturbed (lower T-BMAL1 levels and shift in its peak expression time) in presence 
of raised intracellular [Ca2+] by ATXII, thus suggesting that changes in intracellular [Ca2+] 
are not only associated with changes in Bmal1 gene circadian pattern but also affect its protein 
expression levels in the aetiology of AF. In addition, the higher T-BMAL1 protein expression 
levels towards the end of each circadian day may link to the morning prevalence of these 
events. Interestingly, the T-BMAL1 protein showed almost similar pattern as the control 
profile (apart from timepoint 28 hours) following Ranolazine treatment (in presence of 
ATXII), which further support its contribution in restoring the raised intracellular [Ca2+]-
induced effects by inhibiting NaP channels. Our findings also revealed that T-BMAL1 protein 
expression follows the Bmal1 mRNA expression pattern under control conditions due to 
similar periodicity reported. Whereas, T-BMAL1 protein expression under raised intracellular 
[Ca2+] did not follow the mRNA gene expression, which reported shortening of the periodicity 
by at least 6 hours.  This implies that the half-life of T-BMAL1 protein (~5 hours) might be 
too long to facilitate a rapid circadian rhythm, hence when the mRNA is speed up 
significantly, the protein will no longer track on to that and therefore there will be uncoupling 
between the protein and mRNA levels which is indicated by the shift in periodicity observed 
under raised intracellular [Ca2+]. Thus, further supports the involvement of Ca2+ level changes 
in mediating the T-BMAL1 protein expression changes observed.  
In addition, considering that phosphorylation regulates T-BMAL1 fate and transcriptional 
activity, by altering its structural conformation and causing it to become activated or 
deactivated or modifying its function, we further investigated the protein expression and 
circadian pattern of BMAL1 phosphorylation status at Serine 42 residue (pBmal1-Ser42) in 
order to determine whether the changes reported during AF-raised [Ca2+]i are leading to and/or 
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possibly contributing to Bmal1 gene and protein circadian disturbances.  Absence of an 
oscillatory pattern and low levels of phosphorylated BMAL1-Ser42 protein expression were 
observed under control conditions.  The protein levels of pBMAL1-Ser42 significantly 
increased under raised [Ca2+]i and presented a 20-hour rhythmic pattern, suggesting that raised 
[Ca2+]i might possibly affect BMAL1 protein phosphorylation status at Ser42 residue. 
Additionally, the contribution of raised [Ca2+]i driving pBMAL1-Ser42 rhythmic pattern 
through NaP mechanism mediating AF maybe due to the periodicity shortening observed 
compare to control conditions, which might link to the AF frequency to occur during certain 
time of the day.  However, due to the lack of information regarding the activity of Ranolazine 
on reversing such effect, due to significantly low pBMAL1-Ser42 protein levels observed, it 
is not clear whether such changes are driven by the proposed Ca2+/NaP pathway on its 
phosphorylated form.  
Studies performed so far, reported that BMAL1 protein expression detected in different extend 
in the different cellular compartments (i.e. nucleus) (Kondratov et al., 2003; Dang et al., 2016). 
Thus, this raised the question whether changes in raised [Ca2+]i, are also associated with 
changes in T-BMAL1 cellular localisation status contributing to its disturbed circadian rhythm 
observed under AF underlying mechanisms. We reported high T-BMAL1 nuclear localisation, 
under control conditions which is in line with previously reported evidence of high nuclear T-
BMAL1 accumulation at our observed times (Tamaru et al., 2003, Kondratov et al., 2003; 
Dang et al., 2016). Interestingly, the nuclear T-BMAL1 protein expression pattern was 
consistent with the T-BMAL1 protein expression pattern observed under control conditions, 
indicating possible effect of serum during certain times of the day.  In addition, the lack of 
studies investigating the effects of pathological Ca2+ levels (in vivo and in vitro) on T-BMAL1 
protein cellular shuttling marks the importance and uniqueness of our findings.  Raised [Ca2+]i 
not only increased T-BMAL1 nuclear expression levels, but also shifted its nuclear shuttling 
pattern across time (when compare to control). Thus, suggesting that despite the effects of 
increased [Ca2+]i on gene/protein expression, Ca
2+ homeostasis also affects T-BMAL1 cellular 
localisation which immediately has an impact on its function and subsequently affects its 
circadian expression as a key protein driving the circadian molecular mechanism. 
Furthermore, the peak of mean T-BMAL1 cellular expression following a circadian day (at 
28 hours) might also be associated with the morning prevalence of AF-events. Similarly, to 
gene/protein expression experiments previously conducted as part of this thesis where NaP 
inhibitor was used, Ranolazine minimised and almost prevented the ATXII effects on T-
BMAL1 nuclear cellular shuttling pattern providing further evidence of the involvement of 
raised [Ca2+]i in affecting T-BMAL1 cellular expression and localisation under Ca
2+/NaP AF 
mechanism. Also, similarly to its effect on T-BMAL1 protein expression, Ranolazine partially 
lowered the mean T-BMAL1 cellular fluorescent when compare to ATXII, further supporting 
its inhibitory activity on NaP channels following changes in Ca
2+ homeostasis.  
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6.1.3. Involvement of BMAL1 in AF underlying mechanisms  
One of the main underlying mechanism for the observed Ca2+-mediated changes in Bmal1 
gene/protein expression is the activation of Ca2+/CaM-dependent protein phosphatase 
calcineurin, which may have direct or indirect effects by activating PP1, a known protein 
phosphatase which reported to modulate the levels of BMAL1 and other clock genes (Gallego 
et al., 2006; Vanselow et al., 2006; Meng et al., 2008; Koshibu et al., 2009; Schmutz et al., 
2011). Our study reports for the first time that that the specific calcineurin inhibitor (CAIP) 
alone did not have any effects in control conditions, but partially prevented ATXII effects on 
T-BMAL1 protein expression in total synchronised HL1-6 cell lysate suggesting possible 
involvement of calcineurin activity mediating T-BMAL1 protein expression changes in the 
aetiology of AF.  However, further experiments need to be conducted for the identification of 
possible calcineurin phosphorylation target site on T-BMAL1, despite the Ser42 residue 
which reported high pBMAL1 protein expression in presence of calcineurin inhibitor 
following ATXII treatment. This is different to the literature, considering that CAIP inhibits 
calcineurin and prevents its binding to Ca2+; hence it was expected to also lower pBMAL1-
Ser42 protein expression levels. Studies reported BMAL1 phosphorylation at Ser90, which 
could also be a potential target site for calcineurin activity (Tamaru et al.; 2009; Sahin et al., 
2015; Tamaru et al., 2015). Additionally, the T-BMAL1 nuclear cellular shuttling pattern 
observed under CAIP treatment (in presence of ATXII), showed slightly higher nuclear T-
BMAL1 protein levels across the two circadian cycles when compare to control conditions. 
Our results are supported by Schmutz et al., (2011) who reported, slightly higher levels of 
nuclear BMAL1 protein accumulation in I1 (PP1 endogenous inhibitor) mutant mice (when 
compare to control wildtype mice), indicating that PP1 may similarly affects BMAL1 protein 
levels and influences its subcellular localisation.  Therefore, considering that calcineurin 
activates PP1 indirectly (by I1-Thr35 dephosphorylation) under raised intracellular [Ca2+], 
and the fact that similar nuclear T-BMAL1 protein levels were observed in our in vitro model, 
suggests a possible calcineurin-PP1 signalling pathway mediating T-BMAL1 protein 
localisation in atrial cells. In addition, despite the observed increased expression levels under 
CAIP treatment in presence of ATXII, pBMAL1-Ser42 protein expression oscillated in a 
circadian manner in HL1-6 atrial cells, whereas in presence of CAIP treatment alone 
pBMAL1-Ser42 presented a non-rhythmic pattern with various oscillations across time.  Thus, 
strongly supporting the involvement of calcineurin in driving BMAL1 protein circadian 
pattern in atrial arrhythmic events.  However, further experiments need to be conducted for 
the identification of possible calcineurin phosphorylation target sites on T-BMAL1, despite 
the Ser42 residue due to the enhanced levels of expression of BMAL1 phosphorylated form. 
Another consequence of raised intracellular Ca2+ in atrial myocardium is alteration in gap 
junctional connexin protein expression and phosphorylation status. Our study reports for the 
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first time an oscillatory pattern of T-Cx43 protein expression in HL1-6 cells, under control 
conditions. Since the association of connexins in the occurrence of normal electrical 
conductance across the heart and subsequently propagation of action potential is well 
documented, our findings further propose diurnal variation in the occurrence of such actions 
which is also supported in the literature (Bollmann et al, 2000). This also propose that at the 
given times when T-Cx43 protein levels are low, the action potential velocity also decreases; 
a predisposing AF risk factor. Therefore, in future studies it might be possible by screening 
T-Cx43 circadian rhythmic profile from atrial myocytes of patients or people at high risk 
developing AF, to provide more evidence for better understanding, prognosis and prophylaxis 
plans against AF occurrence. Raised [Ca2+]i disrupted T-Cx43 protein expression pattern with 
earlier peak and trough points when compare to control, thus providing evidence of NaP 
channel opening under ATXII treatment affecting its potential circadian rhythmicity. Thus, 
considering that this is an important factor contributing to the generation of AF, it proposes 
that the disruptive gap junction conductance (due to changes in T-Cx43 protein expression) is 
responsive for the alteration in Bmal1 gene/protein circadian expression observed under raised 
[Ca2+]i - AF underlying mechanisms.  Ranolazine, partially recovered the raised [Ca
2+]i effects 
on T-Cx43 protein expression, thus supporting its inhibitory activity on NaP channels and 
provide further evidence that the ATXII-induced changes in T-Cx43 protein expression were 
due to raised [Ca2+]i.  
Our study also reports for the first-time protein expression oscillatory patterns of 
phosphorylated Cx43 at Ser368 (pCx43-Ser368) in HL1-6 atrial cells, suggesting the 
involvement of clock genes regulating its expression. Raised [Ca2+]i resulted in circadian 
pCx43-Ser368 protein expression levels across time, and increased periodicity compared to 
control conditions suggesting the true involvement of Ca2+ in driving the  circadian expression 
of Cx43 phosphorylation status. However, even though raised [Ca2+]i resulted in circadian 
pCx43-Ser368 protein oscillatory expression, the lower protein expression levels observed are 
different to the reported high pCx43-Ser368 protein expression observed under pathologic 
conditions (i.e. raised [Ca2+]i). This might be a sign of cells desynchronisation and 
subsequently clock gene and protein expression desynchrony. Clock genes were reported to 
exhibit dampened rhythmicity following synchronisation under a certain period of time, due 
to gradual loss of cell synchronisation (van der Veen et al., 2012).  Therefore, this suggests 
that due to the poor synchronisation and the dampening of signals, pCx43-pSer368 protein 
expression levels are indeed under the control of clock genes, which further supports our 
hypothesis. Ranolazine, restored pCx43-Ser368 protein expression levels and oscillatory 
pattern, proposing the involvement of raised [Ca2+]i in this pathway. To further strengthen 
this, similar T-BMAL1 protein expression pattern was observed under Ranolazine treatment, 
which propose an immediate association of circadian mechanisms driving connexin 
expression in occurrence of AF. In addition, to provide further insights on the intracellular 
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signalling pathway driving such effects, pCx43-Ser368 protein expression levels and 
circadian pattern were restored in presence of calcineurin inhibitor, revealing calcineurin 
involvement in mediating the ATXII-effects.  Raised Ca2+/CaM shown to be associated with 
atrial arrhythmias by inducing activation of calcineurin which further causes activation of PP1 
indirectly (by I1-Thr35 dephosphorylation) to dephosphorylate Cx43-Ser365 and induce 
Cx43-Ser368 phosphorylation by PKC or PP2A (Jabr et al., 2016). Thus, proposing the 
Ca2+/calcineurin signalling pathway driving T-BMAL1 protein expression and localisation in 
atria, through Cx43 phosphorylation at Ser368 via activation of PP1-induced 
dephosphorylation at Cx43-Ser365.  
Our study also reports high T-Cx40 protein expression levels under control conditions when 
compare to ATXII treatment alone or in presence of NaP inhibitor (which was also unable to 
reverse the ATXII effects), thus suggesting absence of T-Cx40 involvement in AF mediating 
pathways in atria as well as its contribution in T-BMAL1 protein expression changes. 
Interestingly, similar T-Cx40 and T-Cx43 levels were observed following quantification of 
fluorescent bands under control conditions and this is in line with immunohistochemical 
staining studies of healthy atrium in animals who reported similar expression of Cx40 and 
Cx43 under physiological conditions (Gros et al., 1994; Verheule et al., 1997; van der Velden 
et al., 1998). However, in presence of calcineurin inhibitor T-Cx40 protein expression levels 
significantly increased compared to control and ATXII treatment alone. Raised [Ca2+]i shown 
to increased Cx40 phosphorylation levels and such change was solely mediated by calcineurin 
with partial involvement of PP2A in guinea pig left atrium (Hatch et al., 2015), thus suggesting 
possible contribution of calcineurin effect through the same pathway in our study. However, 
considering the absence of raised [Ca2+]i effect on T-Cx40 expression in presence of ATXII 
alone, further experiments need to be conducted in order to support the above statement.  
Furthermore, the low levels of connexin protein expression under control conditions, support 
the use of a healthy model throughout these experiments. This also suggests that HL1-6 cells 
are an exceptional in vitro model for the study of connexins as a tool to provide further 
understanding in circadian AP propagation and conduction velocity under physiological and 
pathophysiological conditions. Analytical methods to western blot analysis, such as confocal 
microscopy imaging can also be used to investigate possible alterations of cellular connexin 
protein expression localisation, as well as, indication of the degree of connexin 
phosphorylation levels. Finally, multielectrode arrays (MEAs) can be used to correlate 
connexin lateralisation with action potential conduction velocity measurements across the 48 
hours, and link possible action potential changes at specific time with connexin levels.  
Persistent activation of NaP channels is also known to maintain atrial abnormal electrical 
activity during atrial arrhythmias. We have shown that the key molecular components of NaP 
(Nav1.5.) show an oscillatory trend under control conditions, which was disturb in presence 
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of ATXII.  Also, Nav1.5. protein expression levels increased under raised [Ca2+]i, a 
characteristic of NaP channel behaviour from this subtype, as the release of Ca
2+ occurs during 
the plateau phase were NaP channels are active. This further supports the involvement of 
Nav1.5. Nap subtype in the proposed mechanism leading to AF, as well as highlights its role 
in driving the disturbed Bmal1 gene/protein expression via raised [Ca2+]i. To further 
strengthen our findings and support the direct association of Bmal1 with Nav1.5. NaP 
channels, induced cardiac specific deletion of Bmal1 clock gene in mouse ventricular 
myocytes, reported loss of SCN5A gene circadian expression which governs Nav1.5. channel 
protein expression (Schroder et al., 2013). The Nav1.5. expression observed in the presence 
of Ranolazine following ATXII treatment, with similar peaks and troughs as the control group 
suggests possible antagonistic effect of Ranolazine on recovering the ATXII effects. 
Additionally, despite the low Nav1.1. protein expression levels observed under ATXII 
treatment, which is in contrast with the proposed high protein levels following the used of NaP 
channel activators, circadian Nav1.1. protein expression levels were observed under control 
conditions. Thus, suggesting the absence of Nav1.1. in driving Bmal1 gene/protein expression 
changes via increased intracellular [Ca2+], as a model for AF, but also further strengthens the 
involvement of Nav1.5. as the key molecular component of NaP.  
6.1.4. Summary 
The novel findings of this study summarised in Figure 6.1. indicate that intracellular overload 
of [Ca2+], leads to facilitation of disturbed Bmal1 clock gene circadian rhythmicity, protein 
expression and cellular localisation in HL1-6 cells in vitro model and the underpinning cellular 
mechanism is AF-induced pathway.  These results provide the foundation for future animal 
and human studies to answer the question of whether altered clock gene circadian rhythmicity 
increase the risk of AF occurrence.   
Furthermore, understanding the molecular and cellular mechanisms involved in high-[Ca2+]i-
induced Bmal1 circadian arrhythmicity will help in monitoring the effects of altered clock 
genes as an AF treatment or prevention agent.  Sustained activation and prolonged opening of 
NaP channels subtype Nav1.5. by ATXII treatment, stimulates overload of [Na
+]i which leads 
to reduction of the electrochemical gradient for Ca2+ extrusion by the NCX exchanger (3 Na+ 
ions with 1 Ca2+ ion), causing overload of [Ca2+]i in HL1-6 atrial cells. The ATXII-induced 
raised [Ca2+]i  highly disturbed Bmal1 gene and protein circadian rhythmic pattern, as well as 
cellular localisation via indirect changes in connexin 43 phosphorylation status at Ser368 
residue due to activation of Calcineurin/PP1 known pathway or direct effect of Calcineurin 
on BMAL1-Ser42 residue. Such patterns were fully reverse in presence of Ranolazine NaP 
channel inhibitor, BAPTA-AM Ca2+ chelator and Calcineurin selective inhibitor (CAIP) 
further confirming the involvement of Ca2+-activated Calcineurin leading to the development 
of AF due to disturbed gap junction conduction and Bmal1 circadian rhythmicity. 
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This thesis additionally warns the public to be aware of the involvement of clock genes, in 
particular Bmal1, in development of atrial-related diseases such as AF.  Lastly, we advise the 
public to be considerate of the times of the day that Bmal1 expression rises, for immediate 
association with AF occurrence. 
 
 
Figure 6.1. Proposed mechanism of BMAL1 regulation in HL1-6 atrial cells.  Under pathologic conditions, 
such as Atrial Fibrillation (AF), persistent activation of NaP channels leads to sustain rise of intracellular [Ca2+] 
([Ca2+]i) due to reduction of the electrochemical gradient for Ca2+ extrusion by the NCX exchanger (which under 
physiological conditions it exchange 3Na+ to 1Ca2+). Rise [Ca2+]i together with calmodulin (CaM) lead to 
activation of Calcineurin (Cn; Ca2+/CaM – dependent protein phosphatase).  Such mechanism is mimic in vitro 
by Anemonia suclata toxin II (ATXII), reversed by Ranolazine NaP channel inhibitor, and prevented by 
Calcineurin autoinhibitory domain selective inhibitor (CAIP).  Cn caused changes to Connexin 43 (Cx43) 
phosphorylation status (but not Cx40) at Serine 368 (Ser368) via known activation of protein phosphatase 1 
(PP1), and subsequent disturbed gap junctional communication which is considered arrhythmogenic.  Cn caused 
similar changes to BMAL1 phoshphorylation status at Serine 42 (Ser42), proposing its involvement in AF 
development due to disturbed gap junction condution and/or Ca2+ homeostasis via Nav1.5. channel activation.   
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6.1.5. Limitations and future work  
Our study is based on the use of HL1-6 cells in vitro model for the investigation of atrial 
pathologies. The use of HL1-6 cardiomyocytes for the investigation of cardiac related 
pathologies and more specifically atrial arrhythmias has been previously stated.  However, for 
future compatibility to humans and achieving the next phase of potential treatment strategies 
and better prognostic tools a more concrete model is possibly required.  For example, the use 
of fresh atrial disperse cells that are closer to an in vivo atrial model, or even human atrial 
tissue samples (obtained from atrial biopsy) will allow stronger validation of our findings in 
humans. In addition, population studies of people at high risk developing AF (<65 years of 
age) or even AF patients could help in determine in full extent the involvement of circadian 
clock genes in cardiac electrophysiology, as well as the importance of its disruption as a 
predispose risk factor for the generation of cardiac pathologies.  It is also worth stating that 
the use of either human size nocturnal animals that are active at night during similar hours 
when AF occurs, and sleep during the day could provide further inside on the circadian 
physiological characteristics of the disease.  
On another note, when it comes to comparison and validation of techniques used, our results 
from Chapter 3 suggested rhythmic Bmal1 clock gene expression in HL1-6 cells under control 
conditions, NaP channel inhibitor and BAPTA-AM Ca
2+-chelator, using real-time monitoring 
of Bmal1 transcription and recording of Bma11 bioluminescence, which further supports the 
true presence of a circadian pattern of this gene in atrial cells.  However, such pattern was 
highly disrupted in presence of ATXII alone (10 hours).  The large phase shifts observed may 
be an indication of atrial sensitivity to mechanical stress that undergoes during the treatment 
or serum-shock synchronisation, despite the confirmed effects using MTS cell viability assay 
which reported a small reduction in the number of viable cells throughout a 3-day treatment 
period. There are various assays available for the investigation of viable cells in culture, 
however MTS assay eliminates a liquid handling step during the assay procedure, which 
makes the protocol more convenient and minimise extra steps that might increase the chances 
of contamination hence affecting the cell’s viability (Riss et al., 2013).  At the same time, 
additional experiments using the proposed in vivo models mentioned above can certainly play 
a key role in eliminating possible induced stress effects as the treatment steps throughout 
similar protocol will be emitted.  
While Bmal1 clock gene expression displayed circadian rhythmicity using bioluminescence 
technique under most proposed treatment conditions, RT-QPCR experiments reported an 
endogenous non-circadian Bmal1 mRNA expression in HL1-6 cells which was altered (in less 
extend than the one observed in bioluminescent model; ~ 6-hour shift in the peak expression 
time only) following treatment with ATXII. The absence of circadian rhythmic pattern using 
RT-QPCR technique may be due to the involvement of mechanical stress of the cells during 
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the experimental steps involved up to their lysis step just before the collection of each 
timepoint interval for the evaluation of circadian rhythmicity across the two circadian cycles.  
Mechanical stress is also known to shift the circadian clock in cardiac cells (van der Veen et 
al., 2012), which can explain the aberrant circadian patterns observed in our data.  This 
hypothesis can also be adopted to explain the effects of timing of culturing (a mechanically 
stressful procedure), which also results in a larger range of phase shifts in the atrium.  Stress 
can be due to mechanical movement of the dish (were the cells were seeded) during the media 
and/or serum content replacement step, or due to changes in gas pressures during removal of 
the dishes in and out of the CO2 incubators throughout the experimental protocol.  Similarly, 
opening the lid of the sealed culture dish to provide air exchange may also affect the phase 
shit, concluding that mechanical change highlights the possibility that increased cardiac 
activity might itself result in resetting of the circadian clock of the atria.  Additionally, the 
absence of strong serum-shock synchronisation effect across time, may be due to the inability 
of serum pulse to fully synchronised the cells, as well as, the intracellular clocks across the 
cultures.  Hence, the rhythms of genes that naturally exhibit lower amplitude oscillations may 
not be detected fully at the populations, therefore repetition of the experiments using a 
different pharmacological stimulus rather than serum-shock, such as dexamethasone, to 
synchronise the HL1-6 cells might provide further insights in our findings (Balsalobre et al., 
2001).  
Western blotting technique was also used for the investigation of protein expression 
oscillatory patterns of genes of interest in Chapter 4.  T-BMAL1 protein expression exhibited 
a trend of oscillation across time, with an approximately 20-hour rhythmic pattern under 
control conditions, similar to the one observed using RT-QPCR technique.  In addition, T-
BMAL1 protein expression was disturbed in less extend compare to Lentivirus 
bioluminescence technique, in presence of ATXII treatment.  This supports that T-BMAL1 
protein expression follows the Bmal1 mRNA expression pattern under control conditions due 
to similar periodicity reported. Whereas, T-BMAL1 protein expression under raised 
intracellular [Ca2+] did not follow the mRNA gene expression, which reported shortening of 
the periodicity by at least 6 hours.  This implies that the half-life of T-BMAL1 protein (~5 
hours) might be too long to facilitate a rapid circadian rhythm, hence when the mRNA is speed 
up significantly, the protein will no longer track on to that and therefore there will be 
uncoupling between the protein and mRNA levels which is indicated by the shift in periodicity 
observed under raised intracellular [Ca2+].   
To further support the above statement, studies have shown that it is very likely that the genes 
failing to exhibit rhythmic mRNA expression may show oscillatory protein levels, and vice 
versa (Kojima et al., 2011).  Following translation of mRNA into protein, it is usually assumed 
that there is direct correlation between the levels of mRNA and protein expression since post-
transcriptional processes are key to the final synthesis of the native protein.  However, it has 
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been shown that protein and mRNA abundances are not following a normal distribution 
(Taylor et al., 2005; Wang et al., 2012).  Transcriptome analyses study revealed that 
approximately 5-10% gene’s expression exhibit circadian rhythmicity at steady-state mRNA 
levels in any given organism or tissue (Duffield., 2003).  For transcripts to be rhythmic, is 
essential to have relatively short half-lives.  A model investigating the way mRNA stability 
impact the amplitude of transcripts was set by Wuarin et al., (1992) who revealed that the 
more stable the transcript is, the lower the amplitude of its cycling will be. Therefore, the 
regulation of mRNA stability, and/or decay or its decay rate, plays an important role in the 
cycling of transcripts.  Other post-transcriptional mechanisms also play an important role in 
rhythmic expression.  For instance, there are few cases were protein synthesis rhythms can be 
uncoupled from mRNA rhythms, suggesting that translation can also be a key regulatory node 
in mRNA rhythmic expression.  Previous studies of the heart proteome revealed that protein 
rhythms do not necessarily reflect temporal mRNA expression (Zhang et al., 2014).  In fact, 
up to 20% of soluble proteins showed rhythmic expression and more than half of the cycling 
proteins tested did not exhibit corresponding rhythmic mRNA expression. 
There are several reasons for the poor correlation between the levels of mRNA and protein.  
For instance, there are numerous complicated and varied post-transcriptional mechanisms 
involved in turning mRNA into protein that are not yet fully well-defined to be able to 
compute protein concentrations from mRNA.  Also, proteins may differ substantially in their 
in vivo half-life as mentioned above, as well as the significant amount of error and noise in 
both protein and mRNA experiments that limit our ability to get a clear picture.  For example, 
RT-QPCR might have its own limitations in detecting mRNA expression, such as possible 
crosslinking between the two probes or poor quality of mRNA collected across the several 
timepoints.  Also, given the evidence that the clock in the cells was shifted by the lysis 
treatment, the use of a more robust technique (Lentivirus bioluminescence) for the 
investigation of circadian characteristics, further supports and strengthens our original 
findings.  Additionally, the accuracy of RT-QPCR observations is critical considering the 
small number of samples collected, hence further experiments need to be conducted to confirm 
our initial findings.  Furthermore, the cases of significantly low levels of protein expression 
across time, may be due to possible cell desynchronisation due to loss of serum-shock effect 
(van der Veen et al, 2012). During serum-shock, these cells are highly synchronised and 
expressed as a net protein expression at given times, however, with time this dampens and the 
clock gene, as well as the protein become no longer synchronised. Even though the gene itself 
is expressed when it fades away, the protein expression could equally follow a similar pattern. 
To strengthen this, it has been reported that following synchronisation under a certain period 
of time, clock genes start exhibiting dampened rhythmicity due to gradual loss of cell 
synchronisation (van der Veen et al., 2012).   
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It is also worth stating that studies performed so far, assessed BMAL1 protein expression 
levels via immunoprecipitation experiments, and reported that BMAL1 expression detected 
in different extend in the nuclear and cytoplasmic compartments of the cell (Kondratov et al., 
2003; Dang et al., 2016).  Hence, additional immunoprecipitation experiments can provide 
further insight in our study considering that higher T-BMAL1 protein expression levels were 
reported in the nuclear compared to the cytoplasmic compartment of the cell. For better 
visualisation and confirmation of the interventions used throughout this study, BMAL1 
protein localisation was investigated using immunofluorescence technique and presented in 
Chapter 5.  The increased T-BMAL1 nuclear localisation under control conditions was 
consistent with the T-BMAL1 protein expression pattern observed using western blot 
technique indicating possible effect of serum-shock pharmacologic intervention mostly in the 
nuclear compartment of the cell.  Whereas, ATXII significantly increased T-BMAL1 nuclear 
localisation and phase shift its expression when compare to control, as similarly observed 
under all proposed methods. Thus, suggesting that despite the effects of increased intracellular 
[Ca2+] on gene/protein expression, also affects T-BMAL1 cellular localisation which 
immediately has an impact on its function and subsequently affects its circadian expression as 
a key protein driving the circadian molecular mechanism.  Interestingly, the peak of mean T-
BMAL1 cellular expression right after a circadian day (at 28 hours) might also associated with 
the morning prevalence of such events.  
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